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Up to 50% of Breast Cancer Survivors (BCS) do not take tamoxifen as prescribed, which 
increases the risk of recurrence and mortality. Few psychosocial predictors of non-adherence 
have been identified and no published studies have described interventions to improve 
tamoxifen adherence. The aims of this PhD were to examine barriers to tamoxifen adherence 
in BCS and to develop a psychoeducational intervention to improve adherence. To address 
limitations with previous research, this PhD used the Common Sense Model (CSM) and the 
Theory of Planned Behaviour (TPB) as a framework for investigating non-adherence. A 
systematic review found few consistent predictors of non-adherence and highlighted a need 
for more research on modifiable factors. A qualitative study showed that adherence was 
related to the beliefs patients hold about tamoxifen and how they weigh these beliefs up 
against their side effects (n=32). In a large questionnaire study (n=777), components from 
the CSM and the TPB explained between 17% and 46% of the variance in non-adherence. 
Unintentional non-adherence was reported more frequently than intentional non-adherence 
but was harder to explain.  
Women within their first year of treatment were sent follow up questionnaires at 3, 6 and 12 
months (n=345). Reported rates of non-adherence increased significantly over time, as did 
perceived intensity of side effects. Results identified severable variables associated with 
non-adherence: ethnicity, employment status, necessity/concerns differential and perceived 
behavioural control. Both models provided excellent discrimination between adherent and 
non-adherent women. A psychoeducational self-management booklet was developed and 
was trialled in a small study, which supported the feasibility and acceptability of the 
intervention (n=41). Significant improvements were seen to variables associated with 
adherence, such as side effects, medication beliefs and self-efficacy for managing symptoms.  
The results from these studies highlight factors associated with tamoxifen non-adherence, 
which can be used clinically to identify patients at risk of non-adherence, and as the basis for 
interventions to improve adherence. Initial testing of a psychoeducational self-management 
intervention showed promising results. Combining constructs from both the CSM and the 
TPB provided the best understanding of non-adherence. Future research should apply this 
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1. Introduction to Breast cancer  
1.1.  Chapter overview  
To give context for the body of work presented in the thesis, this chapter will provide an 
overview of breast cancer and tamoxifen. The clinical characteristics of breast cancer will be 
described, followed by the aetiology and epidemiology of the disease. Treatment options 
will then discussed, with a focus on hormone therapy and tamoxifen. The psychological 
impact of breast cancer and breast cancer survivorship will then be summarised.  
1.2. Structure of the breast and breast cancer   
1.2.1. Structure of the breast  
The female breast is made up mostly of adipose or fatty tissue. It also contains a complex 
network of lobes and ducts. A healthy breast contains up to 20 lobes, which are made up of 
smaller lobules, where milk is produced in women who are nursing. Lobes and lobules are 
connected to the nipple by thin tubes known as milk ducts. Breast cancer usually forms 
within these lobes and ducts.  It occurs when cells divide and grow in irregular and 
uncontrolled ways. Every time a cell is multiplied, the DNA is copied. Sometimes this DNA 
is copied with errors which change the instructions for how a cell should multiply. These 
errors are usually corrected by repair genes, however when they do not get corrected, the 
error is reproduced and replicated in new cells. Over time, these abnormal cells multiply and 
develop into a lump called a tumour.  
The lymphatic system plays an important role in fighting infections and bacteria. It is also 
responsible for destroying abnormal cells such as cancer cells. The lymphatic system 
consists of lymph nodes, small bean-shaped collections of immune cells, and lymph vessels. 
Lymph vessels are very thin tubes found throughout the body. They carry a liquid called 
lymph, which fights infections and destroys damaged or abnormal cells. When a cancer cell 
breaks away from a tumour, it will travel to other parts of the body through the lymphatic 
system or the blood stream. Most of these cancer cells will be destroyed by the body, but 
some may travel to become tumours elsewhere. If breast cancer cells are found in nearby 
lymph nodes, such as under the armpit, it is an indication that the cancer has broken away 
from the tumour and is therefore more likely to spread to other parts of the body (Breast 
Cancer Now, 2017).  
1.2.2. Classification of breast cancer  
Breast cancer is a collection of different diseases which have distinct histopathological 




World Health Organisation (WHO) report estimates that there are seventeen distinct 
histological types of breast cancer (Ellis et al., 2003). Breast cancer which has not spread 
beyond the breast or lymph nodes is known as primary breast cancer. Cancers which have 
spread to other organs in the body are known as secondary or metastatic cancer. If a breast 
cancer has the ability to spread to other organs it is classed as invasive breast cancer. Some 
breast cancers carry cellular receptors. For example, around three quarters of breast cancers 
are oestrogen receptor positive (ER+), which means that cancer cells in these tumours 
require oestrogen for survival (Harrell et al., 2007). These cancer cells are stimulated by 
oestrogen to divide and grow. Around two thirds of ER+ breast cancers are also 
progesterone receptor positive (PR+). The best prognosis is found for tumours which are 
both ER+ and PR+ as the tumour is less aggressive and there are more treatment options 
(Dunnwald, Rossing, & Li, 2007). The tumour can also be assessed for the percentage of 
cells in the tumour which test positive for hormone receptors. This is known as an Allred 
score and can range from 0-8, where a score of 8 indicates that there are more receptors and 
a score of 0 indicates hormone receptor negative cancer (Dabbs, 2014). A higher score 
indicates that there will be greater benefit of Hormone Therapy (HT). 
Cancer cells can also be tested for HER2 status. Cancers which are HER2 positive have high 
levels of HER2 genes, which causes over-expression of the HER2 protein. This then causes 
increased proliferation of cancer cells. Approximately 15-25% of breast cancers are HER2 
positive (Piccart-Gebhart et al., 2005). These cancers tend to grow at a faster rate and have a 
higher rate of recurrence. Breast cancers which are triple negative, i.e. that are not positive 
for any of the above receptors, have a worse prognosis as they cannot benefit from targeted 
therapy. Around 15% of invasive breast cancers are triple negative (Cleator, Heller & 
Coombes, 2007).  
1.2.2.1. DCIS/LCIS  
Ductal Carcinoma in Situ (DCIS) is an early form of breast cancer which occurs when breast 
cancer cells are contained within the breast ducts and have not spread into other breast 
tissue. This type of cancer is non-invasive, but may become invasive if left untreated. 
Lobular Carcinoma in Situ (LCIS) is a condition where abnormal cells are found in the 
lobules of the breast. Whilst LCIS is not seen as cancer and does not require treatment, 
women with LCIS are at increased risk of developing breast cancer in the future (Cancer 
Research UK, 2017a).    
1.2.2.2. Invasive cancer  
The most common type of breast cancer is invasive ductal cancer, accounting for 50-80% of 




breast cancer. Invasive ductal cancer originates in the cells of the ducts and spreads into 
surrounding breast tissue. Women with invasive ductal cancer may experience changes in 
the shape or size of the breast or changes to the skin or nipple. Invasive lobular cancer 
occurs when cancer cells that originated in the lobes have spread to surrounding breast 
tissue. Invasive lobular cancer is less common than invasive ductal cancer, accounting for 
around 5-15% of all cases (Cristofanili et al., 2005).  
1.2.3. Staging  
Breast cancers are assigned a stage at diagnosis which determines the treatment plan and 
prognosis. The TMN staging system takes into account the size of the tumour (T), whether it 
has spread to the lymph nodes (N), and if it has spread elsewhere in the body (M). Each of 
these factors is considered individually and an overall stage is given (Table 1.1).  For 
example, if a tumour was under 2cm with no evidence of spreading, the cancer would be 
staged as T1 N0 M0.   
Another common staging system is the numbered staging system which also takes into 
account the tumour size, nodal involvement and amount of metastasis. Stage I cancers are 
less than 2cm, have spread to 0-3 auxillary lymph nodes and have not spread elsewhere in 
the body. Stage II/III breast cancers have not metastasised but can involve larger tumours 
and more lymph node involvement. Stage IV breast cancer has metastasised. Stages I – IIIA 
are known as early breast cancer (Table 1.2).  
Cancer cells can also be assigned a grade based on examination under a microscope. Lower 
grades indicate cells which look like normal breast cells. Higher grade cancers grow faster 
than lower grade cancers. The stage and grade of the tumour will affect the treatment course 
and the prognosis. Doctors can input the stage and grade of the cancer into computer 
programs (e.g. Adjuvant! Online, PREDICT, Nottingham Prognostic Indicator) to provide 










Table 1.1 TNM Staging System of breast cancer 
Tumour  
TX Primary tumour cannot be assessed  
T0 No evidence of primary tumour  
Tis 
Cancer cells are only growing in the most superficial layer of tissue 
(DCIS/LCIS) 
T1 Tumour <20mm 
T2 Tumour >20mm but <50mm 
T3 Tumour >50mm 
T4 Tumour of any size with direct extension to the chest wall and/or the skin 
Nodes  
NX Lymph nodes cannot be evaluated  
N0 Nearby lymph nodes do not contain cancer 
N1 Cancer has spread to 1-3 axillary lymph nodes 
N2 
Cancer has spread to 4-9 axillary lymph nodes, or has spread to internal 
mammary lymph nodes  
N3 
Cancer has spread to 10 or more lymph nodes under the arm, clavicle or 
collarbone, or has spread to internal mammary nodes and axillary nodes, 
or has spread to lymph nodes above the clavicle 
Metastasis  
M0 No distant cancer spread 
M1 Distant metastasis were found 
Source: http://emedicine.medscape.com/article/2007112-overview 
Table 1.2 Numbered staging system for breast cancer  
Stage T N M 
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1 M0 
 T1 N1 M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 





1.3. Incidence, mortality and survival  
1.3.1. Incidence  
Breast cancer is the most common cancer in the UK and is the third most common cause of 
cancer-related death (Cancer Research UK, 2017b). There were 46,417 new cases of breast 
cancer diagnosed in England in 2014 (Office for National Statistics, 2016). Almost four out 
of five of these cases are diagnosed in women aged 50 and over (Office for National 
Statistics, 2012). Across 2006-2009, 41% of diagnosed breast cancers were stage I, 45% 
Stage II, 9% Stage III and 5% were Stage IV (Lyratzopoulos et al., 2012). Incidence rates in 
the UK have risen by 72% since the mid-1970s (Cancer Research UK, 2014a). This may be 
caused by widespread screening programs detecting early cancers such as DCIS which may 
never go on to cause any problems for the patient (Bleyer & Welch, 2012; DeSantis, Ma, 
Bryan, & Jemal, 2014). It may also be a result of lifestyle changes, as increased alcohol 
consumption, higher body fat and use of hormone replacement therapy (HRT) are all related 
to increased risk of breast cancer (Parkin, Boyd & Walker, 2011; World Cancer Research 
Fund/American Institute for Cancer Research, 2016; Writing Group for the Women’s Health 
Initiative, 2002). Increased rates may also be a result of women having children later in life 
or having fewer children (DeSantis et al., 2014).  
1.3.2. Survival  
There are 11,600 breast cancer deaths in the UK each year, which equates to around 32 
women per day (Cancer Research UK, 2014a). Due to improvements in screening and 
treatment, more women than ever are surviving breast cancer and death rates have fallen by 
40% in the last 30 years (Cancer Research UK, 2014a). Table 1.3 shows the average survival 
rates for one, five and ten years post diagnosis. The prognosis is dependent on the type and 
stage of breast cancer. For example, triple negative breast cancer is associated with a worse 
prognosis and higher rates of mortality because it does not respond to targeted therapy (Dent 
et al., 2007). Prognosis is improved for women who have ER+ or PR+ tumours (Dunnwald 
et al., 2007).  
Table 1.3 Breast cancer survival rates  
 Overall  Stage I Stage II  Stage III Stage IV 
Survival rates for one year  98% 100% 100% 97% 67% 
Survival rates for five years   85% 90% 70% 50% 13% 





1.3.3. Recurrence  
The chance of a recurrence remains high, even after treatment. Cancer which reoccurs in the 
breast area is known as a local recurrence. The cancer can also spread beyond the breast and 
lymph nodes in the arm into the tissues and lymph nodes around the chest, neck and 
breastbone, which is known as a regional recurrence. These cancer cells are more likely to 
spread elsewhere in the body (Susan G. Komen, 2017). Cancer which spreads to other 
organs or to the bones is known as secondary or metastatic breast cancer. Cancer cells can 
spread through the bloodstream or lymph fluid and become trapped in different organs and 
tissues. Risk of recurrence is highest within the first two years after diagnosis (Saphner, 
Tormey, & Gray, 1996), but may still be substantial up to twenty years after diagnosis (Early 
Breast Cancer Trialists' Collaborative, 2005).  
1.4.  Risk factors and causes of breast cancer  
1.4.1. Age 
As people age, there are greater opportunities for replication errors when cells divide. 
Therefore, the risk of breast cancer increases as women get older (Cancer Research UK, 
2014a). Most breast cancers occur in women over 50, and the incidence of breast cancer is 
extremely low before age 30 (Singletary, 2003).  
1.4.2. Family history  
Having a first degree relative (mother, sister or daughter) diagnosed with breast cancer 
approximately doubles the risk of developing breast cancer (Nelson et al., 2012; Pharoah, 
Day, Duffy, Easton, & Ponder, 1997). The National Institute for Health and Care Excellence 
(NICE) recommends that women who have a first degree relative who was diagnosed under 
the age of 40, or who have two first degree relatives with breast cancer should visit the 
breast clinic for assessment. However, whilst family history is an important risk factor, only 
3% of breast cancer is linked to a known breast gene. The main genes identified to date are 
BRCA1 and BRCA2. Women who have these genes have a 45-90% lifetime risk of 
developing breast cancer. Additionally, TP52 and PTEN genes have also been shown to 
increase the risk of breast cancer, but are much rarer (McPherson, Steel, & Dixon, 2000).  
1.4.3. Hormones  
As some cancer cells are stimulated by oestrogen, high levels of oestrogen can increase the 
risk of breast cancer. For example, women who start menstruating early (<11 years) may 
have a higher risk of breast cancer due to increased oestrogen exposure (Collaborative 




women who have children later in life, may also have a higher risk as their oestrogen 
exposure has not been interrupted by pregnancy (Ma, Bernstein, Pike, & Ursin, 2006). The 
Collaborative Group on Hormonal Factors in Breast Cancer (2002a) found the longer 
women breast feed, the more they are protected against breast cancer, with the risk of breast 
cancer decreasing by 4% for every 12 months of breast feeding, and by 7% for each birth. 
The oral contraceptive (OC) pill has also been linked to breast cancer risk. The International 
Agency for Research on Cancer (IARC) classified current or recent use of combined 
oestrogen-progestogen OCs as a cause of breast cancer (IARC, 2014). Research shows that 
current users of OCs have a slightly but significantly higher risk of breast cancer than non-
users (Gierisch et al., 2013; Nelson et al., 2012). However, the breast cancers diagnosed in 
OC users tend to be less advanced than those diagnosed in never users. Furthermore, whilst  
OCs may be a risk factor, breast cancer incidence is low in women on OCs as they tend to be 
younger, and therefore OCs are only linked to an estimated 1% of female breast cancers in 
the UK (Parkin, 2011). The increased risk of breast cancer declines after women stop using 
OCs and is diminished entirely after ten years (Collaborative Group on Hormonal Factors in 
Breast Cancer, 1996). 
Several large studies such as the Million Women study in the UK and the Women’s Health 
Initiative Randomised Controlled Trial in the US have found increased risk of breast cancer 
for women taking HRT (Beral, 2003; Writing Group for the Women's Health Initiative 
Investigators, 2002). Women who took continuous HRT for five years had a 24% higher risk 
of invasive breast cancer than women who were taking placebos. It has been estimated that 
3% of all breast cancers in the UK are attributed to HRT use (Parkin, 2011). However, the 
Million Women Study showed that past users of HRT are not at increased risk of breast 
cancer.  
1.4.4. Other risk factors  
Other potential risk factors include breast density, weight, diet and alcohol consumption. 
The World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) 
have classed body fatness as a risk factor for post-menopausal breast cancer and greater 
weight at birth as a probable cause of pre-menopausal breast cancer (WCRF/AICR, 2016), 
with an estimated 9% of all breast cancers in the UK being linked to excess body weight 
(Parkin et al., 2011). Meta-analyses have shown that the risk of breast cancer is increased for 
women who drink more units of alcohol per day (Allen et al., 2009; Collaborative Group on 
Hormonal Factors in Breast Cancer, 2002b). Parkin et al. (2011) linked an estimated 6% of 




1.5. Treatment  
Treatment options vary significantly depending on the type and stage of the cancer, the size 
of the tumour, the grade of the cells and the patient’s menopausal status. Computer programs 
can be used to assess how each treatment will affect the risk of recurrence. Ultrasounds are 
usually conducted before surgery to examine the lymph nodes. If results look abnormal, a 
fine needle aspiration is used to extract fluid or cells for testing to determine if the cancer 
has spread into the lymph nodes. Women with locally advanced breast cancer may be given 
chemotherapy or HT before surgery to shrink a tumour, which is known as neoadjuvant 
treatment. Adjuvant treatment is given after surgery to kill any remaining cancer cells and 
reduce the risk of a recurrence.  
1.5.1. Surgery 
Most patients receive surgery to remove the cancerous cells and reduce the likelihood of the 
cancer recurring or spreading. Patients can either undergo a lumpectomy, where the tumour 
is removed with a border of healthy tissue, or a mastectomy, where the whole breast is 
removed. Some patients may also have a quadrantectomy, which is where a quarter of the 
breast tissue is removed, but this is less common. Quadrantectomy and lumpectomies are 
known as breast-conserving surgery and are much less invasive than mastectomies. After the 
lumpectomy, tissue samples are sent to a pathologist to be examined. This will determine if 
there are cancer cells in the healthy tissue. If cancer cells are found in the tissue then more 
surgery may be needed. Lymph nodes can also be assessed during surgery using a sentinel 
lymph node biopsy. If cancer is found in the lymph nodes then a second operation will be 
conducted to remove the lymph nodes.  
Survival and recurrence rates are comparable between patients treated with breast-
conserving surgery plus radiation and with mastectomy (Fisher et al., 2002; van Dongen et 
al., 2000).  Breast-conserving surgery is often preferable as it preserves some breast tissue 
and has a reduced impact on the patient. However, mastectomies are still performed, 
especially if the tumour is large, if the lump is the middle of the breast, if there is more than 
one area of cancer in the breast or if there are areas of DCIS in the breast. Women who 
undergo a mastectomy are offered breast reconstruction.  
1.5.2. Chemotherapy  
Chemotherapy can be offered as adjuvant or neoadjuvant treatment. It works by using 
cytotoxic drugs to prevent cancer cells from dividing and growing. Several large trials have 
shown that neo-adjuvant chemotherapy is effective in shrinking tumours, thus allowing the 




(Bonadonna et al., 1998; Fisher et al., 1997). A large meta-analysis by the Early Breast 
Cancer Trialists’ Collaborative Group (EBCTCG) has shown that adjuvant chemotherapy 
can reduce breast cancer mortality by about one third, with greater benefits found in women 
with lymph node metastases (EBCTCG, 2012). The benefit is also greater in younger 
women than older women, perhaps due to the suppressive effects of chemotherapy on 
ovarian function in younger pre-menopausal women (EBCTCG, 2005). Multi-agent 
chemotherapy (polychemotherapy) has been shown to be more effective than single agent 
based therapy (EBCTCG, 2012). It is most often given intravenously, but oral delivery is 
increasingly common (Neuss et al., 2013). Chemotherapy can stop the ovaries from 
producing oestrogen, which may stimulate an early menopause in pre-menopausal women.  
1.5.3. Radiotherapy  
Radiotherapy uses radiation to destroy cancer cells. It is usually delivered post-surgery in 
order to remove any remaining cancer cells and reduce the risk of a recurrence. A large 
meta-analysis of over 10,000 patients found that radiotherapy can halve the rate of 
recurrence over ten years and reduce the rate of mortality by about a sixth (EBCTCG, 
2011a). Treatment with breast-conserving surgery and radiotherapy is shown to be equally 
as effective as a total mastectomy (Fisher et al., 1985; Litière et al., 2012).  
1.5.4. Ovarian Ablation  
Ovarian ablation is a treatment given to pre-menopausal women with early stage breast 
cancer. It refers to any treatment used to remove the ovaries or stop the ovaries from 
working, thus reducing levels of oestrogen in the body.  Ovarian ablation may involve 
treatment with a hormonal drug such as Goserelin (Zoladex), which stops the production of 
oestrogen from the ovaries. This is usually a reversible procedure. Women can also have an 
operation known as an oophectomy to remove their ovaries or can receive radiation on the 
ovaries to permanently stop them working.  
1.5.5. Biological therapy  
Biological therapies work by changing the way cancer cells interact, which stops them from 
sending signals to divide and grow. The most common treatment is Trastuzuman (Herceptin) 
which is used in women with HER2 positive cancer. Herceptin, which binds to the HER2 
receptors to inhibit cancer cell growth, can significantly reduce the risk of recurrence and 
breast cancer mortality (Piccart-Gebhart et al., 2005) Current recommendations are for a 12 




1.5.6. Adjuvant hormone therapy  
Adjuvant hormone therapy (HT) is prescribed to women with hormone receptor positive 
breast cancer. It is a systemic treatment, which means it acts to control any remaining cancer 
cells across the body. The two main types of adjuvant HT are aromatase inhibitors (AIs) and 
selective oestrogen receptor modulators (SERMs). SERMs work by blocking the oestrogen 
receptor and preventing oestrogen from stimulating cancer cells. The most commonly 
prescribed SERM is tamoxifen. Other SERMs such as raloxifene are used in the prevention 
of breast cancer in healthy women but are not usually used to treat the disease. AIs (i.e. 
anastrazole, letrozole, exemestane) stop the production of oestrogen in post-menopausal 
women. HT is one of the most effective systemic treatments for breast cancer and given the 
prevalence of ER+ breast cancer, researchers believe that HT has a greater global impact 
than any other treatment in cancer medicine (Aguilar et al., 2010; Sledge et al., 2014).  
1.6. Tamoxifen  
Tamoxifen is usually taken as a 20mg tablet once a day. It is converted by the liver into the 
active form hydroxytamoxifen by an enzyme called cytrochrome P450 isoenzyme 2D6 
(CYP2D6). Once converted, hydroxytamoxifen binds to the oestrogen receptor but does not 
activate the receptor and therefore does not stimulate the cells to divide and grow.  
1.6.1. Efficacy of tamoxifen  
Tamoxifen was initially synthesised as a drug for contraception before scientists realised its 
potential in breast cancer. The first trial of tamoxifen was conducted at the Christie Hospital 
in 1970 and the drug was approved in the UK in 1972. In 1998, the EBCTCG conducted a 
meta-analysis of 55 studies (n=37,000) and found that five years of adjuvant tamoxifen 
could halve the risk of recurrence in ER+ breast cancers (proportional recurrence 
reductions=47%, SD=3). This meta-analysis was updated in 2005, with results showing that 
the benefits of tamoxifen clearly persist for 15 years post diagnosis (EBCTCG, 2005). The 
most recent meta-analysis showed that for women with ER+ breast cancer, five years of 
tamoxifen could reduce breast cancer mortality by about a third (RR=0.70, p<0.001; 
EBCTCG , 2011b). Across all time periods, the reduction in rate of recurrence was about 
39% (RR=0.61, p<0.001). The benefits of tamoxifen are found regardless of age, 
menopausal status and use of chemotherapy, but are only shown in women with ER+ disease 
(EBCTCG, 1998).  
As well as being used in breast cancer survivors (BCS), tamoxifen is also licensed as a 
prophylaxis in women at high risk of developing breast cancer. The National Surgical 




effectiveness of tamoxifen at preventing breast cancer (NSABP P-1 trial). Results showed 
that the incidence of ER+ breast cancer was reduced by 57% after seven years of tamoxifen 
(Fisher et al., 2005), with an incidence rate for invasive breast cancer of 43 women per 1000 
in the placebo group and 25 per 1000 in the tamoxifen group. The International Breast 
Cancer Intervention Study 1 (IBIS-I) recruited 7154 high risk women across 9 countries and 
randomised them to five years of tamoxifen or placebo. At the 16 year follow up, the risk of 
developing breast cancer was significantly reduced in the tamoxifen group (HR=0.71, 95% 
CI=0.60-0.83, p<.001; Cuzick et al., 2015).  
Until recently, tamoxifen was the gold standard treatment for pre and post-menopausal 
women (Palmieri, Patten, Januszewski, Zucchini, & Howell, 2014). However, AIs are now 
being considered as first line treatment for post-menopausal women. Due to their mechanism 
of action, AIs can only be prescribed in post-menopausal women and therefore tamoxifen 
remains the recommended treatment in pre-menopausal women. Whilst pre-menopausal 
women produce oestrogen through their ovaries, this ceases once women reach the 
menopause. In post-menopausal women, oestrogen is still produced in other parts of the 
body, where it is converted from androgens by the enzyme aromatase. AIs work by 
preventing aromatase from converting androgens to oestrogen, and therefore lowering 
circulating oestrogen levels. They cannot be prescribed in pre-menopausal women as they do 
not stop the ovaries from producing oestrogen.  
The first trial to compare AIs with tamoxifen was the Arimidex, Tamoxifen, Alone or in 
Combination (ATAC) trial, which randomised 9366 postmenopausal women to receive 
either anastrazole or tamoxifen. Results showed anastrazole was both more effective and less 
toxic than tamoxifen (Baum et al., 2002). This trial was followed by the BIG I-98 and 
TEAM trials, which compared five years of AIs, five years of tamoxifen and a switch 
protocol (2-3 years of tamoxifen followed by 2-3 years AIs) in postmenopausal women. As 
with the ATAC study, Disease Free Survival (DFS) was higher in the AI group than the 
tamoxifen group but there was no evidence for superiority between the switch protocol and 
five years of tamoxifen (The Breast International Group 1-98 Collaborative Group, 2005; 
van de Velde et al., 2011). In a meta-analysis of almost 10,000 women, Dowsett et al. (2009) 
found that two to three years of tamoxifen followed by 2-3 years of AIs was more effective 
than five years of tamoxifen. The results of these studies have led to NICE and the American 
Society for Clinical Oncology recommending AIs as primary treatment for post-menopausal 
women (Burstein et al., 2010; NICE, 2009). Tamoxifen is recommended if AIs are not 
tolerated or are contraindicated and remains the standard of care in pre or peri-menopausal 
women. Pre or peri-menopausal women can also be offered ovarian suppression alongside 




More than half of recurrences in ER+ breast cancer occur after five years (Johnston & Yeo, 
2014) and therefore there is a need to identify ways to protect women for longer. Until 
recently, there was no indication that HT should be prescribed for longer than five years. 
This was based on the results of the Scottish Adjuvant Tamoxifen trial and the NSABP-14 
trials, which showed no additional benefit for women taking tamoxifen beyond 5 years 
(Fisher et al., 1996; Stewart, Prescott, & Forrest, 2001). However, whilst the NSABP-14 had 
a relatively large sample size (n=2892), the Scottish Adjuvant Tamoxifen trial was smaller, 
with only 342 women being randomised in the follow up study. Two recent large studies 
have challenged the assumption that there are no benefits for continuing tamoxifen treatment 
for a further five years. In the Adjuvant Tamoxifen; To Offer More? (aTTom) trial 
(n=6953), ten years of tamoxifen was associated with a 25% reduction in risk of recurrence 
and a 23% reduction in mortality (Gray et al., 2013). The Adjuvant Tamoxifen Longer 
Against Shorter (ATLAS) trial (n=6846), conducted across 36 countries, also showed 
superiority of ten years  of tamoxifen for women with ER+ breast cancer, with reductions in 
both recurrence and mortality (Davies, Pan, Godwin, Gray, & Peto, 2012). Combining the 
results of both studies shows significant reductions in mortality (RR=0.85, 95% CI=0.77-
0.94, p=.001; Palmieri et al., 2014). The results of these trials are now being translated into 
clinical practice, with pre-menopausal women being offered another five years of tamoxifen, 
or a switch to an AI, after the first five years of treatment (Burstein et al., 2014; NICE, 
2013a). Several studies have also assessed the effectiveness of extended AI treatment after 
five years of tamoxifen (Goss, 2006; Jakesz et al., 2007; Mamounas, 2001). Results show 
reduced recurrence, higher DFS and overall survival in those taking extended AIs compared 
to those taking placebo. The clear benefits of an additional 5 years of letrozole over placebo 
led to the MA.17 trial being un-blinded after 2.4 years and all patients being offered 
extended letrozole treatment (Goss et al., 2005).  
1.6.2. Side effects of tamoxifen  
Tamoxifen and AIs have similar side effects profiles, as they both work by depriving the 
body of oestrogen. However, incidence of certain side effects does differ between 
treatments. The side effects listed by drug manufacturers are shown in Table 1.4. Analysis of 
the ATAC trial showed that bone fractures were more common in the anastrazole group, 
whereas endometrial cancer was more common in the tamoxifen group (Buzdar et al., 2006). 
Vasomotor symptoms, difficulty with bladder control and gynaecological symptoms are 
more severe in patients treated with tamoxifen whereas musculoskeletal pain and vaginal 
symptoms are worse in AIs (Ganz et al., 2016). Cardiac failure and other cardiovascular 
events were higher in AIs (Cella & Fallowfield, 2008). Decreased bone density, arthralgia, 




Price, Giobbie-Hurder, Thurlimann, & Gelber, 2011). Conversely, tamoxifen exerts a 
beneficial influence on bone metabolism in post-menopausal women. However, whilst AIs 
are associated with poorer bone health, they lack the life threatening adverse events seen 
with tamoxifen, such as thromboembolic complications and endometrial cancer.  
Tamoxifen acts as an agonist in the endometrium and can therefore cause gynaecological 
symptoms such as vaginal bleeding or discharge, or increased risk of endometrial cancer 
(Blaha et al., 2009).  The endometrial cancer risk is a significant concern for patients, but is 
far outweighed by the benefits of taking tamoxifen in terms of reducing the risk of breast 
cancer recurrence. The incidence of endometrial cancer in the UK is very low to begin with: 
there were only 28 cases per 100,000 women in 2014 (Cancer Research UK, 2014b). 
Table 1.4 Side effects associated with tamoxifen and AIs 
 Side effects of tamoxifen Side effects of anastrazole (AI) 
Very common 
(may affect 
more than 1 in 
10)  
Hot flushes, vaginal 
bleeding/discharge, skin rash, nausea, 
fluid retention, tiredness  
Hot flushes, skin rash, nausea, 
headache, joint pain, arthritis, 
osteoporosis, feeling weak 
Common (may 
affect up to 1 in 
10 people) 
Anaemia, light-headedness, headache, 
hair loss, cataracts, leg cramps, muscle 
pain, genital itching, thickening of the 
womb lining, allergic reactions, blood 
clots, confusion, eye problems  
Hair loss, muscle pain, allergic 
reactions, loss of appetite, 
tiredness, vaginal dryness, 
vaginal bleeding, diarrhoea, 
vomiting, bone pain 
Uncommon 
(may affect up 
to 1 in 100) 
Cancer of the endometrium, 
pancreatitis, inflammation of the 
lungs, blood disorders  
Hepatitis, hives 
Rare (may affect 
up to 1 in 1000) 
Abnormal menstrual cycle, 
endometriosis, vaginal polyps, skin 
rashes, cancer of the womb, damage to 
nerve cells in optic nerve, liver 
disorders 
Skin rash, inflammation of 
blood vessels  
Very rare (may 
affect up to 1 in 
10,000) 
Cutaneous lupus erythematosus, skin 
blistering, thrombophlebitis 




Therefore the increased risk does not translate to large numbers of women. The increased 
risk is also only shown in post-menopausal women. The NSABP prevention trials have 
showed no statistically significant difference in endometrial cancer incidence in the 
tamoxifen or placebo groups for women aged below 50 (Fisher et al., 1998). Furthermore, in 
a recent study, tamoxifen only led to increased endometrial cancer in cases where there were 
womb abnormalities at baseline (Potkul et al., 2016). If a woman had a normal scan when 




Thromboembolic complications such as strokes, deep vein thrombosis and pulmonary 
embolisms are also more common with tamoxifen than with AIs. The ATAC trial showed 
that at 68 months, the risk of venous thromboembolic complications was elevated in the 
tamoxifen group (5%) compared to the anastrazole group (3%; Buzdar et al., 2006).  
Hot flushes and night sweats (HFNS) are a result of withdrawal of oestrogen and are 
common in both women taking AIs and women taking tamoxifen (Harris et al., 2002; Moon, 
Hunter, Moss-Morris, & Hughes, 2016).  Whilst HFNS are a symptom of the menopause 
and therefore may still occur in healthy women, women with breast cancer are five times 
more likely than age matched controls to experience these symptoms and are also more 
likely to experience longer, more frequent and more severe HFNS (Carpenter, Johnson, 
Wagner, & Andrykowski, 2002; Harris, Remington, Trentham-Dietz, Allen, & Newcomb, 
2002; Marino et al., 2014). Additionally, women who take tamoxifen are twice as likely to 
experience HFNS as other BCS and are more likely to report severe HFNS (Harris et al., 
2002; Morales et al., 2004). Many patients report weight gain whilst taking tamoxifen, but as 
several studies found no differences in weight gain between patients in the tamoxifen and 
placebo arms of trials (Day et al., 1999; Nyrop, Williams, Muss, & Shachar, 2016), it is 
unclear if weight gain is a side effect of tamoxifen treatment. Cognitive deficits, or “chemo 
brain” is a well acknowledged side effect of chemotherapy (Raffa et al., 2006), and some 
recent studies have suggested that a similar cognitive decline is also associated with 
tamoxifen treatment (Bakoyiannis, Tsigka, Perrea, & Pergialiotis, 2016; Chen et al., 2014). 
These deficits affect attention, concentration, verbal and visual memory, language and motor 
skills. However, the majority of studies investigating cognitive function in HT are 
underpowered and have flawed designs (Zwart, Terra, Linn, & Schagen, 2015) and therefore 
further research is needed to establish the effects of HT on cognitive function. Some patients 
also report low mood or changes in mood whilst taking tamoxifen (Ganz, Rowland, 
Desmond, Meyerowitz, & Wyatt, 1998; Moon et al., 2016). It is unclear if this is related 
specifically to tamoxifen or to breast cancer survivorship. Two studies have shown no 
differences in rates of depression between women taking tamoxifen and women taking a 
placebo, suggesting that tamoxifen is not associated with depressed mood (Day et al., 1999; 
Love, Cameron, Connell, & Leventhal, 1991).   
Several studies suggest that HT side effects may be valuable markers of treatment efficacy. 
Women who reported vasomotor symptoms in the ATAC trial were less likely to experience 
a recurrence (Cuzick, Sestak, Cella, Fallowfield, & Grp, 2008). In another study, hot flushes 
were a stronger predictor of breast cancer specific outcomes than age, hormone receptor 
status or stage of cancer at diagnosis (Mortimer et al., 2008). Fontein et al. (2013) found that 




women with non-specific or no adverse events. These effects may be due to CYP2D6 
activity, where side effects are an indication that the drug is being metabolised. However, 
the relationship between side effects and treatment efficacy may be driven by a common 
third factor which both increases reporting of adverse events and improves clinical outcomes 
(Pritchard, 2013). For example, women who are more focused on their health and who 
engage more in healthy behaviours, may be more likely to notice and report side effects, as 
well as being more likely to have improved clinical outcomes.  
Research with women taking HT has shown that the most bothersome side effects for 
patients are hot flushes, weight gain, insomnia and joint symptoms (Garreau, Delamelena, 
Walts, Karamlou, & Johnson, 2006). These symptoms have a negative impact on emotional, 
physical and social functioning and are associated with anxiety and sleep problems in BCS 
(Boehm et al., 2009; Garreau et al., 2006; Hunter & Chilcot, 2013). Management options for 
these symptoms are limited and physicians often underestimate the effects of symptoms on 
patients and fail to help women to manage symptoms (Fellowes, Fallowfield, Saunders, & 
Houghton, 2001; Leonard, Lee, & Harrison, 1996; van Londen et al., 2014b).  HFNS can be 
treated with HRT, but this is contraindicated in ER+ BCS due to the potential increased risk 
of breast cancer. Selective Serotonin Reuptake Inhibitors (SSRIs) can reduce hot flush 
severity, but some also interfere with the breakdown of tamoxifen. NICE recommends that 
venlaflaxine is used in the treatment of HFNS in BCS as it does not interfere with tamoxifen. 
However, many BCS are keen to avoid additional medications which likely have side effects 
and instead state a preference for natural treatments (Hunter et al., 2004). One non-
pharmacological treatment is Cognitive Behavioural Therapy (CBT) for HFNS, which is 
recommended by NICE guidelines (NICE, 2015). A six week program of group CBT has 
been proven to be effective at reducing HFNS problem rating and improving social/physical 
functioning in a large RCT of BCS (Mann et al., 2012). Management options for other 
symptoms are also lacking. There is some evidence that yoga might reduce general pain, 
muscle aches and physical discomfort in BCS taking HT, but long term follow up is needed 
to establish how long these effects last (Carson, Carson, Porter, Keefe, & Seewaldt, 2009; 
Peppone et al., 2015). To treat vaginal dryness and dyspareunia, non-hormonal lubricants 
and vaginal moisturisers can be used but oestrogen treatments should be avoided. Juraskova 
et al. (2013) have shown some promise for a treatment composed of olive oil, vaginal 
exercise and moisturiser to relieve dyspareunia and improve sexual function and Quality of 




1.7. Living with breast cancer survivorship  
1.7.1. Psychological impact  
The psychological impact of breast cancer often persists long after treatment has finished.  
Whilst patients do not tend to see themselves as still having breast cancer, the vast majority 
see themselves as survivors; a process which is seen as continuing across the lifespan 
(Bowman, Deimling, Smerglia, Sage, & Kahana, 2003; Jagielski, Hawley, Corbin, Weiss, & 
Griggs, 2012). Some BCS report feeling like they are left in an ambiguous state between 
being ill and being healthy (Powers, Gullifer, & Shaw, 2016) and others feel permanently 
“branded” by the disease (McKenzie & Crouch, 2004).  
Most women are focussed purely on survival during treatment, and the emotional impact of 
the cancer may not become apparent until remission. Feelings of uncertainty, vulnerability 
and ambivalence are common at the end of treatment (Lethborg, Kissane, Burns, & Snyder, 
2000). Support from healthcare professionals stops almost immediately after primary 
treatment in the UK, and in some cases, social support will also decrease once friends and 
family perceive things to be back to normal. Studies have shown that nearly half of patients 
experience depression or anxiety in the year after diagnosis (Burgess et al., 2005; Gold et al., 
2016) and that around 15-24% still experience these symptoms up to four years after 
diagnosis (Bleiker, Pouwer, van der Ploeg, Leer, & Ader, 2000; Burgess et al., 2005; 
Cvetković & Nenadović, 2016). This psychological distress has been shown to impact on 
clinical outcomes; after controlling for known clinical and histopathological prognostic 
factors, low distress was predictive of longer DFS and overall survival (Groenvold et al., 
2007).  
Common psychological concerns for BCS focus on dating or relationships, body image and 
sexual dysfunction (Ganz et al., 1996). However, some of these concerns, such as sexual 
dysfunction, are associated with natural ageing and are also present in healthy post-
menopausal women.  Younger women are shown to have higher levels of distress than older 
women (Costanzo et al., 2007), which may be related to concerns regarding premature 
menopause, body image and infertility (Howard-Anderson, Ganz, Bower, & Stanton, 2012).  
Another psychological concern is the fear that the cancer will return. Up to 70% of BCS 
show clinical levels of Fear of Cancer Recurrence (FCR; Thewes et al., 2012). Coping with 
this FCR is often rated as an unmet need for cancer survivors (Stanton et al., 2005) and may 
be problematic for patients. It is associated with poor QOL (Koch et al., 2014), depressive 
symptoms (Deimling, Bowman, Sterns, Wagner, & Kahana, 2006) and more intrusive 
thoughts about illness (Simard, Savard, & Ivers, 2010). FCR remains stable across the 




(Costanzo et al., 2007; Koch et al., 2014; Simard et al., 2013).  Some researchers have 
identified unhelpful meta-cognitions which are linked to FCR in younger women, such as 
negative beliefs about worry and need for control over cognition (Thewes, Bell, & Butow, 
2013). Beliefs that women hold about their illness and its treatment have also been shown to 
be associated with FCR in BCS taking HT (Corter, Findlay, Broom, Porter, & Petrie, 2013). 
As well as distress, persistent fatigue is also prevalent in BCS. Around one quarter to one 
third of BCS report fatigue at two to five years post diagnosis (Bower et al., 2006; Cella, 
Davis, Breitbart, & Curt, 2001; Servaes, Gielissen, Verhagen, & Bleijenberg, 2007). Post-
cancer fatigue is related to increased depression, pain and sleep disturbance (Bower et al., 
2000).   
However, whilst some studies indicate heightened distress in BCS, others have found no 
differences in QOL between BCS and healthy controls (Ganz et al., 1998; Helgeson & 
Tomich, 2005) or show good adjustment in BCS (Costanzo et al., 2007). Many women also 
identify positive aspects from the cancer experience (Ganz et al., 1996). For example, 
women report growing as individuals and focussing more on the things which are deemed 
important (Hodgkinson et al., 2007). Furthermore, Deimling et al. (2006) found that whilst 
one third of BCS worried about a recurrence, their QOL was not dramatically compromised 
(Deimling et al., 2006).  
1.7.2. Impact on fertility  
Some women are unable to have children after treatment for breast cancer. Chemotherapy 
can cause amenorrhoea and infertility in pre-menopausal women. This amenorrhoea may be 
permanent or may reverse after treatment. Periods are more likely to re-start in women who 
are younger (<35 years). Women who do have periods after chemotherapy are still more 
likely to experience an early menopause as a result of the treatment. It is possible for pre-
menopausal women to become pregnant whilst taking tamoxifen, as tamoxifen does not 
cause infertility, and may actually increase fertility. However, it can cause significant foetal 
abnormalities and therefore becoming pregnant whilst taking tamoxifen is not 
recommended. After tamoxifen treatment, women should be able to conceive, provided they 
have not naturally gone through the menopause during treatment.  
1.8.  Summary  
This chapter has highlighted the high prevalence of breast cancer in the UK. Three quarters 
of these breast cancers are ER+ and can be treated with HT such as tamoxifen. The research 
described above highlights the clinical importance of taking tamoxifen. The research in this 
PhD will focus on women with ER+ breast cancer who are prescribed tamoxifen. This is 




women who are at high risk of developing breast cancer. There will be a focus on women 
who are within their first two years after primary treatment, in order to investigate how 

























2. Medication adherence and persistence: theoretical perspectives and 
methodological considerations  
2.1.  Chapter overview  
This chapter will provide a brief overview of research around medication adherence. It will 
first summarise the extent and impact of non-adherence across conditions and will review 
factors associated with non-adherence. It will then review methods for measuring non-
adherence, before discussing the extent of non-adherence to tamoxifen specifically. Finally, 
two social cognition models (the Theory of Planned Behaviour and the Common Sense 
Model) will be discussed in the context of understanding medication adherence.  
2.2. Non-adherence to medications 
2.2.1. Defining non-adherence  
The terms adherence and compliance are often used interchangeably. Compliance is defined 
as “the extent to which a patient acts in accordance with the prescribed interval and dose of 
a dosing regimen” (Cramer et al., 2008, page 44). This definition assumes that the patient is 
passive and does not actively agree to the treatment recommendations. Adherence, however, 
involves the patient taking a more active role in their treatment decisions. The World Health 
Organisation (WHO) define medication non-adherence as “the extent to which a person’s 
medication taking behaviour corresponds with agreed recommendations from a health care 
provider” (Sabate, 2003, page 3). Adherence usually refers to the proportion of the 
medication the patient is taking, and non-adherence can refer to taking both more and less 
than the prescribed dosage, as well as not adhering to strict dosing and timing regimens. In 
addition to non-adherence, patients can also be non-persistent or they could not initiate 
treatment. The term non-persistence, or discontinuation, is used to describe patients who 
terminate treatment against their health care provider’s advice before the recommended 
duration. Non-initiation refers to patients who are offered a treatment but decide not to begin 
treatment.  
Non-adherence can be termed as intentional, where the patient makes a deliberate decision 
not to take their medication, or unintentional, where they may forget or not understand the 
instructions. Unintentional non-adherence tends to be reported more frequently than 
intentional non-adherence (Riegel & Dickson, 2016; Unni & Farris, 2011). However, this 
may be due to patients feeling more comfortable admitting to forgetting their medication 
than to deliberately not taking it (Atkins & Fallowfield, 2006). Furthermore, whilst 




significant overlap across the behaviours. If taking the medication is important to a patient, 
they will probably set up stringent routines in order to remember to take it (Clifford, Barber, 
& Horne, 2008). Therefore, patients who believe more strongly in the importance of their 
medication may be less likely to forget their medication as well as less likely to deliberately 
skip doses. Intentional and unintentional non-adherence are also not mutually exclusive. A 
patient could forget some doses or not follow the instructions properly, as well as 
deliberately skipping some doses to avoid side effects.  
2.2.2. Impact and rates of medication non-adherence  
Between 30% and 50% of all medication for chronic illness is not taken as prescribed 
(Sabate, 2003). Adherence in life threatening illnesses, such as cancer, is often assumed not 
to be a problem, due to the severity of the diagnosis. However, Lebovits et al. (1990) found 
that only 57% of oral chemotherapy was taken as prescribed in a sample of breast cancer 
patients. In a large review across illnesses, rates of medication non-adherence were highest 
in HIV, arthritis, gastrointestinal disorders and cancer (DiMatteo, 2004a). Optimum 
medication adherence is usually defined as 80%, but can be higher in some conditions such 
as HIV, where up to 95% is considered optimal (Osterberg & Blaschke, 2005).  
Non-adherence has strong implications for global healthcare, as poor adherence can 
dramatically reduce the effectiveness of medications. Researchers have suggested that 
increasing adherence may have a greater impact on the health of the population than 
improvements in any specific medical treatment (Haynes, McDonald, Garg & Montague, 
2002). For example, it has been estimated that better adherence to hypertension treatment 
could prevent 89,000 premature deaths a year in the US (Cutler et al., 2007). Implications of 
non-adherence include poor clinical outcomes, drug resistance and medications being 
presumed ineffective and discontinued or escalated. DiMatteo, Giordani, Lepper & Croghan 
(2002) conducted a meta-analysis of 63 studies examining the association between 
adherence to medical treatment and clinical outcomes. Results showed the odds of a good 
outcome were almost three times higher if the patient was adherent. However, the authors 
acknowledge that the studies were correlational and that there may therefore be a chance that 
instead of adherence influencing outcomes, clinical outcomes may influence adherence. 
Alternatively, both adherence and outcomes may be driven by a third variable such as life 
circumstances, personality or quality of health care.  
As well as the significant clinical impact of non-adherence, there are also more general 
economic and societal costs. Non-adherence to medications can cause disease exacerbation 
or relapse, which results in increased hospital admissions and surgeries (Goodhand et al., 




with leukaemia who took less than 85% of the recommended dose of imatinib had higher 
inpatient costs, pharmacy costs and outpatient costs. This increase in healthcare service use 
results in costs of up to $100 billion a year in the US (Coambs et al., 1995; Osterberg & 
Blaschke, 2005). As well as direct healthcare costs, there are also indirect costs of non-
adherence, such as disability payments and medically related absenteeism. For example, in 
the US, medication non-adherence in chronic conditions is associated with a higher number 
of days on short term disability or absent from work (Carls et al., 2012).   
2.2.3. Measuring non-adherence 
Medication adherence is difficult to measure and there is no gold standard measurement 
tool. One issue with assessing adherence is the Hawthorne effect, where participants may be 
more inclined to adhere if they know they are being monitored. Measurement methods tend 
to fall into two broad categories; objective measurements and subjective measurements. 
Objective measurements include biomarkers, electronic monitoring, pharmacy data and pill 
counts. Biomarkers in blood are often the most accurate way to measure if a drug has been 
ingested. However, this is a very costly method, it is intrusive to the patient, and it is not 
feasible for all medications. As tamoxifen has a long half-life (terminal elimination half-life 
5-7 days), detection of the substance is not an accurate assessment of whether it has been 
taken recently. Furthermore, tamoxifen metabolism is complex and varies across individuals, 
which limits the utility of biomarkers as a measurement of adherence (Kisanga et al., 2004).   
An alternative less obtrusive assessment is to count how many pills the patient has taken. 
One way of measuring this is using electronic monitoring, such as Medication Event 
Monitoring System (MEMS) caps, which record when the medication packet has been 
opened. However, MEMS caps only record when the medication was opened and not if it 
was actually taken. MEMS is also criticised for inducing the Hawthorne effect (Bruxvoort, 
2015; Sutton et al., 2014). Ethically, patients must be made aware that their behaviour is 
being measured. There are also practical issues with using the MEMS cap; in a study of 
Anti-Retroviral Treatment adherence, 36% of participants reported that they did not use the 
MEMS cap consistently (Bova et al., 2005). However, researchers have shown that the 
Hawthorne effect is limited to 40 days (Deschamps et al., 2006) and that the benefits of 
MEMS outweigh the drawbacks (Sutton et al., 2014).  
Prescription refill rates provide another measurement of how much medication the patient 
has taken. A medication possession ratio is calculated as the total days’ supply of medication 
dispensed divided by the number of days that the patient should be taking the medication. 
Patients are usually classed as non-adherent if they take less than 80% of the prescribed 




adherence, as < 80% adherence is associated with increased risk of mortality (Hershman et 
al., 2011). Discontinuation can be measured by identifying gaps in prescription refill rates, 
for example gaps of 30-180 days. However, prescription refill rates can only be used in 
settings where medications are covered by a single payer, and similarly to the MEMS cap, it 
isn’t possible to tell if the patient has actually ingested the medication. Another method is 
pill counts, where the patient brings their pill packet to the researcher to count how many 
pills are in the container. This is a fairly simple and unobtrusive measure. However, patients 
can bias the measure by discarding pills before their appointment if they want to appear 
adherent (Osterberg & Blaschke, 2005). Furthermore, counting inaccuracies are common 
and can result in inflated levels of adherence (Matsui et al., 1994).  
Subjective measurements include self-report measures such as questionnaires, interviews 
and diaries, which are simple, cheap and easy to administer. However, they often over-
estimate adherence rates, most likely due to the patient wanting to please the researchers or 
because they fear chastisement (Berg & Arnsten, 2006; Bruxvoort et al., 2015). Recall bias 
might also be an issue if the patient is asked to recollect their previous medication taking 
behaviour over a significant period of time. Despite these problems, significant positive 
relationships have been found between patient reported adherence and objective adherence 
measures (Atkinson et al., 2016; Fairley, Permana, & Read, 2005; Shi et al., 2010). 
Questionnaire and diary methods tend to have higher concordance with objective measures 
than interviews (Garber, Nau, Erickson, Aikens, & Lawrence, 2004; Hawkshead & Krousel-
Wood, 2007).  Non-judgemental statements are added to some questionnaires in order to 
normalise non-adherence and reduce social desirability bias. Assurance that the results will 
not be passed on to clinic staff can also reduce social desirability bias (Williams, Amico, 
Bova, & Womack, 2013). Self-report measures have the advantage of allowing researchers 
to measure both intentional and unintentional non-adherence, which is not possible with the 
objective measures described above. Furthermore, whilst self-report measures may over-
estimate adherence rates, they are likely to correctly identify those who report non-
adherence (Sabate, 2003). Medical records can also be used to measure adherence, but they 
tend to correlate poorly with more objective measures, due to Healthcare Professionals 
(HCPs) over-estimating adherence rates. In one study, providers recognised non-adherence 
for less than half of patients whose pharmacy data indicated non-adherence (Meddings, 
Kerr, Heisler, & Hofer, 2012).  
Much of the research on HT non-adherence utilises pharmacy refill rates to measure non-
adherence, although there is also a large body of research using self-report measures. A 
simple yes/no self-report measure was shown to be associated with oestrogen serum levels in 




measure of adherence. Furthermore, Atkinson et al. (2016) found positive correlations 
between objective measures and self-report in oral anti-cancer medication adherence. 
However, others studies have shown poor correlation between self-report and more objective 
measures of HT adherence. In a group of 50 women taking Aromatase Inhibitors (AIs), all 
women reported high levels of adherence and yet the prescription data showed that only 
69% of women were highly adherent (Ziller et al., 2009). Waterhouse, Calzone, Mele, and 
Brenner (1993) found self-reported adherence rates were significantly higher than those 
reported with MEMS, whilst Font et al. (2012) found low concordance between self-report, 
prescription refill rates and physician report for HT adherence.  
As described above, there are several different approaches to the measurement of non-
adherence, yet there are limitations associated with all these approaches and there is no gold 
standard measurement. Very few methods provide a completely accurate and reliable 
measurement of adherence, and the most reliable methods are costly and impractical to 
implement. The majority of research studies rely on prescription refill rates, self-report 
measures or electronic monitoring. Self-report measures are the most feasible, and whilst 
they are a subjective measure, steps can be taken to improve their reliability. These include 
using validated scales, reducing social desirability concerns, defining the adherence 
construct of interest and using optimised question response formats (Stirratt et al., 2015) 
Researchers have suggested that using multiple methods of measurement would improve 
accuracy, by overcoming some of the limitations associated with individual approaches 
(Lam & Freso, 2015; Lehmann et al., 2014; Sabate, 2003). A composite measure can also be 
created by encompassing these various measurements. This composite measure provided 
better prediction of HIV medication adherence than any individual method (Liu et al., 2001).  
Another issue with the measurement of adherence is the categorisation of non-adherence or 
non-persistence, which varies significantly across studies, as does the terminology used to 
describe behaviours. The definition of non-adherence is slightly more consistent than 
persistence, with the majority of prescription refill studies categorising women as non-
adherent if they collect prescriptions for less than 80% of their recommended doses. 
However, with self-report measures, it is not possible to obtain this information and the cut-
offs for non-adherence vary, with some studies classifying participants as non-adherent if 
they report missing one dose in a week and others if they miss one dose a month. Validated 
questionnaires help to provide consistency as they specify guidelines for scoring the 
questionnaires.  Recent efforts have been taken to obtain consensus on the terminology used 
to describe non-adherence behaviours (ABC Project Team, 2012). This consensus would aid 




2.2.4. Factors affecting medication non-adherence   
Due to the significant clinical implications of non-adherence, a large amount of research has 
been conducted with the aim of identifying determinants of medication non-adherence. Over 
700 individual factors have been investigated (Kardas, Lewek & Matyjaszczyk, 2013). The 
WHO grouped these into five main factors: 1) health system/health care professional related, 
2) condition related, 3) patient related, 4) therapy related, 5) social/economic factors (Sabate, 
2003; see Figure 2.1). They suggest that adherence is a multidimensional phenomenon 
which can be influenced by any of these factors. Health system factors include poor 
medication distribution services, short consultations and patient/physician relationship. 
Whilst there has been relatively little research investigating health system-related factors, 
some studies have investigated the effects of patient/physician relationship and physician 
communication on non-adherence. Several reviews have shown that non-adherence is 
associated with discordance between doctor and patient and poor patient physician 
communication (Jackson, Clatworthy, Robinson, & Horne, 2010; Osterberg & Blaschke, 
2005). In a meta-analysis of 127 studies, there was a 19% higher risk of treatment non-
adherence if the physician communicated poorly with the patient (Haskard Zolnierek & 
DiMatteo, 2009). Condition related factors, such as severity of symptoms or rate of disease 
progression, are not consistently related to medication adherence (Jackson et al., 2010; 
Khdour, Hawwa, Kidney, Smyth, & McElnay, 2012).  
 





















Patient related factors include the patient’s knowledge, beliefs, attitudes, expectations, mood 
or personality. A recent review found a small, positive association between health literacy 
and adherence (r=0.14; Miller, 2016). However, this relationship was strongest among non-
medication regimes. Tae et al. (2016) found limited knowledge of the prescribed regimen 
was associated with non-adherence to medication in Inflammatory Bowel Disease (IBD). 
This is supported by studies showing that educational interventions can improve medication 
adherence (Clerisme-Beaty et al., 2011; Newman-Casey, Weizer, Heisler, Lee, & Stein, 
2013). However, studies on the relationship between adherence and knowledge are often 
cross-sectional. Therefore, it is not possible to determine the direction of the relationship. 
Patients may be non-adherent because they have poor knowledge of their illness or 
treatment, or they may have poor knowledge because they are not interested in taking the 
medication. The relationship between adherence and self-efficacy is more consistent. A 
review found that of 19 studies testing a relationship between medication adherence and 
self-efficacy, 17 found a significant effect (Holmes, Hughes, & Morrison, 2014). There is 
also a fairly consistent relationship between treatment beliefs and medication adherence. 
Khdour et al. (2012) found that adherence to Chronic Obstructive Pulmonary Disorder 
medication was influenced more by patients’ perceptions of their treatment and health than 
by demographic or disease factors. A meta-analysis showed that treatment adherence was 
significantly positively associated with patients’ beliefs of the severity of their disease 
(DiMatteo, Haskard & Williams, 2007). Beliefs around medication necessity are also 
significantly associated with adherence, as are concerns about medications (Holmes et al., 
2014). However, again, the majority of this research is correlational and cause and effect 
cannot be inferred.  
Several studies have shown a link between depression and non-adherence, with depressed 
patients being up to three times more likely to be non-adherent to treatment 
recommendations (Berry, Blonquist, Hong, Halpenny, & Partridge, 2015; DiMatteo, Lepper 
& Croghan, 2000; Goodhand et al., 2013; Jackson et al., 2010; Khdour et al., 2012). 
However, Zwikker, van den Bemt, van den Ende and van Dulmen (2014a) reviewed the 
available literature on longitudinal associations between depression and medication non-
adherence, and found the cross-sectional relationship was not maintained over time, maybe 
due to the low quality of evidence. Alternatively, the authors propose that depression 
correlates with non-adherence at the time, but has no effect on later non-adherence.  
Some studies have found relationships between adherence and therapy related factors, such 
as increased number of doses per day or number of medications prescribed (Claxton, Cramer 
& Pierce, 2001; Vermiere, Heamshaw, Van Royen, & Denekens, 2001). However, in a 




related factors such as dosage, therapy duration or treatment history. Treatment side effects 
may also show an association with non-adherence, but these effects are not consistently 
found (Jackson et al., 2010; Partridge, Ades, Spicer, Englander, & Wickerham, 2007; 
Verbrugghe, Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013).  
Mixed results have been found for the effects of social or economic factors on adherence 
rates (Balkrishnan, 1998; Falagas, Zarkadoulia, & Pliatsika, 2008; Sabate, 2003). 
Demographic factors are also often found to be poor predictors of medication non-adherence 
(Greer, Pirl, Park, Lynch & Temel, 2008; Jackson et al., 2010; Vermiere et al., 2001). Some 
studies have found differences in adherence rates across different races, potentially due to 
cultural differences or social inequalities (Sabate, 2003). However, the effect between race 
and medication adherence is inconsistent (Jackson et al., 2010; Vermiere et al., 2001). Some 
studies have found that older (Verbrugghe et al., 2013) or younger age (Aggarwal & Mosca, 
2010) is associated with increased non-adherence, but overall, the results are inconsistent 
and they vary substantially across conditions (Jackson et al., 2010; Sabate, 2003; Vermiere 
et al., 2001). Social support appears to show some associations with adherence. DiMatteo 
(2004b) conducted a meta-analysis across illnesses and found significant positive 
associations between practical social support and emotional support, family cohesiveness 
and treatment adherence. The results of this meta-analysis have been supported by a recent 
review (Kardas et al., 2013). However, the majority of research in the review was cross-
sectional and there is wide variation in the definition and measurement of social support.  
Despite the vast amount of research interest, no factors have been consistently highlighted as 
predictors of medication adherence (Dunbar-Jacobs & Rohay, 2016; Vermiere et al., 2001). 
It is likely that this lack of consistency is due to the fact that predictors of adherence vary 
across conditions and treatments. Whilst there are some common factors which are related to 
adherence across conditions, such as self-efficacy or medication beliefs, there are specific 
factors relating to individual medications and conditions. For example, age may be 
particularly relevant in tamoxifen adherence, as younger women may struggle more than 
older women with symptoms associated with early menopause. Furthermore, there are issues 
associated with the measurement of adherence. Dunbar-Jacobs and Rohay (2016) found that 
predictors of adherence vary significantly depending on the method used to measure 
adherence. For example, in patients with diabetes or rheumatoid arthritis, income was 
associated with MEMS adherence but not self-report adherence; whereas comorbidities were 




2.3. Non-adherence to tamoxifen  
2.3.1. Extent of non-adherence to tamoxifen  
Systematic reviews have found adherence rates to HT ranging from 41-96% (Ayres, 
Baldoni, Borges, & Leira Pereira, 2014; Murphy, Bartholomew, Carpentier, Bluethmann, & 
Vernon, 2012). Hershman et al. (2010) analysed pharmacy records from 8769 women in the 
US and found that only half of patients took HT at the optimum schedule for the full 
duration of treatment. Kimmick et al. (2015) measured self-report HT adherence rates in 124 
women and found 34% reported intentional non-adherence and 59% reported unintentional 
non-adherence. Research suggests that HT adherence rates fall across the course of 
treatment. For example, Partridge, Wang, Winer, and Avorn (2003), Seneviratne et al. 
(2015) and Wu, Stafkey-Mailey, and Bennett (2012) found that whilst around 77% of the 
sample were adherent in the first year of treatment, this fell to around 50% by the fouth or 
fifth year. As found in most conditions, adherence tends to be highest when measured by 
self-report and lower when measured with prescription refill data (Font et al., 2012; 
Grunfeld, Hunter, Sikka, & Mittal, 2005; Kimmick et al., 2009; Simon, Latreille, Matte, 
Desjardins, & Bergeron, 2014).  
As well as high rates of non-adherence, studies also show that many women do not persist 
with HT treatment. However, the majority of studies do not measure both non-adherence and 
non-persistence, so it is not possible to determine the total proportion of women who are not 
taking their medication as prescribed. In a review of clinical trials, Chlebowski & Gellar 
(2006) found that 25% of women prematurely discontinued treatment. This estimate is likely 
higher in clinical practice, where non-persistence rates are higher than those seen in clinical 
trials (Hadji, 2010). Large studies in clinical practice have found that only 49-69% of 
women persist for the full treatment duration (Brito, Portela, & Vasconcellos, 2014b; van 
Herk-Sukel et al., 2010). The majority of studies find non-persistence rates of around 40-
50% (Hadji et al., 2013b; Makubate, Donnan, Dewar, Thompson, & McCowan, 2013; 
McCowan et al., 2008; Owusu et al., 2008), which is supported by a meta-regression of 17 
studies (Huiart, Ferdynus, & Giorgi, 2013). However, most of these studies do not have the 
information necessary to exclude patients with metastasis or patients who may have 
discontinued due to contraindications. There are a large number of reasons a patient could 
stop taking HT, and not all of these reasons should be classed as non-persistence. For 
example, a patient may have to stop treatment due to local recurrence or metastasis, or due 
to a life-threatening side effect such as thromboembolism. Alternatively, they may choose to 
stop taking it because they cannot see any benefits, or because they do not want to feel that 




that the term non-persistence should only be used when there is a chance that the outcome 
could be modified, rather than in cases where discontinuation was inevitable. The majority 
of large pharmacy refill studies have not recorded the reasons why women discontinued, and 
are therefore unable to censor women who have been recommended by their physician to 
discontinue treatment (Barron, Connolly, Bennett, Feely, & Kennedy, 2007; Hadji et al., 
2013b; Nekhlyudov, Li, Ross-Degnan, & Wagner, 2011; Ziller et al., 2009). It is likely, 
therefore, that the true incidence of non-persistence (where the outcome of non-persistence 
could have been prevented) is lower than the percentages reported in these studies. Other 
studies have attempted to censor women at time of death, BC recurrence and contralateral 
BC, but have reported unrealistically low rates of recurrence (1-5%), which may mean that 
they are not correctly identifying all patients who have had a recurrence (Hershman et al., 
2010; Huiart et al., 2013). Guth et al. (2012) only classed women as non-persistent where the 
patient had a choice about stopping treatment, and excluded women with local/systemic 
breast cancer recurrence, those who were deceased and those who had contraindications for 
HT. They found a non-persistence rate of 17% over three years. However, as this study used 
self-report data, it likely under-estimated non-persistence levels.  
One group of authors have provided non-persistence rates, as well as the non-adherence 
rates for those that persisted. Hershman et al. (2010) followed up 8769 women for 4.5 years 
and found that 2790 (32%) women discontinued treatment. Of those that continued, 28% 
were non-adherent (19% of the original total sample). These numbers show that of the 
original 8769 women, only 49% were fully adherent across the follow up period. Similar 
studies have found that 33-50% of the original sample took their medication as prescribed 
(Hershman et al., 2015; Hershman et al., 2014; Neugut et al., 2011). However, due to issues 
with classification and measurement of non-adherence/non-persistence, it is not possible to 
calculate the total proportion of non-adherent patients in many studies. For example, some 
papers on non-adherence are not clear as to whether non-persistent women were removed 
from analysis, or if they were classed as non-adherent. Others simply state that women who 
were non-persistent were removed from analysis, without providing the numbers of non-
persistent women.  
The majority of women who discontinue tamoxifen do so within the first year (Fink, 
Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004; Huiart et al., 2012; Owusu et al., 2008; 
Ziller et al., 2009). One study found that 14.5% of patients had stopped taking tamoxifen 
within 90 days (Barron et al., 2007). Therefore, it is important to intervene and reduce non-
persistence at the early stages of tamoxifen treatment. In addition to non-adherence and non-
persistence, 7-30% of women who are prescribed tamoxifen do not initiate treatment, 




increased risk of recurrence and mortality (Cluze et al., 2012; Livaudais et al., 2012). This 
rises to 50% in a low income Medicaid-insured sample, perhaps due to side effects being 
particularly hard to manage for patients who are socioeconomically vulnerable or who have 
poor access to support (Wheeler et al., 2014). Some studies have compared tamoxifen 
adherence rates to adherence rates for AIs and have found superior adherence for tamoxifen 
(Brito, Portela, & de Vasconcellos, 2014a; Chirgrin et al., 2016). However, this may be due 
to the increased familiarity for tamoxifen in the general public and may reverse as AIs are 
prescribed more frequently.  
Overall, research suggests that between 7-50% of women prescribed HT do not initiate 
treatment. Of women who have at least one prescription for HT, around 23-50% of women 
do not take it as prescribed. In addition to this, around 50% stop taking it prior to the 
prescribed duration. This suggests that a large proportion of women who could benefit from 
HT are not receiving these benefits. However, very few studies take all three behaviours into 
consideration and therefore it is not possible to get an estimate for the total proportion of 
women who are not taking HT as prescribed. Future research incorporating clear and concise 
measurements of the different behaviours would provide clear information of the scope of 
the problem.  
2.3.2. Impact of non-adherence to tamoxifen  
Non-adherence to oral cancer medications has significant implications (Hershman, 2016). 
The benefits of any medication are dramatically reduced if the drug is not taken as 
prescribed. Whilst clinical trials show substantial benefits of taking HT, these benefits may 
not be translated to clinical practice where adherence rates are much lower. Both non-
adherence and non-persistence to HT have been associated with increased mortality (Chigrin 
et al., 2016; Hershman et al., 2011; Hsieh, Chen, Cheung, Chang & Yang, 2014; Makubate 
et al., 2013; McCowan et al., 2008; Valachis et al., 2016; Winn & Dusetzina, 2016). In one 
study, women who were non-persistent with HT had an almost threefold risk of recurrence 
(OR=2.88, CI=1.11-7.46; Barron, Cahir, Sharp & Bennett, 2013). Another study found that 
early discontinuation was associated with a 26% increase in all-cause mortality, and of the 
women that continued treatment, non-adherence was associated with a 49% increase in all-
cause mortality (Hershman et al., 2011). When the cut off for non-adherence was raised 
from 80% to 90%, the detrimental effect of non-adherence on mortality was removed. This 
suggests that taking less than 80% of the prescribed dose is detrimental to survival, but that 
women taking above 80% of their medication are not at increased risk of mortality. 
However, whilst studies show an overall impact of adherence on risk of recurrence, the 




tumour related clinical characteristics. For some individuals, tamoxifen may only reduce the 
risk of recurrence by a few percentage points, but for others the impact could be much 
greater. In addition to decreased survival, low adherence is also associated with a loss of 
quality adjusted life years, increased medical costs, higher hospitalisation rates and longer 
hospital stays (McCowan et al., 2013; Partridge, 2006; Waterhouse et al., 1993). However, 
the relationship between non-adherence and survival may not be causal. It could be driven 
by variables such as negative psychological outlook or other negative health behaviours, 
which may influence both adherence and DFS (Hershman, 2016). Studies have shown that 
adherence is associated with improved clinical outcomes, even when patients are adhering to 
a placebo (Coronary Drug Project Research Group, 1980). This supports the idea that there 
may be common factors which cause patients both to adhere to treatment and to have 
improved clinical outcomes.   
2.4.  Models of non-adherence  
Social cognitive models help us to understand individual differences in health behaviour that 
demographic or clinical variables have largely failed to explain. By listing determinants of 
non-adherence which can be modified through intervention, these models also provide a 
blueprint for intervention development and enhance comparisons across studies. Previous 
interventions to improve adherence have been criticised for lacking a theoretical framework 
(Horne et al., 2005). Therefore, this PhD will use models of health behaviour as a framework 
for understanding non-adherence and to aid with development of an intervention to improve 
adherence. There are a range of social cognitive and psychological models which have been 
applied to health behaviours such as adherence. Some of the most commonly researched 
models include the Health Belief Model (HBM), the Theory of Planned Behaviour (TPB), 
the Transtheoretical Model of Change (TTM) and the Common Sense Model (CSM) 
(Holmes et al., 2014; Horne & Weinman, 1998). More recently, the COM-B model has been 
developed, but this has received less research attention. A brief overview of these models is 
provided below, followed by a detailed explanation of the models used within this thesis.  
The HBM proposes that behaviour is driven by the perceived threat, perceived barriers and 
perceived benefits associated with the behaviour, as well as the individual’s self-efficacy 
(Rosenstock, 1974). The model shows weak predictive power, mostly due to problems 
around testing the model, poor construct definition and weaknesses in predictive validity of 
the psychological components (Armitage & Connor, 2000; Harrison, Mullen & Green, 1992; 
Tanner-Smith & Brown, 2010). Several studies have shown that both the TPB and the CSM 
explain greater proportions of variance in health behaviour than the HBM (Bish, Sutton & 




The TTM is a stage based theory which suggests that individuals go through five stages of 
change before undergoing a health behaviour (Prochaska & DiClemente, 1982). The model 
has been the subject of extensive criticism (Adams & White, 2005; Armitage, 2009; West, 
2005). Whilst the TTM may be a useful tool for identifying people at risk of non-adherence, 
it doesn’t provide information for how to maintain adherence behaviours (Genberg et al., 
2013; Horne & Weinman, 1998). A review by Bridle and colleagues showed limited 
evidence for interventions based on the TTM (Bridle et al., 2005). Furthermore, NICE 
guidance has suggested that the TTM should not be used in behaviour change interventions 
as it does not explain or predict behaviour change (NICE, 2014). The COM-B is a new 
model (Michie, van Stralen, & West, 2011), which brings together a range of key variables 
across different social cognition models. However, the model includes a large number of 
constructs and there is little guidance on selecting or measuring constructs.  
Due to the criticisms associated with the models described above, it was felt that the CSM 
and the TPB had the best potential for understanding the complex behaviour of tamoxifen 
non-adherence. The decision to measure constructs from both models was based on 
suggestions from previous research stating that the use of multiple models of health 
behaviour could enhance both understanding of behaviour and effectiveness of interventions 
(Corda et al., 2010; Holmes et al., 2014; Michie et al., 2008; Nigg & Jordan, 2005). The 
CSM and the TPB appear to complement each other theoretically, as they reflect how a 
patient feels about their illness and their treatment, and how they feel about actually taking 
the medication. The models also cover some of the key elements which have been 
consistently highlighted as important determinants of non-adherence; self-efficacy, treatment 
beliefs and social support (DiMatteo, Haskard-Zolnierek & Martin, 2012; Holmes et al., 
2014; O’Carroll et al., 2011). Furthermore, interventions based on these models have shown 
some success at improving adherence (Petrie et al., 2012; O’Carroll et al., 2013; Webb & 
Sheeran, 2006).   
2.4.1. Common Sense Model of Illness Representations  
The CSM proposes that patients are active problem solvers who will try and make sense of 
and to reduce a given illness or health threat (Leventhal, Diefenbach, & Leventhal, 1992). 
The model was developed from an earlier parallel processing model of fear, showing that 
cognitive and emotional information were processed as separate but interacting systems 
(Leventhal, 1970). The CSM suggests that patients engage in a system of parallel processing 
where they deal with both the perceived reality of the health threat (cognitive level) and the 
emotional reaction to the health threat (emotional level) (Diefenbach & Leventhal, 1996; 




selecting appropriate coping strategies and appraising the success of these coping strategies. 
There is a feedback loop within the model, where information from each of these stages is 
fed back to earlier stages. In the cognitive level, patients hold implicit common sense beliefs 
about their illness. These cognitive representations reflect how people perceive, understand 
and react to threats to health, and they guide the selection of coping behaviours which will 
attempt to resolve the health threat. Leventhal et al. (1992) identified five key perceptions 
that form cognitive representations; identity, timeline, consequences, causes and cure/control 
(see Table 2.1).  
Table 2.1 Illness perceptions 
Illness perceptions defined by Leventhal et al. (1992) 
Identity The label given to the illness or symptom experiences  
Causes Beliefs around what caused the illness  
Timeline Perceived chronicity of illness 
Cure/control The extent to which the patient feels the illness can be cured 
or controlled  
Consequences Perceived consequences of the illness  
Additional illness perceptions identified by Moss-Morris et al. (2002) 
Treatment control Belief in the treatment or recommended advice 
Personal control  Belief in personal control and self-efficacy  
Timeline acute/chronic Perceived chronicity of illness 
Timeline cyclical The extent to which symptoms come and go over time  
Emotional representations Assessment of the emotional responses generated by the 
illness 
Coherence  The extent to which a patient’s illness representation 
provides a coherent understanding of the illness 
 
In parallel with cognitive processing, a health threat or illness can also evoke emotional 
reactions. For example, finding a lump might evoke strong feelings of fear and worry in 
some patients, whereas others might not have a strong emotional reaction, or may feel a 
different emotion such as anger or sadness.  These emotional responses will feed into the 
selection of coping actions, both to control the illness threat and to regulate emotions 
(Leventhal et al., 2012).  The cognitive and emotional processing arms are highly 
interactive, with emotions influencing illness cognition and vice versa (Cameron & Moss-
Morris, 2010). For example, worry can promote rumination and cause people to be 
hypervigilant to symptoms, and low mood can increase reporting of physical symptoms 
(Salovey & Birnbaum, 1989). Hagger & Orbell (2006) showed that health threats such as 
abnormal cancer screening results can cause a range of emotional responses, such as anxiety, 
distress, guilt or sadness, and that these emotional responses are related to both cognitive 
and emotional representations of the illness. However, little attention has been paid to the 




The CSM is a dynamic model and the relationships between concepts are bi-directional. A 
fundamental premise of the CSM is that selection of coping behaviours, such as visiting the 
doctor, taking aspirin or resting, will be driven by the patient’s illness representation. The 
outcomes of these coping behaviours are then appraised in terms of their success of 










For example, a patient may assume they have a mild headache and choose to drink water or 
take paracetamol to cope with the illness. If these coping strategies do not work, and the 
headache persists, the patient might modify their illness perceptions towards something 
more serious and long lasting. This may then lead to alternative coping strategies, such as 
visiting the GP. Illness representations, coping styles and appraisal can also be updated 
based on changes in somatic experiences or if the patient obtains new information, for 
example from the media or friends (Leventhal et al., 1992). As medication adherence is a 
potential coping behaviour, the CSM assumes that it should be influenced by the patient’s 
perception of their illness and whether it makes sense for them to take a medication, based 
on these perceptions (Leventhal, Phillips, & Burns, 2016).  
The CSM believes that there are several heuristics individuals use to make sense of illnesses. 
One of these is the symmetry rule, where patients expect to experience symptoms when they 
feel ill. Asymptomatic conditions such as hypertension or prophylactic medications therefore 
violate the symmetry rule. This is also likely the case in BCS taking tamoxifen, as there are 
no symptoms to be controlled. If the patient is not experiencing any symptoms, they may 
assume they are not ill. Non-adherence in these cases is a common-sense application of the 
symmetry rule (Diefenbach & Leventhal, 1996). Therefore, in chronic asymptomatic 



































than we would in illness models where the medication is actively controlling symptoms 
(Leventhal et al., 2016). This discrepancy between the acute representation and the demands 
of a chronic condition help to explain why people do not adhere to their medication.   
The Illness Perceptions Questionnaire (IPQ) was developed to measure and quantify 
cognitive representations of illness (Weinman, Petrie, Moss-Morris & Horne, 1996). It 
measures the following perceptions: identity; causes; timeline beliefs; consequences and 
cure/control. The IPQ has been used countless times to assess the impact of cognitive 
representations on a range of health outcomes (Horne & Weinman, 2002; Murphy, Dickens, 
Creed & Bernstein, 1999; Rutter & Rutter, 2002; Scharloo et al., 1998).  The questionnaire 
was revised several years later in order to improve the internal consistency of some 
subscales and to increase the scope of the measure (Moss-Morris et al., 2002). This Revised 
Illness Perceptions Questionnaire (IPQ-R) improved issues relating to the cure/control and 
timeline subscales (Table 2.1). Factor analysis showed that the cure/control dimension 
actually loaded onto two separate components; treatment control and personal control. The 
timeline scale was modified to include cyclical beliefs which were not included in the 
original scale. Finally, emotional representations and coherence were added to the 
questionnaire. Emotional representations form a key component of the CSM and yet were 
not assessed with the original IPQ. Illness coherence reflects the extent to which a patient’s 
illness representation provides a coherent understanding of the illness. The revised scale was 
validated in a sample of 711 patients across eight illness groups. It showed good internal and 
test-retest reliability and sound discriminant group and predictive validity. The authors 
recommend that the scale is modified for use in different illness contexts, due to the unique 
characteristics of different illnesses (Moss-Morris et al., 2002). A shortened eight-item IPQ 
has also been developed for clinical use (Broadbent, Petrie, Main & Weinman, 2006). Whilst 
the IPQ-R shows good psychometric properties and demonstrated relationships with various 
clinical outcomes, including survival (Chilcot, Wellsted & Farrington, 2010; French, Cooper 
& Weinman, 2006; Jopson & Moss-Morris, 2003; Mann, Ponieman, Leventhal, & Halm, 
2009; Whittaker, Kemp, & House, 2007), several issues with the measurement have been 
identified.  
Think-aloud studies have shown that patients can struggle to answer questions on the IPQs 
(McCorry, Scullion, McMurray, Houghton, & Dempster, 2013b; van Oort, Schroder, & 
French, 2011). There is a need to establish the face validity of the questionnaires before they 
are applied to different illnesses. Simply changing the word ‘illness’ to the specific illness is 
likely to be an insufficient modification (McCorry et al., 2013b). There are likely to be other 
issues with the questionnaire, such as in illnesses where patients may not have overt 




illnesses, overall scores on IPQ subscales are not sufficient for informing intervention 
development and may not be particularly informative (French &Weinman, 2008; Phillips, 
Leventhal, & Burns, 2017). The IPQ-R has also been criticised for being a static measure 
which fails to represent the dynamic nature of the CSM (Leventhal et al., 2016; Phillips et 
al., 2017). Novel approaches to assessing illness perceptions include having patients draw 
their illness (Broadbent, Petrie, Ellis, Ying, & Gamble, 2004) or using materials such as clay 
to produce a representation of their cancer (Harrow, Wells, Humphris, Taylor, &Williams, 
2008).  
Illness representations have been studied extensively as predictors of non-adherence. 
Identity (Llewelyn, Miners, Lee, Harrington, & Weinman, 2003), consequences (Brewer, 
Chapman, Brownlee, & Leventhal, 2002; Horne & Weinman, 2002), timeline (Byer & 
Myers, 2000; Van der Have, 2016), causes (Chen, Tsai, & Chou, 2011), emotional responses 
(Daleboudt, Broadbent, McQueen, & Kaptein, 2011; Patel & Taylor, 2002), treatment 
control (Searle, Noman, Thompson & Vedkara, 2007) and personal control (Ross, Walker & 
MacLeod, 2004) have all been linked with medication adherence in a range of conditions. 
From a theoretical perspective, the CSM would assume that patients who perceive more 
serious consequences from their illness would be more adherent, as they should want to 
engage in coping behaviours to reduce the consequences of their illness. This is supported in 
Ross et al. (2004) and Llewellyn et al. (2003).  However, in a study with asthma patients, 
illness consequences had a negative association with adherence (Horne & Weinman, 2002). 
This may be because patients who are adherent had better control over their illness and were 
therefore experiencing fewer symptoms. This highlights a common issue with CSM 
research; it is often not possible to determine whether the illness perceptions are influencing 
the behaviour, or if the behaviour is influencing the illness perception, both of which are 
proposed within the CSM.  
In patients with hypertension, reporting more illness-related symptoms was associated with a 
weaker sense of control over the illness, resulting in lower medication adherence (Chen et 
al., 2011). That identity was a significant predictor of adherence in an asymptomatic 
condition like hypertension highlights the importance of understanding how patients 
perceive their symptoms and shows that perceptions are often inaccurate. Personal control is 
another perception which varies across studies. Ross et al. (2004) found a negative 
relationship between personal control and adherence in patients with hypertension, perhaps 
because people who felt in control had other options for controlling their illness and were 
less likely to take medication. Conversely, Chen et al. (2011) found a positive relationship 
between personal control and adherence in another group of patients with hypertension. The 




such as household income or locus of control. These discrepancies could also be due to 
measurement error or differences in interpretation of items across illnesses.  
A recent meta-analysis reviewed the evidence for the relationship between illness 
perceptions and adherence to a range of self-management behaviours including medication 
adherence. The combined effects sizes ranged from 0.04 to 0.13, indicating weak 
relationships (Aujla et al., 2016). This supports the results of a previous meta-analysis which 
found weak relationships between illness representations and adherence, suggesting that the 
CSM is not a useful model for predicting medication adherence (Brandes & Mullan, 2014). 
However, the authors of these reviews combined results from a range of health behaviours 
(medication, diet, exercise, cholesterol control) and across a range of illnesses. The CSM 
does not presume that relationships between CSM components will be equal across different 
illnesses, individuals and coping strategies. In fact, as described above, there is evidence to 
suggest that the relationships between illness representations and adherence will differ 
significantly across contexts and conditions. Therefore, combining results across conditions 
is not an appropriate test of the CSM. Furthermore, these meta-analyses have only 
investigated illness perceptions which make up one part of the CSM, and should therefore 
not be used to discredit the model as a whole. Studies in these reviews have also been 
criticised for using static, generic measures of illness perceptions, which fail to take into 
account the unique biomedical processes and experiences associated with different illnesses 
(Phillips et al., 2017). The meta-analyses have also not included more proximal beliefs, such 
as beliefs about treatment efficacy which may show stronger relationships with adherence 
(Horne, Weinman, & Hankins, 1999; Philips et al., 2017).  
2.4.1.1. Medication beliefs  
An extended CSM has since been proposed with the addition of these medication beliefs 
(Figure 2.3), which are categorised as necessity and concern beliefs (Horne et al., 1999). 
Necessity beliefs represent the patient's perceived need for the treatment. These beliefs may 
not be synonymous with the treatment’s efficacy, but reflect how necessary the patient feels 
the medication is for them for their current and future health. Concerns include immediate 
side effects, long term effects on the body, addiction or dependence, immunity or tolerance 
and a preference for alternative medicine. Adherence is a potential strategy for coping with 
an illness threat, and whether someone chooses this strategy is likely to be influenced by 
how they perceive their medication as well as how they perceive their illness. Whilst non-
adherence to a medication might seem irrational from the HCPs perspective, to the patient, it 
likely reflects a common-sense, rational response based on their illness and treatment 




a medication, patients weigh up their concerns against how necessary they perceive the 
medication to be. This is known as the Necessity Concerns Framework (NCF).  
The Beliefs about Medicines Questionnaire (BMQ) was developed to provide measurement 
of medication beliefs (Horne et al., 1999). It consists of four subscales; General-Overuse, 
General-Harm, Specific-Necessity, Specific-Concerns. The general subscales reflect 
people’s overall views of medications in general, whereas the specific subscales are used to 
assess beliefs about a specific medication and tap into the NCF. Both necessity beliefs and 
concerns have been found to be significantly associated with medication adherence 











For example, in a longitudinal study in older adults with multiple illnesses, changes in 
intentional non-adherence were predicted by changes in necessity beliefs, after controlling 
for clinical and sociodemographic factors (Schuz et al., 2011). Phatak & Thomas (2006) 
found that medication beliefs explained 22% of the variation in non-adherence to chronic 
drug therapy. In a meta-analysis, Horne et al. (2013) found that for every one standard 
deviation increase in necessity beliefs, the odds of adherence increased by a factor of 1.7 
(95% CI=1.6-1.9), and for every one standard deviation increase in concerns, the odds of 
adherence decreased by 50% (OR=0.5, 95% CI=0.5-0.6). Medication beliefs are more 
powerful predictors of adherence than clinical or demographic factors (Horne & Weinman, 
1999). To further represent the cost-benefit analysis that patients undergo, it is possible to 
calculate a differential score between necessity and concerns, by subtracting the concerns 
score from the necessity score. This differential score, which takes into account the weighing 
Medication beliefs 































Figure 2.3 Extended Common Sense Model with addition of medication beliefs (Horne 




of concerns against perceived need, is a more consistent predictor of non-adherence than 
necessity or concerns alone (Foot, Caze, Gurjal, & Cottrell, 2016; Horne & Weinman, 
1999).  
The NCF has also been used to investigate differences between intentional and unintentional 
non-adherence. Clifford et al. (2008) found that the necessity/concerns differential was 
predictive of intentional but not unintentional non-adherence in patients with chronic 
illnesses. However, in another large cross-sectional study across illness groups, unintentional 
non-adherence was predicted by necessity beliefs (Gadkari & McHorney, 2012). This is 
likely because people who have high necessity beliefs will place high importance on making 
sure they do not forget their medication and will set reminders or implement strategies to 
help them remember. Concern beliefs have also been associated with unintentional non-
adherence (Unni & Farris, 2011). The fact that these beliefs are associated with unintentional 
non-adherence suggests that the behaviour may not be as unconscious as previously thought, 
and may be more of a motivated forgetting where patient’s beliefs about the medication 
influence how much salience they place on remembering to take it (Lehane & McCarthy, 
2007; Unni, 2008; Wroe, 2002). 
Researchers have proposed that relationships between illness perceptions and adherence may 
be mediated through treatment beliefs. In a sample of patients with asthma, the influence of 
illness perceptions on treatment adherence was found to be largely mediated by necessity 
beliefs (Horne & Weinman, 2002). Patients who have few asthma consequences and who 
perceive a short timeline were less likely to believe in the necessity of the preventer 
treatment and were therefore less adherent. Similarly, Ross et al. (2004) found that higher 
necessity beliefs were associated with perceptions that the illness would last a long time, 
stronger consequences and stronger beliefs in the likelihood of cure. Concern beliefs were 
best predicted by emotional responses, perception of consequences and age. These results 
support the assumption that medication beliefs are more proximal to adherence than illness 
beliefs (See Figure 2.3).  
Unni & Shiyanbla (2016) conducted a cluster analysis of illness and treatment beliefs in 392 
patients with asthma. They found five distinct clusters. The first two clusters resulted in 
patients being adherent. These clusters were termed “rationally accepting” and “illness 
stimulated accepting”. The other three clusters were associated with non-adherent behaviour 
and were termed “indifferent”, “ambivalent” and “sceptical”. Patients who were indifferent 
had low necessity beliefs, low concerns and low threatening illness representations (e.g. high 
control, low identity, low emotional representations). Patients who were ambivalent, 




representations (e.g. high consequences, high timeline beliefs). Finally, patients who were 
sceptical had low necessity beliefs, high concerns and high threatening illness 
representations. The differences between these three non-adherent clusters highlight how 
complex the behaviour of non-adherence is.  
2.4.1.2. Research using the CSM in breast cancer patients  
The CSM has been used as a framework for investigating a range of outcomes in oncology 
patients. For example, Thong, Kaptein, Vissers, Vreugdenhil, & van de Poll-Franse (2016) 
found that increased consequences and emotional representations were associated with 
increased odds of mortality in colorectal cancer survivors, after controlling for demographic, 
clinical and lifestyle factors. In BCS, illness perceptions have been associated with physical 
and mental health (Rozema, Vollnick, & Lechner, 2009), psychological distress (Fischer et 
al., 2013), fatigue (Corbett, Groake, Walsh, & McGuire, 2016), physical activity (Costanzo, 
Lugtendorf & Roeder, 2011), quality of life (QOL; Ashley, Marti, Jones, Velikova, & 
Wright, 2015) and fear of recurrence (Corter et al., 2013). Timmers et al. (2014) assessed 
adherence to anti-cancer agents, and found optimal adherence was associated with higher 
treatment control. In a similar study, adherence to capecitabine in cancer patients was 
associated with a range of illness perceptions (Timmers et al., 2016). However, no research 
has applied the CSM to medication adherence in BCS.  
Whilst no research has applied to the CSM to adherence in BCS, several studies have used 
the NCF, with mixed results. In a cross-sectional study of 205 BCS taking tamoxifen, lower 
scores on the necessity scale were associated with increased odds of non-adherence. No 
effects were found for concerns or for the general subscales of the BMQ (Grunfeld et al., 
2005). Arriola et al. (2014) conducted a similar study in the US, showing that necessity 
beliefs were a significant predictor of HT adherence in a multivariate regression model. 
Concern beliefs showed univariate associations with adherence but were not significant in 
the multivariate analysis when controlling for other covariates. However, these studies were 
all cross-sectional and used relatively small sample sizes. A larger study was conducted with 
2351 BCS in the US. Results showed that perceived therapy necessity was associated with 
adherence, but concerns were not (Stanton, Petrie, & Partridge, 2014). Another three studies 
found no effects of either necessity or concern beliefs on HT adherence or persistence 
(Bender et al., 2014; Friese et al., 2013; Walker, Rosenberg, Stanton, Petrie, & Partridge, 
2016). However, two of these studies had very high levels of adherence, and the others used 
non-validated measures of beliefs or adherence. Furthermore, Bender et al. (2014) used pre-
therapy measures, where patients may have not yet developed their medication beliefs. Two 




adherence (Brett et al., 2016; Bright, Petrie, Partridge, & Stanton, 2016). The results of these 
studies suggest that more research is needed to clarify the relationship between medication 
beliefs and HT non-adherence.  
2.4.2. Theory of Planned Behaviour   
The central aim of the TPB is to predict behaviour and understand its causes (Ajzen, 1991). 
The theory states that intention to perform a behaviour is the most immediate determinant of 
actual behaviour. Intention is in turn influenced by attitudes, subjective norms and perceived 
behavioural control (PBC; Figure 2.4). The theory also proposes a direct link between PBC 
and behaviour. Patients’ attitudes towards behaviours are determined by their beliefs about 
the behaviour and whether the behaviour has a favourable or unfavourable outcome.  
Subjective norms represent whether the majority of other people would approve or 
disapprove of the behaviour, or if the patient believes that other people in a similar situation 
are performing the behaviour. It also takes into consideration how important the patient 
believes it is to follow the social norms, which is referred to as their motivation to comply. 
PBC represents the individual’s perception of their ability to perform the behaviour. It has 
been argued that this is a distinct construct to self-efficacy, as self-efficacy focuses more on 
internal factors whereas PBC also takes into account more general external factors such as 
time pressures, availability of help or financial constraints (Bandura, 1992). Therefore, PBC 
can vary across different situations and actions due to the differing internal and external 
barriers. The relative importance of each TPB component in predicting intention and 
behaviour also varies across behaviours and situations (Ajzen, 1998). The TPB has its 
origins in social psychology, and whilst it has been applied to health psychology, it is most 
often used to explain preventative health behaviours such as smoking cessation, physical 
activity or alcohol use. 
Several studies have found support for the TPB in predicting a range of health behaviours. A 
meta-analytic review by Armitage & Connor (2001) found that across health behaviours, the 
average multiple correlation between intention/PBC with behaviour was 0.52 and the 
average multiple correlation of attitude, subjective norm and PBC with intention was 0.63. 
Godin & Kok (1996) reviewed the TPB across a range of health behaviours and found the 
theory could explain 41% of the variance in intention, with attitude and PBC being the most 
consistent predictors of intention. However, the model has come under significant criticism 
in recent years. In 2014, Sneihotta, Presseau and Araujo-Soares outlined key issues with the 
















They cited a recent systematic review showing that the TPB only accounted for 19% of the 
variance in health behaviour (McEachan, Conner, Taylor, & Lawton, 2011). Furthermore, it 
was found that the theory was less effective at predicting behaviour when studies were 
longitudinal, if they used objective measures of behaviour and when they used samples other 
than university students. Although the model proposes that intention is the most immediate 
determinant of behaviour, research has shown an inability of intentions to predict behaviour, 
which is known as the intention-behaviour gap. Whilst this gap can often be substantial, 
Ajzen (2011) has argued that when intention and behaviour are measured within shorter 
intervals, the intention/behaviour correlation is higher. When there are large gaps between 
measurement of intentions and behaviour, however, there is a possibility that unforeseen 
events may prevent someone from carrying out their intentions, resulting in poor correlation 
between intention and behaviour. This suggests that the TPB may be better able to predict 
treatment initiation and immediate adherence rather than longer term adherence and 
persistence.  
The theory was also criticised for its focus on rational reasoning, which ignores the role of 
emotions and unconscious influences on behaviour (Sniehotta et al., 2014). However, Ajzen 
(2015) argued that Sneihotta’s arguments were misguided and were the result of poor 
understanding of the TPB. He argued that the TPB never assumes that the individual is 
acting rationally or that their beliefs and attitudes accurately represent reality. Instead, the 
theory assumes that intention and behaviour are influenced by attitudes, subjective norm and 
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PBC, but that these factors may be based on information which is incomplete, biased or 
inaccurate, much like illness perceptions. Another criticism of the TPB is the lack of 
consideration for how demographic or personal factors might influence behaviour. Finally, 
Sniehotta et al. (2014) argued that there is a deficit of experimental tests and that the theory 
does not help with intervention development. Hardeman et al. (2002) conducted a review of 
24 studies assessing interventions based on the TPB, concluding that there was insufficient 
evidence to make assumptions on the usefulness of the theory. However, Trafimow (2014) 
pointed out that it is very hard to achieve large amounts of behaviour change, and this should 
therefore not be a specific criticism of the TPB. Implementation intentions, which tie 
specific behaviours to environmental cues, have shown promise at changing health 
behaviours by increasing the likelihood that intentions will translate into behaviour 
(O’Carroll, Chambers, Dennis, Sudlow & Johnston, 2013; Sheeran & Orbell, 2000). Conner 
(2015) argued that instead of retiring the TPB, we should focus on the contributions it 
continues to make in the health domain, and the ways in which the theory can be extended.  
Despite the criticisms associated with the TPB as a whole, a large amount of research has 
found it to be a good framework for understanding medication adherence. Bane, Hughes & 
McElnay (2006) studied medication adherence in 139 hypertensive outpatients. Regression 
analysis showed that intention and subjective norms explained 41% of the variance in 
medication adherence. Sivell, Elwyn, Edwards and Manstead (2013) found that intentions to 
undergo breast surgery were predicted by subjective norms, PBC and attitudes. In a study of 
117 South Africans with hypertension or diabetes, Kagee & van der Merwe (2006) found 
that attitudes, PBC and subjective norms accounted for 47% of the variance in intentions to 
adhere and 23% of the variance in self-reported adherence. Similar results have been found 
in medication adherence in organ transplant patients (Chisholm, Williamson, Lance, & 
Mulloy, 2007), adherence to a gluten free diet (Sainsbury & Mullan, 2011), medication 
adherence in epilepsy (Lin, Updegraff, & Pakpour, 2016), adherence to HRT (Legare et al., 
2003) and mammography uptake (Godin et al., 2001; Rutter, 2000). There are also several 
benefits to the TPB which highlight its utility for understanding medication adherence. 
Firstly, the constructs are clearly defined and the relationships between constructs are clearly 
specified. Secondly, the model comprises few concepts and therefore it is possible to test the 
full model in smaller sample sizes.  
2.4.2.1. Research using the TPB in breast cancer patients  
Whilst several studies have found the TPB to be a useful framework for understand breast 
screening behaviours and intentions (Mason & White, 2008; Rutter, 2000; Tolma, Reininger, 




study found that attitude, subjective norms and PBC explained 45% of the variance in 
intentions to exercise in a sample of BCS, and that intentions were a significant predictor of 
exercise behaviour (Blanchard, Courneya, Rodgers & Mumaghan., 2002). Similarly, 
Courneya, Friedenreich, Sela, Quinney and Rhodes (2002) found that adherence to an 
exercise program for cancer survivors was predicted by gender, extraversion, normative 
beliefs and PBC. However, in both these studies exercise was measured with self-report 
measures. Objective activity monitors may provide a more accurate assessment of exercise 
adherence. As of yet no research has used the TPB as a framework for understanding 
medication adherence in BCS.   
2.4.3. Comparison of models  
The TPB provides a useful framework for understanding medication adherence; however, it 
is still only able to account for up to 40% of the variance in intention and behaviour. 
Likewise, studies show that the CSM is only about to account for up to 27% of the variance 
in medication adherence (Chen et al., 2011; Horne & Weinman, 2002; Llewelyn et al., 
2003). Therefore, focussing solely on one model may provide insufficient explanation of 
adherence behaviour. There is considerable overlap across most models of health behaviour, 
but each model brings unique contributions, which may aid with explanation of behaviour. 
Combining the CSM and the TPB may present greater understanding of why women do not 
adhere to tamoxifen, as the benefits of one model may overcome the shortcomings of 
another. Combining these models also has the potential to enhance the effectiveness of 
interventions to improve adherence (Holmes et al., 2014; Michie et al., 2008). Whilst very 
little research has been conducted to compare models of health behaviour, several studies 
have suggested that understanding of health behaviours would be enhanced by use of both 
the CSM and the TPB (Hunter, Grunfeld, & Ramirez, 2003; Orbell, Hagger, Brown, & Tidy, 
2006; Sivell, Edwards, Elwyn, & Manstead, 2011).  
The CSM proposes that whether or not someone takes their tamoxifen is dependent on 
whether the medication taking behaviour makes sense to the patient in light of their common 
sense beliefs about their illness and treatment. If they perceive their breast cancer to be a 
serious ongoing condition, they may be more likely to take tamoxifen. If they perceive 
tamoxifen to be unnecessary for them because they do not perceive any illness threat, they 
are unlikely to take it. Conversely, the TPB proposes that adherence is motivated by how 
patients feel about actually taking the medication, whether they perceive any barriers to 
taking it and whether it is a socially acceptable behaviour. The CSM overlooks the ease or 
difficulty of actually performing the behaviour and any social norms associated with the 




about their illness or if they have concerns about the medication. There is also no assessment 
of emotion or emotional responses within the TPB. There is therefore reason to believe that 
the two theories may complement each other well in the context of medication adherence. 
Alternatively, by testing and comparing models we may be able to identify superiority of 
either the CSM/TPB at explaining tamoxifen non-adherence.   
Orbell et al. (2006) compared the CSM and the TPB in 660 patients receiving abnormal 
cervical smear test results. Hierarchal regressions showed that whilst TPB variables could 
explain 42% of the variance in intentions to attend a follow up clinic, illness perceptions 
could only explain 4%. Furthermore, when predicting actual clinic attendance, adding CSM 
variables to the demographic variables did not significantly improve the model fit, but 
adding TPB variables did. However, whilst the TPB does offer superior prediction of 
intention and completion of treatment, discriminant function analysis showed that 
consideration of both models was important in distinguishing between those who attended 
all of their appointments as scheduled after being prompted, or ceased attending. Whilst the 
CSM appears to offer little explanation of behaviour in this study, results may not be 
generalizable to a sample that have already been diagnosed with an illness and already hold 
representations of the illness. Moreover, this study did not measure treatment beliefs, which 
may have improved the predictive power of the CSM.  
In a similar study, Hunter et al. (2003) compared the CSM and the TPB in the context of 
help-seeking for breast symptoms. Five hundred women completed a questionnaire assessing 
CSM and TPB components. Results showed that illness perceptions accounted for 22% of 
the variance in help-seeking intention. Addition of TPB components significantly improved 
the model fit and explained a further 7% of variance. Significant predictors were identity, 
attitude and PBC. The two models provided lower explanation of variance than in the Orbell 
et al. (2006) study, and in contrast with the previous study, results showed that the CSM 
explained more variance than the TPB. These discrepancies may be related to the 
populations studied. In Hunter et al. (2003), women were asked about hypothetical 
symptoms and behaviour, whereas in Orbell et al. (2006), participants were already faced 
with a health threat and an associated behaviour to control the health threat. The TPB is 
therefore much more likely to be relevant in this second population, where participants may 
have already begun appraising their ability to carry out the behaviour. The healthy women in 
the breast cancer study are unlikely to have thought about the TPB variables in relation to 
this hypothetical behaviour. Furthermore, Hunter et al. (2003) did not include emotional 
representations, which may have enhanced the CSM, and found low reliability for some of 
the IPQ-R subscales. Nevertheless, both studies show that combining the CSM and the TPB 




undergo a two stage appraisal process where they evaluate the health threat (CSM), 
alongside the advantages and disadvantages of the health behaviour (TPB). This two stage 
process is likely to be relevant in tamoxifen adherence, as beliefs relating to the health threat 
and the medication efficacy may be equally as relevant as beliefs relating to the patient’s 
ability to take the medication. As described above, researchers have suggested that using 
multiple models can provide greater understanding of behaviour and is therefore likely to 
enhance effectiveness of interventions (Corda et al., 2010; Holmes et al., 2014; Michie et al., 
2008; Nigg &Jordan, 2005).  
2.5. Overview of thesis  
The current thesis aims to identify barriers associated with adherence to tamoxifen in BCS. 
Understanding tamoxifen adherence and identifying modifiable barriers to adherence will 
aid in the development of interventions to increase adherence rates, which have the potential 
to improve clinical outcomes. Chapter 3 provides the results of a systematic review which 
was conducted to examine the pre-existing literature on barriers and facilitators of HT 
adherence. Both clinical/demographic factors and modifiable psychosocial factors were 
identified. Chapter 4 presents a qualitative study which was carried out in order to gain 
understanding of what it was like for women to take tamoxifen, what motivates women to 
take it, and what factors might be associated with non-adherence or discontinuation. Non-
adherence is a complex and multi-faceted behaviour, and researchers have highlighted a 
need for more qualitative research to help understand why people do not take their 
medication and to develop interventions to increase adherence (Harrow et al., 2014; 
Verbrugghe et al., 2013).  
Previous research on tamoxifen non-adherence has focussed on clinical and demographic 
factors and has largely failed to use validated models of health behaviour as a framework for 
understanding non-adherence. These models help to identify determinants of adherence and 
provide a blueprint for intervention development. This PhD will use two models of health 
behaviour as a framework for understanding tamoxifen non-adherence; the CSM and the 
TPB. In order to measure illness perceptions, a key component of the CSM, there was a need 
to modify the existing IPQ-R in order to ensure it was relevant and applicable to BCS. The 
modification and validation of this questionnaire is presented in Chapter 5. Chapter 6 
presents a large cross-sectional study carried out to identify factors associated with 
tamoxifen non-adherence and to test the utility of the CSM and TPB at explaining non-




Chapter 7 presents cross-sectional analysis exploring the experience and attribution of 
menopausal symptoms of women taking tamoxifen. This analysis helps to provide context 
for what it is like for women to take tamoxifen, and helps to explain why women might 
become non-adherent. As a limitation with previous work using the CSM and TPB is the 
lack of prospective data, Chapter 8 provides a longitudinal analysis of predictors of 
tamoxifen non-adherence. This will identify if the predictors of non-adherence identified in 
the cross-sectional analysis will also predict later non-adherence. Women in their first year 
of treatment were followed up at three time points to examine how adherence changes over 
time and to identify predictors of change over time. As the CSM is a dynamic model which 
proposes that illness representations and coping styles will be adjusted over time, changes in 
psychological variables over time were also examined. At the time of writing the thesis, no 
studies have designed interventions to improve tamoxifen adherence, despite the high 
prevalence and clinical importance of non-adherence. Chapter 9 describes the development 
of a self-management intervention for women taking tamoxifen. The intervention was 
informed by the results of the previous studies to help support women with their tamoxifen 
treatment, with the aim of improving adherence rates. Feasibility and acceptability of this 
intervention is described in Chapter 10. Finally, an overall discussion of the thesis is 
















3. Systematic Review of barriers and facilitators of hormone therapy 
adherence and persistence 
3.1.  Chapter overview  
The previous chapter has shown that tamoxifen non-adherence is an issue of significant 
clinical importance. Therefore, there is a need to understand non-adherence further and to 
identity factors which may be associated with non-adherence. This current chapter describes 
a systematic review of barriers and facilitators to Hormone Therapy (HT) adherence and 
persistence. This review was a vital step in meeting the aims of the PhD and informing the 
remaining body of research. The aims of the systematic review were to identify factors 
related to HT adherence or persistence, including clinical or demographic factors as well as 
modifiable psychosocial factors. The results of this review will help to inform the qualitative 
study by highlighting any areas where more in-depth investigation may be needed, such as 
the relationship between side effects and adherence. It will also inform the longitudinal 
study by identifying which measures have been validated in this population, if there are any 
gaps in the literature and if there are any promising results which warrant further 
investigation. The review will also inform the intervention development by highlighting if 

















3.2. Published paper  
This chapter is published in the following article: 
Moon, Z., Moss-Morris, R., Hunter, M. S., Carlisle, S., & Hughes, L. D. (2017). Barriers 
and facilitators of adjuvant hormone therapy adherence and persistence in women with 
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Barriers and facilitators of adjuvant hormone therapy adherence and persistence in 
women with breast cancer: a systematic review 
Purpose: Nonadherence to hormone therapy in breast cancer survivors is common and 
associated with increased risk of mortality. Consistent predictors of nonadherence and 
nonpersistence are yet to be identified, and little research has examined psychosocial factors 
that may be amenable to change through intervention. This review aimed to identify 
predictors of nonadherence and nonpersistence to hormone therapy in breast cancer 
survivors in order to inform development of an intervention to increase adherence rates. 
Methods: Studies published up to April 2016 were identified through MEDLINE, Embase, 
Web of Science, PsycINFO, CINAHL and gray literature. Studies published in English 
measuring associations between adherence or persistence and any predictor variables were 
included. Eligible studies were assessed for methodological quality, data were extracted and 
a narrative synthesis was conducted. 
Results: Sixty-one eligible articles were identified. Most studies focused on clinical and 
demographic factors with inconsistent results. Some evidence suggested that receiving 
specialist care and social support were related to increased persistence, younger age and 
increased number of hospitalizations were associated with nonadherence, and good patient–
physician relationship and self-efficacy for taking medication were associated with better 
adherence. A small amount of evidence suggested that medication beliefs were associated 
with adherence, but more high-quality research is needed to confirm this. 
Conclusion: Some psychosocial variables were associated with better adherence and persis-
tence, but the results are currently tentative. Future high-quality research should be carried 
out to identify psychosocial determinants of nonadherence or nonpersistence that are 
modifiable through intervention. 
Keywords: breast cancer, adherence, persistence, hormone therapy 
 
Introduction 
Breast cancer is the most common cancer in the UK, with 150 women being diagnosed 
every day.
1
 Three quarters of breast cancers contain receptors for estrogen and are known as 
estrogen receptor positive (ER+). While breast cancer survival rates are increasing, it is still 
the second most common cause of death from cancer in women.
1
 To increase survival rates 
and reduce the risk of recurrence, many women with ER+ breast cancer are prescribed 
hormone therapy (HT), such as tamoxifen, or aromatase inhibitors (AIs), which block the 
effects of estrogen on cancer cells. Five to ten years of HT significantly reduces rates of 






significant clinical benefits, many women do not take HT as prescribed, which leads to a 
significantly increased risk of mortality and recurrence.
4–6
 
Adherence to tamoxifen and AIs ranges from 65% to 79% and 72% to 80%, respectively, 
but falls over the course of treatment to ~50% by the fourth or fifth year.
7–9
 Furthermore, 
half of patients discontinue HT by 5 years,
10,11
 suggesting that a significant proportion of 
patients are not receiving the full clinical benefits of HT. An understanding of the 
mechanisms behind nonadherence would facilitate development of effective interventions, 
with a view to improving adherence and ultimately increasing the survival benefits 
associated with HT. Clinical and demographic factors may be useful as identifiable risk 
factors but cannot be modified through intervention. Psychosocial factors, however, are 
typically modifiable and are highly suitable targets for intervention. For example, illness and 
medication perceptions, such as necessity and concern beliefs, are predictive of adherence in 
other illnesses
12,13
 and have been successfully modified.
14,15
 
A previous review of HT adherence and persistence concluded that little was known about 
the impact of clinical, demographic, or psychological factors and highlighted a need to 
research modifiable factors.
16
 A significant amount of research has been published since 
2012, warranting an up-to-date review. In 2015, Cahir et al
17
 carried out a systematic review 
of modifiable determinants of adherence with a view to developing behavioral interventions. 
Although the review was useful, there were several limitations, which are addressed by the 
current review. First, the main conclusions were that side effects, the number of prescription 
medications and the type of practitioner (general practitioner [GP] vs oncologist) influenced 
HT adherence or persistence. These factors are mostly not suitable for behavior change 
intervention. A more targeted review of modifiable psychosocial predictors would provide 
further guidance for the development of an intervention. Second, as gray literature databases 
and conference abstracts were not included in the search, some key studies are missing from 
Cahir et al’s review. Finally, the authors conducted a meta-analysis, but due to significant 
heterogeneity, only a very small proportion of studies could be included, limiting the value 
of the results. For example, although 13 studies investigated the effects of the number of 
prescription medications, only four studies were eligible for the meta-analysis. Therefore, a 
narrative synthesis may be more appropriate. Van Liew et al
18
 conducted a narrative 
synthesis concluding that social support, patient-centered interactions, anxiety and 
medication beliefs were reliably associated with adherence or persistence. However, this 
review conducted a limited search of only two databases and may have missed some 
important eligible studies. Furthermore, empirical interest in this area is growing and a 





The current review aims to build upon and address limitations in the previous reviews and 
identify factors related to HT adherence or persistence by: 
(1) conducting an updated and broader search to ensure that all relevant articles are 
identified; 
(2) searching gray literature databases to identify unpublished literature; 
(3) combining modifiable psychosocial factors with demographic, clinical and health 
care factors to provide a comprehensive overview of nonadherence and 
nonpersistence in this population; and 
(4) conducting a narrative synthesis as opposed to a meta-analysis, due to the 
anticipated significant heterogeneity within the included studies. 
Methods 
Search strategy 
The review was conducted in accordance with PRISMA guidelines.
19
 The following 
databases were searched from inception to April 2016: MEDLINE, Embase, Web of 
Science; PsycINFO and CINAHL. Search terms included a combination of terms related to, 
1) breast cancer, 2) nonadherence or nonpersistence, and 3) HT. Specific search terms are 
listed in Table S1 (Appendix A). Reference lists of included articles were screened, and gray 
literature databases were searched. 
Study selection 
Inclusion/exclusion criteria are shown in Table 1. Participants had to be female, >18 years of 
age and prescribed adjuvant HT for primary breast cancer. Studies had to be conducted in 
clinical practice, as adherence rates are often higher in clinical trials.
20
 After removing 
duplicates, one author (ZM) screened titles and abstracts and excluded irrelevant articles. 
Full texts were then screened for inclusion by two authors (ZM and SC) using a predefined 
screening table, and one disagreement was resolved. Authors of conference abstracts were 
contacted to identify unpublished articles, and two authors responded with the full-text 
articles. 
Data extraction 
Information was extracted on study design, participant characteristics, adherence 
measurement, outcome measures and study results. Data were extracted by one researcher. 
Another researcher independently extracted data from 10% of articles, and there were no 
disagreements. 
Quality assessment (QA) 
The QA tool was adapted from Pasma et al
21
 based on recommendations from Sanderson et 
al.
22
 Studies were assessed on methods for selecting study participants and measuring study 




initiated nonadherence (eg, due to contraindications). Studies scored 1 if they met each 
criterion and 0 if it was not met or was unclear. The proportion of criteria met was indicated 
by a percentage, as some criteria were not applicable for all articles. One author (ZM) con-
ducted QA, and another author (SC) verified a random subset of 10% of articles. An 
additional author (LDH) resolved one discrepancy. 
Results 
A total of 6,140 articles were identified, and after removing duplicates and screening titles 
and abstracts, 120 full-text articles were screened. Sixty-one articles were included in the 
review (Figure 1). There was heterogeneity between studies in terms of outcome measures, 
type of effect sizes, definitions of adherence and predictor variables. It is, therefore, 
inappropriate to conduct a meta-analysis. 
Characteristics of studies 
The majority of studies were conducted in North America (n=34) and Europe (n=17; Table 
2). The mean sample size was 3,042 (range 82–26,179), and there were 181,793 unique 
participants. Two studies included data analyzed from the same sample.
23,24 
One study was a 
follow-up analysis
25
 using the same sample as a previous study.
26
 All studies were included 
in the review. Studies were cross-sectional (n=16), retrospective (n=32) and longitudinal 
(n=13). Average follow-up for retrospective and longitudinal studies was 3.1 years (SD 
=1.4) and 2.7 years (SD =1.4), respectively. Twelve studies included patients prescribed 
tamoxifen, seven studies included patients prescribed AIs and 42 studies included patients 
on either therapy. Studies measured nonadherence (n=25), discontinuation/nonpersistence 
(n=29), or both (n=6). 
Table 1. Inclusion and exclusion criteria for studies in the review  
Inclusion criteria Exclusion criteria 
Patients were all female and aged > 18 years Articles not in the English language or where 
the full text was not available  
Patients had been prescribed adjuvant HT to 
treat primary breast cancer 
Studies including only DCIS or Stage IV 
patients 
Studies had to be conducted in clinical 
practice 
Studies using an intervention to improve 
adherence 
Studies had to present statistical tests of 
association between HT adherence or 
persistence and a correlate or predictor.  
Studies investigating initiation to HT 
 Studies not providing primary data  









































Figure 1. Flow diagram showing results of search strategy.   
Abbreviations: HT, Hormone therapy. SSRN, social science research network. 
Number left to screen on full text 
N = 120 
Duplicates 
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N = 2381 
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N = 3760 
Records 
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Does not fit 
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N = 12 
Conference 
abstracts (full text 
not received) 
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Not available in 
English language: 
N = 1  
Eligible for review 
























Identified through database screening 
Databases: Medline, Embase, PsycINFO, 
CINAHL, Web of Science 
N = 5986 
Grey literature: Opengrey, Healthcare 
Management Information Consortium and SSRN, 
WorldCat Dissertations, British Library eThos 
site 
N = 154 
Total: 6140 
Identified through reference 
screening  




One study measured interruption, defined as a 60-day gap in treatment. Measurements 
included Medication Event Monitoring System (MEMS; n=2), medical records (n=4), 
prescription records (n=27), self-report (n=21) and a combination of measures (n=7). Of the 
studies using self-report, only six studies used validated measures. Nonpersistence was 
defined as gaps in treatment of 45 days (n=3), 60 days (n=8), 90 days (n=2) and 180 days 
(n=6). 
Risk of bias in included studies 
The average quality score was 74%, ranging from 33% to 100% (Table 3). The majority of 
studies were of moderate quality, but there were eleven low- (<50%) and 22 high-quality 
(>80%) studies. Several studies using self-report data had a risk of selection bias, and some 
studies failed to use validated measures (Table 3). Only one-third of the studies removed 
women from analysis who had had a recurrence or died and, therefore, were no longer 
prescribed HT. 
Summary of results 
The percentage of women categorized as adherent ranged from 47% to 97% (mean=74%, 
SD=13%) and fell from an average of 79% in the first year of treatment to 56% in the fourth 
or fifth year. Studies using MEMS found the highest adherence rate (93%), followed by self-
report (82%) and prescription refill rates (75%). Unintentional nonadherence (e.g., 
forgetting) was specifically measured in three studies and was found to be more common 
than intentional nonadherence (mean =31% vs 15%).
27–29
 Discontinuation ranged from 9% to 
63% (mean =30%, SD =12%). Discontinuation rose from an average of 21% in the first year 
to 48% in the fifth year. Rates of discontinuation were similar across different measurements 
(prescription refill, self-report and medical records). In some studies, nonpersistence and 
nonadherence are clearly separated, making it possible to combine the nonpersistence rates 
(23%–32%) with the nonadherence rates (9%–28%) to calculate the total proportion of the 
original sample who are not taking their medication as prescribed. In these studies, this 
amounts to 33%–50% across 2–4 years of treatment, which highlights the extent of the 
problem of nonadherence in this population.
8,30–32
 However, it is not possible to calculate this 




























693 (598) US 52+ 90% Caucasian, Stage I-
IIB, post-menopausal 
AIs / TAM Non-persistence (no 
longer using drug at 
5 years) 
Self-report 






2816 (2346) Ireland 35+ Recruited at initiation of 
therapy 
TAM Non-persistence 










91 US 57 88% Caucasian, Stage I-
IIIa, ER+, recruited at 
initiation of therapy 
AIs / TAM Adherence (% 
MPR) 
MEMS 






381 (197) US < 80 72% Caucasian, Stage I-III 
ER+ 
AIs / TAM Persistence (5 years 
of therapy) 
Self-report 





e (3.3 years) 
5861 (5861) Brazil 58 Stage I-IV AIs / TAM 
(64% TAM) 
Non-adherence 
(MPR < 80%) 
Prescription refill 
data 





e (5 years) 
5861 (5861) Brazil 58 Stage I-IV AIs / TAM 
(64% TAM) 
Non-persistence (60 
days no supply) 
Prescription refill 
data 





e (3 years) 
5150 (5150) US 76 88% Caucasian, Medicare 
beneficiaries 












218 (196) France 18 – 40 Stage I-III, pre-menopausal, 
HR+, recruited at initiation 
of therapy 
TAM Interruptions (2+ 







125 (120) NZ 56 Stage I-II, HR+ AIs / TAM 
(74% TAM) 
Adherence (never 







e (2 years) 
346 (346) Canada n/s Stage I-III, HR+  AIs / TAM 
(81% TAM) 
Non-persistence (no 





























303 (292) n/s 55+ Stage I  - II, 76% ER+, 
 recruited at initiation of 
therapy 





Fink et al.  (2004)
26
  Longitudinal  
 (2 years) 
690 (516) US 65+ Stage I-IIIa, ER+, 
recruited at initiation of 
therapy 
TAM Non-persistence (no 
longer taking 
tamoxifen) 
Telephone interview  
Font et al. (2012)
38
 Retrospectiv
e (5 years) 
692 (692) Spain n/s Stage I-IIIa, HR+, recruited 
at initiation of therapy 















3133 (539) US 59 48% Caucasian, Stage I – 
III, HR+, recruited at 
initiation of therapy 
HT Persistence (taken 
medication in past 
week) 
Self-report 






116 (110) UK 35 – 65 93% Caucasian TAM Adherence (taken 
drugs every day in 
past week) 
Self-report 
Guth et al. (2012)
53
 Retrospectiv
e (3 years) 
685 (677) Switzerla
nd 
30 – 80 Stage I-III, HR+ AIs / TAM 
(69% TAM) 
Non-persistence 
(did not complete 
therapy) 
Medical records 





e (3 years) 
12,412 
(12,412) 
Germany 64 Post-menopausal, HR+,  
recruited at initiation of 
therapy 
AIs / TAM 
(59% TAM) 
Non-persistence (90 
days no supply) 
Prescription refill 
data 
He et al. (2015)
62
 Retrospectiv
e (5 years) 


































e (4.5 years) 
8769 (8769) US n/s 76% Caucasian 
Stage I-III HR+  
 
AIs / TAM Non-adherence 
(MPR < 80%) and 
Non-persistence 









e (2 years) 
4426 (4426) US 50 + 60% Caucasian 
Stage I – III 
AIs Non-persistence 
(gap of 45 days) 
and adherence 
(MPR > 80%) 
Prescription refill 
data 





e (2 years) 
10,302 
(10,302) 
US 61 79% Caucasian, Stage I – 
III 
HT Non-adherence 
(MPR < 80%), non-









e (4 years) 
26,179 
(26,179) 
Taiwan 52 n/s AIs / TAM 
(70% TAM) 
Non-adherence 
(MPR < 80%) 
Prescription refill 
data 






288 (246) France 18-40 Stage I-III, recruited at 
initiation of therapy 
TAM Non-persistence (90 
days no supply) 
Prescription refill 
data 





e (3 years) 
382 (233) France 65+ Stage I-III, post-
menopausal, recruited at 
initiation of therapy 
AIs Non-persistence (90 
days no supply) 
Prescription refill 
data 






206 (200) US 59 55% Caucasian, Stage I-IV 
HR+  
AIs / TAM Adherence (range 
of scores 0-10) 
Self-report (MARS) 




881 (881) US 21 – 80 85% Caucasian, Stage I-III,  








288 (138) US 40 – 79  90% Caucasian AIs Adherence (range 
of scores 0 - 8) 
Self-report 
(MMAS) 





e (5 years) 
1531 (1531) Australia 45+ n/s AIs / TAM 
(60% TAM) 
Non- persistence 





























e (1 year) 
1491 (951) US 67 59% Caucasian, Stage I-III, 
HR+/unknown,  
recruited at initiation of 
therapy 
AIs / TAM 
(88% TAM) 
Adherence (MPR > 
80%) and 
Persistence (no 










124 (112) US 64 91% Caucasian, Post-
menopausal, HR+, Stage I – 
III,  












e (3 years) 
3620 (3620) Germany 60 
 
Recruited at initiation of 
therapy 
TAM Non-persistence (90 
days no supply) 
Prescription refill 
data 





e (3 years) 
3424 (3424) Germany 61 n/s AIs / TAM 
(61% TAM) 
Non-persistence 









e (5 years) 
3180 (3180) Canada  70 + 
 
Treated with BCS (no 
chemo / mastectomy) 
AIs / TAM 
(81% TAM) 
Non-persistence (60 






e (5 years) 






Lash et al. (2006)
25
 Longitudinal  
 (5 years) 
462 (462) US 65+ Stage I-IIIA, 87% ER+,  






Lee et al. (2014)33  Retrospectiv
e (2 years) 
609 (609) Seoul  54 Asian women, 89% ER+, 
no metastasis 
AIs  Adherence (no gaps 
of over 60 days and 
MPR > 80%) 
Prescription refill 
data  
Liu et al. (2013)
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  Longitudinal  
 (3 years) 
921 (669) US 51 34% Caucasian, Stage I-III, 
Newly diagnosed  
HT Persistence 
(hormone use) 













































3575 (3575) US 69 92% Caucasian, post-




long taking the 
medication)  
Self-report  






515 (515) US < 45  71% Caucasian, Stage I – 
III, HR+, premenopausal,  
TAM Non-persistence (no 
longer taking 
medication) 
Chart review  





e (3 years) 
2207 (2207) US 18+ Stage I-III TAM /AIs Non-persistence 









e (1 year) 
22160 
(22160) 
US 67 90% Caucasian, 
Stage I-III 
AIs Non-adherence 
(MPR <80%) and 
Non-persistence (45 
days no supply) 
Prescription refill 
data 





 (5 years) 
961 (961) US 65+ 80% Caucasian, Stage I-
IIB, ER+ / indeterminate, 
newly diagnosed 
TAM Non-persistence (60 
days no supply) 
Medical records 





e (4 years) 
2378 (2378) US 75 83% Caucasian, Stage I-III, 






Riley et al. (2011)
52
  Retrospectiv
e (1 year) 
9446 (9446) US 65+ 81% Caucasian, Stage I-III, 









e (1 year) 
4626 (4626) Germany n/s Stage I-IV 
post-menopausal HR+ 











129 (129) US 64 81% Caucasian, Stage I – 
IIA, Node negative 
AIs Adherence (how 
many days taken it / 
discontinued) 
Self-report 





e (1 year) 
13593 
(13593) 
US <65 Post-menopausal, recruited 
at initiation of therapy 
AIs Non-adherence 



























e (4 years) 
1149 (1149) New 
Zealand 
60 (24 -99) 80% NZ European, Stage I-
III, HR+, newly diagnosed 
AIs / TAM 
(58% AI) 
Non-adherence 
(MPR < 80%) 
Prescription refill 
data 





 (3 years) 
1062 (1062) US 65+ 89% Caucasian, Stage I-III, 
ER+, recruited at initiation 










176 (161) Canada 57 ER+ AIs / TAM Adherence (MPR > 
80%) 
Interview questions 






2341 (1465) US 56 Stage I-IV,  94% Caucasian, 
HR+  
 
















medication at least 
4 times in past 
month) 
Self-report 
Trabulsi et al. 
(2014)
36
   
Retrospectiv
e (5 years) 
4715 (4715) Canada 65+ Stage I-III,  recruited at 
initiation of therapy 
AIs / TAM 
(95% TAM) 
Non-persistence (60 
days no supply) 
Prescription refill 
data 





e (5 years) 
1451 (1451) Nether-
lands 
n/s Stage I-III  77% HR+ 
recruited at initiation of 
therapy 
TAM / AIs Non-persistence (60 
day no supply) 
Prescription refill 
data 






82 (82) US 39 (22-45) 90% Caucasian, Stage 0-IV, 
diagnosed < 40, HR+, 
TAM / AIs 
(89% TAM) 
Non-adherence 
(score 7+ on 
MMAS) 
MMAS  





 (6 months) 
198 (198) Pitts-
burgh 
59 98% Caucasian, Stage I-III, 
recruited at initiation of 
therapy  
AIs / TAM 
(15% TAM) 
Non-adherence 





e (3 years) 
2071 (1741) Sweden n/s Stage I-III, ER+, recruited 
at initiation of therapy 








































Wu et al. (2012)
58
  Retrospectiv
e (4 years) 
612 (331) US 62 41% Caucasian, Stage I-III, 
HR+/unknown, recruited at 
initiation of therapy 
AIs / TAM 
(45% TAM) 









e (1 year) 
100 (89) Germany 68 Post-menopausal, recruited 
at initiation of therapy 
AIs / TAM 
(50% TAM) 










139 (139) Egypt 50 Stage I-I, HR+, during 
Ramadan 




Interview questions  
Abbreviations: AIs, aromatase inhibitors; BCS, breast-conserving surgery; ER+, estrogen receptor positive; HR+, hormone receptor positive; HT, hormone therapy; MARS, 
Medication Adherence Rating Scale; MMS, Medication Monitoring System; MMAS, Morisky Medication Adherence Scale; MPR, medication possession ratio; n/s, not 






Table 3. Quality Assessment 
 A B C D E F G H I PERCENTAGE 
Aiello Bowles et al. (2012) 1 1 1 1 0 1 1 0 n/a 75% 
Barron et al. (2007) 0 1 1 1 1 1 1 0 1 78% 
Bender et al. (2014) 1 0 1 1 0 1 1 0 0 56% 
Bhatta et al. (2013) 1 1 0 0 1 0 1 0 n/a 50% 
Brito et al. (2014a) 1 1 1 1 1 1 1 0 0 78% 
Brito et al. (2014b) 1 1 1 1 1 1 1 0 1 89% 
Cheung et al. (2015) 1 1 1 1 1 1 1 1 1 100% 
Cluze et al. (2012) 1 0 1 0 1 1 1 1 1 78% 
Corter (2013) 1 1 0 1 1 1 1 0 1 78% 
Danilak & Chambers (2013) 1 1 1 1 1 1 1 0 1 89% 
Demissie et al.(2001) 1 1 0 1 1 1 1 1 0 78% 
Fink et al. (2004) 1 0 1 0 1 1 1 0 1 67% 
Font et al. (2012) 1 1 1 1 1 1 1 1 0 89% 
Friese et al. (2013) 1 1 0 1 1 1 1 1 1 89% 
Grunfeld et al. (2005) 0 0 1 1 0 0 1 0 n/a 38% 
Guth et al. (2012) 1 1 0 1 1 1 1 1 1 89% 
Hadji et al. (2013) 1 1 1 1 1 1 1 0 0 78% 
He et al. (2015) 1 1 1 1 1 1 1 1 1 100% 
Hershman et al. (2010) 1 1 1 1 1 1 1 1 1 100% 
Hershman et al. (2014) 0 1 1 1 1 1 1 0 0 67% 
Hershman et al. (2015) 1 1 1 1 1 1 1 0 1 89% 
Hsieh et al. (2015) 1 1 1 1 1 1 1 0 1 89% 
Huiart et al. (2012) 1 1 1 1 1 1 1 1 1 100% 
Huiart et al. (2013) 1 1 1 1 1 1 1 1 0 89% 
Jacob Arriola et al. (2014) 1 0 1 1 1 1 1 1 0 78% 
Kahn et al. (2007) 1 0 0 0 1 1 1 1 n/a 63% 
Karmakar (2013) 1 0 1 1 0 1 1 1 n/a 75% 
Kemp et al. (2014) 1 1 1 1 1 1 1 1 1 100% 
Kimmick et al. (2009) 1 1 1 1 1 1 1 0 1 89% 
Kimmick et al. (2015) 1 1 1 1 1 1 1 0 1 89% 
Kostev et al. (2013) 1 1 0 1 1 1 1 0 0 67% 
Kostev et al. (2014) 0 1 0 1 1 1 1 0 0 56% 




 A B C D E F G H I PERCENTAGE 
Kuba et al. (2016) 1 1 0 1 0 0 1 0 0 44% 
Lash et al. (2006) 1 0 0 0 1 1 1 0 0 44% 
Lee et al. (2014) 1 1 1 1 1 1 1 1 1 100% 
Liu et al. (2013) 1 0 0 1 1 0 1 0 0 44% 
Livaudais et al. (2012) 1 1 0 1 1 1 1 0 n/a 75% 
Llarena et al. (2015) 1 1 1 1 1 1 1 1 n/a 100% 
Nekhlyudov et al. (2011) 1 1 1 1 1 1 1 0 0 78% 
Neugut et al. (2011) 1 1 1 1 1 1 1 1 1 100% 
Owusu et al. (2008) 1 1 0 1 1 1 1 1 0 78% 
Partridge et al. (2003) 1 1 1 1 1 1 1 1 1 100% 
Riley et al. (2011) 1 1 1 1 1 1 1 0 0 78% 
Schmidt et al. (2014) 1 1 0 1 1 1 1 0 0 67% 
Schover et al. (2014) 0 1 0 1 0 1 0 0 n/a 38% 
Sedjo & Devine (2011) 1 1 1 1 1 1 1 0 0 78% 
Seneviratne et al. (2015) 1 1 1 1 1 1 1 0 0 78% 
Sheppard et al. (2014) 1 1 0 1 1 1 1 1 0 78% 
Simon et al. (2014) 1 0 1 1 1 1 1 0 n/a 75% 
Stanton et al. (2014) 1 0 1 1 1 1 1 0 n/a 75% 
Tinari et al. (2015) 0 1 0 0 1 1 1 0 n/a 50% 
Trabulsi et al. (2014) 1 1 1 1 1 1 1 1 0 89% 
Van Herk-Sukel et al. (2010) 1 1 1 1 1 1 1 1 1 100% 
Walker et al. (2016) 1 0 1 0 0 1 0 1 n/a 50%  
Wickersham et al. (2013) 1 0 1 1 1 1 1 0 0 67% 
Wigertz et al. (2012) 1 1 1 1 1 1 1 0 1 89% 
Wouters et al. (2014) 0 0 1 0 1 1 1 0 n/a 50% 
Wu et al. (2012) 1 1 1 1 1 1 1 0 0 78% 
Ziller et al. (2009) 1 0 1 1 0 1 0 0 0 44% 
Zeeneldin et al. (2012) 1 0 0 1 0 0 1 0 n/a 38% 
Notes: A: Are the main features of the study population described? B: Is participation .80% or 60%–
80% with no difference between responders and nonresponders? C: Is adherence measured 
appropriately and clearly described? D: Are other outcome variables measured appropriately? E: Did 
the analysis control for confounding? F: Are quantitative measures of association presented? G: Was 
the number of cases in the multivariate analysis at least ten times the number of independent variables 
in the final model? H: Was physician recommended nonadherence removed? I: Were losses of 
patients to follow-up taken into account? 
Abbreviation: n/a, not applicable. 
 
For example, many studies provide nonadherence figures (using self-report, MEMS and 
prescription refill) without being explicit as to whether nonpersistent women were removed 
from analysis or were classed as nonadherent. Others stated that those who discontinued 




authors have classed participants who discontinued treatment as nonadherent and some have 
allowed participants to be both nonpersistent and nonadherent. Therefore, accurate estimates 
of nonadherence and nonpersistence rates are currently lacking. 
Correlates of adherence and persistence 
A large number of variables showed no significant relationship with HT adherence or 
persistence (Table 4). The remaining factors are discussed later. For the purpose of 
synthesizing results, variables have been classed as having a positive effect, a negative 
effect, or no effect on adherence/persistence. A positive/negative effect indicates a 




The majority of clinical factors showed no consistent associations with adherence or showed 
mixed results (eg, tumor size, previous chemotherapy and lymph node status). Switching 
between HTs was associated with decreased adherence in seven studies
23,28,33–37
 and 
increased adherence in three studies.
8,38,39
 The majority of articles did not specify the 
direction of switching between medications. 
Regarding overall side effects, two studies showed a negative relationship with 
adherence
27,29
 and three studies found no significant effects (Table 5). Hot flushes/vasomotor 
symptoms, incontinence, gastrointestinal symptoms and sex-related symptoms were not 
associated with adherence, whereas weight concerns were associated with decreased odds of 
adherence.
40,41
 Cognitive, gynecological, musculoskeletal and sleep/fatigue-related 
symptoms were associated with lower odds of adherence in some studies, but the effects 




Similar to adherence, the majority of clinical factors were not reliably associated with 
persistence for the prescribed treatment duration. Three studies found that a codiagnosis of 
osteoporosis or diabetes was related to increased persistence.
43–45
 However, mixed results 
were found for the effects of comorbidities in general, with the majority of studies finding 
no significant associations. 
Five studies found that experiencing any/severe side effects was associated with decreased 
odds of persistence,
25,35,46–48
 but three studies found no significant effects. Women who expe-
rienced menopause-related side effects were up to three times less likely to persist
10,49,50
 in 
three studies but more likely to persist with treatment in two studies.
48,51
 Hair thinning was 






 Gynecological symptoms were associated with increased odds of 
persistence in one study,
51
 but another two studies found no significant effects. 
Health care factors 
Adherence 
Consultations with an oncologist or mastologist increased odds of adherence in two studies 
compared to women without these consultations.
9,23
 Experiencing more hospitalizations was 
associated with lower odds of adherence.
9,23,34,36
 Higher monthly prescription costs were 
associated with decreased odds of adherence in four studies,
30,32,34,52
 but two studies found no 
significant effects. 
Persistence 
Five studies showed that odds of persistence increased by 21%–66% if treatment was 
received by an oncologist or a gynecologist as opposed to a general practitioner,
32,43–45,53
 
while two studies found no significant effect. Five studies found that being prescribed more 
medications per month was associated with increased odds of persistence;
7,25,26,54,55
 however, 
an additional study showed the opposite effect
32
 and three studies found no significant 






Table 4. Results from included studies  
Predictor variables Number of studies finding positive/negative effect   
 Adherence Persistence 
Clinical variables   
Menopausal status (Pre vs. Post) No effects: 3  Positive: 0 Negative: 0 No effects: 4  Positive: 0 Negative: 1
35
  
Laterality No effects: 1 Positive: 0 Negative: 0 No effects: 2 Positive: 0 Negative: 0 
Larger tumour size No effects: 1     Positive: 1
37
  Negative: 0 
No effects: 
10  
Positive: 0 Negative: 0 
























































8,35†,49,64,94   Negative: 2
24,26†
 
Surgery (yes / no) No effects: 3  Positive: 1
23 











 No effects: 0     Positive: 1
49 
 Negative: 0 








13   








  Negative: 0 
AI (vs. tamoxifen)  No effects: 5  Positive: 4
35,36,38,39  Negative: 4
  










































Diabetes / Osteoporosis  No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 3
43-45  
Negative: 0 
Healthcare variables  
Mastologist visits   No effects: 0 Positive: 1
23
 Negative: 0 No effects: 0 Positive: 1
24 
 Negative: 0 
Oncologist (vs no oncologist)  No effects: 0 Positive: 2
9,23  
 Negative: 0 No effects: 3  Positive: 2
24,49† 
 Negative: 0 
Oncologist vs. Surgeon  No effects: 0 Positive: 0 Negative: 0 No effects: 1 Positive: 0 Negative: 0 
Non surgeon as provider  No effects: 0 Positive: 1
36
  Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Primary care vs. oncologist / gynaecologist  No effects: 1 Positive: 0 Negative: 1
32
  No effects: 2
 






Predictor variables Number of studies finding positive/negative effect   
 Adherence Persistence 
Oncologist vs. Gynaecologist  No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 1
60
  
More prescription medications  No effects: 8 Positive: 2
33,36  









Complementary / Alternative Medicine use No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 1
7
 
90 day prescription refill period (vs. 30 
days) 
No effects: 0  Positive: 1
8
 Negative: 0  No effects: 0 Positive: 1
8
  Negative: 0 
More Hospitalisations  No effects: 1  Positive: 0 Negative: 3
23,34,36  





Higher monthly costs  No effects: 2 Positive: 0 
Negative: 4 








 Negative: 0 No effects: 2  Positive: 1
24
 Negative: 0 
Having children No effects: 3 
 
Positive: 0 Negative: 0 No effects: 4 Positive: 0 Negative: 0 




 Negative: 0 No effects: 15  Positive: 1
24
  Negative: 0 
Younger age (<40/50) No effects: 3  
 
Positive: 1
59  Negative: 9 
9,23,28,31,33†,34,38,39,58
  
No effects: 6 
  



































Race (other vs. Caucasian)   No effects: 8 Positive: 0 Negative: 2
9,27†
  No effects: 7 Positive: 0 Negative: 1
30
 
Race (black vs. Caucasian) No effects: 3 
 
Positive: 0 Negative: 4
8,31,32,52
 No effects: 5 Positive: 0 Negative: 0 
Race (Latina vs. Caucasian) No effects: 0 Positive: 0 Negative: 0 No effects: 1  Positive: 0 Negative: 0 
Race (Hispanic vs. Caucasian)  No effects: 5 Positive: 0 Negative: 0 No effects: 4  Positive: 1
11†
 Negative: 0 
Race (Asian vs. Caucasian) No effects: 4 Positive: 0 Negative: 0 No effects: 3  Positive: 1
8
 Negative: 0 
Race (Less-acculturated Latina vs. 
Caucasian) 
No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 1
50
  Negative: 0 
Maori or Pacific vs. NZ European No effects: 0 Positive: 0 Negative: 1
59
 No effects: 0 Positive: 0 Negative: 0 





















Predictor variables Number of studies finding positive/negative effect   
 Adherence Persistence 






No effects: 7 Positive: 0 Negative: 1
31† 
 
Smoking No effects: 0  Positive: 0 Negative: 1
23
 No effects: 1  Positive: 0 Negative: 2
24†,65
  
Alcohol  No effects: 0  Positive: 0 Negative: 1
23
  No effects: 1
 
 Positive: 0 Negative: 1
24
 
Higher BMI  No effects: 1  Positive: 0 Negative: 0 No effects: 4  Positive: 0  Negative: 0 
Psychosocial variables – related to HT treatment and healthcare professionals 
Perceived efficacy of HT No effects: 1  Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 0 
HT concern beliefs  No effects: 6  Positive: 0 Negative: 2
27†,67
  No effects: 0 Positive: 0 Negative: 0 




 Negative: 0 No effects: 0  Positive: 0 Negative: 0 
Neutral or negative decisional balance 
score (beliefs)  
No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 2
25,26  
 
Coping Appraisal (beliefs about HT 
efficacy and self-efficacy over costs) 
No effects: 0 Positive: 1
69
  Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Negative emotions about HT  No effects: 0 Positive: 0 Negative: 2
35,68†
  No effects: 0 Positive: 0 Negative: 1
35
 
Positive emotions about HT No effects: 1 Positive: 1
68†
 Negative: 0 No effects: 0 Positive: 1
35 
 Negative: 0 
Perceived importance of HT No effects: 0 Positive: 1
61
 Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Adherence Estimator (beliefs about 
efficacy, value, and cost of HT) 
No effects: 0 Positive: 1
42†
 Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Symptom attribution No effects: 1  Positive: 0  Negative: 0  No effects: 0  Positive: 0  Negative: 0  
Being involved in decision making / 
discussed HT with doctor   
No effects: 0 Positive: 0 Positive: 0 No effects: 2  Positive: 1
48
   Negative: 0 
Not told about side effects  No effects: 0 Positive: 0 Positive: 0 No effects: 0 Positive: 0 Negative: 1
48
  
Patient/physician relationship  No effects: 0 Positive: 1
35 
 Negative: 0 No effects: 0 Positive:1
35†
 Negative: 0 
Value of doctor’s opinion  No effects: 0 Positive: 161  Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Patient/physician  communication No effects: 0 Positive: 1
67†
 Negative: 0 No effects: 3 Positive: 2
50,64†
  Negative: 0 
Received right amount of support  No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 1
48
  Negative: 0 
Being able to ask questions  No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 1
10
 Negative: 0 
Self-efficacy in patient/physician 
interaction   
No effects: 0 Positive: 1
27†
 Negative: 0 No effects: 0 Positive: 1
50 
 Negative: 0 
Understanding information  No effects: 1  Positive: 0 Negative: 0 No effects: 0 Positive: 1
10 
 Negative: 0 
Sufficient information given  No effects: 0 Positive: 0 Negative: 0 No effects: 1 Positive: 1
55†




Predictor variables Number of studies finding positive/negative effect   
 Adherence Persistence 
Perceived self-efficacy (learning about 
medication)  
No effects: 0 Positive: 1
29
 Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Perceived self-efficacy (taking medication) No effects: 0 Positive: 3
27,29,69
  Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Practical problems  No effects: 0 Positive: 0 Negative: 1
29
 No effects: 0 Positive: 0 Negative: 0 
Psychosocial variables – related to breast cancer 
Fear of cancer recurrence No effects: 3  Positive: 0 Negative: 0 No effects: 0 Positive: 2
10,55†
 Negative: 0 
High coherence beliefs No effects: 0 Positive: 1
46
  Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Personal control, illness consequences No effects: 1 Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 0 
Treatment control  No effects: 0  Positive: 1
46†
 Negative: 0 No effects: 0 Positive: 0  Negative: 0  
Perceived ageism in cancer care No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative:1
64†
 
General psychosocial variables  
Quality of life / emotional health  No effects: 2  Positive: 0 Negative: 1
40†
 No effects: 5  Positive: 0 Negative: 0 
Optimism No effects: 0 Positive: 0 Negative: 0 No effects: 0 Positive: 1
64†
  Negative: 0 
Fatalism No effects: 0 Positive: 0 Negative: 0 No effects: 1
 
 Positive: 0 Negative: 0 
Anxiety  No effects: 4
 
 Positive: 0 Negative: 1
40†
 No effects: 1  Positive: 0 Negative: 1
49
 
Depression No effects: 3 Positive: 0 Negative: 3
34,40†,41†  





Low social support  No effects: 1  Positive: 0 Negative: 0 No effects: 0 Positive: 0 Negative: 3
10,64†,70
 
Cognitive impairments No effects: 0 Positive: 0 Negative: 0 No effects: 2  Positive: 0 Negative: 1
54 
 
Expressing a desire for future fertility  No effects: 0 Positive: 0  Negative: 0  No effects: 0  Positive: 0  Negative: 1
65
  
Note: *The effect was not significant in multivariate analysis or was not tested in multivariate analysis. 









Three studies found that women who were hospitalized more were less likely to persist with 
treatment,
24,56,57
 but one study found no significant effects. Women who used 





Nine studies showed lower odds of adherence for women under the age of 40/50 
years,
9,23,28,31,33,34,38,39,58
 one study found the opposite,
59
 and three studies showed no 
significant effects. Six studies found that older women (>65/75 years) were less likely to be 
adherent.
9,30–33,59 
However, two studies found the opposite effect
28,60 
and six studies found no 
effects. Four studies found that being black was associated with lower odds of adherence 
than being white,
8,31,32,52 





There was a trend suggesting that younger (<45/50 years) women had lower odds of 
persistence,
8,24,43,45,54,60,62
 but this was not always supported. Nine studies showed that older 
women were less likely to persist with treatment,
8,11,30,32,48,54,57,62,63
 but seven studies found no 
significant association and one study found the opposite effect.
49 
Psychosocial factors 
The following variables showed significant effects on adherence but were only tested in one 
study: illness coherence
46
 and self-efficacy regarding learning about medication
29
 (positive 
effect on adherence) and practical problems associated with medication taking
29
 (negative 
effect on adherence). Optimism showed a positive effect on persistence
,64
 and expressing a 




There was some evidence suggesting that medication beliefs were related to adherence. 
Three studies showed that “necessity beliefs”, defined as judgments of personal need for the 
treatment,
12
 were significantly related to increased adherence.
35,66,67
 The adherence estimator 
measures perceived need for medication, concerns and affordability and categorizes people 
as low, medium and high risk for nonadherence. Women who were high risk were more 
likely to report being nonadherent.
42 
Negative and positive emotions regarding therapy were 
related to decreased and increased adherence, respectively,
35,68
 and perceived importance of 




 found that coping appraisal, 
defined as the effectiveness of taking HT and self-efficacy in ability to take HT, minus the 




Table 5. Relationship between side effects and HT adherence / persistence 
Variable Number of studies showing positive / negative effect  
 Adherence Persistence 
Any side effects 
2 x negative 
27†,29
 
3 x no effects  




2 x no effects
 
 
Severe side effects 0 
2 x negative 
25,48
  
1 x no effects  
Overall hormone / menopause related 0 
1 x positive 
51†
 





Hot flushes / vasomotor symptoms / 
sweating  
5 x no effects  








1 x no effects  
Overall sleep / fatigue related  2 x no effects  2 x no effects 
Gynaecological symptoms 
1 x positive 
42†
 




3 x no effects 
1 x positive 
51† 
2 x no effects  
Sex related symptoms 4 x no effects
 
 2 x no effects  
Joint aches and pains / osteoporosis  
2 x negative 
40†,41†  
2 x no effects  
 
2 x no effects  
Weight concerns 
2 x negative 
40†,41 
1 x no effects 
1 x no effects 
Incontinence /bladder control 3 x no effects 1 x no effects 
Hair thinning / loss 0 1 x positive 
51†
 
Headaches 0 1 x negative
 51†
 
Loss of appetite  0 1 x negative 
51†
 
Gastrointestinal symptoms 2 x no effects 0 
Cognitive symptoms 
2 x negative 
40†,41†  
1 x no effects  
0 
Note. Individual symptoms which were only tested in one study and were not significant are not listed 
in the table (shortness of breath, eyesight changes, breast sensitivity, fractures/broken bones, retaining 
water). †indicates that the effect was not significant in multivariate analysis or was not tested in 
multivariate analysis.  
 
Four studies found no effects of necessity beliefs on adherence.
27,40,46,68
 These four studies 
had small sample sizes and may have lacked power to find a significant effect. However, 
where effect sizes were given, they were relatively small. Three studies found a positive 
relationship between perceived self-efficacy for medication taking and adherence.
27,29,69
 
Variables relating to patient–physician relationship tended to be associated with adherence. 
Patient–physician relationship quality,35 value of doctor’s opinion,61 frequency of physician 
communication
,67 
and self-efficacy in patient–physician communication27 were positively 
associated with adherence. However, several of these were only tested in univariate analysis 








Having a neutral or negative decisional balance score, i.e., believing that the benefits of the 
treatment do not outweigh the harms, was associated with three times lower odds of persis-
tence within the first 2 years of therapy.
26
 A 5-year follow-up study supported this 
relationship but with a smaller effect size.
25
 Positive and negative emotions regarding HT 
were associated with increased/decreased odds of adherence.
35
 
Results for patient–physician relationship were mixed. Two studies found that perceptions of 
better physician communication were associated with increased odds of persistence,
50,64 
but 
three studies found no significant effects. However, one of these effects was nearing 
significance.
25
 Being involved in decisions and discussing HT with a doctor were found to 
have no significant effects on persistence in two studies and a positive effect in one study.
48
 
However, being able to ask questions and understanding information,
10
 self-efficacy in 
patient–physician interaction,50 and receiving the right amount of support48 were 
significantly related to increased persistence. 
Two studies showed that no longer fearing cancer recurrence was associated with an 
increased risk of treatment interruption,
10,55 
but this did not remain significant in multivariate 
analysis.
55
 Three studies found that women reporting low levels of social support were less 




This article reviewed the evidence for clinical, demographic and psychosocial predictors of 
HT adherence and persistence to present a holistic view of the evidence base. Empirical 
interest in this area is growing, and this review builds upon previous reviews by 
incorporating 27 new studies. One previous review concluded that social support, patient-
centered interactions, anxiety and beliefs were related to nonadherence/nonpersistence.
18
 
While this current review supports some of these findings, new research has questioned 
whether anxiety is related to nonadherence. Cahir et al
17
 found that side effects and follow-
up care with a GP (vs oncologist) was negatively associated with persistence and the number 
of medications was positively associated with persistence. This review supported the 
previous findings that receiving care from an oncologist was associated with increased 
persistence but found mixed results for the number of medications and side effects. This 
review also highlighted new factors, such as younger age and hospitalizations, and moved 
beyond these findings to identify modifiable factors, such as self-efficacy for medication 
taking. 
Researchers and clinicians often assume that side effects, especially menopausal symptoms, 
trigger nonadherence.
71,72 




and adherence/persistence, the relationship was not always supported.
73
 However, studies 
investigating the effects of hot flushes were low to moderate quality, so further high-quality 
research is needed. Several studies found that nonadherent or nonpersistent women reported 
fewer side effects, possibly as a result of not taking the medication. Future research should 
therefore measure adherence and side effects at several time points to see how the 
relationship changes across time. Qualitative research has shown that some women would 
not discontinue HT regardless of its side effects (Moon Z, Moss-Morris R, Hunter M, 
Hughes L., unpublished data, 2017), which may account for the inconsistent relationship 
between side effects and adherence. 
Being treated by specialists rather than a general practitioner increased persistence. These 
physicians may provide more specialized and informed care,
43
 leading to women being more 
educated and having positive treatment beliefs, although this was not measured directly. An 
intervention focusing on knowledge and beliefs may support women who did not receive 
this from their physician. This is supported by the studies showing that medication beliefs 
are related to adherence levels.
26,35
 Furthermore, several studies showed that variables 
relating to the patient–physician relationship and physician communication were associated 
with increased odds of adherence. These results suggest that training primary care physicians 
to provide more specialized care could improve adherence rates. 
Some evidence suggested that women whose insurance data indicated nonadherence or 
nonpersistence over 1–5 years were more likely to have been hospitalized over the same 
period. These women may have not taken their medication while in hospital, but as no data 
were provided for adherence levels during the hospitalization, no strong conclusions can be 
made. There was relatively consistent evidence from moderate- to high-quality studies, 
suggesting that younger women had lower odds of adherence and slightly less consistent 
evidence for a relationship between younger age and nonpersistence. This is in line with 
previous reviews into adherence in cancer and other illnesses.
74,75 
Young women may not 
take HT due to issues around early menopause or fertility
24
 as HT precludes conception. In 
addition, young women do not adjust as well to a cancer diagnosis, which may affect 
adherence.
54,76 
Results were mixed for the relationship between older age and adherence or 
persistence. 
In terms of modifiable factors, three studies found that women who reported few sources of 
social support were more likely to discontinue treatment. The importance of social support 
in maintaining adherence has been highlighted previously,
77,78
 but social support was only 
found to relate to persistence in this review. Discussing the importance of maintaining good 
social networks and disclosure of cancer status may increase levels of perceived social 






 Self-efficacy for medication taking, defined as the patient’s confidence in 
their ability to take the medication as prescribed, was associated with increased odds of self-
reported adherence.
27
 Self-efficacy for medication taking could be modified by teaching 
patients strategies to remember to take their medication and helping patients to overcome 
other practical barriers through modeling, goal setting, or confidence building. Similar 




Patients who held stronger beliefs regarding how efficacious, necessary, important and 
affordable HT is were more likely to have higher self-reported adherence, as were women 
who reported more positive emotions around HT. In addition, women who felt that the risks 
of the treatment outweighed the benefits were three times more likely to discontinue. This 
relationship between beliefs and adherence is supported by the Necessity Concerns 
Framework (NCF) and has been demonstrated previously.
83,84 
The NCF suggests that 
adherence is related to holding high perceptions of the necessity of the medication and low 
concerns. These beliefs are often shown to be more powerful predictors of adherence than 
clinical or sociodemographic characteristics and have been successfully modified through 
intervention.
35,83,85 
However, the studies investigating beliefs in this review were low- to 
moderate-quality cross-sectional studies and some used unvalidated measures. In addition, 
while medication concerns are often found to be predictive of adherence,
83
 the majority of 
studies found nonsignificant results. This suggests that it may be more important to measure 
how people weigh up their concerns against their necessity beliefs. 
The variability between studies may reflect the heterogeneous populations studied. There 
were discrepancies in geographic location, health care systems and clinical characteristics. 
Furthermore, while several studies recruited patients at the initiation of treatment, many 
studies did not specify the stage of treatment. Research has shown that determinants of 
adherence vary significantly over time.
10 
Therefore, future research should try to recruit 
patients at the same time point, explicitly state participants’ stage of treatment and follow 
them over the duration of the prescription period. 
The results from this review suggest that there are no strong predictors of HT adherence or 
persistence. Reviewing high-quality studies in isolation (n=22) reflected this pattern of 
inconsistent results. However, the high-quality studies did support the trend of higher rates 
of discontinuation in older women and lower adherence in black women, suggesting a need 
to further investigate these relationships. The majority of predictors investigated, such as 
age, are not amenable to change through intervention. Future research is needed to identify 
psychosocial factors that have been shown to impact on adherence in other conditions. For 




illnesses but have not been investigated fully in HT adherence.
12,86
 This review identified 
one study investigating illness perceptions, which found that coherence beliefs, ie, patients’ 
ratings of their understanding of their breast cancer, were the only significant predictors of 
nonadherence in multivariate analysis.
46
 Self-efficacy for taking medication, social support 
and medication beliefs provide potential targets for intervention. However, higher quality 
research is needed in order to clarify the relationship between medication beliefs and 
adherence. Interventions could also focus on training clinicians and general practitioners to 
improve patient–physician communication. 
There are several limitations to this review. It was not possible to conduct a meta-analysis 
due to significant heterogeneity between studies. This heterogeneity also makes it difficult to 
compare across studies and make conclusions based on significant predictors of 
nonadherence. Although a wide search was conducted and attempts were made to identify 
gray literature, some relevant articles may not have been identified. The conclusions are 
limited by the methodological quality of the included studies. There was a risk of selection 
bias in some studies, which means a subset of the population who are potentially more at 
risk of nonadherence may not be included. Sixteen studies were cross-sectional which limits 
assumptions about causality. Two studies used MEMS to measure adherence and found very 
high levels, most likely due to the Hawthorne effect where adherence increases because 
patients know that they are being monitored.
87
 The most common measurement of adherence 
and persistence was prescription refill, which is known to be the most objective measure.
88
 
However, this measurement is still flawed, as we do not know if the patient actually took 
their medication. Several studies used physician ratings, which are likely to grossly 
overestimate adherence levels.
89
 Self-report measures are also susceptible to overreporting 
due to social desirability. Four studies overcame these limitations somewhat by using 
validated questionnaires. 
There are several reasons that a patient may be recommended by their physician to 
discontinue treatment, such as recurrence and contraindications. These patients should not be 
classified in the same way as women who choose to discontinue HT and should be removed 
from analysis. Around a third of studies attempted to adjust for this by removing women 
who had a recurrence or who died. Seven studies did not allow patients to switch 
medications and still be considered persistent, and 13 studies were unclear as to whether 
they allowed this. Furthermore, only a few studies have clearly distinguished between 
nonadherence and nonpersistence and provided independent figures for both. Without this 
information, it is not possible to determine the full medication-taking behavior of these 
patients and, therefore, the clinical impact. The behaviors and outcomes of completely 




understand these as independent with unique predictors. Future research needs to be clear 
about how nonadherence rates are classified and ideally to provide independent rates for 
nonadherence and nonpersistence.  
Conclusion 
Understanding the determinants of nonadherence is essential when designing interventions 
to improve HT adherence and ensuring that patients realize the full benefits of HT. The main 
conclusions that can be drawn from this review are that while clinical and demographic 
factors may be useful in order to identify women at risk of nonadherence, extensive research 
has not yet identified any consistent predictors. There was some evidence that increased 
adherence was related to younger age, fewer hospitalizations and better patient–physician 
relationship, but these relationships were not always supported. Persistence was related to 
receiving treatment from a specialist. In terms of modifiable factors, there was some 
evidence to suggest that beliefs about HT, social support and self-efficacy for taking 
medication were related to adherence and persistence. In order to guide effective 
interventions to improve HT adherence and persistence, future research should focus on 
these factors and on identifying additional potentially modifiable factors, which have been 
shown to be related to adherence in other illnesses.
13
 Furthermore, strategies to improve 
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3.3.  Update to published paper  
The systematic review included papers published up until April 2016. Several studies have 
been published since this date. The following section will outline these studies and review 
the findings in relation to the systematic review presented in Section 3.2. Brett et al. (2016) 
conducted a questionnaire study in 292 Breast Cancer Survivors (BCS) in the UK. Bivariate 
analyses using chi-squared were conducted and showed that intentional non-adherence, 
measured with the Medication Adherence Rating Scale (MARS), was associated with more 
side effects, lower necessity beliefs and higher concerns. Unintentional non-adherence on 
the other hand was associated with younger age, post-secondary education and paid 
employment. When these factors were entered together in multivariate analyses, the only 
significant predictors of non-adherence were presence of side effects (OR=4.38, 95% 
CI=1.60-12.00) and concerns (OR=1.18, 95% CI=1.03-1.35).  
In another large questionnaire study, switching therapies, better patient-oncologist 
relationship and higher necessity beliefs were all associated with increased adherence, and 
negative emotions about HT were associated with non-adherence (Bright et al., 2016). 
Emotions about HT were also examined in a questionnaire study conducted in 523 BCS in 
the US (Hershman et al., 2016). Results showed that positive attitudes to HT after initiation 
of treatment were associated with lower odds of non-persistence in the multivariate analysis. 
Women in the highest income category also had lower odds of non-persistence. However, no 
relationship was found between persistence and age, race, marital status, education, 
employment status, tumour stage, lymph node status, comorbidities, chemotherapy, type of 
HT, decisional balance score or social support. Emotional support was found to be 
associated with non-adherence in a cross-sectional study of 261 BCS in Ireland (Quinn, 
Fleming, & O’Sullivan, 2016). Non-adherence was also associated with younger age, being 
employed and experiencing side effects. All these effects, except age, remained significant 
in the multivariate analysis. Several other demographic variables such as education and 
marital status showed no effects on adherence.  
Jacob, Hadji and Kostev (2016) reviewed data on 29,245 patients prescribed HT. Results 
showed that older women (>70 years), women treated in gynaecological practice (vs. general 
care) and those with more comorbidities had lower odds of non-persistence. Nestoriac et al. 
(2016) found a correlation between baseline side-effect expectations and adherence rates two 
years later. Cahir, Barron, Sharp and Bennett (2017) found that of 17 previously identified 
risk factors, only age, marital status, previous medication use and antidepressant use were 




discriminate well between women at high or low risk of non-persistence, suggesting there is 
a need to examine other risk factors. These new studies were of moderate quality, as were 
the majority of studies in the review. They largely provide support for the findings in the 
review, although there were several new factors identified in these recent studies which were 
not supported in the review, such as employment status. Additionally, Brett et al. (2016) 
provided one of the first comparisons of intentional and unintentional non-adherence, with 
results suggesting there may be unique predictors associated with each behaviour.  
These new studies support the conclusions found in the systematic review that there are few 
consistent clinical or demographic predictors of HT non-adherence or non-persistence. The 
results of Jacob et al. (2016) also support the systematic review finding that women treated 
in gynaecologist or oncologist practices are less likely to discontinue than women treated in 
general care. As discussed in the review, this is possibly due to the increased knowledge and 
beliefs found in specialists compared to general practitioners. Alternatively, it could be 
related to higher levels of trust in the HCP. With regards to potentially modifiable factors, 
one new study found a significant relationship between adherence and concerns (Brett et al., 
2016), but despite this finding, the majority of studies in the review found no effects for this 
relationship. The lack of an effect in the review may be due to the poor methodological 
quality of the previous studies; three of the studies which did not find an effect for concerns 
used non-validated questions to assess concerns (Bhatta et al., 2013; Stanton et al., 2014; 
Walker et al., 2016), and one study found very high rates of adherence which may have 
affected the results due to a lack of variance (Bender et al., 2014). Therefore, more high 
quality research is needed to establish the effect of medication concerns on HT adherence.  
The new studies also support the previous conclusions that necessity beliefs, positive 
attitudes about HT and improved patient/physician relationship are associated with increased 
adherence and that negative emotions about HT are associated with decreased adherence. 
However, Hershman et al. (2016) found no effect of decisional balance score or social 
support on persistence, which contrasts with the effects summarised in the systematic 
review. The two studies in the systematic review finding multivariate effects of social 
support on persistence included younger women, for whom social support may be more 
important (Cluze et al., 2012; Huiart et al., 2012). Moreover, these studies simply measured 
the number of persons providing social support, whereas Hershman et al. (2016) asked 
people to rate their perceived level of social support, suggesting that the quantity of support 
available may be important. Quinn et al. (2016) found that emotional support was related to 
non-adherence, but social or financial support were not. More research is needed to explore 
the effects of social support on HT adherence. With regards to decisional balance score, two 




likely to discontinue treatment (Fink et al., 2004; Lash et al., 2006), whereas Hershman et al. 
(2016) found no significant effects for this relationship. Hershman et al. (2016) did not 
provide information for how they created or measured this variable, which may account for 
the lack of an effect. Furthermore, they measured decisional balance at baseline, when 
women may not have had time to develop their beliefs about treatment. The new studies 
summarised here also add support to the relationship between side effects and adherence, but 
again, this relationship remains fairly inconsistent, with many studies showing no 
relationship between side effects and adherence.  
The systematic review showed a very variable and inconsistent pattern of results, and the 
addition of these new studies has not provided much clarity. This variation is likely due to 
variability in the populations studied and the measurements of both adherence and predictor 
variables. Study populations varied in terms of the geographic location, the age range of 
participants, the time since initiation of treatment and the type of HT. All of these factors 
may contribute to the range of different results seen in the systematic review. In addition to 
this, adherence and persistence were categorised and measured in a range of different ways, 
with women being categorised as non-adherent if they missed over 20% of doses in some 
studies, and if they reported missing only one dose in others. Categorising adherence in this 
manner is likely to lead to significant variability in the literature.  Finally, the quality of the 
included studies varied considerably. There is a need for higher quality research to attempt 
to disentangle some of these effects. However, whilst the overall picture was very 
inconsistent, there were some fairly consistent results which warrant further research, such 
as medication beliefs and self-efficacy for medication taking.  
3.4. Summary  
There are few consistent clinical and demographic factors associated with non-adherence. 
There was some evidence to suggest that adherence was associated with younger age, fewer 
hospitalisations and better patient/physician relationship and that persistence was associated 
with receiving care from a specialist. Evidence is mixed for the relationship between side 
effects and adherence. Few studies have attempted to identity modifiable psychosocial 
factors, although research interest in this area is increasing. Potentially modifiable factors 
identified in the literature so far include necessity beliefs, attitudes towards HT, social 
support and self-efficacy for medication taking. These results support the use of the 
Common Sense Model (CSM) and Theory of Planned Behaviour (TPB), as most of the 
factors mentioned above are covered within these models. The systematic review 
highlighted that the majority of research investigating medication beliefs was of low to 




More research is also needed to identify additional modifiable factors associated with HT 
adherence. The vast majority of research conducted so far has failed to use a theoretical 
framework when investigating determinants of HT non-adherence. Using validated theories 
provides a structured framework for investigating key determinants of non-adherence, they 
help with comparison and replicability across studies and they aid with intervention 
development (Holmes et al., 2014). Therefore, there is a need to conduct more high quality 





















4. A qualitative study to explore the experiences of breast cancer survivors 
taking tamoxifen 
4.1.  Chapter Overview  
Several qualitative studies have been carried out recently to explore the experiences of 
women taking Hormone Therapy (HT). These studies were not included in the systematic 
review, but they can provide interesting insights into why women may become non-adherent 
or non-persistent. For example, Cahir et al. (2015a) interviewed 31 women in Ireland and 
found that women who were adherent and persistent had strong beliefs in the necessity and 
efficacy of HT. They were also motivated to take HT by their fear of recurrence. A similar 
study was conducted by Harrow et al. (2014) in Scotland. Analysis of the interviews showed 
that side effects do not necessarily affect adherence, and that patient’s beliefs about HT may 
be more important. Van Londen et al. (2014b) found that participants who experienced 
bothersome side effects would weigh up the pros and cons of continuing HT. In the US, 
Wells et al. (2016) found that adherence to HT was facilitated by a medication taking 
routine, taking HT with other medications and understanding the consequences of sub-
optimal adherence. In this study, side effects were the most commonly mentioned barrier. 
Finally, Verbrugghe et al. (2015) interviewed 31 Breast Cancer Survivors (BCS) taking HT 
in Belgium. Results suggested that adherence was related to the balance between the burden 
of HT (impact of treatment, HT expectations, lack of recognition from healthcare 
professionals) and capacity to take HT (personal coping resources, social support).  
Incorporating the results of the qualitative studies with the conclusions from the systematic 
review adds further support to the relationship between side effects and adherence (Wells et 
al., 2016). It also reinforces quantitative findings showing that adherence is related to 
necessity beliefs, and suggests that adherence may be related more to the interplay between 
beliefs and side effects than to side effects alone (Cahir et al., 2015a; Harrow et al., 2014; 
Van Londen et al., 2014). Furthermore, the qualitative studies support the review findings of 
relationships between self-efficacy for medication taking and adherence (Verbrugghe et al., 
2015). Cahir et al. (2015a) identified fear of recurrence as a motivator for adherence; a 
finding which was not supported by the studies in the systematic review. The qualitative 
studies also highlight the importance of establishing a medication taking routine and 
understanding the consequences of non-adherence, factors which were not assessed in the 
systematic review. Verbrugghe et al. (2015) also highlighted social support as a facilitator to 




The systematic review described in Chapter 3 provides conflicting and inconsistent evidence 
on predictors of HT adherence or persistence. Most of the relationships between adherence 
and potential determinants show both positive and negative effects, as well as often showing 
null effects. Therefore, there is a need to attempt to untangle some of these effects and to 
examine the lived experience of women taking tamoxifen. Quantitative analysis does not 
allow for in-depth exploration of some of these factors, such as the relationship between side 
effects and adherence. In contrast, qualitative analyses are designed to permit open-ended in-
depth exploration of peoples’ experiences and beliefs. This in-depth analysis provides 
context for what it is like for women to take tamoxifen, helps with understanding and 
interpreting some of the quantitative results, and provides information for intervention 
development. For example, when examining patients’ side effects, qualitative analyses allow 
a broader exploration than quantitative methods, which within the confines of questionnaires 
cannot examine which side effects are most bothersome, and how these side effects may 
interact with other variables. This chapter describes a qualitative study with BCS taking 
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Understanding tamoxifen adherence in women with breast cancer: a qualitative study  
Objective. Non-adherence to tamoxifen is common in breast cancer survivors and is 
associated with poor clinical outcomes. This study aimed to understand womens’ 
experiences of taking tamoxifen and to identify factors which may be associated with 
nonadherence. 
Design. A qualitative study using semi-structured interviews. 
Methods. Thirty-two breast cancer survivors who had been prescribed tamoxifen took part 
in interviews conducted face to face or over the telephone. They were transcribed verbatim 
and analysed using inductive thematic analysiswith elements of grounded theory.  
Results. A key theme identified in the data was weighing up costs and benefits of treatment, 
which resulted in women falling into three groups; tamoxifen is keeping me alive, tamoxifen 
is not worth the reduced risk of recurrence, or conflicting beliefs about the harms and 
benefits of treatment. Additional themes were living with risk of recurrence and information 
& support.  
Conclusions. Women who believed that the necessity of tamoxifen outweighed its costs 
were more likely to be adherent, whereas women who thought that the benefits did not 
outweigh the side effects were more likely to have discontinued. A third more ambivalent 
group believed strongly in the importance of treatment, but were struggling with side effects 
and were often non-adherent. Patients sometimes felt unsupported and discussed a need for 
more comprehensive information. To increase adherence, future research needs to explore 




Breast cancer is the most common cancer among women worldwide with around 1.7 million 
women diagnosed per year (American Cancer Society, 2015). Over three quarters of these 
breast cancers are oestrogen receptor positive (ER+), which means that the cancer cells are 
stimulated by the hormone oestrogen (Harrell et al., 2007). Hormonal therapies (HT) such as 
tamoxifen are prescribed to female breast cancer survivors in order to reduce the risk of the 
cancer returning by blocking oestrogen receptors in cancer cells. They are one of the most 
effective systemic treatments for ER+ positive breast cancer and can almost half the rate of 
recurrence (Aguilar et al., 2010; Early Breast Cancer Trialists' Collaborative Group, 1998). 
Recent research has suggested that extending the prescription from five to ten years brings 




Despite this, many women do not take their treatment in accordance with agreed 
recommendations from their healthcare provider which is termed as non-adherence by the 
World Health Organisation (Sabate, 2003). Non-adherence can consist of missing or altering 
doses and/or taking medication “holidays”. Non-adherence can be intentional, where the 
patient makes a deliberate decision not to take the medication as prescribed, unintentional 
where the patient may forget or not understand the instructions, or a combination of both.  
Some women also stop treatment completely before the recommended duration of five to ten 
years, which is known as non-persistence or discontinuation. Both non-adherence and non-
persistence are associated with increased risk of breast cancer recurrence and mortality 
(Barron, Cahir, Sharp, & Bennett, 2013; Hershman et al., 2011). Studies show that by the 
fifth year of treatment, up to 50% of women have discontinued (Hadji et al., 2013; Owusu et 
al., 2008). 
Adherence rates range over the course of treatment from 41-88% (Murphy, Bartholomew, 
Carpentier, Bluethmann, & Vernon, 2012) and fall to 50% by the fifth year of treatment (Lee 
et al., 2014; Partridge, 2003). As non-adherence and non-persistence have similar effects on 
clinical outcomes, they will both be referred to as “(non)-adherence” when discussing the 
implication of the research. This is consisten with taxonomies of adherence which define 
non-persistence as a type of non-adherence (Helmy et al., 2017; Vrijens et al., 2012).  
Whilst there has been an attempt to understand the reasons for non-adherence, the majority 
of research has focussed on clinical and demographic factors, with few consistent predictors 
identified (Moon et al., 2017a; Murphy, et al., 2012). Improving adherence rates is 
increasingly important as tamoxifen is now being prescribed for up to ten years instead of 
five years (Burstein et al., 2014) and is recommended as prophylaxis for women at high risk 
of breast cancer (NICE, 2013b).  
Tamoxifen lowers circulating oestrogen levels and as a result, is associated with a wide 
range of menopausal side effects. Hot flushes and night sweats are prevalent, occurring in 
around 80% of women taking tamoxifen (Moon et al., 2016). Other common menopausal 
side effects include loss of libido, fatigue, vaginal dryness and weight gain, which occur in 
more than one in ten women. Changes to mood and irritability are reported in 11% - 67% of 
patients taking tamoxifen (Cella & Fallowfield, 2008; Moon et al., 2016). Tamoxifen is 
often prescribed to younger, pre-menopausal women, many of whom would not normally be 
experiencing menopausal symptoms. Non-adherence is often assumed to be driven by these 
side effects (Demissie, Silliman, & Lash, 2001; Lash, Fox, Westrup, Fink, & Silliman, 
2006), however little research has investigated empirically if this is the case. Whilst a small 




adjuvant HT, researchers have highlighted a need to conduct more research to understand the 
complex problem of non-adherence and to develop interventions to increase adherence 
(Harrow et al., 2014; Verbrugghe, Verhaeghe, Lauwaert, Beeckman, & Van Hecke, 2013). 
One qualitative study found that women struggled with their understanding of the hormonal 
nature of tamoxifen (Pellegrini et al., 2010). Another found that many women suffered side 
effects which reduced their quality of life (QOL), but did not affect adherence (Harrow, et 
al., 2014), contradicting assumptions that side-effects resulted in non-adherence. However, 
non-adherent women and those who were premenopausal were under-represented in this 
study. Another study interviewed women prescribed HT and found that patients were 
surprised by the wide range of side effects they experienced (Van Londen et al., 2014). They 
were offered little support with coping with the side effects and had to develop strategies of 
their own. Verbrugghe et al. (2015) found that expectations regarding tamoxifen, 
information and social support contributed to HT non-adherence.   
This previous research provides insight into the experiences of women prescribed HT, but 
the studies tended to focus more on the experiences of side effects and less on understanding 
if and how non-adherence is impacted by side-effects. Furthermore, the majority of previous 
research has investigated tamoxifen jointly with aromatase inhibitors, which have a 
significantly different side effect profile (Howell et al., 2005) and are usually prescribed to 
older, post-menopausal women. More research is needed to understand why women may not 
adhere to tamoxifen treatment, in order to develop ways to improve adherence. This research 
aimed to use an inductive qualitative approach to elicit a broad understanding of women’s 
lived experiences of tamoxifen, their motivation to adhere to treatment and identify reasons 
for non-adherence and non-persistence, in their own words. A better understanding of 
adherence and non-adherence in this population will provide invaluable knowledge for 
clinicians, but will also contribute to the design and development of interventions to improve 
both adherence and quality of life in women taking tamoxifen.  
Methods 
Participants  
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207).  Patients were eligible if they had been prescribed tamoxifen for a breast 
cancer diagnosis, were female, over 18, spoke fluent English, and able to consent for 
themselves. Participants were recruited from a London breast clinic, local support centres 
and through online advertisements to ensure a range of menopausal status at diagnosis and 




Twenty-one women were approached in clinic and given information about the study. After 
being given two days to decide if they wanted to participate, these patients were contacted 
by the researcher. Twelve agreed to participate in the study. The remaining women could not 
be contacted. Online advertisements were placed on the following websites: Facebook; 
Macmillan Online Community; Asian Women’s Breast Cancer Group; and Cancer Research 
UK Cancer Chat. Twenty-one women responded to these advertisements, were screened for 
eligibility and given information about the study. One woman declined to take part and 
interviews were arranged with the remaining twenty participants. Recruitment continued 
until data saturation was reached, defined as the point at which no new themes emerged.  
Participants were all female, aged from 36 to 77 (mean=55, SD=10.6) (Table 1). Treatment 
duration ranged from 2 months to 6 years, with a mean duration of 23 months (SD=20). 
Thirty-eight percent of participants were in their first year of treatment.  
Procedure  
Clinic patients were told about the research by their clinician, and then introduced to a 
researcher. The researcher then gave the patient verbal information and an information sheet 
to take away. Patients were interviewed face to face in a private room or over the telephone. 
Informed consent was obtained prior to each interview. The interviews were based on a 
semi-structured interview schedule (Table 2). Questions were open ended and patients were 
encouraged to bring up issues which felt important to them. Patients were told that the 
researchers were interested in hearing their experiences regardless of whether they were 
currently taking their medication. Interviews were audio recorded and transcribed verbatim. 
Two researchers carried out the interviews.  
Data analysis 
The interviews were anonymised and pseudonyms applied before being transcribed by a 
professional transcription company. All transcripts were checked against the recordings for 
accuracy. The interviews were analysed using thematic analysis, as described by Braun and 
Clarke (2006), incorporating elements of grounded theory (Glaser & Strauss, 2009). Data-
analysis methods were chosen to optimise validity of the data and to develop a coherent 
picture of the patient’s experiences. Inductive thematic analysis is a theoretically flexible 
approach which allows in-depth exploration of interviewees’ experiences and perceptions 
with data-driven identification of patterns without preconceived assumptions of predefined 
theories or frameworks (Braun & Clarke, 2014). Elements of grounded theory were used to 














Adherence Side effects 
Sylvie 52 Post  White 2 years  Discontinued 
Severe: HF, 
mood changes, 
poor sleep  
Mary 49 Pre  White 6 months  Adherent   Mild  
Elisabeth 37 Unsure White 5 months  Adherent  
Mild / 
moderate  
Arlene  62 Post  White 2 years  Adherent   
Moderate / 
Severe  
Lisa  55 Peri White  3 months  Adherent   Moderate  
Holly 51 Peri White  4 months  Adherent   None  
Emma 45 Pre  White  
1 year, 2 
months  
Adherent   Mild  
Lauren  62 Post White  18 months  Adherent  
Mild / 
Moderate  
Dominique  45 Unsure  
Black 
British  
 3 years  Adherent  Mild 
Joanna  46 Unsure  
Black 
British  
1 year, 2 
months  
Adherent Mild  
Barbara 64 Post White 1 year  Non-adherent 
Mild / 
moderate  
Vanessa 63 Post White  2 years  Adherent  Mild  
Kate 52 Pre White  14 months  Non-adherent  Moderate  
Lorena 58 Post  White  1 year  
Discontinued 




Bonnie 61 Peri White 
4 years 8 
months  
Discontinued   Severe  
Tania 54 Peri 
British 
Indian  
 1 year, 6 
months  
Adherent Moderate  
Claudia  60 Post White  1 year Adherent  Mild  




 7 months  Adherent  Mild 
Anita 50 Peri White 2 years  Discontinued  Severe  
Marcia 54 Unsure White 2 months Adherent  None  
Celia 67 Post White   7 months  Non-adherent   
Moderate / 
Severe  
Katie  56 Post  White  4 months  Adherent    
Mild / 
moderate  
Hayleigh 36 Pre White  4 years  
Discontinued 
(for fertility 
reasons)   
None  
Jenny  62 Unsure 
Black 
British  
1 year  Adherent   Severe 
Julie  61 Post White  6 years  Adherent   None  
Ellen  50 Pre White 2 years  Adherent    None  




5 years  Non-adherent  
Moderate / 
Severe  


















Adherence Side effects 




5 years  Adherent Mild  
       
Frances 77 Post  White 
2 years, 2 
months  
Adherent  None  
Anna 60 Post  White   2 years  Adherent  None  
Lucy 53 Post 
Black 
British  
5 years  Adherent Mild  
 
Table 2 Interview schedule  
Interview Questions Prompts 
General Questions  
How long have you been taking tamoxifen for? 
Do you know which brand you were taking? 
When were you diagnosed with breast cancer?  
 




Social life?  
Tell me about the experience of taking 
tamoxifen?  
Has anything changed over time?  
What would you change about tamoxifen?  
Adherence  How / when do you take it?  
How do you remember to take it? 
How often do you take it?  
Tell me about the practical side of taking 
tamoxifen?  
 
Knowledge about tamoxifen   
What is your understanding of why you are 
taking tamoxifen?  
How long will you keep taking tamoxifen?  
Prior beliefs / expectations 
Treatment benefits  
Concerns 
Prescription process   
Tell me about how you were prescribed 
tamoxifen?  
Who / when? 
What information were you given? 
Relationship with this person?  
Overall  
Do you have anything else to add? 




After familiarisation with the data, one author generated initial codes, working 
systematically though the data set. Codes were based on language used by the participants 
and were applied to each new unit of meaning. Codes were organised into potential themes 
using thematic maps and tables following discussions with all authors. Themes were 
internally consistent, coherent and distinctive and were mapped onto the study aims. 
Following grounded theory, patterns and links between themes were developed in order to 
move beyond a purely descriptive analysis and to generate a theory within which to 
understand the data. Codes and themes were discussed within the research team and were 




ensure the analysis was grounded in the data, that all items had been given equal attention 
and to ensure no data had been missed. Analysis was iterative and involved constant 
comparison; a technique key to both thematic analysis and grounded theory which involves 
data, codes and themes being constantly compared.  
Characterising patients as adherent  
For the purpose of analysis, women were categorised as adherent or non-adherent (Table 1) 
based on information given in the interviews, after being explicitly asked about their 
medication taking behaviour. Women were considered adherent if they spoke about taking 
all or nearly all of their medication and non-adherent if they regularly skipped or halved the 
medication, or took treatment breaks. A few women self-reported having discontinued 
treatment. Women spoke consistently and explicitly about their medication taking 
behaviour, specifying if they forgot or skipped doses, which facilitated categorisation. For 
example, non-adherent women spoke about halving doses (e.g. “So I’ve had breaks off it and 
then I’d go on…because you’re meant to take twenty milligrams a day. I’d do half doses like 
ten milligrams instead.”) whereas adherent women spoke about never missing doses (e.g. “I 
never forget to take it.  If I do, everybody says have you taken your tablet, have you taken 
your tablet?”). Two researchers independently classified women and there was 100% 
concordance between ratings. Two researchers also listed side effects experienced and 
classified women as experiencing mild, moderate or severe side effects based on their 
discussion of the impact of the side effects on their QOL. Agreement was 97% for the rating 
of severity and 89% for the list of side effects experienced. All discrepancies were resolved 
after discussion. 
Results 
Thirty two women were interviewed. Interviews lasted on average 44 minutes (range 16-81). 
Twenty-three women were classed as adherent, four were non-adherent and five had 
discontinued. Two of the women  discontinued on their doctors’ recommendations; one due 
to blood clots and one so that she could conceive. 
Figure 1 shows the themes and subthemes identified in the data. A key theme for all women 
was the process of weighing up costs and benefits of treatment, which first consisted of 
moving from initial acceptance of treatment, and then resulted in women largely falling into 
one of three groups; tamoxifen is keeping me alive; tamoxifen is not worth the reduced risk 
of recurrence; or conflicting beliefs around the harms and benefits of treatment. Additional 




which contributed to women’s beliefs about treatment and how they weighed these beliefs 
up. Each of these themes and corresponding subthemes will be discussed in turn.  
Weighing up costs and benefits of treatment  
Moving from initial acceptance of treatment. When the women were first prescribed 
tamoxifen, they are happy to follow whatever treatment their healthcare professional (HCP) 
recommended.  
“It wasn't a choice at all. I mean they're professionals so I just listened to what they 
said.” (Barbara, 64, non-adherent) 
However, over time, some women begin to question these initial beliefs and weigh them up 
against what it is actually like to take tamoxifen. This resulted in women falling into one of 
three groups; those who held beliefs that tamoxifen was keeping them alive; those who felt 
that the benefits of tamoxifen were not worth the reduced QOL and those who had 













Figure 1. Themes and subthemes identified in the data. Themes are represented by bold text 
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Tamoxifen is keeping me alive  
Many patients held very strong beliefs regarding the necessity of taking tamoxifen. They felt 
it was incredibly important to take it every day. Whilst some patients spoke about wanting to 
avoid going through cancer treatment again, others were more motivated by a fear of death. 
Some women were also driven specifically by a desire to stay alive for their children.  
“Well since the option is keep taking it or be dead, it’s not much of a choice for 
me.” (Vanessa, 63, adherent)  
Some participants were less certain about the efficacy of tamoxifen, but they still felt it was 
necessary for them to keep taking it.  
“Whether like you say with me it would have come back, I just don’t know. I’d 
rather take it than not.” (Ellen, 50, adherent) 
As well as necessity beliefs, some women held strong beliefs regarding the control 
tamoxifen gave them over their risk of recurrence. They liked the fact that tamoxifen was a 
preventive measure and that it made them feel that they were actively doing something to 
prevent the cancer returning.   
“[taking tamoxifen] makes me feel better as well, because I feel like I am doing 
something actively to prevent it.” (Joanna, 46, adherent)  
For some women these control beliefs were so strong that they were concerned about what 
would happen when their prescription ended.  
“In one way I was quite looking forward to stopping, but then as it got nearer, I 
thought, ooh, it’s like a safety blanket being taken away isn’t it?” (Julie, 61, 
adherent)  
Most women with strong necessity and control beliefs felt that they far outweighed any 
concerns they had. They were willing to experience some side effects if it meant they could 
stay alive and stop the cancer coming back.  
 “Taking tamoxifen just kind of pales into insignificance and it seems like a very 
small price to pay for not getting breast cancer again.” (Katie, 56, adherent) 
The majority of these women were experiencing no side effects or mild side effects. 
However, some did have side effects which impacted on their QOL, including anxiety, 
forgetfulness, reduced libido and hot flushes. Despite this, they were willing to keep taking 
tamoxifen as their beliefs around the necessity of tamoxifen and their desire to stay alive was 




“I never stopped taking it because I thought the nausea and things like that, come 
on its keeping you alive so stop moaning.” (Michelle, 77, adherent)  
In order to help them cope with the side effects, many of these women developed coping 
strategies, such as meditating, removing layers of clothing and exercising. Whilst the 
majority of women who were adherent had positive views around tamoxifen and were happy 
to keep taking the medication, one woman disconfirmed this by having negative emotions 
and beliefs about tamoxifen, yet continuing to take it. She felt that tamoxifen was a reminder 
of the fact that despite finishing her primary treatment, she still cannot get on with her life.  
“I absolutely hate taking this tablet. It’s a very powerful drug. It’s not just the side 
effects. It’s a reminder of what I had.” (Lauren, 62, adherent) 
Despite this strong dislike of taking tamoxifen, this patient’s necessity beliefs and fear of 
recurrence were strong and she therefore made sure she took tamoxifen every day.   
 “I’d be too frightened to be honest not to take it.” (Lauren, 62, adherent) 
Taking tamoxifen is not worth the reduced quality of life  
Whilst some patients had strong necessity beliefs which outweighed their side effects, others 
felt that the benefits of taking tamoxifen were outweighed by the severe side effects they 
were experiencing, which led them to discontinue treatment.  
“I just couldn’t survive anymore taking it. My side effects were so bad I couldn’t 
work…When I stopped and realised the difference, there was no way I was going 
back on it.” (Bonnie, 61, discontinued)  
Patients talked about not having enough energy to participate in their lives. They could not 
maintain relationships with family members and withdrew from social activities. Due to side 
effects like severe fatigue and depression, tamoxifen had a huge impact on their sense of 
self, causing them to feel like completely different people. 
“When I was on tamoxifen, I was basically stuck in bed or sitting on the sofa feeling 
very sorry for myself. Just totally different person completely.” (Anita, 52, 
discontinued) 
Two women also experienced severe depression and suicidal thoughts. Depression was 
attributed more to the overall impact of the side effects, which mainly included fatigue, 
insomnia and muscle cramps, than directly to tamoxifen.  
 “I can’t say that tamoxifen in itself was affecting my moods, but the repercussions 




having the most effect; was it the drug itself or was it just the repercussions of 
taking it?” (Bonnie, 61, discontinued) 
One woman had a strong perception that tamoxifen was causing her to feel suicidal and she 
felt that this was the tipping point for her to discontinue.  
 “I felt so low, was having suicidal thoughts, really didn't feel like myself at all, I 
was in so much pain and that I'd made the decision that I was going to come off 
tamoxifen.” (Anita, 52, discontinued) 
These patients received little support from their healthcare teams in how to deal with the side 
effects, which exacerbated the impact on their lives. HCPs failed to acknowledge that the 
symptoms they were experiencing were related to tamoxifen and therefore did not offer any 
assistance.  
 “I actually was made to feel as if I was having like a mental breakdown...I don’t 
feel as if I was supported properly.” (Anita, 52, discontinued) 
These women still felt that tamoxifen was an effective treatment for reducing a risk of 
recurrence, but they no longer felt that the benefits of treatment were worth the side effects 
and the impact on their QOL. Participants were confident that they had made the right 
decision and were willing to risk the chance of a recurrence or death in order to improve 
their immediate QOL.  
 “I thought actually I would rather be myself for however long that is, rather than be 
miserable for a longer period, and depending on what… whether the recurrence 
might occur or not I just thought well I’ll take that chance.” (Sylvie, 52, 
discontinued)   
Conflicting beliefs around the harms and benefits of tamoxifen 
Other patients had conflicting beliefs around the harms and benefits of tamoxifen. They 
were in turmoil trying to weigh up these beliefs, and to select a behavioural outcome to 
avoid cognitive dissonance. Many of these women made the decision to skip or halve doses 
of tamoxifen.  
“I’ve got to the stage where sometimes I’ll just give it a miss…I just get so fed up of 
taking it, I just want to give myself a break.” (Miriam, 41, non-adherent)  
These patients were struggling to cope with side effects such as fatigue, joint pain, hot 




“It [tamoxifen] is horrible. It really is the most revolting tablet I’ve ever had to 
take.” (Kate, 52, non-adherent)  
As well as struggling to cope with side effects, patients also had concerns about the 
increased risk of cancer elsewhere.  
“I worry more, not about the recurrence, but occurrence in a different part of my 
body due to this drug that I’m taking.” (Miriam, 41, non-adherent)  
In addition to this, women struggled with negative emotions around tamoxifen. For example, 
some women saw tamoxifen as a reminder of having had cancer, others had negative 
feelings relating to the impact of cancer treatment on their fertility and some had strong 
negative feelings about tamoxifen due to their experience of side effects. These negative 
emotions caused women to attribute a lot of their symptoms to tamoxifen.  
 “It is a hard drug to take because of everything it does. You think tamoxifen’s done 
that, and I do blame it for a lot of things.” (Kate, 52, non-adherent)  
Despite these side effects, women wanted to keep taking tamoxifen to reduce their risk of 
recurrence.  
“If it was for anything else other than the cancer I would have stopped it, there's no 
questions, but because of the cancer is such a big thing, you know the possible 
return of it, that's the only reason I'm struggling with it” (Celia, 67, non-adherent) 
However they were equally as concerned about the side effects and their reduced QOL.  
 “But it’s like you’re damned if you do and you’re damned if you don't. It’s that 
worry if you don’t take it, oh god, if they find something again then I think it’s 
because I didn’t take the tamoxifen. But on the other hand it’s living with all these 
side effects on it.” (Kate, 52, non-adherent)  
Modifying their dosage allows the patient to feel like they are doing something to prevent 
the risk of cancer returning, but also allows them to exert some control over side effects. 
However, some patients felt guilty when they missed doses and ultimately resumed 
treatment if the guilt was too much, or if the fear of recurrence became too strong.   
“When I don't take it I think oh, god, I should be taking it. I just feel so guilty when I 






Information & support  
Lack of information. Some patients felt that they were not always given enough 
information when prescribed tamoxifen. They had to do their own research on what to 
expect. Some had very basic knowledge around what tamoxifen was or why they were 
taking it.  
“I didn’t know anything about it. Really no one’s sort of explained what it is. They 
just said tamoxifen will help stopping recurrence.” (Arlene, 62, adherent)  
How informed women feel about tamoxifen is likely to influence how necessary or 
important they feel it is, which feeds in directly to the previous theme of weighing up beliefs 
about treatment. Additionally, women felt that if they had been told about what side effects 
to expect they would have been more prepared, which could then improve their management 
and experience of side effects, potentially reducing the numbers of women who discontinue 
treatment. 
Lack of support. Many women did not feel that they received the support they 
needed from their HCPs in dealing with the side effects. They would have liked to have been 
warned about how bad they could be and given emotional support in dealing with them. This 
is also linked to the previous theme of weighing beliefs about treatment, as this support may 
have helped women who were struggling with side effects, potentially leading them not to 
discontinue treatment or skip doses.  
“I think there should be more help, psychologically, with side effects of tamoxifen. I 
think people ought to be warned.” (Kate, 52, non-adherent) 
Some patients went back to their breast clinic or GP for help with their side effects, but were 
not offered any practical coping strategies for how to reduce the impact of the side effects on 
their QOL. Patients also wanted more long term monitoring and support whilst they were 
taking tamoxifen.  
“I would like there to be more help for people who get this extreme fatigue, whether 
it's from the radiotherapy or tamoxifen.” (Celia, 67, non-adherent)   
Lack of validation with side effects. Some HCPs dismissed or belittled the side 
effects women were experiencing. Patients were told that their symptoms were not 
associated with tamoxifen, which left them feeling invalidated and frustrated.  
 “This is the one thing that I do find a lot of women struggling most with, that they 
feel so…they’re just not listened to. They’re not being validated in what they’re 




Furthermore, some patients also felt that their families did not fully appreciate the extent of 
their side effects and thought the effects of tamoxifen were just linked to previous breast 
cancer.  
“I really do think my family thought that I had fallen into a depression and 
everything just because of the cancer. I think they thought that I thought I was going 
to die or I just was full of doom and gloom. But it was just out of my control really.” 
(Anita, 52, discontinued)   
Living with increased risk of recurrence  
Fear of recurrence. Whilst most women did not identify as still having cancer, 
nearly all spoke about living in fear of cancer returning. They did not let this fear impact on 
their daily life, but said it would always be at the back of their mind. Some were not able to 
relax and were concerned that any little problem might be a sign of cancer.  
“I find it very difficult to be honest…I think the thing is anything that you find that 
you feel that is not right in your body then you start thinking ‘I wonder if it’s 
something serious’.” (Arlene, 62, adherent) 
This fear of recurrence relates to how necessary women feel that tamoxifen is for them, 
which then plays a key role in whether or not they adhere to treatment. Women who fell into 
the tamoxifen is keeping me alive group spoke about being motivated by avoiding a 
recurrence. Women who felt that tamoxifen was not worth the reduced QOL were less 
concerned about a recurrence then they were by their side effects. Most women said that 
they tried to block out this fear and not think about it. Some cited taking tamoxifen as a way 
to help them control it. Others talked about making changes to their lifestyle to try and be 
healthier. A few women felt that there was nothing they could do to control the risk of 
recurrence.  
“That would be my biggest fear is, it’s not, I suppose if it’s going to come back it’s 
possibly when, but I can’t live my life like that.  So I kind of like have to block it and 
just continue as much as I can.” (Elisabeth, 37, adherent)    
Uncertainty about recurrence. Participants reflected on the uncertainty of cancer 
regarding why it comes back or whether it will come back. They said this uncertainty and 
fear was hard to deal with.  
“Someone said to me it’s like having a sword dangling above your head, and it is. 
You just feel like tomorrow you don’t know what’s going to happen. It’s always 




For women who were trying to decide whether or not to take tamoxifen, this uncertainty 
made it harder for them to make a decision.   
“I can never know what the right answer is, because I don't know whether the 
cancer will come back. I can't know until it happens.” (Celia, 67, non-adherent) 
Women who had discontinued tamoxifen were happy in their decision because they said 
they wouldn’t be able to guarantee that they wouldn’t have a recurrence of cancer even if 
they were taking tamoxifen.   
“I’ll have to deal with that if it happens, and the thing is you’ve no idea, you have 
no way of knowing if it would’ve happened anyway. I’m happy enough” (Bonnie, 61, 
discontinued)  
Discussion 
These results provide insight into the experiences of patients who initiated tamoxifen. 
Initially, women in this study were happy to take tamoxifen and did not question the 
doctor’s decision. Over time, however, they weighed up the benefits of taking tamoxifen 
against the harms, leading to some patients becoming non-adherent or non-persistent. 
Women who felt that the necessity of taking tamoxifen far outweighed the side-effects were 
more likely to be adherent. Women who felt that the side effects were not worth the benefits 
were more likely to self-report discontinuing treatment. Some women were struggling to 
cope with the side effects but did not want to discontinue treatment due to their strong 
beliefs in the necessity of tamoxifen. In order to cope with this and control the side effects, 
they skipped or halved doses. Patients in this study fell into one of these three distinct 
groups, but this may not generalise to all women.  
Whilst some women were happy with their decision to discontinue treatment, and felt it was 
the right choice for them, others were keen to continue treatment but were struggling with 
side effects, and some did not fully understand how tamoxifen helps them.  These latter two 
groups may benefit from interventions informed by the results of this study, such as detailing 
how tamoxifen works to reduce recurrence or self-management and support for side effects. 
Furthermore, if we can intervene early to support women with side effects, we may be able 
to prevent patients reaching the stage where it is no longer worth it for them to take 
tamoxifen.   
Many patients felt that they were not given enough information about tamoxifen. If women 
went to their HCPs for help, they were often not given support in managing their side 
effects. Additionally, some women felt that their HCPs did not validate their experience of 




literature (Boehm et al., 2009; Garreau, Delamelena, Walts, Karamlou, & Johnson, 2006). 
Some side-effects had a significant impact on women’s QOL, prohibiting them from 
working or socialising. The majority of women did not know how to manage these side 
effects, which exacerbated their impact on social, physical and emotional functioning. In 
extreme cases, the accumulation of unmanaged side effects led to patients feeling depressed 
and suicidal.  
Whilst the data was analysed using an inductive approach and a reflexive process was used 
to avoid any pre-conceived knowledge and biases, the themes that were generated fit well 
within the Self-Regulation Model of Illness Perceptions (Leventhal, Diefenbach, & 
Leventhal, 1992) and the Necessity Concerns Framework (Horne & Weinman, 1999). Illness 
perceptions, such as perceptions around the risk of recurrence, do seem to impact on 
adherence, as do beliefs about the necessity of tamoxifen. The Necessity-Concerns 
Framework suggests that when deciding whether to take medication, patients weigh up their 
concerns against their beliefs regarding how necessary the medication is for them (Horne & 
Weinman, 1999). These beliefs have been shown to relate to HT adherence and persistence 
(Fink, Gurwitz, Rakowski, Guadagnoli, & Silliman, 2004; Jacob Arriola et al., 2014). This 
study contributes new understanding by moving beyond the generic model and showing the 
specific beliefs held by these patients and how they influence behaviour. It highlights the 
strength of  some women’s necessity beliefs and shows the variability of the cost-benefit 
analysis across women;  some women’s’ desire to stay alive were so strong that they  
reported tolerating any side effects whereas others would rather not live with the side effects 
despite the risk of recurrence. Women may hold such strong necessity beliefs because the 
outcome of not taking the medication is so serious.  
Women also had concerns about tamoxifen, but these seemed to focus almost exclusively on 
the experience of side effects, rather than other common concerns such as dependency. The 
beliefs women held were also consistent with the Self-Regulation Model of Illness 
Perceptions (Leventhal, Diefenbach, & Leventhal, 1992), which proposes that coping 
behaviours such as adherence are influenced by patient’s beliefs about their illness (Chilcot, 
Wellsted, & Farrington, 2010). Patients in this study held strong beliefs regarding the extent 
to which tamoxifen could control their risk of cancer. The results of this study give 
interesting insight into the specific illness perceptions held by breast cancer survivors taking 
tamoxifen. These women did not perceive themselves as currently having cancer, but did 
feel at risk of a recurrence and struggled to cope with the uncertainty surrounding this. This 




This study suggested that side effects can cause women to discontinue treatment, which has 
been shown in several quantitative studies (Demissie, et al., 2001; Simon, Latreille, Matte, 
Desjardins, & Bergeron, 2014; Wouters et al., 2014). However, there is an inconsistent 
relationship between side effects and adherence, with some studies finding no significant 
effects (Fink, et al., 2004; Kostev et al., 2013). The results from this study suggest that 
adherence is not just related to the experience of side effects, but how women weigh these 
up against their beliefs; that is that just the experience of side effects is not sufficient to 
cause non-adherence. This may explain the inconsistent effects found previously. 
Furthermore, adherence rates may be related more to the perceived impact of side effects, 
than the side effects themselves as evidenced by the fact that nearly all of the women 
experienced side effects to some extent but most persisted with their tamoxifen treatment. 
This weighing up process is also supported by trade-off studies showing that women with 
more severe side effects needed larger gains in survival to make HT worthwhile (Duric et 
al., 2005; Thewes et al., 2005).  
Previous research has suggested that forgetting is a significant driver in HT non-adherence 
(Atkins & Fallowfield, 2006). However in this study, forgetting did not seem to be a 
problem for women. Women who felt that the benefits of tamoxifen outweighed the side 
effects were motivated to keep taking it every day and established routines which helped 
them to remember. Women who missed doses reported doing so deliberately, such as taking 
breaks when on holiday or skipping doses to avoid side effects. Although this is based on 
self-reported responses and should be treated with caution, non-adherence through forgetting 
is often more commonly self-reported than deliberately skipping or changing doses. This 
could be due to socially-desirable reporting and the perception that forgetting is more 
“acceptable” than deliberately not following a prescription (Atkins & Fallowfield, 2006).  
Some women did not feel that the benefits of tamoxifen were worth the reduced QOL, which 
may be related to the fact that the benefits are hidden and there is no reduction in symptoms 
which can be attributed to medication taking (Meyer, Leventhal & Gutmann, 1985). The 
information women receive about their treatment and side effects is therefore incredibly 
important in increasing their necessity beliefs. All women should be given personalised 
information, so they are able to make decisions about tamoxifen based on the extent to 
which it will benefit them. Women also wanted to be warned about what side-effects to 
expect. Previous research has shown that women who experienced side effects they were not 
told about were significantly more likely to discontinue HT (Kahn, Schneider, Malin, 
Adams, & Epstein, 2007). Furthermore, women who receive less information about HT are 
less likely to initiate treatment (Friese et al., 2013) and more likely to take treatment breaks 




Patients also need to be informed about the importance of taking tamoxifen as prescribed. 
Some women deliberately missed or halved doses and still wanted to appreciate the benefits 
of tamoxifen. These women may not be aware that by reducing the dosage of tamoxifen they 
are reducing the effectiveness (McCowan, et al., 2008). If they were more educated about 
the implications of taking less than 80% of the prescribed dose, they may be more motivated 
to take it as prescribed.  
Qualitative research provides a unique opportunity to understand a clinical problem from the 
patient’s perspective. This study had a large diverse sample, recruited through a range of 
locations and used in-depth interviews which enhance the richness and generalisability of 
the results. However, there were several limitations. Firstly, women who had chosen not to 
initiate tamoxifen were not included in the study. Future research should interview these 
women to understand the reasons behind their decision. Second, the study may have under-
represented women who were non-adherent as there may be a selection bias where non-
adherent women were less likely to respond to advertisements. However, there is reason to 
believe that women with negative experiences may also be biased to respond to 
advertisements. Twenty nine percent of participants were either non-persistent or non-
adherent, but research shows this figure could be as high as 50% (Partridge, Wang, Winer, & 
Avorn, 2003). Including more women who were non-adherent or non-persistent may have 
given further insights into what drives these behaviours. However, interviewing adherent 
women gives interesting insight into what motivates women to keep taking treatment, even 
when they are experiencing severe side effects. Finally, several of the women in the study 
had discontinued tamoxifen or had been taking it for some time and there may be issues of 
recall bias.  
Clinical implications  
Women who are given clear information about tamoxifen and how it might personally 
benefit them are in a much better position to make a decision on whether it is worth it for 
them to take it. Whilst for some women it is a logical choice to discontinue tamoxifen, 
others are keen to continue treatment but cannot cope with the side effects. Supporting these 
women may stop them from reaching the point where they have to discontinue. For women 
who are not fully informed, increasing necessity beliefs by providing information may help 
to improve adherence rates and allows women to make an informed decision about 
continuing treatment. Patients should also be informed about the importance of taking 






This study suggests that the main reason women are non-adherent or non-persistent with 
tamoxifen is because they are struggling with the side effects and they do not believe that the 
benefits of the treatment outweigh the side effects. Women expressed a need for more 
information about tamoxifen. Supporting women with their side effects and providing more 
information on the benefits of tamoxifen should help to increase adherence and improve 
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4.3. Summary  
The results from this study will help to inform the development of a psycho-educational self-
management intervention to improve tamoxifen adherence in BCS. Whilst some women 
were happy with their decision to stop taking tamoxifen, others were struggling with this 
decision. They wanted to discontinue treatment to avoid the side effects but they were not 
prepared to lose the benefits of tamoxifen. This suggests that supporting these women to 
effectively cope with their side effects may help them to continue with tamoxifen treatment 
without detriment to their quality of life. Furthermore, helping women to manage their side 
effects may prevent women from reaching the stage where it is no longer worth it for them 
to take tamoxifen. The qualitative study also suggested that increasing necessity beliefs may 
improve adherence rates, supporting the results seen in the systematic review. Several 
psychoeducation based interventions have shown success at increasing necessity beliefs 
(Bender et al., 2010; Petrie, Perry, Broadbent & Weinman, 2012). Participants also 
discussed a lack of support and information from their HCPs. This suggests there is a need 
for a self-management intervention to provide the support that women may feel is lacking 
from their HCPs. This is supported by the relationship between patient/physician 
relationship and adherence shown in the systematic review, and is especially important as 
the NHS moves away from regular follow up towards Open Access Follow Up, where 
patients may receive less regular unprompted support from their physicians.  The results 
from the qualitative study also showed that the majority of participants’ concerns focussed 
on side effects. More generic concerns such as dependency or tolerance did not seem 
relevant in this population. One additional concern which was identified was the risk of 
endometrial cancer, which will be addressed in the intervention.    
The qualitative results show that understanding how women weigh up their beliefs about 
tamoxifen may be more important than just investigating side effects. Some women will 
continue to take tamoxifen regardless of their side effects, whereas others may discontinue 
once they experience any side effects. Their reaction to these side effects depends on how 
necessary they perceive the tamoxifen to be, and how motivated they are to avoid a 
recurrence. This may explain the inconsistent relationship found between side effects and 
adherence in the systematic review. The inconsistency may be due to the fact that side 
effects will not cause non-adherence if the patient has high enough necessity beliefs. Taking 
both studies together suggests that whilst side effects are a key driver for non-adherence, the 
beliefs women hold about tamoxifen or breast cancer may be more important predictors. 
This provides important information to help with supporting these patients clinically, and 




The qualitative study also supports the findings of the systematic review by suggesting that 
medication beliefs are a key determinant of non-adherence. These results support both the 
Necessity Concerns Framework (NCF) and the Common Sense Model (CSM), by 
identifying key illness and treatment beliefs which appear to be associated with non-
adherence to tamoxifen. Furthermore, the qualitative results suggest that patients may be 
driven by their fear of a recurrence, a finding which was not seen consistently in the 
systematic review. The systematic review presented an inconsistent picture of predictors of 
non-adherence, and whilst the qualitative study has helped to understand some of these 
factors from the patient’s perspective, this was not a generalizable study and it does not 
allow for examination of effect size or significance of relationships. Therefore, there is a 
need to test the variables identified in the previous studies in a quantitative analysis. Moving 
beyond the previous studies to a large longitudinal questionnaire study helps to determine 
the strength of the relationship between key determinants and non-adherence. Furthermore, 
the cross-sectional analysis allows us to test key elements from the CSM and Theory of 
Planned Behaviour (TPB) to determine which model provides more explanation of non-
adherence and which factors remain significant over and above clinical or demographic 
variables. The majority of studies in the systematic review have failed to use theoretical 
models when investigating non-adherence. These models provide a structured framework for 
investigating key determinants of non-adherence and help with development of interventions 
(Holmes et al., 2014). Using a theoretical framework may increase the effectiveness of 
interventions to improve adherence (Horne et al., 2005). As discussed in Chapter 2, studies 
have shown that both the CSM and the TPB have been useful in predicting medication non-
adherence, yet no published studies have applied these theories to tamoxifen non-adherence. 
As well as this evidence, the qualitative results supported the use of the CSM and the NCF, 
by showing that womens’ beliefs about their medication and their cancer are related to non-
adherence. Therefore, there was a need to investigate the utility of key aspects of these 
models to explain tamoxifen non-adherence. This analysis is presented in Chapter 6. The 
next chapter, Chapter 5, presents the modification of the Revised Illness Perceptions 







5. Modification of the illness perceptions questionnaire for use in breast cancer 
survivors  
5.1. Chapter Overview  
Illness perceptions are a key component of the Common Sense Model of Illness 
Representations (CSM) and have been reliably associated with medication adherence in a 
range of conditions (Brewer et al., 2002; Chen et al., 2011; Daleboudt et al., 2011; Horne & 
Weinman et al., 2002; Van der Have et al., 2016). These illness perceptions are usually 
measured using the Illness Perceptions Questionnaire (IPQ; Weinman et al., 1996), the Brief 
IPQ (Broadbent et al., 2006) or the Revised Illness Perceptions Questionnaire (IPQ-R; 
Moss-Morris et al., 2002). These questionnaires were developed and validated in a range of 
different long term conditions, and the authors recommend that they are modified for use in 
different illnesses due to the unique characteristics and aetiology of each illness (Moss-
Morris et al., 2002). However, despite these recommendations, any modifications made are 
usually very minor, such as adding relevant symptoms or causes or making small changes to 
the language. These minor modifications will most likely fail to pick up the unique 
characteristics of different illnesses. Therefore there is a need for the questionnaire to be 
tailored to the specific patient population. This need is particularly strong in a sample such 
as Breast Cancer Survivors (BCS), where patients may not feel that they currently have an 
illness, due to the fact that they have been treated for their breast cancer and are now 
controlling the risk of a recurrence. Several studies have suggested that breast cancer 
survivors are in a conflicting state where they may feel neither sick nor healthy (McKenzie 
& Crouch, 2004; Powers et al., 2016). Whilst many women see themselves as survivors, and 
do experience a range of psychosocial and medical implications following treatment 
(Bowman et al., 2003; Fallowfield & Jenkins, 2015), many also feel that they have put the 
active illness behind them. The IPQ-R was developed for patients with an active illness and 
with relevant symptoms to control. It was therefore expected that BCS would have difficulty 
answering some of the questions on the IPQ-R relating to active illness and symptom 
control.  For example, the IPQ-R asks participants the extent to which they agree or disagree 
with the statement “my breast cancer will last a long time”. It was anticipated that women 
may have difficulty interpreting and answering items like this, as they may not feel that they 
currently have breast cancer. Similarly, items around symptom control such as “there is a lot 
I can do to control my symptoms” or “my symptoms come and go in cycles” may need to be 
modified, as women may confuse these symptoms with the side effects of their medication. 
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Measuring illness representations in breast cancer survivors (BCS) prescribed 
tamoxifen: Modification and validation of the Revised Illness Perceptions 
Questionnaire (IPQ-BCS) 
Objective: The Revised Illness Perceptions Questionnaire (IPQ-R), widely used to assess 
illness perceptions, may fail to measure unique characteristics of different illnesses. This 
study modified and validated the IPQ-R for breast cancer survivors to provide detailed 
understanding of the specific illness perceptions held by these patients.  
Design: Initial modifications were made following qualitative interviews and were revised 
in a think-aloud study. The modified scale was tested in 753 breast cancer survivors 
prescribed tamoxifen. Modifications included adding a tamoxifen consequences scale and 
adapting the timeline scales to measure beliefs around risk of recurrence and cure. A 
confirmatory factor analysis was conducted on the modified questionnaire and an 
exploratory factor analysis on the causal beliefs scale. Test–retest reliability, internal 
consistency and construct validity were also examined.  
Results: The proposed eight-factor structure showed acceptable model fit, with high 
loadings and good reliability for all subscales. Correlations between subscales were 
consistent with theory and previous research. 
Conclusions: The IPQ-BCS is valid and reliable, and provides unique understanding of 
specific perceptions held by this population, including beliefs surrounding risk of recurrence 
and consequences of ongoing hormonal treatment. Identifying these perceptions will aid 
development of interventions targeting depression, fear of recurrence and medication non-
adherence.  
Keywords: illness perceptions; scale validation; confirmatory factor analysis; IPQ-R; breast 
cancer; tamoxifen 
Introduction 
Illness representations or perceptions, which form part of the Common Sense Model of Self-
Regulation (CSM; Leventhal, Diefenbach, & Leventhal, 1992), predict a range of outcomes, 
including quality of life (QOL) (Petrie, Jago, & Devcich, 2007), fatigue (Jopson & Moss-
Morris, 2003) and poor physical and mental health (Frostholm et al., 2007; Whittaker, 
Kemp, & House, 2007). The CSM proposes that patients’ coping behaviours, such as 
adherence, are guided by their cognitive and emotional representations of their illness. 
Cognitive representations include common sense beliefs about the illness identity (the 
symptoms/label associated with the illness), the cause(s), consequences, 
timeline and controllability of the illness. Patients also have emotional representations, such 




perception of the coherence of their illness representations (Moss-Morris et al., 2002). The 
development of the Illness Perceptions Questionnaire (IPQ; Weinman, Petrie, Moss-Morris, 
& Horne, 1996), the Brief Illness Perceptions Questionnaire (Brief IPQ; Broadbent, Petrie, 
Main, & Weinman, 2006) and the Revised Illness Perceptions Questionnaire (IPQ-R; Moss-
Morris et al., 2002) allowed researchers to quantify illness representations and increased 
empirical research on the role of illness perceptions in areas such as coping, medication 
adherence and health outcomes. 
The IPQ-R has shown good internal reliability and test–retest reliability, as well as sound 
discriminant, known group and predictive validity (Moss-Morris et al., 2002). However, it 
was developed as a generic scale for use across different illness groups and therefore may 
not provide insight into the unique beliefs of different patient groups (French &Weinman, 
2008). Whilst the authors of the IPQ-R recommend that the scale is modified for use in 
different contexts (Moss-Morris et al., 2002), validated modified versions are currently 
lacking. Researchers often rely on very minor modifications such as adding symptoms or 
causes which may not tap into illness-specific beliefs. Thinkaloud studies have shown that 
patients can struggle to answer questions on the IPQ. Patients enrolled in physiotherapy or a 
preoperative exercise programme had some difficulty completing the Brief IPQ and 
occasionally misinterpreted questions (van Oort, Schroder, & French, 2011). Another study 
showed that patients with type 2 diabetes had difficulties with the concepts of cure and 
symptoms and misunderstood the negative wording on some questions on the IPQ-R 
(McCorry, Scullion, McMurray, Houghton, & Dempster, 2013b).This highlights the need to 
explore the face validity of IPQ-R items in different groups of patients and to test the face 
validity of modifications using thinkaloud methods. 
One patient group for whom modifications may be particularly pertinent are breast cancer 
survivors (BCS). There are around three million BCS living in the US and another 200,000 
women are diagnosed with breast cancer every year (American Cancer Society, 2014). These 
patients have completed their active treatment and may no longer consider themselves to be 
ill, although continued therapy and monitoring are required. They may therefore struggle to 
answer questions on the IPQ-R about current illness or current symptom control. However, 
BCS experience a myriad of psychosocial issues and measuring illness perceptions is 
relevant to understanding these ongoing reactions to their previous cancer. For example, 
around a quarter of BCS experience depression or fatigue, and up to 70% show clinical 
levels of fear of cancer recurrence (FCR) (Cvetković & Nenadović, 2016; Servaes, 
Gielissen, Verhagen, & Bleijenberg, 2007; Thewes et al., 2012). Others also struggle to cope 
with long-term hormonal therapy such as tamoxifen, which is prescribed for up to 10 years 




of all breast cancers; Harrell et al., 2007). Whilst tamoxifen is one of the most effective 
systemic treatments available for breast cancer, it can cause unpleasant side effects (Garreau, 
Delamelena, Walts, Karamlou, & Johnson, 2006) and both non-adherence and non-
persistence rates are often as high as 50% within five years of treatment (Hershman et al., 
2010; Kostev, Haas, & Hadji, 2012; Owusu et al., 2008). Non-adherence to tamoxifen is 
associated with significantly increased risk of recurrence and mortality (Barron, Cahir, 
Sharp, & Bennett, 2013; Hershman et al., 2011; Makubate, Donnan, Dewar, Thompson, & 
McCowan, 2013). However, little is known about how illness perceptions and beliefs 
may affect adherence in this population. 
An IPQ modified to address beliefs about a past illness, possibility of recurrence and 
ongoing adjuvant treatment will allow researchers to investigate illness representations 
alongside BCS-specific coping (including adherence) and psychological outcomes. The 
CSM has been suggested as a useful framework for understanding FCR (Fardell et al., 2016) 
and other breast cancer survivorship issues (Kaptein et al., 2015). Further, identifying illness 
perceptions idiosyncratic to BCS could aid development of interventions, which have the 
potential to improve psychological well-being and QOL (Simard et al., 2013).  
This study aimed to modify the IPQ-R for use with BCS. We focused specifically on women 
taking tamoxifen in order to get a more homogenous sample and to tap into illness beliefs 
specific to adjuvant therapy. Following advice from French and Weinman (2008), we used a 
mixed methods approach to modify and validate the questionnaire. The specific objectives 
were: 
(1) To conduct qualitative interviews based on the CSM to elicit key beliefs held by 
BCS taking tamoxifen; 
(2) To use these interviews to develop a modified version of the IPQ-R (the IPQ-
BCS); 
(3) To test the face validity of this modified questionnaire using think-aloud 
interviews and modify further if indicated; 
(4) To assess the factor structure, internal consistency and test–retest reliability of 
the modified IPQ-BCS in a large cross-sectional study of BCS; 
(5) To assess construct validity of the new subscales using inter-correlations 
between subscales and relationships between subscales and psychological variables 
(beliefs about medications and distress). It was hypothesised that IPQ-R subscales 
would show correlations similar to that found in previous research (Hagger & 
Orbell, 2005; Moss-Morris et al., 2002). We hypothesised that distress would be 
associated with higher consequences, identity, emotional representations and risk of 




control; and that tamoxifen concerns would correlate consequences and identity 
beliefs. 
Method 
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207). 
Qualitative study 
Participants and procedure 
Participants were recruited through an oncology clinic in a London hospital and through 
online advertisements, as part of a larger study investigating women’s experiences of taking 
tamoxifen. Patients were eligible if they were female, over the age of 18 and had been 
prescribed tamoxifen post primary breast cancer. Patients were told about the research by 
their clinician, and if interested, they were introduced to a researcher and given an 
information sheet. Women who responded to online advertisements were screened for 
eligibility and given information about the study. 
A follow-up call was made two days later to arrange an interview. This was part of a larger 
qualitative study to explore women’s experiences of taking tamoxifen. Patients were 
interviewed face to face or over the telephone. Informed consent was taken prior to each 
interview. Interviews were recorded and transcribed verbatim. Participants were first asked a 
series of general questions about their experience of tamoxifen, before being asked specific 
questions regarding their illness perceptions for modification of the IPQ-R (See Table 1 for 
interview schedule). Thirty-two women took part in the larger qualitative study, of whom 18 
were asked the additional questions specifically relating to the modification of the 
questionnaire. Data collection for these additional questions ceased once data saturation was 
reached and only these questions were analysed in this study. Thus, data from 18 women 
were analysed. Participant demographics are shown in Table 2. 
Item development 
Interviews were analysed using deductive analysis. Using the CSM as a framework, themes 
were generated around prevalent beliefs and perceptions. Changes to the questionnaire were 
made to reflect the language used by participants. A key theme was that women did not 
identify as currently having breast cancer. All questions were amended to avoid asking 
women about their breast cancer in the present tense. Original and amended items are shown 




A second theme suggested women attributed few symptoms to breast cancer. Therefore, the 
identity scale was amended to assess symptoms which were (a) attributed to breast cancer, 
(b) to tamoxifen treatment and (c) to their previous/other treatment.  
Table 1. Interview schedule for qualitative interviews  
(1) Are there any specific side effects that you have experienced?  
 Ones that your doctor did not tell you about? 
(2) Do you believe that your previous treatment has cured your breast cancer? 
(3) Do you still experience ongoing effects from your previous treatment (chemo, 
surgery, radio)?  
(4) Do you still see yourself as having breast cancer?  
 What is your relationship with breast cancer?  
(5) What do you see as the main consequences of Tamoxifen? 
(6) What do you see as the main consequences of breast cancer? 
(7) Do you think that tamoxifen is preventing a risk of recurrence?  
(8) What else might be impacting a risk of recurrence?  
(9) Is there anything else you can do to control this (prevent risk of recurrence)?  
 
Analysis of the interviews elicited specific tamoxifen-related symptoms. Ten new 
symptoms, such as hot flushes and change in sex drive, were added to the original list of 14 
symptoms in the core version of the IPQ-R (See Table 3 for list of additional symptoms). 
When asked about control, consequences and causes, women tended to discuss their risk of 
recurrence instead of their breast cancer. Therefore, to effectively assess control beliefs, the 
personal and treatment control subscales were amended so that the word ‘illness’ was 
replaced with ‘risk of recurrence’. The treatment control items were asked specifically in 
relation to tamoxifen. In addition to the existing illness consequences scale, a new scale was 
added to assess the consequences of taking tamoxifen, as this was a dominant theme 
identified in the interviews. 
With regard to timeline beliefs, the interviews showed that women did not have symptoms 
which come and go. The cyclic timeline scale was removed and a new scale was added to 
assess risk of recurrence. Likewise, the timeline acute/chronic scale was amended to assess 
the extent to which women believe that their breast cancer is cured, as the interviews showed 
that these beliefs were much more pertinent than beliefs around the chronic nature of breast 
cancer itself. The coherence scale was modified to measure understanding of tamoxifen 
treatment rather than breast cancer. Finally, as women discussed fear around risk of 
recurrence rather than fear around breast cancer, the emotional representations scale was 
amended to reflect this. The cause scale was modified by adding breast cancer-specific 
causes such as hormonal influence and removing causes which were not applicable. 




Table 2. Demographics characteristics of participants.  
 











Age  mean (SD) 
 53 (10.2)  
Range 36 –  63  
53 (9.2) 
Range 37 – 63   
53 (10.5)  
Range 30 – 91  
56 (10.3) 
Range 38 - 82 
Race   n (%) 
     White British  
      Other  
 
13 (72%) 
5 (28%)  
 








Age left full time 
education n (%) 
     16 or under 








Menopausal status at 
diagnosis  n (%) 
     Pre-menopausal  
     Menopausal  
     Post-menopausal  
     Unsure 
 
4 (22%) 
2 (11%)  
9 (50%) 










33 (4%)  
 
Months since breast 
cancer diagnosis  
Mean (SD)  
36 (25) 
Range 1 year – 
5.5 years 
25 (19)  
Range 1 year – 
6 years  
33 (24) 
Range 2 
months – 16 
years  
45 (25) 
Range 1 month 
– 9 years 
Stage at diagnosis n 
(%) 
     Stage I  
     Stage II  





93 (12%)  
 
Previous treatment   n 
(%) 
     Lumpectomy  
     Single mastectomy  
     Double mastectomy 
     Chemotherapy  

















557 (74%)  
 
Note. SD, Standard deviation. Blank spaces indicate incidences where data was not collected.  
 
Think-aloud study 
After item modification, a think-aloud study was conducted to examine if items on the new 
IPQ-R were being understood and interpreted in the expected way. Eleven women from the 
interview study were invited to take part in the think-aloud study and eight agreed. Think-
aloud studies involve patients verbalising their thought process as they answer the 
questionnaire (Ericsson & Simon, 1998). These methods have been used previously to 
examine questionnaires assessing illness perceptions (van Oort et al., 2011), theory of 
planned behaviour (French, Cooke, McLean, Williams, & Sutton, 




Table 3. Examples of changes made to the original IPQ-R.  
 Previous item New item  
Identity scale   Change in libido, hot flushes, leg 
cramps, loss of concentration, night 
sweats, joint pain, vaginal 
dryness/itchiness/discomfort, feeling 
down, changes to periods, feeling 
lightheaded 
Timeline acute / 
chronic (cure) 
My illness will last for a long 
time 
My breast cancer is cured  
Breast cancer 
consequences 
My illness has major 
consequences on my life 
My breast cancer still has major 
consequences on my life 
Tamoxifen 
consequences 
-  I can’t function normally whilst 
taking tamoxifen 
Personal control My actions will have no effect 
on the outcome of my illness 
My actions will have no effect on the 
risk of cancer coming back 
Treatment control Tamoxifen treatment can 
control my illness 
Tamoxifen treatment can control my 
risk of recurrence 
Coherence My breast cancer is a mystery 
to me 
Tamoxifen is a mystery to me 
Timeline cyclical 
(risk of recurrence)  
I go through cycles in which 
my breast cancer gets better 
and worse 
There is a good chance my cancer 
will come back 
Emotional 
representations 
I get depressed when I think 
about my breast cancer 
I get depressed when I think about 
my risk of recurrence 
Causes   Hormonal influence, exercise 
 
Participants were asked to complete the modified IPQ-BCS and to verbalise everything they 
were thinking as they were completing the questionnaire. If they were quiet for a long period 
of time, they were prompted to think aloud as they were considering the question. The think-
aloud sessions were conducted over the telephone and participants consented to be audio 
recorded. 
 The think-aloud interviews showed that women could understand the questionnaire and that 
they found it relevant and applicable. However, several issues were identified which led to 
further modifications. The instructions to both the identity and cause scales were modified to 
improve their clarity. A few participants remarked that some items in the personal and 
treatment control scales were worded too severely and that they were unsure how to answer 
them. Therefore, the items were amended to reflect this. Several other items were revised 
slightly to enhance the chance they would be applicable for all participants or to ensure they 
were being correctly interpreted. Some women remarked on the repetitiveness of questions, 







Participants and procedure 
Participants were recruited through oncology clinics at 25 NHS Trusts throughout England 
and through online advertisements. Patients were eligible if they had a diagnosis of primary 
breast cancer and if they had been prescribed tamoxifen. Participants had to be female and 
over the age of 18. Patients were approached by a member of their clinical team during a 
routine clinic appointment or received an invitation in the post from their clinical team. They 
were given information about the study along with the questionnaire and a return envelope. 
After providing informed consent, participants either completed the questionnaire in the 
clinic or took it home to return to the researcher. Participants who were recruited online 
responded to an advert and after being screened for eligibility, were sent information about 
the study along with a link to an online questionnaire. Participants gave informed consent 
whilst completing the online questionnaire. A separate sample was recruited to assess the 
test–retest reliability of the IPQ-R. This sample was recruited from four NHS Trusts. 
Participants were given information about the study from the clinical team and once 
consented, they completed the first questionnaire in clinic. Participants were either posted 
the second questionnaire or given a link to complete it online two weeks later, whichever 
was their preference. Telephone reminders were made if the second questionnaire had not 
been returned within one week. 
Measures 
Modified IPQ-R (IPQ-BCS). Participants completed the modified version of the IPQ-R 
(IPQ-BCS), which included subscales measuring identity, cure beliefs, risk of recurrence, 
tamoxifen consequences, breast cancer consequences, personal control over recurrence, 
tamoxifen control, coherence, emotional representations and causes. All questions were 
scored on a five-point Likert-type scale ranging from Strongly Agree to Strongly Disagree 
with the exception of the identity scale where participants ticked each column to indicate if 
they experienced that symptom. Each subscale included four items, with the exception of 
cure beliefs, tamoxifen consequences and emotional representations, which included five 
items. The identity subscale was calculated by totalling the number of symptoms which were 
attributed to tamoxifen. Symptoms which were added to the original list of symptoms are 
shown in Table 3. 
Hospital Anxiety and Depression Scale. The Hospital Anxiety and Depression Scale 
(HADS) is a 14-item scale measuring depression and anxiety (Zigmond & Snaith, 1983). 
The total distress scale was used in this study, as a large meta confirmatory factor analysis 




subscales (Norton, Cosco, Doyle, Done, & Sacker, 2013). Each item is scored on a scale of 
0–3, with higher scores reflecting higher levels of distress. The HADS has shown good 
reliability in patients with breast cancer (Matthews et al., 2014; Stanton, Petrie, & Partridge, 
2014). 
Beliefs about Medicines Questionnaire. The Beliefs about Medicines Questionnaire (BMQ)-
Specific measures beliefs surrounding the necessity of taking medications and concerns 
about adverse effects (Horne, Weinman, & Hankins, 1999). The word medication was 
replaced with the word tamoxifen for all items. Each item is rated on a five-point Likert-type 
scale. A higher score on each subscale indicates stronger necessity or concern beliefs. The 
scale has been used many times in BCS with Cronbach’s alpha values of .79–.86 and .72–.84 
for the necessity and concerns scale, respectively (Bender et al., 2014; Corter, Findlay, 
Broom, Porter, & Petrie, 2013; Jacob Arriola et al., 2014). 
Statistical analysis 
Missing data were less than 5% and were replaced using mean substitution. A CFA was 
conducted on the modified IPQ-BCS using Mplus version 7 to test the hypothesised model 
of eight subscales (cure beliefs, tamoxifen consequences, risk of recurrence, breast cancer 
consequences, personal control, treatment control, coherence and emotional representations). 
CFA is the gold standard method for evaluation of construct validity in psychometric tests 
(Hu & Bentler, 1999). The CFA was conducted using weighted least squares with means and 
variances corrected, as the data were measured on an ordinal categorical scale. Multiple 
indices were used to assess model fit. Chi-squared was not used as it is sensitive to sample 
size (Byrne, 2001). The comparative fit index (CFI), root mean square error of 
approximation (RMSEA) and Tucker– Lewis index (TLI) were used. CFI or TLI values of 
greater than .95 suggest acceptable model fit (Hu & Bentler, 1999). RMSEA values of .08 
indicate reasonable fit and values of under .06 indicate good fit (Hu & Bentler, 1999). The 
reliability of each subscale was tested using Cronbach’s alpha. Test–retest reliability was 
assessed using intraclass correlation of each subscale at baseline and two-week follow-up. 
Discriminant validity was assessed using inter-correlations between IPQ-R dimensions. 
Construct validity was assessed by examining the correlations between IPQ-R dimensions 
and additional variables (beliefs about medications and distress). It is recommended that the 
causal attribution scale be examined in an exploratory fashion (Dempster & McCorry, 
2012); therefore, exploratory factor analysis (EFA) was used as it does not specify an 
underlying factor structure. Item frequencies were visually inspected and items were 
removed if the majority of participants did not see them as a cause. An EFA was then 
conducted using the SPSS R-menu for ordinal factor analysis based on polychoric 




parallel analysis (Horn, 1965). The factor analysis was conducted using Maximum 
Likelihood extraction and Geomin Q-Q rotation. 
 
Results 
Data were collected from 753 participants. Participants were all female and had been 
diagnosed with Stage I–III breast cancer (Table 2). Mean age was 53 (SD = 10.5) and 
participants were on average 33 months post breast cancer diagnosis (SD = 24, range 2 
months–16 years). 
Confirmatory factor analysis 
The sample size exceeded the requirements of at least three cases per item (Tabachnick & 
Fidell, 2007). Visual inspection of the data showed the items generally correlated as 
expected within the eight subscales, indicating that a CFA was appropriate. The 35-item 
IPQ-BCS showed acceptable model fit (RMSEA = .08, 95% CI = .08–.09, CFI = .95, TLI = 
.94). In order to reduce the length of the scale, one item (with the lowest factor loading) was 
removed from each of the three subscales with five items (tamoxifen consequences, cure 
beliefs and emotional representations). Removing these items did not change the overall 
model fit, and therefore this briefer questionnaire is preferred where 
all subscales have four items. Table 4 shows the factor loadings for each of the items under 
each of the subscales. Factor loadings were all well above the required threshold of .40 
(Ford, MacCallum, & Tait, 1986), ranging from .63 to .95. 
Internal and test–retest reliability 
All scales showed excellent reliability, with Cronbach’s alpha values ranging from .76 to .92 
(Table 4). Test–retest reliability was tested in a separate sample of 48 women. Participants 
completed the questionnaire twice; on average, 18 days apart (range 11–31). The intra-class 
correlation coefficients for each scale ranged from .77 to .94, indicating excellent test–retest 
reliability (Table 4).  
EFA on cause items  
Item frequencies and correlations were explored visually and two items were removed from 
the EFA. Item 3 (A germ or virus) was removed as it did not correlate with other items and 
only 5% of participants agreed that it might be a risk factor for recurrence. Item 12 
(smoking) was also removed, as only 24% of participants provided data for this question. 
Hormonal influence was the strongest item, with 81% of participants agreeing that it was a 




Parallel analysis was used on 11 causal items to assess the number of factors to retain, and 
indicated a three-factor solution, explaining 46% of the total variance. Factor loadings are 
shown in Table 5. The first factor, labelled psychological attributions, included items 
relating to stress, worries and emotional state. The second factor, labelled health behaviours, 
included items such as diet and eating habits and exercise. These two factors showed good 
reliability (.85 and .72, respectively). The final factor included item 11 (ageing) and item 13 
(hormonal influence). However, hormonal influence had a factor loading of below .4 and the 
reliability of the factor was very low (.44). Therefore, these items might be best considered 
individually and not as part of a subscale. Item 2 (runs in the family) and item 5 (chance or 
bad luck) did not load onto any factors.  
Examination of the identity scale 
Each symptom was experienced by at least 13% of participants. Over 40% of participants 
had experienced pain, weight loss/gain, hot flushes, night sweats, fatigue, sleep difficulties, 
joint pain and loss of sex drive. Patients experienced on average 7.8 symptoms (SD = 5.9). 
Symptoms were more commonly attributed to tamoxifen (mean = 5.8, SD = 4.9) than to 
breast cancer (mean = 2.1, SD = 3.2) or previous/other treatment (mean = 2.0, SD = 3.6). As 
symptoms were rarely attributed to breast cancer, identity was represented by the total 
number of symptoms attributed to tamoxifen. All symptoms were most commonly attributed 
to tamoxifen, with the exception of pain which was attributed to breast cancer by 29% of 
participants and to tamoxifen by 14% of participants. Hot flushes were the most common 
symptom attributed to tamoxifen (65%), followed by night sweats (55%), weight loss/gain 
(41%), joint pain (37%), fatigue (35%), leg cramps (35%) and vaginal dryness, itchiness or 
discomfort (35%). These results provide support for the validity of the symptoms included in 




Table 4. Confirmatory Factor Analysis of the eight-factor IPQ-R. 






Cure            
My treatment has been effective in curing my breast cancer 0.74          
I no longer have breast cancer  0.89          
My breast cancer is cured  0.85          
I still see myself as having cancer  0.81          
Breast cancer consequences            
My breast cancer still has major consequences on my life  0.87         
My breast cancer currently does not have much effect on 
my life  
 0.66         
I still experience long lasting effects from my original 
treatment for breast cancer   
 0.69         
My breast cancer currently causes difficulties for those 
who are close to me (e.g. emotional difficulties)  
 0.75         
Tamoxifen consequences            
Tamoxifen has major consequences on my life    0.63        
I can’t function normally whilst taking tamoxifen    0.89        
Taking tamoxifen has had an impact on those around me   0.88        
My work / social life has been affected by taking 
tamoxifen 
  0.95        
Risk of recurrence            
There’s a good chance my cancer will come back     0.91       
I expect to have a recurrence of cancer in the future      0.95       
I am extremely likely to have a recurrence    0.92       











Personal control            
There are things I can do to stop the cancer coming back     0.79      
What I do has an influence on whether my cancer comes 
back  
    0.77 
     
There is nothing I can do to help my risk of recurrence     0.87      
My actions will have no effect on the risk of cancer 
coming back  
    0.81      
Tamoxifen treatment can reduce my risk of recurrence      0.82     
There is very little that can be done to stop the cancer 
coming back 
     0.84     
 Taking tamoxifen will help stop the cancer coming back      0.78     
There is nothing that can help my risk of recurrence       0.82     
Coherence            
Tamoxifen is a mystery to me       0.76    
I understand how tamoxifen helps prevent cancer 
recurrence  
      0.80    
I don’t understand how much tamoxifen can help me       0.83    
I have a good understanding of why I am taking tamoxifen       0.82    
Emotional representations            
I get depressed when I think about my risk of recurrence        0.91   
I worry about my risk of recurrence        0.90   
When I think about the cancer coming back I get upset        0.90   
My risk of recurrence makes me feel afraid        0.94   
Cronbach’s alpha 0.81 0.79 0.87 0.90 0.81 0.76 0.81 0.92   






Inter-correlations between the IPQ-BCS subscales are shown in Table 6. The direction and size of the 
correlations are consistent with previous research (Hagger & Orbell, 2005; Moss-Morris et al., 2002), 
and with what would be expected due to the underlying theory. Tamoxifen consequences and breast 
cancer consequences were positively correlated. Both consequences scales correlated positively with 
emotional representations and risk of recurrence and negatively with cure beliefs and treatment 
control. Cure beliefs had a moderate negative correlation with risk of recurrence. Personal control and 
treatment control were strongly correlated. Both control scales correlated positively with coherence 
and cure beliefs and negatively with risk of recurrence. Emotional representations was negatively 
correlated with cure beliefs and treatment control and positively correlated with risk of recurrence. 
Identity beliefs correlated positively with tamoxifen consequences, risk of recurrence, breast cancer 
consequences and emotional representations 
 





Factor 2:  
Health behaviours 
Factor 3: 
External causes  
Stress or worry  .771 .066 -.040 
Family problems  .907 -.004  -.014 
My own emotional state  .818 -.009  .096 
Diet or eating habits  -.004 .840 -.146 
My own behaviour  .097  .622 .064 
Exercise -.008  .686 .059 
Pollution in the 
environment  
.212 .400 .044 
Ageing .043 .004 .788 
Hormonal influence  -.097 .209  .330 
Runs in the family  .076 .076  .112 
Chance or bad luck  .002 .067 .239  







Table 6. Correlations between IPQ-R subscales.  
 1 2 3 4 5 6 7 8 9 
1. Cure  1         
2. Tamoxifen 
consequences 
-.14** 1        
3. Risk of 
recurrence 
-.45
** .23** 1       
4. Breast cancer 
consequences  
-.31








** -.17** -.35** -.22** .58** 1    








-.12** .56** .19** .36** .04 .00 .05 .25** 1 
 **p <0.01, *p<0.05  
 
Table 7. Correlations between IPQ-R subscales, HADS distress and BMQ necessity and 
concerns. 
  Distress Concerns 
Necessity 
beliefs 
Cure  -.20** -.18** -.04 
Tamoxifen consequences .53** .56** .10* 
Risk of recurrence  .31** .19** .12** 
Breast cancer consequences .55** .40** .15** 
Personal control  -.15** -.08* .02 
Treatment control  -.21** -.23** .15** 
Coherence -.15** -.28** .07 
Emotional representations  .45** .36** .23** 











To further explore the validity of the constructs of the IPQ-BCS subscales, correlations were 
examined with distress using the HADS and treatment beliefs using the BMQ. These 
correlations were consistent with hypothesised relationships and supported the construct 
validity of the IPQ-R dimensions (Table 7). HADS distress correlated positively with 




cure beliefs and treatment control. BMQ tamoxifen concerns correlated positively with IPQ-
BCS tamoxifen consequences, breast cancer consequences, identity and emotional 
representations, and negatively with treatment control and coherence. BMQ tamoxifen 
necessity beliefs correlated positively with IPQ-BCS emotional representations and 
treatment control. 
Discussion 
This paper developed and validated a modified version of the IPQ-R for use with BCS 
prescribed tamoxifen. The modified version includes an identity scale which has been 
modified to assess symptoms attributed to tamoxifen, the original illness consequences scale 
and a new tamoxifen consequences scale. The timeline acute scale was amended to measure 
cure beliefs and the timeline cyclical was replaced with a risk of recurrence scale. The 
personal control, treatment control and emotional representations scales were amended to 
assess risk of recurrence rather than current cancer. The coherence scale was amended to 
measure coherence around tamoxifen rather than breast cancer. The 35-item IPQ-BCS 
showed acceptable model fit, with high factor loadings on the conceptual subscales, and high 
reliability for all subscales. To decrease participant burden, this was reduced down to a 32-
item questionnaire where each subscale has four items. This modification did not affect 
model fit and the reliability for each scale remained high, demonstrating that the removed 
items were redundant and that the shortened questionnaire is sufficient to understand these 
constructs. This modification and validation of the IPQ-R for use in BCS was a vital step in 
furthering understanding of illness perceptions held by BCS. The qualitative interviews we 
conducted showed that women would have had difficulty answering questions on the 
original IPQ-R regarding their current illness and breast cancer symptoms. The think-aloud 
study showed that items on the modified IPQ-BCS were easy to interpret and to answer. 
These results provide support for the CSM and the idea that BCS hold perceptions about 
their previous breast cancer and ongoing treatment and survivorship. Investigating these 
illness perceptions will enhance understanding of the psychosocial issues associated with 
breast cancer survivorship and will help with developing interventions to reduce distress or 
improve QOL in this population. The modified IPQ-BCS assesses beliefs which would not 
have been assessed with the original IPQ-R, such as beliefs around risk of recurrence and 
cure. These beliefs are likely to be relevant to understanding FCR and depression in BCS. 
The benefit of using the IPQ-BCS to assess FCR is that it allows examination of both 
perceptions of risk (risk of recurrence scale) and emotional responses to this risk perception 
(emotional representations scale). Whilst they are correlated, perceptions of the likelihood of 
a recurrence differ from the emotions (e.g. fear; distress) that women feel in response to this 




QOL will aid development of interventions to reduce FCR. Furthermore, the IPQ-BCS 
allows these risk of recurrence beliefs to be measured alongside other illness perceptions, 
such as control and consequences, which feed into beliefs around risk of recurrence (Fardell 
et al., 2016). The IPQ-BCS could be supplemented with a more complex FCR scale which 
also assesses hypervigilant checking behaviours, functional impairment of FCR or FCR in 
relation to actual risk. 
The IPQ-BCS also measures beliefs regarding tamoxifen treatment specifically, rather than 
the more generalised treatment control scale included in the IPQ-R. The IPQ-BCS assesses 
consequences of ongoing tamoxifen treatment as well as breast cancer consequences, and 
measures treatment control specifically with regard to tamoxifen treatment. This scale could 
therefore be used to identify illness and treatment beliefs related to non-adherence in this 
population. Previous studies have found problems with the treatment control subscale of the 
IPQ-R, such as low reliability and cross-loading of items (Brzoska, Yilmaz-Aslan, 
Sultanoglu, Sultanoglu, & Razum, 2012; Ibrahim, Desa, & Chiew-Tong, 2011; Moss-Morris 
et al., 2002). This is likely due to participants being unsure as to which treatment the 
questions are referring to. Amending this subscale to specifically assess tamoxifen treatment 
may have overcome these issues, as the IPQ-BCS treatment control subscale showed good 
reliability and was free from cross-loading. This scale could also be amended to assess 
treatment control specific to aromatase inhibitors or hormone therapy in general. 
The EFA on the cause scale produced three factors. Factor one (psychological attributions) 
and factor two (health behaviours) showed good reliability. However, some items did not 
load onto any factors or had low factor loadings. These results are not consistent with the 
original IPQ-R factor structure (Moss-Morris et al., 2002). However, several papers have 
found a factor structure which is hard to interpret (Nicholls, Hill, &Foster, 2013; 
Wittkowski, Richards, Williams, & Main, 2008). In a sample of Greek cancer patients, 
Giannousi, Manaras, Georgoulias, and Samonis (2010) also found that items 2 (hereditary), 
5 (chance or bad luck) and 11 (ageing) did not load onto any factors. Whilst hormonal 
influence and chance or bad luck did not load onto any factors in this analysis, they were the 
most consistently endorsed causes and therefore, they should be considered as individual 
items in future analysis or larger subscales related to these constructs should be developed . 
Whilst attempts were made to amend the cause scale to enhance its applicability, further 
modifications may be needed to develop a more robust factor structure. 
Correlations between IPQ-BCS subscales were consistent with theory and previous research 
and showed good construct validity. The original consequences scale correlated positively 
with the new tamoxifen consequences subscale, but the correlation was only moderate, 




their tamoxifen treatment. Previous research in a cancer setting has found overlap of the 
consequences and emotional representations scales, where items from both subscales loaded 
onto the same factor (Giannousi et al., 2010). However, the IPQ-BCS correlations between 
these subscales were only moderate and the hypothesised factor structure was supported, 
suggesting that emotional representations around recurrence are distinct from consequences 
of breast cancer. The risk of recurrence scale, which was adapted from the previous timeline 
cyclical scale, showed that having high beliefs of a recurrence was associated with higher 
consequences, higher emotional representations and lower cure beliefs. 
The personal and treatment control subscales were positively correlated, but the correlations 
were low enough to support the assumption of two distinct constructs, which is consistent 
with previous research (Dempster & McCorry, 2012; Giannousi et al., 2010; Moss-Morris et 
al., 2002). Women who scored highly on the two control subscales were less likely to 
believe they would have a recurrence, more likely to believe their breast cancer had been 
cured and more likely to have higher coherence beliefs. Women who attributed a high 
number of symptoms to tamoxifen were significantly more likely to believe they would have 
a risk of recurrence and less likely to believe they were cured, but these were small 
correlations. This is consistent with correlations found in previous research (Hagger & 
Orbell, 2003) and suggests that there is a relationship between symptom experience and 
perceptions of risk. 
The correlations between IPQ-BCS subscales, HADS distress and BMQ treatment beliefs 
provided further support for construct validity. Higher concerns about tamoxifen were 
associated with higher tamoxifen consequences, a greater number of symptoms attributed to 
tamoxifen and to a lesser extent, higher breast cancer consequences. This is expected in this 
population as tamoxifen concerns focus almost exclusively on side effects (Moon, Moss-
Morris, Hunter, & Hughes, 2016) and are therefore related to beliefs around consequences 
and symptom attribution. Understanding the interactions between illness perceptions and 
medication beliefs may help understand medication non-adherence in BCS (Horne & 
Weinman, 2002). HADS distress was associated with tamoxifen consequences, breast cancer 
consequences and emotional representations. These relationships make theoretical sense, as 
greater illness consequences are likely to contribute to levels of distress. However, as this 
was cross-sectional data, the direction of the effect cannot be established. It may be that 
women who experience higher levels of distress perceive greater consequences from their 
illness or ongoing treatment. 
Strengths of this study include the large sample size and robust analysis. The scale was 
amended based on interviews with patients, and before being analysed, it was subject to 




England, which should enhance the generalisability of the results. However, there were 
several limitations. Firstly, participants from the same sample were used to develop the 
items on the questionnaire and to test the questionnaire in the think-aloud studies. Secondly, 
the factor structure has only been tested and validated in one sample. Future research could 
test whether the IPQ-BCS could be modified further for use in different cancer types with 
similar survivorship issues to BCS. Overall, results suggest that the modified IPQ-BCS is a 
valid and reliable measure. It is well understood in BCS and has a clear factor structure with 
10 distinct constructs (cause, identity, cure, tamoxifen consequences, risk of recurrence, 
breast cancer consequences, personal control, treatment control, coherence and emotional 
representations). Utilising this scale will help us understand how women feel about their 
illness and their ongoing treatment as they move into survivorship. Illness perceptions have 
been shown to be relevant to many of the psychosocial issues inherent to BCS, such as 
fatigue, non-adherence, distress and FCR. Using the IPQ-BCS will allow researchers to see 
how dimensions such as emotional representations and sense of coherence affect illness 
behaviours such as adherence, or outcomes such as QOL and survival, and will help 
generate interventions to support these patients. Whilst the scale was developed for 
tamoxifen treatment, it is likely it will be equally as applicable for women who have been 
prescribed other hormonal therapy such as aromatase inhibitors. It can also be used in other 
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5.3. Summary  
This paper reports on the modification of the IPQ-R for BCS. The scale is valid and reliable 
and can therefore be used to examine illness perceptions held in BCS in a range of contexts, 
including distress, fear of recurrence, quality of life, health behaviours and survival. Using 
the IPQ-BCS would overcome any limitations associated with using non-validated scales, or 
with using the generic IPQ-R to measure these constructs. In particular, the scale was 
developed to explore the relationship between illness perceptions and tamoxifen adherence 























6. More than just side effects: the role of clinical and psychological factors in 
non-adherence to tamoxifen    
6.1. Chapter Overview  
This chapter describes a large cross-sectional study to compare the Common Sense Model 
(CSM) and the Theory of Planned Behaviour (TPB) in explaining tamoxifen non-adherence. 
This study also forms the basis of the longitudinal study which is presented in Chapter 8. 
Women in the cross-sectional study who were in their first year of adjuvant treatment were 
followed up for one year.  
The previous chapters have shown that there are few consistent predictors of tamoxifen non-
adherence. Bringing the results of the qualitative study and systematic review together 
suggests that one of the key factors associated with non-adherence is how women weigh 
their side effects up against their beliefs about tamoxifen and about their breast cancer. 
However, so far, few modifiable factors have been identified. In order to improve 
understanding of psychosocial factors associated with non-adherence and to develop an 
intervention to improve adherence rates, there is a need to identify more modifiable factors. 
The previous studies have suggested several variables which may be important for 
tamoxifen non-adherence, including side effects, medication beliefs, social support and self-
efficacy for medication taking. The cross-sectional study allows these variables to be tested 
in a large robust study using validated measures, and using models of health behaviour as a 
framework. This will help to provide clarity on the strength and direction of relationships, 
and will give much needed information for intervention development. Using a large 
quantitative design will also allow for elements from the CSM and TPB to be tested. Results 
will provide insight into which factors provide the best explanation of non-adherence, and 
will identify if either model provides superior explanation. If both models provide good 
prediction, then a more parsimonious model may be able to be created. This could reduce 
redundancy, aid with design of future studies and enhance the effectiveness of future 
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More than just side effects: the role of clinical and psychosocial factors in non-
adherence to tamoxifen  
 
Objectives: Tamoxifen non-adherence is apparent in up to half of breast cancer 
survivors and is associated with increased risk of recurrence and reduced quality of life. 
However, factors contributing to non-adherence in this population are currently poorly 
understood. This study explored the relationship between key components of the Common 
Sense Model of Illness Representations (CSM) / the Theory of Planned Behaviour (TPB) 
and intentional and unintentional non-adherence in a large sample of women prescribed 
tamoxifen following primary breast cancer.  
Design: Cross-sectional questionnaire study (n=777).  
Methods: Women were eligible if they were over 18, had been diagnosed with primary 
breast cancer and had been prescribed tamoxifen. Participants were recruited in clinic or 
online and completed questionnaires assessing illness perceptions, treatment beliefs, 
adherence, quality of life, social support, distress and the key TPB components. Logistic 
regressions were conducted to test elements from each model and to identify correlates of 
intentional and unintentional non-adherence.  
Results: Patients were classified as non-adherent based on Medication Adherence 
Rating Scale scores. 44% of the population were non-adherent; 41% reported unintentional 
non-adherence and 9% reported intentional non-adherence. Study variables accounted for 




than unintentional non-adherence 
(Nagelkerke R
2
=17%). Intentional non-adherence was best explained by a combination of 
TPB and CSM variables, but these variables did not contribute significantly to unintentional 
non-adherence.   
 Conclusions: The TPB and the CSM provide a useful framework for understanding 
intentional tamoxifen non-adherence. Elements from both models should be considered 










Breast cancer is the most common cancer in women in the UK, and whilst survival rates are 
improving, it is still the second most common cause of cancer-related death in the UK 
(Cancer Research UK, 2014). About 75% of breast cancers are oestrogen receptor positive 
(ER+), which means the cancer cells are stimulated by oestrogen (Harrell et al., 2007). 
Adjuvant hormonal therapy (HT) such as tamoxifen is prescribed to women with ER+ breast 
cancer to reduce the risk of recurrence. Tamoxifen, which works by blocking the oestrogen 
receptor, reduces the risk of recurrence by 46% and the risk of mortality by 26% (Early 
Breast Cancer Trialists' Collaborative Group, 1998). It is prescribed for between five and ten 
years and is one of the most effective systemic therapies available for ER+ early breast 
cancer (Aguilar et al., 2010).  
Treatment adherence, defined as the extent to which patients take their medication as 
prescribed (Sabate, 2003), is often not considered to be an issue with cancer patients, due to 
the life threatening nature of the illness (Wu, Stafkey-Mailey, & Bennett, 2012). However, 
despite the clear clinical benefits of tamoxifen, many patients either stop taking their 
medication early or do not take the full dosage. Non-adherence ranges from 6% - 55% 
(Ayres, Baldoni, Borges, & Leira Pereira, 2014; Hershman et al., 2011; McCowan, Wang, 
Thompson, Makubate, & Petrie, 2013) and rises over time (Hershman et al., 2010; Partridge, 
Wang, Winer, & Avorn, 2003). This variability in adherence rates is likely due to variations 
in study design and populations, such as different healthcare and cultural contexts. 
Furthermore, there is significant variability in the tools used to assess adherence, with 
studies utilizing self-report measures reporting higher rates of adherence (Moon et al., 2017). 
A further 50% of patients completely discontinue tamoxifen within five years (Kostev et al., 
2013; van Herk-Sukel et al., 2010), which is known as non-persistence. Non-adherence and 
non-persistence to tamoxifen are associated with increased risk of death and early recurrence 
(Barron, Cahir, Sharp, & Bennett, 2013; Hershman et al., 2011; Makubate, Donnan, Dewar, 
Thompson, & McCowan, 2013), as well as fewer quality adjusted life years and increased 
medical costs (McCowan et al., 2013). This indicates a need to understand why women are 
not adhering, so we can intervene to increase adherence rates and improve clinical outcomes. 
Identifying psychosocial predictors of non-adherence is essential in the development of 
interventions, as these factors have the potential to be modified. For example, medication 
beliefs and perceived control over medication taking are associated with medication 
adherence in a range of conditions (Conner, Black & Stratton, 1998; Horne & Weinman, 
1999) and have been successfully targeted in interventions (Petrie et al., 2012; Sheeran & 
Orbell, 2000).   However, evidence on modifiable psychological predictors of tamoxifen 




Murphy, Bartholomew, Carpentier, Bluethmann, & Vernon, 2012), with an emphasis in the 
literature on non-modifiable clinical and demographic factors.   
Non-adherence can be conceptualised as intentional, where the patient makes a deliberate 
decision not to adhere, or unintentional, where they may forget or not understand the 
instructions. Unintentional non-adherence is more prevalent in breast cancer, however this 
may be due to forgetting being more socially acceptable and therefore more frequently 
reported (Atkins & Fallowfield, 2006; Unni & Farris, 2011). Some studies suggest that 
unintentional non-adherence may be related to medication beliefs (Gadkari & McHorney, 
2012; Schüz et al., 2011), which questions how unintentional these behaviours are. 
However, recent studies in breast cancer have supported the idea of a distinction between 
unintentional and intentional non-adherence (Kimmick et al., 2015; Wouters et al., 2014). 
Understanding these different types of non-adherence and the associated predictors would be 
useful in tailoring interventions to improve adherence.  
Tamoxifen is associated with side-effects, including hot flushes, vaginal dryness and low 
mood, which are often assumed to drive non-adherence. However, the relationship between 
side-effects and non-adherence is inconsistent (Moon et al., 2017). Whilst a recent 
systematic review has found some evidence for potentially modifiable psychosocial 
correlates of HT non-adherence, including self-efficacy for medication taking, medication 
beliefs and social support (Moon et al., 2017), previous research has largely failed to use 
theoretical models when investigating non-adherence. Theory provides a structured 
framework for investigating key determinants of non-adherence and helps with intervention 
development (Holmes, Hughes, & Morrison, 2014). This study will use two popular models 
of health behaviour to investigate tamoxifen non-adherence; the Common Sense Model 
(CSM) and the Theory of Planned Behaviour (TPB). These models have been used 
extensively to predict health behaviours, but to the best of our knowledge, no peer reviewed 
research has applied them to tamoxifen adherence.  
The TPB proposes that adherence is driven by intentions to engage with treatment, which are 
in turn influenced by subjective norms, attitudes and perceived behavioural control (PBC), 
which also exerts a direct influence over behaviour (Ajzen, 1991). Previous studies have 
supported the TPB as a framework for understanding non-adherence (Kagee & Van der 
Merwe, 2006) with key TPB variables explaining large proportions of variance in 
medication adherence (Bane, Hughe, & McElnay, 2010; Conner et al., 1998). The CSM 
proposes that patients hold illness representations, or implicit common sense beliefs about 
their illness, which are used as a framework for making sense of and coping with an illness 




given to the illness and symptoms experienced), causal beliefs, timeline beliefs, treatment 
control, personal control and consequences. Patients also hold emotional representations of 
their illness. These illness perceptions have been associated with adherence in several 
studies, highlighting the utility of the CSM as a framework for investigating non-adherence 
(Brewer, Chapman, Brownlee, & Leventhal, 2002; Patel & Taylor, 2002; Ross, Walker, & 
MacLeod, 2004). The CSM is a dynamic model where illness perceptions affect selection of 
coping strategies, and the outcome of these coping strategies affects illness perceptions. The 
explanatory power of the CSM has been improved by the addition of medication beliefs, 
which may act as a more proximal determinant of non-adherence. These medication beliefs 
include concerns, and necessity beliefs, which relate to how necessary the patient feels the 
medication is for their current and future health. Necessity and concern beliefs are stronger 
predictors of adherence than clinical or demographic factors (Horne & Weinman, 1999). The 
differential between necessity and concern beliefs is often used to predict non-adherence and 
represents a cost-benefit analysis patients may undergo before making decisions about 
treatment (Horne & Weinman, 1999; Wileman et al., 2011). This framework also includes 
more general beliefs about medication, but the specific beliefs (necessity/concerns) have 
been shown to be more important in relation to medication adherence (Grunfeld et al., 2005; 
Horne & Weinman, 1999; Zwikker et al., 2014a).  
The primary aim of this study was to explore the relationship between key aspects of the 
CSM and TPB and both intentional and unintentional non-adherence, in order to facilitate 
the development of interventions to improve adherence. Elements from both models were 
included to heighten the explanatory power and to explore both perceptions around cancer 
survivorship (CSM) and the medication taking behaviour itself (TPB), as it was felt that both 
these sets of variables may have an influence on non-adherence. Testing both models 
concurrently allows for a broader range of predictor variables to be tested, and may allow for 
creation of a more parsiminous model. Demographic, clinical and other psychosocial 
variables such as distress and social support were controlled for in the analysis as they have 
previously shown associations with tamoxifen non-adherence (Moon et al., 2017). Based on 
previous research, we hypothesise  that unintentional non-adherence will be reported more 
frequently than intentional non-adherence, and that psychological variables from the CSM 
andTPB, such as necessity and concern beliefs, will be related more to intentional than 
unintentional non-adherence.  
As adherence rates fall across time (Nekhlyudov, Li, Ross-Degnan, & Wagner; Schover, 
Baum, Fuson, Brewster, & Melhem-Bertrandt, 2014),  a secondary aim was to investigate 
whether adherence was higher in women who were nearer the beginning of treatment. 




women who are later on in treatment were also explored, to provide understanding of how 
illness or treatment beliefs differ across the treatment trajectory. Little is currently known 
about the illness beliefs held by these patients or how they may change over time.  
Method  
Participants and procedure  
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207). Women were eligible for the study if they were over 18, had been diagnosed 
with primary breast cancer and had been prescribed tamoxifen. Patients were recruited 
through 27 oncology clinics across England and through online advertisements. In clinic, 
eligible women were identified by clinic staff and were told about the research during their 
appointment. Patients were given an information sheet and consent form as well as verbal 
information about the study. They could complete the questionnaire in clinic, take it away 
and return it using a stamped addressed envelope, or complete it online. Informed consent 
was taken from all participants. Some patients were recruited through a postal invitation sent 
out by clinic staff to eligible patients.  Online advertisements were placed on patient support 
websites and Facebook groups. When a participant saw this advertisement, they contacted 
the researcher who gave them information about the study and screened them for eligibility. 
They were then either posted the questionnaire or given a link to complete it online. The 
questionnaire took between 20 – 30 minutes to complete.  
Measures  
Sociodemographic and clinical variables 
Participants provided data on demographic (age, ethnicity, relationship status, 
employment status, age left full time education, menopausal status at diagnosis), clinical 
(breast cancer stage, previous treatment, comorbidities) and treatment related factors (date 
prescribed tamoxifen, duration of tamoxifen treatment, type of prescribing clinician).  
Social Support  
Social support was measured using the Multidimensional Scale of Perceived Social 
Support (Zimet, Dahlem, Zimet, & Farley, 1988). Each item was scored on a seven point 
scale, with higher scores indicating higher levels of support. The scale has demonstrated 
good internal and test-retest reliability and has been used successfully to measure social 
support in patients with breast cancer (Oztunc, Yesil, Paydas, & Erdogan, 2013). Internal 






Distress, measured using The Hospital Anxiety and Depression Scale (HADS), was 
included as a covariate (Zigmond & Snaith, 1983). The scale includes seven items 
measuring depression and seven measuring anxiety. Following recent recommendations, the 
scale was used as a measure of general distress (Norton, Cosco, Doyle, Done, & Sacker, 
2013).  The scale showed good reliabity in the current study (α=.91). 
Side effects  
The FACT-ES is a quality of life scale for patients with breast cancer taking HT 
(Fallowfield, Leaity, Howell, Benson, & Cella, 1999). The additional concerns subscale was 
used to measure side-effects. Patients provide an answer on a five point scale from ‘not at 
all’ to ‘very much’ to indicate how much they have experienced each side-effect for a list of 
18 side effects. This provides a combined measure of both number and intensity of side-
effects, representing the overall level of bother from side effects.  The subscale showed good 
reliability in the current study (α =.87). 
Information about treatment 
To assess how informed patients are about their treatment, they were asked the extent to 
which they agreed or disagreed with four statements, such as “I feel confident in my 
understanding of how tamoxifen helps me”. The scale showed good reliability (α =.89) in 
the current study.    
Illness representations  
The IPQ-BCS (Moon, Moss-Morris, Hunter, & Hughes, 2017), a modified version of the 
Revised Illness Perceptions Questionnaire, was used to measure components of the CSM. 
The scale has good psychometric properties and includes ten subscales; cure, risk of 
recurrence, tamoxifen consequences, breast cancer consequences, personal control, treatment 
control, illness coherence, emotional representations, tamoxifen identity and causes of 
recurrence.  The subscales have previously demonstrated good internal reliability with 
Cronbach’s alphas ranging from .76 to .92. Each scale includes four items scored on a 5-
point Likert-type scale, with the exception of the tamoxifen identity and causes of recurrence 
scales. The identity scale includes a list of symptoms where participants indicate if they have 
experienced each symptom and if they attribute it to their tamoxifen treatment. The scale is 
scored by summing the number of symptoms attributed to tamoxifen. The causes of 
recurrence scale includes 14 possible causes. A previous exploratory factor analysis has 
indicated two factors for causes; psychological attributions (e.g. my emotional state) and 




Beliefs about Medicines   
Beliefs about Medicines were measured as part of the extended CSM, which has 
particular relevance for medication adherence. The BMQ-Specific was used to measure 
beliefs regarding the necessity of taking tamoxifen and concerns about adverse effects. The 
scale has previously shown good psychometric properties (Horne, Weinman, & Hankins, 
1999). A differential score was calculated by taking the total score for concerns away from 
the total score for necessity beliefs, as recommended by the authors of the BMQ (Horne & 
Weinman, 1999). A positive differential suggests that the necessity beliefs outweigh the 
concerns.  
Theory of Planned Behaviour  
Items relating to TPB variables were developed following guidelines from Francis et al. 
(2004) and Ajzen (2002). Subscales include intention to take tamoxifen, subjective norms, 
attitude and PBC. Intention, subjective norm and PBC were measured on a 7-point Likert 
scale. Attitudes were measured with five semantic differential scales scored on a ten point 
scale. Each subscale showed good reliability in the current study (α= 0.67 – 0.82), with the 
exception of subjective norms (α= 0.52), however all subscales were included in order to 
fully test the model.  
Adherence 
The Medication Adherence Report Scale (MARS; Horne, Hankins, & Jenkins, 2001) 
includes five statements about taking medication, which are each scored on a five point scale 
from never to always. The scale attempts to avoid any issues regarding social desirability by 
asking questions in a non-threatening and non-judgemental way. The scale has demonstrated 
good internal reliability and test-retest reliability and has been used multiple times in breast 
cancer patients (Boonstra et al., 2013). Scores on the MARS were strongly positively 
skewed and therefore the data was dichotomised based on recommendations from previous 
papers (de Vries et al., 2014). The MARS includes a one item sub-scale on unintentional 
non-adherence (total score of 5) and a four item sub-scale on intentional non-adherence 
(total score of 20), with a total possible overall adherence score of 25. On the basis of 
previous studies, participants were classed as unintentionally non-adherent if they scored 
below 5 and intentionally non-adherent if they scored below 20 on the respective sub-scales 
(Daleboudt et al., 2011; Timmers et al., 2014; de Vries et al., 2014). Participants could be 







Relationships between hypothesized correlates and intentional/unintentional non-
adherence were tested using Cramer’s V for categorical variables and biserial correlations 
for continuous variables.  Separate multiple logistic regressions were carried out to assess 
the relationships between intentional and unintentional non-adherence and components of 
the CSM and TPB. Clinical, demographic and potentially confounding psychosocial 
variables which showed a significant bivariate relationship with non-adherence were entered 
into the first step of the regression models. The CSM and TPB components were entered 
into the next step, to assess their impact on adherence after the demographic variables have 
been taken into account. The ability of components from each model to explain non-




) to measure the proportion of 
variance explained.  Model fit was also assessed by the -2 Log Liklihood statistic (-2LL). 
Lower -2LL values indicate superior model fit, and therefore if the addition of variables 
reduces the -2LL value, the variables have improved the model fit. The reduction in the -
2LL statistic for each step is represented by chi-squared. T-tests using Bonferroni correction 




Demographics of sample  
1246 women were invited to participate from clinics and 758 women completed the 
questionnaire (61% response rate). An additional 60 women were recruited through online 
advertising. Forty-one (5%) women reported having discontinued tamoxifen and were 
removed from the sample. The final sample included 777 women. All participants were 
female, had Stage I-III breast cancer and had been prescribed tamoxifen (Table 1). The mean 
age was 53 (SD=10, range 30-90). Participants were mostly White British (86%), married 
(58%) and employed (65%). Just under half of patients had been prescribed tamoxifen less 
than one year ago, 22% 1-2 years ago and 31% over two years ago. Two thirds of 
participants self-reported being premenopausal or menopausal at time of diagnosis.  
Adherence rates 
Non-adherence was rated using cut-offs on the MARS. 44% (n=340) showed any sign of 
non-adherence, 9% (n=71) reported intentional non-adherence and 41% (n=321) reported 





Explanatory variables  
Means and SDs for each subscale are shown in Table 2. Mean anxiety levels (6.9, 
SD=4.4) were higher than depression rates (4.1, SD=3.8) but both were within normal 
ranges for the general population. The mean distress score was 11.0 (SD=7.5). Participants 
had relatively high beliefs in treatment control (mean=15.3, SD=2.5), illness coherence 
(mean=15.4, SD=2.9) and cure (mean=15.7, SD=3.0). An average of 5.6 symptoms were 
attributed to tamoxifen (SD=4.9).  BMQ differentials were slightly above 0, showing that on 
average, participants had positive necessity-concern differentials (2.1, SD=5.2). Mean scores 
for intentions (6.5, SD=1.2), subjective norm (6.0, SD=1.0) and PBC (6.2, SD=1.0) were all 
high and attitudes were positive (7.9, SD=1.7).   
Intentional non-adherence  
The only demographic or clinical variables associated with intentional non-adherence 
were previously having a double mastectomy (Cramer’s V=.10, p=.01) and months since 
prescribed tamoxifen (rb=.17, p=.01) (See supplementary material, Appendix E). Side-effect 
intensity (rb=.44, p<.001), distress (rb=.37, p<.001), social support (rb =-.19, p=.013) and 
how informed participants were (rb=-.13, p=.030) were also associated with intentional non-






















Table 1. Participant demographics. 
Characteristic  N (%) 
Age 30 – 90             Mean: 53 (SD: 10) 
Ethnicity  666 (86%) White British 
110 (14%) Other  
Relationship status 555 (72%) With partner  
218 (28%) Separated /Divorced /Single/Widowed   
Job status  504 (65%) Employed full time / part time 
209 (28%) Retired / Homemaker / Other  
61 (8%) Unemployed  
Time since prescribed 
tamoxifen 
< 6 months: 206 (28%) 
6 – 12 months: 142 (19%) 
1 – 2 years: 162 (22%) 
2 – 3 years: 99 (13%) 
3 – 4 years: 61 (8%) 
>4 years: 75 (10%)  
Stage at diagnosis Stage I: 308 (40%) 
Stage II: 326 (43%) 
Stage III: 93 (12%) 
Unsure: 35 (5%) 
Missing: 14 (2%) 
Menopausal status at 
diagnosis 
Pre-menopausal/menopausal: 511 (67%) 
Post-menopausal: 212 (28%) 
Unsure: 35 (5%) 
Missing: 18 (2%) 
Previous treatment Lumpectomy: 63% 
Single Mastectomy: 34% 
Double Mastectomy: 6% 
Chemotherapy: 51% 
Radiotherapy: 73%  
Tamoxifen duration One or two years: 16 (2%) 
Five years: 496 (64%) 
Ten years: 190 (25%) 
For life: 1 (0.1%) 
Unsure: 40 (5%) 
Missing: 26 (3%) 
Healthcare professional 
who prescribed tamoxifen  
Oncologist: 595 (77%) 
Surgeon: 130 (17%) 
Nurse: 24 (3%) 
GP: 5 (1%) 













Table 2. Relationship between explanatory variables and non-adherence 












2.10 (5.23) -20 - 20  -0.44*** -0.18*** 
Tamoxifen consequences  10.06 (4.09) 4 – 20 0.49*** 0.12** 
Breast cancer 
consequences  
12.11 (3.71) 4 – 20 0.21*** 0.07 
Risk of recurrence 10.48 (3.45) 4 – 20 0.00 0.04 
Cure  15.66 (3.04) 4 – 20 -0.08 0.04 
 Personal control  13.73 (3.01) 4 - 20 -0.07 0.09 
Treatment control  15.32 (2.46) 6 - 20  -0.09 0.02 
 Coherence 15.38 (2.86) 4 - 20 -0.06 0.01 
Emotional representations 13.23 (4.30) 4 - 20 0.08 0.07 
Attributing side effects to 
tamoxifen 
5.75 (4.87) 0 – 22  0.38*** 0.19*** 
Cause: psychological 
attributions 
9.52 (2.87) 3 - 15  0.23*** 0.09 
Cause: health factors   13.15 (2.99) 4 - 20 -0.03 0.10* 
Attitude 7.86 (1.66) 1 – 10 -0.35*** 0.14** 
 Intention 6.46 (1.18) 1 -7  -0.69*** 0.22*** 
Subjective norm  6.03 (1.03) 1 – 7 -0.19** 0.14** 
Perceived behavioural 
control  
6.18 (1.02) 1-7  -0.70*** 0.22*** 
*** p≤.001, **p<.01, *p<.05 
 
CSM components associated with intentional non-adherence in the bivariate analysis were; 
BMQ differential, tamoxifen consequences, breast cancer consequences, cause: 
psychological attributions and tamoxifen identity.  From the TPB; intention, subjective norm 
and attitude were all associated with intentional non-adherence (Table 2). Two logistic 
regressions were conducted to test separately the measured components of the CSM and 
TPB and a third regression combined the CSM and TPB variables. The model combining 
both the CSM and TPB variables explained the most variance in intentional non-adherence 
(Nagelkerke R
2
=46%) (Table 3). In this model, the variables in Step 1 explained 20% of the 
variance (χ2(5) = 60.06, p<.001, R2=20%). Higher levels of distress (OR=1.06, 95% 
CI=1.02-1.11) and higher intensity of side-effects (OR=1.05, 95% CI=1.03-1.08), having a 
double mastectomy (OR=3.18, 95% CI=1.33-7.60) and a longer duration of tamoxifen 














 OR 95% CI OR 95% CI OR 95% CI 
Step 1        
   Side effect intensity  1.02 0.99 – 1.05 1.03 1.00 – 1.06 1.01 0.98 – 1.05 
   Social support 0.99 0.76 – 1.28 1.01 0.77 – 1.31 0.94  0.70 – 1.26 
   Extent patients feel 
informed about 
tamoxifen  
0.95 0.87 – 1.05 1.01 0.91 – 1.11 1.03 0.91 – 1.15 
   Distress 1.04 0.99 – 1.09 1.03 0.98 – 1.09 1.05 0.99 – 1.12 
   Months since 
prescribed  
1.01 0.99 – 1.03 1.01 0.99 – 1.02 1.01 0.99 – 1.03 
   Double Mastectomy 
(received)  
3.55 1.37 – 9.18 5.35 2.07 – 13.88 6.41 2.26 – 18.19 
Step 2           
Necessity/concerns 
differential 
0.89 0.83 – 0.95   0.97 0.89 – 1.06 
   Tamoxifen 
consequences  
1.15 1.04 – 1.27   1.06 0.94 – 1.19 
   Breast cancer  
consequences  
0.96 0.87 – 1.08   0.93 0.81 – 1.05 
   Risk of recurrence 0.88 0.80 – 0.97   0.87 0.76 – 0.98 
   Cure  0.94  0.84 – 1.06   0.96  0.84 – 1.10 
   Personal control  0.93 0.81 – 1.05   0.97 0.85 – 1.12 
   Treatment control  1.10 0.92 – 1.23   1.05 0.86 – 1.28 
   Coherence 1.02 0.91 – 1.17   1.01 0.87 – 1.16 
  Emotional 
representations 
0.93  0.86 – 1.03   0.96  0.86 – 1.07 
   Attribution of 
symptoms to tamoxifen 
1.03 0.95 – 1.09   1.05 0.96 – 1.14 
   Cause: psychological 
attributions 
2.06 1.34 – 3.05   2.28 1.40 – 3.71 
   Cause: health 
behaviours   
0.58 0.40 – 1.01   0.41 0.24 – 0.72 
   Attitude   1.15 0.90 – 1.47 1.29 0.98 – 1.70 
   Intention   0.69 0.53 – 0.89 0.72 0.53 – 0.98 
   Subjective norm    1.19 0.86 – 1.63 1.11 0.78 – 1.58 
  Perceived 
behavioural control  
  0.43 0.30 – 0.62 0.37 0.24 – 0.56 
 





Step 1 χ2 = 62.1 
(p<.001) 
 





Step 2 Δχ2 (12) = 
50.52 (p<.001)  




Step 2 Δχ2 (4) = 64.4 
(p=.000)  




Step 1 χ2 =60.06 
(p<.001) 
 




Step 2 Δχ2 (16) = 
89.4 (p=.000) 
 
Adding the CSM and TPB variables significantly improved the model fit and explained a 
further 26% of the variance (Δχ2(16) = 89.4, p<.001, R2=46%). After adding these variables, 
the only variable in step 1 still significantly associated with non-adherence was double 




the risk of recurrence (OR=0.87,95% CI=0.76-0.98) and stronger beliefs that health 
behaviours cause a recurrence were associated with decreased odds of non-adherence 
(OR=0.41, 95% CI=0.24-0.72), whereas beliefs that stress caused a recurrence were 
associated with two-fold increased odds of non-adherence (OR=2.28, 95% CI =1.40 – 3.71). 
Higher levels of PBC (OR=0.37, 95% CI=0.24-0.56) and intention (OR=0.73, 95% CI=0.52-
0.98) were associated with decreased odds of intentional non-adherence.  
Unintentional non-adherence  
Individual associations between adherence and variables were tested using Cramer’s V and 
biserial correlations. There were small but significant relationships between unintentional 
non-adherence and ethnicity (Cramer’s V =.09, p=.007), relationship status (Cramer’s V=.13, 
p=.007) and menopausal status (Cramer’s V=.15, p =.001). There was a moderate 
relationship between job status and unintentional non-adherence (Cramer’s V=.22, p<.001) 
and a weak relationship between previous chemotherapy and unintentional non-adherence 
(Cramer’s V=.08, p=.038) (See supplementary material).  Age (rb=.22, p<.001), age left full 
time education (rb=.12, p=.006), side-effect intensity (rb=.14, p<.001), social support (rb=-
.14, p=.007) and months since prescribed (rb=.21, p<.001) were correlated with unintentional 
non-adherence. In terms of variables from the CSM, unintentional non-adherence was 
associated with; necessity/concerns differential, tamoxifen consequences, tamoxifen identity 
and cause: health behaviours. TPB variables associated with unintentional non-adherence in 
the bivariate analysis were PBC, intention, subjective norm and attitudes (Table 2). 
Separate logistic regressions were carried out to test the measured components of the CSM, 
the TPB and then a combination of CSM and TPB variables. The model including the CSM 
variables and the model including a combination of CSM and TPB variables both explained 
17% of the variance in unintentional non-adherence (Table 4). Control variables were 
entered in step one, explaining 13% of the variance in unintentional non-adherence (Δχ2(10) 
= 53.1, p<.001, R
2
=13%). Women who were white (OR=0.48, 95% CI=0.24-0.99) or older 
(OR=0.97, 95% CI=0.94-0.99) had lower odds of non- adherence and women who were 
employed (OR=2.08, 95% CI=1.32-3.30) or had been taking tamoxifen longer (OR=1.02, 
95% CI=1.01-1.03) had higher odds of non-adherence. Adding variables from the CSM/TPB 
in the second step of the model explained a further 4% of variance, but did not significantly 

















 OR 95% CI OR 95% CI OR 95% CI 
Step 1        
   Side effect intensity  1.01 0.99-1.03 1.01 0.99-1.02 1.00 0.98-1.03 
   Social support 0.88 0.75-1.02 0.91 0.79-1.06 0.89 0.76-1.03 
   Ethnicity (white) 0.43 0.21-0.88 0.53 0.26-1.07 0.43 0.20-0.91 
   Age 0.96 0.93-0.99 0.97 0.95-1.00 0.97 0.94-1.00 
   Relationship status 
(with partner) 
0.73 0.47-1.11 0.77 0.51-1.17 0.74 0.48-1.16 
   Employment status  
(employed)  
2.16 1.37-3.38 2.12 1.95-3.33 2.10 1.30-3.39 
   Months since 
prescribed  
1.02 1.01-1.03 1.02 1.01-1.03 1.02 1.01-1.03 
   Chemotherapy 
(received)  
0.99 0.66-1.50 0.93 0.63-1.39 1.01 0.66-1.54 
   Age left full time 
education 
0.99 0.93-1.05 1.02 0.96-1.08 0.98 0.92-1.05 
   Menopausal status 
(premenopausal)  
0.66 0.40-7.09 0.83 0.51-1.34 0.69 0.38-1.10 
Step 2           
   Necessity/concerns 
differential 
0.96 0.93-1.00   0.97 0.93-1.02 
   Tamoxifen 
consequences  
1.00 0.94-1.07   0.98 0.92-1.05 
   Breast cancer 
consequences  
0.98 0.92-1.05   0.97 0.91-1.04 
   Risk of recurrence 0.98 0.92-1.05   0.98 0.91-1.05 
   Cure  1.01 0.95-1.09   1.03 0.96-1.11 
   Personal control  1.01 0.93-1.10   1.03 0.95-1.12 
   Treatment control  1.04 0.94-1.16   1.03 0.92-1.15 
   Coherence 1.02 0.94-1.09   1.04 0.96-1.12 
   Emotional 
representations 
1.01 0.96-1.07   1.02 0.96-1.08 
   Symptoms attributed to 
tamoxifen  
1.03 0.98-1.08   1.03 0.98-1.09 
   Cause:  psychological 
stress 
1.04 0.82-1.31   1.08 0.85-1.38 
   Cause: health 
behaviours   
1.21 0.89-1.63   1.07 0.78-1.46 
   Attitude   0.95 0.84-1.08 0.96 0.84-1.10 
   Intention   1.01 0.82-1.25 1.03 0.82-1.28 
   Subjective norm    0.95 0.79-1.15 0.99 0.80-1.21 
   Perceived behavioural 
control  
  0.80 0.63-1.02 0.78 0.60-1.01 
 





Step 1 χ2 (10) = 
65.65 (p<.001) 
 





Step 2 Δχ2 (12) = 
12.5 (p=.405)  




Step 1 χ2 (10) = 
56.1 (p<.001) 
 




Step 2 Δχ2 (4) = 7.6 
(p=.108)  




Step 1 χ2 (10) = 53.1 
(p<.001) 
 




Step 2 Δχ2 (16) = 





Adherence rates and perceptions in newly prescribed patients  
Compared to women not in their first six months since prescription, women in their first six 
months of tamoxifen prescription reported lower levels of distress (t(427)=-3.04, p=.003) 
and less intense side-effects (t(427) = -6.76, p=<.001) (Table 5). They also had higher 
intentions to take tamoxifen (t(627)=2.36, p=.003) and a more favourable attitude towards 
tamoxifen (t(663)=2.20, p=.028). With regards to illness/treatment beliefs, women within six 
months of prescription had lower scores on tamoxifen consequences (t(743) = -4.33, 
p=<.001), attributed fewer symptoms to tamoxifen (t(489)= 5.94, p=<.001) and were less 
likely to believe they were cured (t(316) = -3.36, p=.001). Women in their first six months of 
treatment also had significantly higher overall adherence rates (t(743) =-2.33, p=.020). 
However, adherence scores and attitudes were no longer significantly different after 
Bonferroni correction.  
 
Table 5. Descriptive statistics and t-tests to compare women in their first six months of 
treatment to women later on in treatment 
* 
Relationship remained significant after Bonferroni correction.  
 
 
Women in their first 
six months of 
treatment (n=206) 
(range 1 – 6 months) 
 
Mean (SD)  
Women not in their 
first six months of 
treatment (n=539) 
(range 6 months – 8 
years) 
Mean (SD) 
p value   
MARS scores  24.34 (1.44) 24.01 (1.76) .020 
Necessity/concerns differential  2.50 (5.36) 1.98 (5.24) .233 
Tamoxifen consequences  9.09 (3.56) 10.45 (4.26) <.001
*
 
Breast cancer consequences  12.33 (3.59) 12.03 (3.80)  .338 
Risk of recurrence 10.41 (3.41) 10.52 (3.51) .703 
Cure  15.01 (3.41) 15.92 (2.84) .001
 *
 
 Personal control  13.59 (3.16) 13.82 (2.98) .366 
Treatment control  15.41 (2.49) 15.34 (2.42) .722 
 Coherence 15.14 (2.98) 15.53 (2.78) .099 
Emotional representations 13.27 (4.20) 13.28 (4.33) .982 
Attributing side effects to 
tamoxifen 
4.36 (3.79) 6.41 (5.09) <.001
 *
 
Attitude 8.09 (1.45) 7.78 (1.71) .028 
 Intention 6.63 (0.75) 6.41 (1.28) .003
 *
 
Subjective norm  6.12 (0.98) 5.98 (1.04) .097 
Perceived behavioural control  6.28 (0.90) 6.14 (1.07)  0.73 
Distress 23.73 (6.70) 25.48 (7.78) .003
 *
 







This study explored associations between key components of the CSM and TPB 
with intentional and unintentional tamoxifen non-adherence. This is one of the largest 
studies to date to investigate psychosocial correlates of tamoxifen non-adherence and to use 
validated models of health behaviour as a framework. Results showed that key elements 
from both theories provide a useful framework for investigating intentional non-adherence. 
Drawing key variables from both the CSM and TPB provided the best explanation of 
intentional non-adherence, but these variables were not able to improve the explanation of 
unintentional non-adherence over and above clinical and demographic factors. Just under 
half of the sample were found to be non-adherent, with much higher percentages for 
unintentional than intentional non-adherence, as hypothesised. The figure of around 44% 
non-adherence has been found in many other studies of HT non-adherence (Kimmick, 
Camacho, Hwang, & Anderson, 2009; Lee et al., 2014; Seneviratne et al., 2015). Other 
studies have also supported the finding of higher rates of unintentional rather than 
intentional non-adherence (Kimmick et al., 2015; Tinari et al., 2015; Wouters et al., 2014). 
However, it is currently unclear if this reflects truly higher rates or the fact that forgetting 
may be more socially acceptable and is therefore endorsed more frequently by respondents 
(Atkins & Fallowfield, 2006). The current study identified unique correlates of intentional 
and unintentional non-adherence, and found poor prediction of unintentional non-adherence 
by psychological models. This suggests that these two types of non-adherence may be 
distinct from each other, and that participants are not simply reporting unintentional non-
adherence as it is more socially acceptable. 
 
The model combining both CSM and TPB variables provided the best fit for 
intentional non-adherence, explaining 46% of the variance. This combined model has been 
useful previously in predicting other health behaviours such as help seeking for breast 
symptoms (Hunter, Grunfeld, & Ramirez, 2003) and cervical cancer screening (Orbell, 
Hagger, Brown, & Tidy, 2006). Conceptualising these sets of beliefs together provides the 
best understanding of intentional non-adherence and is likely to be the best way to improve 
adherence. The results suggest that attitudes and perceptions around medication taking, as 
assessed by the TPB, and perceptions of breast cancer survivorship, as assessed by the CSM, 
are both central to understanding medication adherence. This highlights the importance of 
illness perceptions in breast cancer survivors and builds upon previous research using the 
CSM. Whilst women are no longer currently ill, their illness perceptions around survivorship 
and previous treatment are related to adherence. A recent review has found some evidence 




but concluded that more research was needed (Jones, Smith, & Llewellyn, 2015). Whilst 
intentional non-adherence is reported less often than unintentional non-adherence, this 
behaviour is likely to be harder to modify and it is therefore of great interest that the 
CSM/TPB provide good explanation of this behaviour. Intentional non-adherence is also 
more likely to lead to discontinuation and therefore has strong clinical implications. 
 
High risk of recurrence beliefs were associated with decreased odds of intentional 
non-adherence, probably because the fear of recurrence keeps women motivated to take 
tamoxifen. Stronger beliefs that psychological stress would cause a recurrence were 
associated with increased odds of non-adherence.  If women endorse stress as a cause of 
recurrence then they may feel that there is no benefit in taking tamoxifen, as it does not 
control their stress levels.  The necessity/concerns differential and tamoxifen consequences 
were significantly related to intentional non-adherence in the CSM model. This supports 
previous research suggesting that how people weigh up the necessity and concerns of 
treatment are related to whether or not they adhere (Horne & Weinman, 1999; Wileman et 
al., 2011). However the necessity/concerns differential and tamoxifen consequences were 
not significant once TPB variables were added, suggesting they may share variance with 
intention or PBC. Higher levels of PBC and intention were associated with decreased odds 
of intentional non-adherence. This is consistent with previous studies and theory (Bane et 
al., 2010) and suggests that interventions to improve PBC may help to improve adherence in 
this population. For example, implementation intentions, which are if-then goal plans where 
patients specify “I intend to do X at time Y in location Z”, have been effective at increasing 
cervical cancer screening uptake (Sheeran & Orbell, 2000) and improving adherence in 
stroke survivors (O'Carroll, Chambers, Dennis, Sudlow, & Johnston, 2013).  
 
Side-effects and distress were related to increased intentional non-adherence, but not 
when controlling for CSM and TPB variables. This is consistent with previous research 
which has found inconclusive evidence for the relationship between side-effects and non-
adherence (Moon et al., 2017). Evidence suggests that women weigh up their necessity 
beliefs against their concerns when making decisions about taking tamoxifen (Fink, Gurwitz, 
Rakowski, Guadagnoli, & Silliman, 2004). If women have strong beliefs in the necessity of 
tamoxifen, they may continue to take it, regardless of side-effects. The results from the 
current study support this by showing that illness or treatment beliefs are stronger correlates 
of non-adherence than side-effects alone. This highlights the need to modify these 





Women who had a double mastectomy were six times more likely to be intentionally 
non-adherent than women who did not have a double mastectomy, even after controlling for 
psychological variables. This may reflect a decision made by patients where they feel that 
tamoxifen is less necessary for them after removal of all breast tissue.  A woman’s choice to 
undergo a double mastectomy is a complex decision and is associated with a range of 
factors, such as treatment concerns (Molenaar et al., 2014) and fear of cancer recurrence 
(Nold et al., 2000). Therefore the relationship between non-adherence and receipt of double 
mastectomy may also be driven by one of these factors.  
 
The fact that the majority of clinical and demographic variables were not related to 
intentional non-adherence supports the findings of a recent review showing few consistent 
clinical or demographic predictors of non-adherence (Moon et al., 2017). This lack of clear 
factors on which to screen patients for non-adherence highlights the importance of 
investigating psychological factors as potential avenues for intervention. Results from this 
study suggest that utilising the key variables drawn from the models concurrently will give 
researchers and practitioners the best chance at improving adherence rates. Non-adherence 
appears to be related to perceptions around cancer as well as perceptions of control over 
medication taking. Therefore interventions which focus solely on one of these factors may 
miss out on key predictors of non-adherence.  
 
However, whilst these psychological models provided good explanation for 
intentional non-adherence, adding CSM and TPB variables did not improve the prediction of 
unintentional non-adherence. Furthermore, study variables were only able to explain 17% of 
the variance in unintentional non-adherence, compared to 46% for intentional non-
adherence. Therefore, more research is needed to improve understanding of unintentional 
non-adherence to tamoxifen. Some interventions have shown success at improving 
adherence using reminders or action plans (Brown, Sheeran & Reuber, 2009; O’Carroll et 
al., 2013; Webb & Sheeran, 2006), but as yet, no studies have attempted to improve 
unintentional non-adherence in women taking tamoxifen.  
 
Whilst there were small correlations between medication beliefs and unintentional 
non-adherence, these relationships were not maintained in the regression analysis. This 
contrasts with previous research showing that unintentional non-adherence is predicted by 
medication beliefs (Gadkari & McHorney, 2012; Schüz et al., 2011). However, a recent 
study found that medication beliefs were associated with intentional but not unintentional 




suggests that unintentional non-adherence in this population may be influenced slightly by a 
patient’s medication beliefs, but is much more likely to be due to forgetting or not 
establishing a good medication taking routine. This is further supported by the identification 
of unique predictors of both intentional and unintentional non-adherence.   
 
 Unintentional non-adherence was associated with demographic and clinical 
variables. Women who were white were less likely to be non-adherent than women who 
were not white, however the proportion of women of other ethnicities was small. Women 
who were older had higher odds of adherence, which has also been found in previous studies 
(Brett et al., 2016; Jacob Arriola et al., 2014; Kimmick et al., 2015) and may reflect the fact 
that young women may have difficulties setting a routine around work or raising a family. 
Women who were employed had higher odds of non-adherence, independent of the effects 
of age. This supports findings of recent studies in HT adherence (Brett et al., 2016; Quinn, 
Fleming, & O’Sullivan, 2016) and may be due to practical problems, such as experience of 
side-effects in the workplace. Women with a longer time since tamoxifen initiation also had 
higher odds of non-adherence, which is supported by studies showing that non-adherence 
rates increase over time (Lee et al., 2014; Wu et al., 2012). These results help to identify 
women who are at higher risk of unintentional non-adherence, and who may need further 
support in taking their medication, such as women in the workforce or women from minority 
ethnic groups. However, more research on these relationships is necessary before any 
specific recommendations can be made for improving adherence in these subgroups, 
especially with regards to the results around ethnicity. Results indicate unique correlates of 
intentional and unintentional non-adherence in this population, suggesting interventions 
tailored to the type of non-adherence may be necessary.  
 
Women in their first six months since prescription showed more favourable beliefs 
and perceptions towards tamoxifen than those later in the treatment pathway. They have 
higher intentions to take tamoxifen, lower distress scores, lower scores on tamoxifen 
consequences and attributed fewer side-effects to tamoxifen. These results suggest that it 
may be beneficial to intervene early before women’s intention to take tamoxifen decreases 
and to help them successfully manage their side effects early on. Interestingly, many of the 
illness perceptions were not significantly different which suggests beliefs may not change 
over the course of treatment, which is contrary to the self-regulation proposed by the CSM. 
However, longitudinal research is needed to confirm this.  
 
This study included a large nationwide sample and is, to the best of our knowledge, 




However, there were several limitations to the study. Adherence was measured by self-
report, which may over-estimate adherence rates due to recall bias or socially-desirable 
answering. However, the MARS has been shown to correlate with more objective measures 
(O'Carroll et al., 2013), and non-adherence rates found in this study were comparable to 
studies using prescription refill rates (Partridge et al., 2003; Seneviratne et al., 2015). Taking 
less than 80% of prescribed doses is associated with decreased odds of survival in breast 
cancer patients (Hershman et al., 2011).  Unfortunately we could not operationalise non-
adherence in this way so it is unclear if the levels of non-adherence in this study are related 
to survival. Due to the cross-sectional design, it was also not possible to identify factors 
related to non-persistence. Future research should assess if the CSM and the TPB provide 
good explanation for non-persistence.   We only tested illness and emotional representations 
within the CSM and missed other key elements of the model such as assessment of coping 
behaviours and appraisal. Although medication adherence could be seen as a coping 
behaviour used to control the health threat, we did not measure the appraisal of non-
adherence as a coping strategy. The study was cross-sectional and it therefore limits 
assumptions about causality. Future research should test these models in longitudinal 
studies. Finally, there may be some selection bias, as the response rate was 61% and patients 
who did not take part may be more likely to be non-adherent. 
 
In spite of these limitations, the study makes an important contribution to the 
literature by showing that the CSM and TPB provide a useful framework for understanding 
intentional non-adherence to tamoxifen. It highlights the utility of these theories and 
demonstrates the importance of considering both theories concurrently when designing 
interventions. Results also highlight the extent of non-adherence in this population and 
suggest that unintentional and intentional non-adherence may be distinct behaviours with 
unique correlates. In particular, the study highlights the high proportion of unintentional 
non-adherence. As this behaviour was not explained well by the psychological models, there 
is a need to further understand this behaviour and to develop ways to improve unintentional 
non-adherence. Future research should confirm these findings in longitudinal studies and use 
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The results from this chapter support the findings from the systematic review and qualitative 
study by showing that side effects and medication beliefs were both correlated with 
adherence, and were associated with intentional non-adherence in a logistic regression. 
However the relationship between side effect intensity and non-adherence was no longer 
significant when the CSM/TPB variables were added into the model. This supports the 
findings in the qualitative study which suggest that it may be more important to consider 
how women weigh their side effects up against their beliefs, rather than focussing solely on 
the presence or absence of side effects. It is therefore important for the intervention to target 
medication and illness beliefs as well as supporting women with their side effects. As side 
effects have been shown to be a key contributor to non-adherence, there was a need to 
investigate them further to explore the best ways to support women taking tamoxifen. The 
following chapter presents an analysis of the extent to which different side effects are 
experienced in this population. This provides important information on how to support 
women with tamoxifen side effects, which should help prevent women from becoming non-
adherent.  
The qualitative study showed that fear of recurrence is a motivating factor for women to take 
tamoxifen. This was supported in this analysis, with women who reported stronger beliefs in 
the risk of recurrence having lower odds of non-adherence. This study also builds upon the 
relationship found in the systematic review between social support and non-persistence, by 
showing that social support is also related to non-adherence. The systematic review found a 
relationship between self-efficacy for medication taking and non-adherence, which was 
supported here by the effect of PBC on adherence. Whilst slightly different concepts, these 
results suggest that an important determinant to HT adherence is the amount of control the 
patient feels they have over the medication taking behaviour. This finding has been 
replicated across other long term conditions (Brus, van de Laar, Taal, Rasker & Wigman, 
1999; Holmes et al., 2014; Schoenthaler, Ogedegbe, Allagrante, 2006).  Several 
demographic factors were associated with unintentional non-adherence, including not being 
white, being younger and being employed. Whilst these factors cannot be modified, they 
provide important information on who may be at risk of non-adherence. They also provide 
important information on how interventions may need to be tailored to support people most 
at risk of non-adherence.  
The results from this chapter also present useful information for intervention development. 
The main conclusion is that key elements from the CSM and TPB provide a valuable 




variables from the CSM and the TPB, explained more variance than either model alone. This 
suggests that interventions should draw on variables from both these theories, and target 
beliefs about illness and medication alongside perceptions of the actual medication taking 
behaviour. The results also confirm that perceptions around breast cancer are still relevant in 
Breast Cancer Survivors (BCS), which provides support for the CSM. The CSM and the 
TPB are very common and widely used in health psychology research. The results from this 
study suggest that the models are complemented by each other, and that combining elements 
from both models provides superior explanation of behaviour. Combining the models into 
one more parsimonious model may allow for greater prediction and understanding of non-
adherence. When the models were combined, variables which were previously significant in 
the individual models did not remain significant. This suggests there may shared variance 
between the variables and that there may be some overlap across the models, thus supporting 
the need to create a more parsiminous model.   
As well as confirming the hypothesis that the CSM and TPB are useful frameworks for 
intervention development, results from this study also highlight potentially modifiable 
factors which could be targeted in the intervention. The high percentage of unintentional 
non-adherence is also of great interest for intervention development, highlighting the need to 
focus on forgetting and establishing a good medication taking regimen. Women who had 
been taking tamoxifen for longer had higher odds of non-adherence, which suggests that 
there is a need to try and intervene early on in the treatment pathway to try and prevent 
women from becoming non-adherent later. This is supported by the finding that women in 
their first six months of tamoxifen had higher intentions to take tamoxifen and more 
favourable attitudes towards tamoxifen. They also experienced fewer consequences and 
attributed fewer symptoms to tamoxifen. This suggests that over time, women adjust their 
illness and treatment beliefs, which is consistent with the self-regulatory component of the 
CSM, although this needs to be confirmed in the longitudinal analysis. Clinically, this 
suggests that women are likely to feel more negatively about their treatment over time, 
increasing the likelihood of non-adherence. This supports the need to intervene early on in 
treatment before people’s perceptions become more negative.  
A limitation with this study was the fact that it is cross-sectional and therefore cause and 
effect cannot be inferred. To overcome this, a longitudinal study was conducted which is 
presented in Chapter 8. This analysis allows for examination of whether the associations 
found in the cross-sectional analysis are maintained over time. This analysis focussed on 
women in their first year of treatment, as studies show that the majority of women who 
discontinue HT do so within the first year (Fink et al., 2004; Huiart et al., 2012; Owusu et 




2003; Wu et al., 2012). Furthermore, the cross-sectional analysis showed that women in their 
first six months of treatment had significantly different perceptions than those later on in 
treatment. As this was not a longitudinal analysis, it is not possible to conclude if 
perceptions actually changed over time. A longitudinal design provides better testing of the 
self-regulatory component of the CSM. It was particularly pertinent to explore these changes 
over time in women near the beginning of treatment, as it is likely they will show more 
changes over time as they adjust to their treatment and assimilate new information and 
experiences. Understanding how their beliefs change will provide helpful information for 




















7. Factors related to the experience of menopausal symptoms in women 
prescribed tamoxifen   
7.1. Chapter Overview  
The systematic review, qualitative study and cross-sectional study all highlighted side 
effects as a potential barrier to adherence. In order to gain greater understanding of the 
symptom burden women were experiencing, an additional analysis of the cross-sectional 
sample was conducted. This analysis is presented in the current chapter. The aims were to 
examine how prevalent different side effects were, how severe they were and whether they 
persisted throughout treatment. The study also explored factors associated with experiencing 
these symptoms and whether they were attributed to tamoxifen. The results from this study 
will be used to inform intervention development and to provide a context for interpreting 




















7.2. Published paper  
This chapter is published in the following article:  
Moon, Zoe, Hunter, Myra S, Moss-Morris, Rona, & Hughes, Lyndsay Dawn. (2016). 
Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. 
Journal of Psychosomatic Obstetrics & Gynecology, 1-10.  
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Factors related to the experience of menopausal symptoms in women prescribed 
tamoxifen 
Zoe Moon, Myra S. Hunter, Rona Moss-Morris and Lyndsay Dawn Hughes 
ABSTRACT 
Introduction: Menopausal symptoms are frequent and severe in breast cancer survivors 
taking tamoxifen; however, treatment options are limited for these patients as hormonal 
replacement therapy is contraindicated. This study aimed to explore the experience and 
attribution of menopausal symptoms and identify factors related to the experience of 
menopausal symptoms in women taking tamoxifen. 
Methods: Women who had been prescribed tamoxifen for a diagnosis of primary breast 
cancer were recruited from oncology clinics across England and from online advertisements. 
Seven hundred and forty women completed questionnaires assessing illness perceptions, 
social support, mood and symptom duration/severity. 
Results: Eighty-four percent of women had experienced hot flushes and 80% experienced 
night sweats; of these, 60% experienced severe symptoms. Symptoms persisted throughout 5 
years of treatment and were mainly attributed to tamoxifen. Logistic regressions showed that 
depressive symptoms, previous chemotherapy and being employed were associated with 
increased odds of hot flush or night sweat prevalence. Symptom severity was associated 
with depression, being employed and attributing symptoms to tamoxifen. 
Discussion: These findings have clinical implications in terms of targeting women who are 
more at risk and offering non-hormonal treatment options, such as cognitive behavioural 




Hot flushes and night sweats (HFNS), the main symptom of the menopause, typically 
involve a sudden sensation of heat and warmth, accompanied by reddening of the skin and 
sweating. They are thought to result from disturbances of the temperature regulating 
mechanism in the hypothalamus, triggered by reduced oestrogen levels [1]. Whilst HFNS 
can vary significantly between individuals, women with breast cancer are five times more 
likely than age matched controls to experience these symptoms and are also more likely to 
experience longer, more frequent and more severe HFNS [2–4]. Women who take tamoxifen 
are twice as likely to experience HFNS [2] and more likely to report severe to intolerable 
HFNS [5] than other breast cancer survivors. 
Tamoxifen, or a similar class of drugs (aromatase inhibitors), are prescribed to up to three 




prescribed to women with oestrogen receptor positive breast cancer and work by blocking 
the effects of oestrogen on cancer cells. Tamoxifen is prescribed mainly to pre-menopausal 
women, whereas aromatase inhibitors are prescribed only in post-menopausal women. 
Recent evidence suggests that survival benefits are enhanced if tamoxifen is taken for an 
additional 5 years [7,8]. This increase in treatment duration, accompanied by a rise in breast 
cancer survival rates, means that increasing numbers of women may be suffering from 
HFNS as a consequence of tamoxifen. Studies have indicated that HFNS prevalence in 
breast cancer survivors may be as high as 80% [9–11]. Tamoxifen is associated with a range 
of other side effects including weight gain, insomnia, joint pain and vaginal dryness [12,13]. 
Whilst not life threatening, these symptoms can have a considerable impact on quality of life 
[11]. HFNS in breast cancer survivors are associated with anxiety, sleep problems, poor 
emotional functioning [10] and poor physical health [14]. Furthermore, these symptoms can 
undermine adherence to tamoxifen [15,16].  
One of the key treatments for HFNS, hormone replacement therapy (HRT) [17], is 
contraindicated in breast cancer survivors due to a potential increased risk of cancer 
recurrence, which severely limits treatment options for HFNS in these patients. There are 
some non-hormonal options, such as venlafaxine or gabapentin [18], but many breast cancer 
survivors are keen to avoid additional medications which likely have side effects [10]. 
Several recent papers have called attention to the lack of research into HFNS in breast 
cancer survivors [1,19] and highlighted a need to understand the experiences of these 
women, with a view to identifying safe and effective treatments [10,19,20]. 
Factors associated with HFNS in the general population include lower levels of education 
[21,22], African American race [23,24], younger age [25] and being without a partner 
[26,27]. The cognitive model of HFNS explains how the perception, attribution and 
appraisal of menopausal symptoms are influenced by cognitive factors, beliefs and mood 
[28]. For example, stress or negative affect can reduce the threshold for detection of physical 
sensations, and increase the likelihood that women will attend to, and therefore report, 
HFNS [28,29]. Anxiety has been shown to precede hot flushes [30]; however, studies 
suggest that there is a complex bi-directional relationship between HFNS and depression 
whereby HFNS can cause depressed mood, but may also be a result of depression [1,28,31]. 
Moreover, anxiety and depression are associated with negative beliefs, which in turn affect 
cognitive appraisal of symptoms [28]. For example, negative thoughts such as 
embarrassment, disgust and worry are linked to more problematic hot flushes [32]. The 
common sense model of illness representations posits that how patients represent symptoms 
and where they attribute them will likely guide how they cope with the symptom [33]. This 




adherence or help seeking [34–37]. The cognitive model of HFNS has informed the 
development of cognitive behavioural therapy (CBT) for HFNS, which has been shown to 
reduce the impact of HFNS [38,39]. 
Whilst the cognitive model of HFNS is well accepted in the general population [1,40], the 
experience of menopausal symptoms in women taking tamoxifen remains under-researched. 
This is important considering the increasing rates of breast cancer, partnered with greater 
survivorship and increased duration of tamoxifen treatment. This paper aimed to explore the 
experience and attribution of menopausal symptoms in women prescribed tamoxifen and, 
using the cognitive model and other sociodemographic predictors, identify factors related to 
the experience of HFNS. 
Methods 
The study was approved by the Northampton National Research Ethics Committee (Ref.: 
14/EM/1207), with site specific approvals for each site. 
Participants and procedure 
Participants were recruited through oncology clinics in 27 NHS Trusts across England and 
through advertisements on Facebook groups, Twitter and charity websites between April 
2015 and October 2015. To be eligible for the study, patients had to be female, over 18, have 
a diagnosis of primary breast cancer and currently being prescribed tamoxifen. Women were 
screened in clinic and those who were eligible were invited to participate in the study either 
in the clinic or with a postal invitation. Women who replied to the online advert were 
screened by the researcher. Informed consent was taken from all participants. The 
questionnaire took approximately 15–20 min to complete; participants could complete it in 
clinic or online, or take it away and return it to the researcher using a stamped addressed 
envelope. This formed part of a larger study investigating adherence to tamoxifen. Only 
measures relevant to this study are reported here. 
Measures 
Experience of menopausal symptoms 
Participants were asked to indicate whether they had experienced symptoms using the 
identity scale from the Revised Illness Perceptions Questionnaire (IPQ-R [41]). This 
included the core symptoms from the IPQ-R as well as additional symptoms such as HFNS. 
Participants indicated whether they attributed symptoms to their breast cancer, their 
tamoxifen treatment or to previous cancer treatment. The additional concerns subscale from 
the FACT-ES [42] was used to measure the experience and severity of side effects. The 




good internal consistency and test–retest reliability [42]. Participants rated symptom severity 
on five-point scales, from “not at all” to “very much”. 
Potential predictors 
Women were asked to provide sociodemographic data including their date of birth, age they 
left full-time education, relationship status, employment status, menopausal status (at 
diagnosis), date first prescribed tamoxifen and previous chemotherapy. Menopausal status 
was defined as pre-menopausal, menopausal or post-menopausal. 
Mood 
The Hospital Anxiety and Depression Scale (HADS [43]) was used to measure depression 
and anxiety. Each item is scored on a scale of 0–3, with higher scores reflecting higher 
levels of depression and anxiety. The scale has good internal consistency in patients with 
breast cancer [44,45]. 
Social support 
The Multidimensional Scale of Perceived Social Support [46] was used to measure 
perceived social support. The scale has demonstrated good internal and test–retest reliability 
[46] and has been used successfully to measure social support in patients with breast cancer 
[47,48]. 
Statistical analysis 
Statistical analyses were performed using SPSS v21 (SPSS Inc., Chicago, IL). For analysis 
of symptom prevalence, women were coded as experiencing a symptom if they had selected 
answers on the FACT-ES from a little bit to very much. For analysis of symptom severity, 
women who scored either of the top two answers (quite a bit/very much) were coded as 
experiencing severe symptoms and were compared to women experiencing mild to moderate 
symptoms (a little bit/somewhat). The attribution of symptoms was analysed using responses 
on the IPQ-R. Univariate logistic regressions were calculated to assess the relationships 
between predictor variables and HFNS prevalence. Predictor variables were chosen based on 
the cognitive model and previous literature identifying sociodemographic variables which 
may be related to HFNS. Variables tested in univariate analysis were age, ethnicity, age left 
full time education, relationship status, employment status, menopausal status (at diagnosis), 
chemotherapy, months since first prescribed tamoxifen, anxiety, depression, social support 
and whether symptoms were attributed to tamoxifen. Months since first tamoxifen 
prescription, social support and depression were skewed and log transformations were 
performed. Variables which showed a significant relationship in univariate analysis were 




converted into dichotomous dummy coded variables. The same analysis was then conducted 
to predict experience of severe HFNS in subgroup analyses of participants who had 
experienced these symptoms. 
Results 
Participant rate 
One thousand two hundred and twenty-eight women were posted information about the 
study or approached in clinic. Seven hundred and forty-six women from 27 centres across 
England returned  the questionnaire, giving a response rate of 61%. An additional six 
questionnaires were received from a site with no response rate information. Sixty-one 
women were recruited online. Once women who had reported discontinuing tamoxifen were 
removed (n=73), the sample consisted of 740 women. 
 
Table 1. Demographics of study population  
 N (%) 
Age, mean (SD) 53 (10 
Range 30-90 
Ethnicity  
   White British 681 (92%) 
   Mixed/multiple ethnic 7 (1%) 
   Asian/Asian British 30 (4%) 
   Black/Black British 12 (2%) 
   Other ethnic background 10 (1%) 
Relationship status  
   Single 79 (11%) 
   Married 431 (58%) 
   Widowed 34 (5%) 
   Separated/divorced 91 (12%) 
   Cohabiting 102 (14%) 
Employment status   
  Employed full time 281 (38%) 
  Employed part time  204 (28%) 
  Homemaker 52 (7%) 
  Unemployed 57 (8%) 
  Retired  114 (15%) 
  Other 30 (4%) 
Age left full time education  
   Under 18  366 (49%) 
   Over 18 376 (51%) 
Menopausal status at diagnosis  
   Pre-menopausal 405 (55%) 
   Peri-menopausal 83 (11%) 
   Post-menopausal 202 (27%) 
   Unsure / missing  50 (7%) 









The mean age was 53 (SD=10, range 30–90) (Table 1). Women were diagnosed with stage I 
to stage III breast cancer and were prescribed tamoxifen. The majority of participants were 
married/cohabiting (72%) and were employed (66%). Forty-nine percent left full time 
education under the age of 18. Over half of women were pre-menopausal at diagnosis (55%) 
and had been treated with chemotherapy (52%). Women had been taking tamoxifen for on 
average 20 months (SD=18, range 0.2 months to 10 years). 
Experience, attribution and duration of menopausal symptoms 
A high percentage of participants had experienced hot flushes (84%) and/or night sweats 
(80%) and around 60% of these had experienced severe HFNS (Table 2). Patients also self-
reported experiencing the following symptoms from the FACT-ES; fatigue (53%), weight 
gain (66%), mood swings (67%), loss of libido (68%), vaginal dryness/discharge/itchiness 
(72%) and joint pain (72%). All symptoms were attributed to tamoxifen more often than to 
breast cancer or previous cancer treatment. The symptoms most commonly attributed to 
tamoxifen on the IPQ-R were hot flushes (66%), night sweats (54%), weight loss/gain 
(40%), joint pain (37%), fatigue (35%), sleep difficulties (34%), vaginal 
dryness/discharge/itchiness (34%) and change in sex drive (27%). Figure 1 shows that the 
prevalence of HFNS is high across participants at different time points of treatment, 
including those in their fifth year. In separate analyses of those who had experienced 
symptoms (n=623 for HF/n=587 for NS), the proportion of women experiencing severe 
symptoms remains relatively high across the 5 years, but begins to decrease slightly at 4 
years of treatment (Figure 2). 
Factors related to prevalence of HFNS 
In the univariate analysis, younger age (OR=0.95, 95% CI=0.93–0.97), being employed 
(OR=3.74, 95% CI=2.45–5.72), being premenopausal at diagnosis (OR=1.95, 95% CI=1.29–
2.94), receiving chemotherapy (OR=3.13, 95% CI=2.04–4.80) and having higher levels of 
anxiety (OR=1.09, 95% CI=1.04–1.15) and depression (OR=1.90, 95% CI=1.24–2.90) were 
significantly related to hot flush experience (Table 3). These variables were entered into a 
logistic regression model, which explained 15% of the total variance (Nagelkerke R
2
). 
Women who were employed (OR=2.65, 95% CI=1.44–4.90), who scored higher on the 
HADS depression scale (OR=2.22, 95%CI=1.33–3.70) and who had chemotherapy 







Table 2. Experience and attribution of symptoms  























Hot flushes 84  64  9  8  66 
Night sweats 80 60 7 7  54 




40 - 1% 8 27  
Loss of sex drive  68  46   - - - 
Pain or discomfort 
with intercourse 




72  39  5 5 34 
Weight gain  66  46     




47 - 10  10  40 
Feeling down  37 - 18  8  20  
Mood swings  67 30   - - 
Fatigue  53 - 19 13 35  
Sleep difficulties  44 - 13 9  34  
Joint pain  72  55  6 14 37 
Headaches 53 21 3 8  15 
Loss of 
concentration  
38 - 12 9 24  
Not all women who reported a symptom will have reported how they attributed it, and women could 
select multiple sources of attribution. % with moderate to severe symptoms in separate analysis of 
only those who experienced symptom. these symptoms are not included in the FACT-ES and 
prevalence is derived from the IPQ-R.  
 

















1 - 2 years
(n=136)
2 - 3 years
(n=76)
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(n=45)



























Time since prescribed tamoxifen  
Percentage of women taking tamoxifen who reported hot 








In the univariate analysis (Table 3), experience of night sweats was related to younger age 
(OR=0.97, 95% CI=0.95–0.98), being employed (OR=2.41, 95% CI=1.63–3.56), being 
premenopausal (OR=1.46, 95% CI=1.00–2.11), being without a partner (OR=0.63,95% 
CI=0.43–0.92), receiving chemotherapy (OR=1.91, 95% CI=1.32–2.74) and higher levels of 
anxiety (OR=1.11, 95% CI=1.06–1.16) and depression (OR=2.42, 95% CI=1.51–3.32). 
These variables were entered into a logistic regression model which accounted for 12% of 
the total variance; women with more depressive symptoms (OR=2.41, 95% CI=1.34–4.33) 
and who were employed (OR=2.18, 95% CI=1.24–3.82) were more likely to experience 
night sweats (Table 4).  
Factors related to severity of HFNS 
In the univariate analysis of those who experienced hot flushes (n=623), hot flush severity 
was associated with being employed (OR=1.62, 95% CI=1.07–2.43), premenopausal 
(OR=1.52, 95% CI=1.07–2.14), having chemotherapy (OR=1.56, 95% CI=1.12–2.17), 
higher levels of anxiety (OR=1.07, 95% CI=1.03–1.11) and depression (OR=2.04, 95% 
CI=1.45–2.87) and attributing hot flushes to tamoxifen (OR=2.58, 95% CI=1.77–3.77) 
(Table 5). Variables were entered into a final model which explained 18% of the variance in 
hot flush severity (Table 4). Women who attributed their hot flushes to tamoxifen were 
almost four times more likely to experience more severe hot flushes (OR=3.78, 95% 
CI=2.43–5.77) and women who had more depressive symptoms (OR=1.99, 95% CI=1.22–
3.24) or were employed (OR=1.68, 95% CI=1.03–2.73) were almost twice as likely to 
experience severe hot flushes. 
In the univariate analysis of participants who experienced night sweats (n=587), anxiety 
(OR=1.06, 95% CI=1.02–1.11), depression (OR=2.03, 95% CI=1.46–2.83) and attribution of 
night sweats to tamoxifen (OR=2.63, 95% CI=1.84–3.74) were related to night sweat 
severity. All variables except anxiety remained significant in the multivariate analysis, 
accounting for 11% of the total variance (Table 4). Attributing night sweats to tamoxifen 
(OR=2.80, 95% CI=1.94–4.01) and depression (OR=1.10, 95% CI=1.03–1.17) were both 
linked to increased odds of severe night sweats. 
Discussion 
This paper examined the experience of menopausal symptoms in breast cancer survivors 
taking tamoxifen and explored factors contributing to the experience of HFNS. Results 
showed that 84% of women had experienced hot flushes and 80% had experienced night 
sweats. This is consistent with previous research in the community indicating a prevalence 
of around 80% [9–11], but is much higher than the prevalence of 29–45% found in several 





Figure 2. Percentage of women taking tamoxifen who reported severe hot flushes or night 
sweats.  
Table 3  
Univariate regressions predicting prevalence of HFNS 
 Hot flushes  Night sweats 
 OR  95% CI OR 95% CI 
Age 0.95** 0.93 – 0.97 0.97** 0.95 – 0.98 
Ethnicity  
      Other vs. white British  
1.18 0.68  - 2.06 1.16 0.70 –1.92 
Age left full time education 
     < 18 vs 18 +  
1.05 0.71 – 1.55 1.00 0.70 – 1.42 
Employment status 
     Employed vs not employed  
3.74** 2.45 – 5.72 2.41** 1.63 – 3.56 
Marital status  
     No partner vs. partner  
0.80 0.52 – 1.23 0.63* 0.43 – 0.92 
Menopausal status  
     Pre vs. post-menopausal  
1.95* 1.29 – 2.94 1.46* 1.00 – 2.11 
Chemotherapy 3.13** 2.04 – 4.80 1.91** 1.32 – 2.74 
Months since prescribed  1.10 0.99 – 2.23 1.03 0.94 – 1.13 
HADS anxiety  1.09* 1.04 – 1.15 1.11** 1.06 – 1.16 
HADS depression 1.90* 1.24– 2.90 2.42** 1.51 – 3.32 
Social support  1.35 0.97 – 1.89 1.15 0.85 – 1.54 
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Table 4  
Multivariate regressions predicting prevalence/severity of HFNS 
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Note. ** p < .001 , * p  < 0.05 
Table 5 
Univariate regressions predicting severity of hot flushes (n = 623) and night sweats (n=587)  
 Hot flushes  Night sweats 
 OR  95% CI OR 95% CI 
Age 0.98 0.97 – 1.00 0.98 0.97 – 1.00 
Ethnicity  
      Other vs. white British  
1.24 0.77  - 1.99 1.39 0.86 – 2.24 
Age left full time education 








0.92 – 1.78 
Employment status 
     Employed vs not employed  
1.62** 1.07 – 2.43 1.23 0.81 – 1.87 
Marital status  
     No partner vs. partner  
0.87 0.60 – 1.25 0.86 0.59 – 1.25 
Menopausal status  
     Pre vs. post-menopausal  
1.52* 1.07 – 2.14 1.31 0.92 – 1.85 
Chemotherapy 1.56* 1.12 – 2.17 1.06 0.76 – 1.47 
Months since prescribed  1.02 0.94 – 1.12 1.00 0.92 – 1.09 
HADS anxiety  1.07* 1.03 – 1.11 1.06** 1.02 – 1.11 
HADS depression 2.04** 1.45– 2.87 2.03** 1.46 – 2.83 
Social support  1.56 0.93 – 2.62 1.14 0.69 – 1.91 
Symptom attributed to 
tamoxifen  
2.58** 1.77 – 3.77 2.63** 1.84 – 3.74 
Note. ** p < .001 , * p  < 0.05 
 
women who experienced negative side effects discontinued treatment and were removed 
from the RCTs. 
However, previously, less was known regarding the severity of HFNS in women taking 
tamoxifen [50]. This paper adds new information, by showing that around 60% of women 




reinforces the need to identify who is more at risk and to find ways to help patients manage 
these symptoms [1,19,20]. Participants also reported high levels of joint pain, vaginal 
discharge/dryness/itchiness, loss of libido, mood swings and weight gain. The prevalence of 
fatigue and sleep problems was slightly lower than previously reported in patients taking 
tamoxifen [13,51], but loss of libido, vaginal symptoms and mood swings were higher than 
previous reports have indicated [13,52,53]. Again, all symptoms were reported at a greater 
frequency than found in a review of RCTs [49]. 
Previous studies have suggested that HFNS are less problematic after one year of tamoxifen 
treatment [54,55] and patients are often advised that their symptoms will reduce after a few 
months. However, this study shows that the prevalence of HFNS remains stable (around 
80%) regardless of whether the patient is in her first or fifth year of treatment. The severity 
of symptoms also remains high up until the fourth year of treatment. This highlights the need 
to identify effective strategies to help women to manage their HFNS across the duration of 
treatment. CBT has been shown to reduce HFNS frequency and problem rating in breast 
cancer survivors and can teach women long-term self-management strategies [38,39,56]. 
Up to two-thirds of participants attributed HFNS to tamoxifen. Participants also associated 
other symptoms to tamoxifen, including fatigue, sleep difficulties, joint pain, vaginal 
discharge/dryness/itchiness and weight loss/gain. These symptoms are established side 
effects of tamoxifen [13]. Women who attributed HFNS to tamoxifen were three to four 
times more likely to experience severe symptoms than those who did not attribute their 
symptoms to tamoxifen. More research is needed to confirm the direction of this effect and 
to establish the consequences of attributing symptoms to tamoxifen treatment. Previous 
studies have suggested that symptom attribution is likely to affect coping behaviours [33], 
but this was not tested in the current study. 
After controlling for demographic factors and mood, women who had chemotherapy were 
twice as likely to report hot flushes than women who had not had chemotherapy. This 
conflicts with previous studies in breast cancer patients, showing no association between 
HFNS and chemotherapy [11,57]. However, previous studies included mainly 
postmenopausal women, and the association between chemotherapy and HFNS may be 
stronger in premenopausal women [58]. Chemotherapy can induce an early menopause in 
some patients, increasing the incidence of HFNS [59], which could explain the increased 
HFNS in premenopausal women who have received chemotherapy. 
Women who were employed were twice as likely to experience HFNS and more likely to 
experience severe hot flushes. This has important implications for supporting women in the 




impact negatively on work performance [1,60,61]. Working women have discussed fears 
around embarrassment and others’ reactions [62], which is likely to exacerbate the severity 
of hot flushes. CBT may be helpful to moderate negative thoughts around menopausal 
symptoms in the workplace and to reduce anxiety around stigma.  
Higher scores on the depression scale were associated with twofold increased odds of HFNS 
incidence and increased odds of severe HFNS. This supports the cognitive model of HFNS 
[28], which proposes that depressed mood can affect how patients perceive and appraise 
their symptoms. However, it is likely that there is a bi-directional relationship between 
HFNS and depression, and it is unclear in this study if the depressed mood is a result of the 
HFNS or if it is increasing the likelihood that women will report symptoms. Anxiety was 
associated with increased odds of HFNS in the univariate analysis, but was not significant 
after controlling for other variables. This contrasts with previous studies showing a clear 
relationship between anxiety and hot flushes [30]. However, the lack of relationship between 
anxiety and HFNS has been shown previously in breast cancer patients [63]. 
Age was significantly related to HFNS prevalence in the univariate analysis, but was not 
significant in the multivariate analysis. This is likely due to shared variance between age and 
menopausal status at diagnosis. Younger age has been found to be associated with increased 
risk of hot flushes in breast cancer survivors [5]; however, this effect has not been 
consistently shown [11,13]. Previous studies have shown that ethnicity is related to hot flush 
frequency [64]. African-American women tend to report more hot flushes than Caucasian 
women and Japanese women have been shown to report fewer symptoms [24,65,66]. 
However, these effects are not always shown [67] and the current study found no effect of 
ethnicity on HFNS prevalence or severity. This may be due to the lack of ethnic diversity in 
the study; only 8% of women self-identified as not White British. 
Overall, the results suggest that a high proportion of women experience symptoms such as 
HFNS as well as fatigue, joint pain and vaginal symptoms. These symptoms are often severe 
and women report experiencing them even in their fifth year of treatment. As HRT is 
contraindicated, only 21% of breast cancer survivors receive any treatment for these 
symptoms [11] and there is a need to identify non-hormonal treatments. The North 
American Menopause Society (NAMS) has reviewed evidence for non-hormonal treatments 
and has found some degree of efficacy for selective serotonin reuptake inhibitors in 
menopausal women [68], but results are not conclusive and breast cancer survivors have 
expressed a preference for nonmedical treatments [10]. CBT, which is based on the 
cognitive model of HFNS, is recommended by NAMS [69] and The National Institute for 
Health and Care Excellence [17]. CBT has been shown to improve HFNS problem rating 




identify patients who are taking tamoxifen and have received chemotherapy, as they may be 
more at risk of hot flushes. Furthermore, the results stress a need to support women who 
have returned to work following breast cancer. 
The strengths of this study were the large sample size, use of validated measures and good 
response rate. This is one of the largest samples used to investigate the experience of HFNS 
in women taking tamoxifen. However, that we measured symptom severity and not bother is 
a limitation of this study. Measuring perceived bother from symptoms as opposed to the 
severity may provide a more thorough understanding of the impairment associated with 
these symptoms [66]. An additional limitation was the use of cross-sectional data which 
prohibits causal assumptions for some effects, such as the relationship between hot flushes 
and depression. All measurements were subjective; therefore, the hot flush frequency may 
be more of an assessment of how people perceive their symptoms rather than an objective 
physiological measure. Data were not collected on use of additional medications. Some 
women may be prescribed antidepressants to manage their HFNS, and this could have 
impacted on their mood. A final limitation with the study was the lack of a comparison 
group, such as breast cancer patients not receiving endocrine therapy, with whom to 
compare the results to. 
Conclusion 
Prevalence and severity of HFNS, as well as other symptoms such as vaginal dryness and 
joint pain, are high in breast cancer survivors taking tamoxifen. There is a need to identify 
non-hormonal treatment options such as CBT to help support patients with these symptoms, 
especially as they persist for longer than previously believed. Furthermore, this study shows 
that women who are in employment, received chemotherapy, attribute HFNS to tamoxifen 
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7.3. Summary  
The results from this paper provide interesting context for the symptom experience of Breast 
Cancer Survivors (BCS) taking tamoxifen. A very high proportion of participants 
experienced HFNS, and over half of these had experienced severe HFNS. As previous 
research has shown some relationship between side effects and adherence, this indicates the 
need to address these symptoms in the intervention. This finding supports the results of the 
qualitative study which showed that women reported a high symptom burden. The results 
from this analysis also highlight additional common side effects which will be targeted in 
the intervention: fatigue; weight gain; mood swings; loss of libido; vaginal 
dryness/discharge/itchiness and; joint pain. It is also of interest that many women attributed 
these symptoms to tamoxifen. This suggests that experience of these symptoms may be 
contributing to any negative emotions regarding tamoxifen. Whether attributing symptoms 
to tamoxifen has any negative impact on adherence will be assessed in the following chapter.  
Another finding which is particularly relevant for intervention development is the finding 
that the prevalence of HFNS is high across all time points, including those in their fifth year 
of treatment. This contrasts with the previous consensus that side effects would likely abate 
over time, and suggests that there is a need to support women throughout their treatment 
trajectory. The previous chapters have shown that many women continue with treatment, 
despite experiencing side effects. This current chapter has shown that these side effects are 
very common and are often severe. There is a need to understand why some women are 
motivated to continue with treatment, even when experiencing these side effects. Fully 














8. Psychosocial predictors of non-adherence to tamoxifen in breast cancer 
survivors: A longitudinal analysis   
8.1.  Background 
Previous research into psychosocial predictors of tamoxifen adherence has largely been 
cross-sectional and lacking a theoretical framework. Chapter 6 showed that the Common 
Sense Model (CSM) and the Theory of Planned Behaviour (TPB) are useful frameworks for 
understanding tamoxifen non-adherence, but as this research was cross-sectional, it is not 
possible to infer causality. From cross-sectional studies, it is unclear if a certain illness 
perception may be causing someone to become non-adherent, or if they hold that illness 
perception because they are non-adherent. Longitudinal studies allow researchers better 
examination of causal relationships between potential predictor variables and non-adherence. 
This provides important information for intervening to improve adherence rates. In order to 
design effective interventions, it is important to understand if a change in a variable may be 
associated with a change in adherence levels.  
Furthermore, longitudinal designs allow for examination of changes over time. Following 
the assumptions of the CSM, there is reason to believe that both illness representations and 
coping methods will change over time as new knowledge and experiences are evaluated and 
incorporated. Longitudinal analysis allows for examination of these changes. Leventhal 
proposed that illness representations could be updated at any time, based on new information 
from family, friends, Healthcare Professionals (HCPs) or the media (Leventhal et al., 2016). 
These changes to illness representations will likely cause changes to coping methods. For 
example, if a patient is exposed to new information suggesting that cancer is caused 
primarily by poor diet, they may adjust their illness representations to account for this, and 
may therefore feel that adhering to their Hormone Therapy (HT) is no longer an appropriate 
response to the illness threat. Likewise, the appraisal of coping strategies can also cause 
changes to illness representations, where patients may re-evaluate their perception of the 
illness based on the success or failure of coping strategies. Despite these being key 
assumptions of the CSM, very few studies have tested these relationships longitudinally, 
especially with regards to their effects on medication adherence. 
There is some evidence to suggest that both illness perceptions and medication beliefs 
change over the illness trajectory. For example, Bijsterbosch et al. (2009) examined illness 
perceptions in 241 patients with osteoporosis. Over a six year period, there were small but 
significant changes in illness perceptions. Patients felt they had less personal control over 




increased. In oesophageal cancer survivors, treatment control, consequences and identity all 
decreased over time (Dempster et al., 2011). However, other studies have shown that illness 
representations remain stable over time (Foster et al., 2008; Massey et al., 2013; McCorry et 
al., 2013a; Rutter & Rutter, 2007). The inconsistency across studies suggests that the 
dynamic nature of the CSM may vary across conditions or populations, with more stable or 
asymptomatic illnesses seeing little change over time, but progressive illnesses seeing more 
variation in illness perceptions over time. Studies also differ in the time in which they 
recruited participants. It may be that illness perceptions show significant variation 
immediately after diagnosis as an individual adjusts to the illness and experiences a vast 
amount of change, but are stable later in treatment as their condition also becomes more 
stable. Mixed results are also found for the dynamic nature of medication beliefs, with some 
studies showing variation over time (Massey et al., 2015; Shiyanbola, Farris & Chrischilles, 
2013) and others showing relatively stable beliefs (Gonzalez et al., 2007).  
A small amount of research has examined longitudinal relationships between illness 
perceptions and treatment adherence. A recent meta-analysis found weak relationships 
between illness perceptions and self-management behaviours across a range of both acute 
and chronic illnesses (Aujla et al., 2016). However, as discussed in Chapter 2, the 
relationships between illness perceptions and self-management behaviours can vary 
considerably across illnesses and illness contexts and therefore it does not make theoretical 
sense to combine results across this many illnesses and behaviours. Schuz, Wolff, Warner, 
Ziegelmann and Wurm (2014) found that timeline and control beliefs predicted adherence 
six months later in older adults with multiple illnesses. Van der Have et al. (2016) studied 
126 patients with Inflammatory Bowel Disease and found that stronger timeline perceptions 
and stronger emotional responses predicted non-adherence over the following twelve 
months. However, some studies found no significant relationships between illness 
perceptions and later adherence (French, Wade & Farmer, 2013; Massey et al., 2015).  
With regards to medication beliefs, there is some evidence to suggest that baseline 
medication beliefs predict later adherence. Horne, Cooper, Gellaitry, Date and Fisher (2007) 
found that concerns and necessity beliefs were predictive of Highly Active Antiretroviral 
Therapy adherence in people with HIV 12 months later, after controlling for depression and 
key clinical variables. Zwikker et al. (2014a) reviewed the literature and concluded that the 
majority of studies found no significant effects for the relationship between medication 
beliefs and later non-adherence. However, the majority of these studies did not use the 
Necessity Concerns Framework (NCF) as a framework and did not use a validated tool to 
measure medication beliefs. Since Zwikker’s review, several studies have supported the 




(Gonzalez et al., 2007; Kalichman et al., 2015; O’Carroll et al., 2011; Ruppar, Dobbels & 
De Geest, 2012). For example, increases in necessity and concern beliefs over three months 
were associated with increased and decreased odds of adherence respectively in patients with 
acute coronary syndrome (LaPointe et al., 2011). However, some recent studies have found 
no significant relationship between medication beliefs and adherence over time (French et 
al., 2013; Massey et al., 2015; Schuz et al., 2014; Trachtenberg et al., 2012). Therefore, 
further research is needed to establish the longitudinal relationship between medication 
beliefs and adherence.  
However, the research is a little clearer in Breast Cancer Survivors (BCS) taking Hormone 
Therapy (HT). Fink et al. (2004) investigated the relationship between medication beliefs 
and persistence in breast cancer survivors prescribed tamoxifen. They followed up 516 
women over the age of 65 for two years. By the second year, 16% had discontinued 
treatment, and this was predicted by having a neutral or negative decisional balance score at 
the previous time point (OR=3.3, 95% CI=1.8-5.9). Similar effects were found in the five 
year analysis, with 31% of the sample discontinuing tamoxifen (Lash et al., 2006). Patients 
who had a positive view of tamoxifen at baseline (HR for a ten-point higher score=0.93, 
95% CI=0.83-1.0) and patients with an improving attitude towards tamoxifen (HR for a 10-
point change = 0.93, 95% CI=0.87-1.00) were less likely to discontinue. Bender et al. (2014) 
found no effects of necessity or concerns on adherence measured using Medication Event 
Monitoring System (MEMS) over an 18 month period. However, the lack of effects may be 
due to the very high levels of adherence found (96% of days with correct intake). Hershman 
et al. (2016) followed 523 women over two years, and found that positive attitudes to HT at 
baseline were associated with decreased odds of non-persistence over a two year follow up, 
after controlling for income and age (OR=0.51, 95% CI=0.32-0.81).  
The TPB assumes less of a dynamic nature between components. However, it could be 
presumed that Perceived Behavioural Control (PBC) may increase over time as people 
become more confident about taking their medication, and that attitudes and subjective 
norms may vary over time, depending on external influences such as information from the 
media, HCPs or friends. As with the CSM, the majority of research investigating the 
relationship between adherence and the TPB is cross-sectional (Schwarzer, 2014). One 
longitudinal study found that baseline intentions were predictive of immunosuppressant 
therapy adherence measured over three months with prescription refill rates (Chisholm et al., 
2007). However, another found that intentions did not predict later adherence in patients 
with type 2 diabetes (Zomahoun et al., 2016). The current study is the first to test these 




8.1.1. Aims and hypotheses  
There is evidence that the CSM and the TPB are useful frameworks for investigating 
tamoxifen non-adherence in cross-sectional analyses. However, little research has tested 
these models longitudinally. There is some evidence that beliefs about tamoxifen are related 
to later non-persistence (Fink et al., 2004; Lash et al., 2006) but these studies only measured 
persistence and not adherence and did not use the NCF as a framework. This study aimed to 
examine longitudinal associations between psychosocial predictor variables and tamoxifen 
non-adherence. Studies have shown that the majority of women who discontinue HT do it 
within the first year (Fink et al., 2004; Huiart et al., 2012; Owusu et al., 2008) and that non-
adherence rates increase significantly over time (Partridge et al., 2003; Wu et al., 2012). 
Furthermore, it is likely that there will be changes in illness perceptions whilst patients are 
still relatively early on in treatment. Therefore, it is important to study relationships between 
beliefs and adherence in the first few years of treatment.  
The aims of this study were: 
a) To examine changes in adherence over time in a sample of women newly prescribed 
tamoxifen.  
b) To identify if illness perceptions and treatment beliefs from the CSM change over 
time.  
c) To test the CSM and TPB longitudinally to examine if the relationships found 
between the CSM and TPB constructs and adherence at baseline will extend to 
longitudinal analysis.  
There is currently a lack of evidence examining how TPB constructs change over time. 
Therefore, some hypotheses are based on theoretical assumptions rather than previous 
empirical evidence. However, based on previous research, it was possible to make a series of 
hypotheses regarding adherence and the CSM:  
a) Based on previous research, it is expected that non-adherence rates will increase 
significantly over time.  
b) It is expected that breast cancer consequences will decrease over time, as time from 
initial treatment lengthens. Based on evidence in Chapter 7 showing a high symptom 
burden across treatment, it is expected that tamoxifen consequences and identity will 
remain stable. Likewise, it is expected that risk of recurrence and cure beliefs will 
remain stable, as evidence suggests that perceived risk of recurrence remains high 




c)  As previously argued, we hypothesise that PBC may increase over time as 
participants get more confident in their abilities to take the medication.  
d) Based on associations between medication beliefs and tamoxifen non-persistence, it 
is hypothesised that the necessity/concerns differential will remain a significant 
predictor of non-adherence in the longitudinal analysis.  
e) It is hypothesised that the models will complement each other and that constructs 
from both models, such as medication beliefs and PBC will predict non-adherence.  
8.2.  Methods  
8.2.1. Participants  
Recruitment methods are described in Chapter 6 (Section 6.2). Participants from the cross-
sectional study who were within their first year of treatment and who had not already 
discontinued tamoxifen were sent follow up questionnaires (n=345).  
8.2.2. Procedure  
Participants consented to being sent follow up questionnaires when they were recruited into 
the larger cross-sectional study. Full NHS REC and HRA approval was granted as part of 
the cross-sectional study (REF 14/EM/1207). Participants were sent questionnaires at 3, 6 
and 12 months. The questionnaire was identical to the one used in the cross-sectional study 
as described in Chapter 6, but the questions relating to demographic and clinical variables 
were removed in the follow up questionnaires. The questionnaires were either emailed or 
posted depending on the participant’s preference. If the questionnaire was not completed 
within two weeks, a reminder email or letter was sent. If the questionnaire was still not 
received after a further two weeks, phone calls were made to remind the participant. 
Participants were removed from the study and not sent further questionnaires if they reported 
discontinuing tamoxifen at the previous time point or if they expressed a desire to withdraw 
from the study.  
8.2.3. Statistical analysis  
The sample size for the study was determined using G*Power 3.1.9.2, on the basis of a 
medium effect size. This was determined through the small amount of previous research 
investigating the psychosocial correlates of tamoxifen non-adherence (Grunfeld et al., 2005; 
Arriola et al., 2014). Assuming a medium effect size, testing the two models of health 
behaviour, with a maximum of 19 tested predictors, the sample size needed to achieve 90% 




studies in BCS, we expected 40% attrition over a twelve month period. Therefore, a baseline 
sample size of 320 participants was needed.  
Participants were categorised as adherent or non-adherent following the same guidelines as 
in the cross-sectional analyses (Section 6.2). Non-adherence rates for total non-adherence, 
intentional non-adherence and unintentional non-adherence were calculated for each time 
point. Women who had discontinued tamoxifen were asked to provide a free text response to 
detail their reason for discontinuing. This was to determine whether women had made an 
intentional decision to discontinue treatment or if they were switched onto another 
medication or discontinued by their doctor due to contraindications. The percentage of 
women who intentionally discontinued during the study period was very low and therefore it 
was not possible to predict discontinuation. Instead, these women were classed as non-
adherent in the latent growth models. Therefore, the term “non-adherent” is used to capture 
all participants who were not taking their medication, both permanently and intermittently.  
One-way repeated measures ANOVAs were used to analyse changes in psychosocial 
variables over time, using post-hoc tests with Bonferroni correction. Where the assumption 
of sphericity was violated, the Hunyh-Feldt or Greenhouse-Geisser corrections were used.  
Latent growth models (LGMs) were carried out to model the change in non-adherence rates 
over time and to identify factors associated with this change. In LGMs, initial status and 
growth over time are both modelled as latent variables. With this analysis, it is possible to 
identify: 
1. The initial starting point of non-adherence (the intercept) 
2. Variance within the initial stating point  
3. How non-adherence changes over time (the slope) 
4. Whether there are individual differences in the rate of change  
5. Whether there is a relationship between the intercept and slope 
6. Predictors of both the intercept and the slope 
This analysis was carried out in Mplus v7. The four non-adherence time points were set to 
load onto the slope at 0,3,6 and 12 to represent the timings between measurements (i.e. 
0,3,6,12 months). All loadings onto the intercept factor were automatically fixed to 1. The 
mean of the intercept was constrained to 0, but the mean of the slope, the variances of the 
slope and the intercept and the correlation between the slope and the intercept were 
estimated. The analysis was conducted in two steps. The first step was to establish the model 
of change for an unconditional model just including the non-adherence values. A linear 




to assess the function of growth over time. Model fit was compared using the BIC and 
loglikelihood values, with lower values indicating superior model fit.  
The second step was to add potential covariates to the model. Covariates were able to predict 
both the intercept and the slope. All covariates were measured at baseline. Bivariate 
associations were carried out, and any variable showing a significant effect at p ≤0.10 were 
included in the final model. This slightly less stringent alpha value was set to improve 
chances of identifying all relevant variables, as studies suggest that alpha values of <0.05 
can miss important variables (Bursac, Gauss, Williams, & Hosmer, 2008).  The data meets 
the minimum level of three observations required to test a hypothesis of linearity (Preacher, 
2010) and has a sample well above 100, which is preferred for LGMs (Curran, Obeidat & 
Losardo, 2010). The LGM analysis steps were repeated to analyse intentional and 
unintentional non-adherence separately.  
Once the final LGMs had been constructed to test the CSM and the TPB, the predictive 
probabilities generated from these two models were exported from Mplus into Stata v14.2. A 
ROC analysis was run on the predictive probabilities. This analysis tests the accuracy of the 
two models to discriminate between adherent and non-adherent participants. Scores range 
from 1, which indicates perfect discrimination, to 0.5, which indicates a model with no 
discriminative ability better than chance.  
The variable intentions from the TPB was removed from the LGM analysis as it was 
strongly positively skewed and showed high kurtosis.  
8.3. Results  
8.3.1. Response rate  
The flow of participants through the study is summarised in Figure 8.1. 345 participants 
were eligible for the longitudinal study and were sent the 3 month follow up questionnaire. 
Of these, 315 were returned, giving a 91% response rate. Of the 30 questionnaires which 
were not returned at 3 months, 29 (8%) were lost to follow up and one patient was deceased. 
At the 3 month point, 11 (3%) participants reported discontinuing tamoxifen and one 
requested to withdraw from the study. Therefore, only 332 6 month questionnaires were 
sent. 286 questionnaires were returned (response rate 86% of those sent out, 83% of total 
sample). Reasons for not returning the questionnaire at 6 months were withdrawing from 
study (n=1), discontinued tamoxifen (n=7), patient deceased (n=1) and loss to follow up 
(n=37). Again, a number of participants reported discontinuing tamoxifen (n=22, 7%) or 
withdrew from the study (n=5) and therefore only 306 12 month questionnaires were sent. 




questionnaires were withdrawing from the study (n=1), patient deceased (n=1), discontinued 
tamoxifen (n=1) and loss to follow up (n=43). The 12 month response rate was 75% of the 
total sample and 84% of those who remained eligible and were sent all questionnaires.  
8.3.2. Difference between responders and non-responders  
T-tests were conducted to identify any differences between responders and non-responders 
in baseline data, after removing women who had not responded due to discontinuing 
tamoxifen and women who were deceased. Non-responders at 3 months were more likely to 
be non-adherent (t[30]=2.3, p=.026), had more intense side effects (t[342]=-2.5, p=.014), 





Figure 8.1 Flowchart showing participant retention 
 
At 6 months, non-responders were more likely to be non-adherent (t[41]=2.4, p=.021), had 
more intense side effects (t[322]=-2.9, p=.004), and had higher baseline distress scores 
(t[322]=-2.4, p =.015). Non-responders at 6 months were also more likely to be younger 
(t[321]=3.3, p=.001), to be pre-menopausal (χ2=5.03, p=.025) and to not be white (χ2=9.57, 
p=.002). There were significant differences between responders and non-responders at 12 
months for age, ethnicity and menopausal status, with non-responders being younger 
(t[301]=-3.1, p=.002), more likely to not be white (χ2=4.04, p=0.44) and more likely to be 




Additional analysis was conducted in order to further explore the association between 
retention rates and adherence. After removing women who became deceased during the 
study or who discontinued tamoxifen, women were classified according to how many time 
points they completed. The majority of women completed all four time points (n=222, 64%). 
The remaining participants completed either the first three time points (n=21), the first two 
time points (n=9), only baseline (n=20) or they missed several time points across the follow 
up period (n=21). Mean adherence rates over time for each retention pattern are shown in 
Figure 8.2.  Results show that women who completed all four time points had the highest 
adherence rates, followed by those who completed the first three, then by those who 
completed the first two questionnaires. Finally, participants who only completed the baseline 
assessment had the lowest levels of adherence.  
8.3.3. Participant demographics 
Participant demographics were similar to the demographics of the larger cross-sectional 
sample in Chapter 6 and are shown in Table 8.2. The majority of participants were white 
British (95%), had a partner (76%) and were employed (71%). Age ranged from 30 – 90. 
The mean age was 52 (SD=10.3). Participants mostly had Stage I (41%) or Stage II breast 
cancer (45%) and were premenopausal at diagnosis (55%).  
8.3.4. Missing data  
Aside from participants missing entire time points, item or scale level missing data was 
negligible and was all well under 5%. Missing data were therefore replaced using mean 
imputation. Three participants were missing the Medication Adherence Rating Scale 






Table 8.1 Differences between responders and non-responders 

















Ethnicity (% white)  95%  86%  96%* 84%* 96%* 89%* 
Job status (% employed) 71%  73%  70% 79% 72% 68% 
Menopausal status (% pre) 55% 55%  53%* 73%* 54%* 71%* 
Age M (SD) 52.1 (10.2)* 48.0 (10.5)* 52.1 (10.0)* 46.5 (8.5)* 52.0 (9.5)* 47.3 (9.5)* 
Months since prescribed tamoxifen M 
(SD) 
5.7 (3.8) 6.4 (3.6) 5.8 (3.8) 6.1 (3.9) 5.7 (3.7) 6.4 (4.3) 
MARS total M (SD) 24.4 (1.4)* 23.3 (2.4)* 24.4 (1.3)* 23.6 (2.1)* 24.5 (1.0) 23.89 (1.9) 
Distress M (SD) 10.2 (7.1) 12.9 (8.9) 10.0 (6.9)* 12.9 (8.2)* 9.7 (6.8) 11.7 (8.0 
Side effect Intensity M (SD) 35.2 (11.4)* 40.7 (13.4)* 34.7 (11.0)* 40.4 (13.1)* 34.3 (10.7) 37.9 (13.1) 






Figure 8.2 Graph showing adherence rates across different patterns of retention 
 
8.3.5. Changes in adherence over time  
Scores of 25 on the MARS indicate full adherence, and decreasing scores indicate decreasing rates of 
adherence. As with the cross-sectional analysis, scores on the MARS were strongly skewed towards 
overall adherence. Mean MARS scores decreased significantly from 24.37 (SD=1.38) at baseline to 
24.20 (SD=1.57) at 3 months (t[314]=2.19, p=.029), indicating that people became less adherent 
(Figure 8.3). Mean MARS scores also significantly decreased between baseline and 6 months (24.06, 
SD=1.77; t[284]=4.36, p=<.001) and between baseline and 12 months (24.11, SD=1.6; t[240]=3.95, 
p<.001) (Figure 8.3). Participants were classified as adherent or non-adherent using the same cut offs 
as the previous cross-sectional study (<25 indicating non-adherence). At baseline, 37% of the sample 
was non-adherent. This increased to 39% at 3 months, 45% at 6 months and 48% at 12 months 
A total score was also calculated for the four MARS items measuring intentional non-adherence only. 
Scores of 24 indicate full intentional adherence. There were no significant changes between baseline 
and 3 months, but there was a significant decrease between baseline (23.90, SD=0.51) and 6 months 
(23.70, SD=1.27, t[273]=2.86, p=.005) and between baseline and 12 months (23.69, SD=1.32; 
t[240]=-2.73, p=.007), indicating that participants became more intentionally non-adherent over time. 
Women were categorised as intentionally non-adherent if they scored less than 24 on the MARS. 
Percentages of intentional non-adherence remained stable at 7% between baseline and 3 months. This 
increased very slightly to 8% at 6 months and 10% at 12 months. One item on the MARS measures 

































Table 8.2 Baseline demographic and clinical characteristics of participants 
Demographic / clinical characteristics  N (%)  
Age Range 30 – 90, M=51.7 (SD=10.3)  
Ethnicity  
    White  




Age left full time education  Range 14 – 33, M=18.0 (SD=2.9) 
Job status  
    Employed 




Relationship status  
   With partner  




Menopausal status at diagnosis  
    Premenopausal  




Months since prescribed tamoxifen   
    < 1 month  
   1 - 3 months  
   3 – 6 months  
   6 – 8 months  







Stage at diagnosis  
    Stage I 
    Stage II 
    Stage III 






Previous treatment  
   Chemotherapy  
   Radiotherapy  
   Lumpectomy  
   Single Mastectomy  







Hormone receptor status  
    Positive  
    Negative  




46 (13%)  
Comorbidities  
    0 
    1 
    2 












this item. Rates of unintentional non-adherence increased from 35% at baseline to 38% at 3 months, 
43% at 6 months and 47% at 12 months (Figure 8.4).  
Mean MARS unintentional scores did not change between baseline and 3 months, but there were 
significant decreases between baseline and 6 months (t[227]=3.17, p=.002), and between baseline and 


















Figure 8.4 Graph showing percentage of women classed as non-adherent over time 
 
Between baseline and 3 months, 6% of participants discontinued, 12% became non-adherent, 8% 
became adherent and 74% showed no change. Of those who showed no change, 67% were adherent 
and 33% were non-adherent. Between 3 and 6 months, 5% discontinued, 12% became non-adherent, 
6% became adherent and 77% showed no change. Of those who showed no change, 61% were 
adherent and 39% were non-adherent. Between 6 and 12 months, 5% of participants discontinued, 9% 
became non-adherent and 7% became adherent. The remaining participants (79%) showed no change 
in adherence status, of whom 56% were adherent and 44% were non-adherent.  
Overall, between baseline and 12 months, 15% discontinued, 16% became non-adherent, 4% became 
adherent and 65% showed no change in adherence status. In total, 41 patients discontinued tamoxifen 
over the study period. 23% of these were discontinued by their doctor, 40% were switched to another 
medication, 20% discussed discontinuing with their doctor and 18% reported making their own choice 
to discontinue. Similar rates of discontinuation were seen across all three follow up time points.  
8.3.6. Changes in psycho-social variables over time  
One-way repeated measures ANOVAs were conducted to analyse changes in psychosocial variables 
over time, using post-hoc tests with Bonferroni correction (Table 8.3). Where the assumption of 















































decreased over time, but the effect was not statistically significant (F[2.9,639.6]=2.12, p=.100). 
Intensity of side effects increased significantly over time (F[2.8, 631.3]=2.37, p<.001). Post-hoc tests 
indicated significant increases between baseline and 12 months (p<.001). There were no significant 
changes over time in social support (F[2.9, 651.0]=0.60, p=.613).  
8.3.6.1. Common Sense Model of Illness Representations  
Figures 8.5-8.6 show changes in illness perceptions over time and Table 8.3 presents the descriptive 
data and inferential statistics. One-way repeated measures ANOVAs were conducted to analyse 
changes in these variables. There was a significant effect of time for breast cancer consequences. 
Post-hoc tests showed that breast cancer consequences decreased significantly between baseline and 
12 months (p<.001; Table 8.3). Risk of recurrence beliefs increased slightly over time, but post-hoc 
tests did not identify any significant differences. Symptoms attributed to tamoxifen (identity) 
increased significantly over time, with post-hoc tests indicating significant increases between baseline 
and 3 months (p=.008), baseline and 6 months (p<.001) and baseline and 12 months (p=.002). Beliefs 
in health behaviours as a cause of recurrence increased significantly over time. Post-hoc tests 
indicated significant increases between baseline and 3 months (p=.013) and between baseline and 12 
months (p=.003). Beliefs in psychological stress as a cause of recurrence also increased significantly 
over time, with post-hoc tests indicating significant increases between baseline and 3 months 
(p=.025).  There were no significant changes over time for the remaining illness perceptions 
(treatment control, personal control, coherence, emotional representations, cure and tamoxifen 
consequences).  
Figure 8.7 shows that over time, participants’ belief in the necessity of tamoxifen increased, and their 
concerns about tamoxifen decreased. Therefore, the necessity/concerns differential became more 
positive over time. Post-hoc tests showed that the necessity/concerns differential increased 
significantly between baseline (mean=2.94, SD=5.25) and 6 months (mean=4.12, SD=5.17, p<.001) 






Table 8.3 Changes to psychosocial variables over time 
   Baseline 
Mean, SD  
3 months 





 Main effect of time  
Distress 9.03 (6.34) 9.41 (6.25) 8.87 (6.56) 8.68 (6.74) F(2.9,639.6)=2.12, p=.100 








  F(2.8, 631.3)=2.37, p<.001 
Social support  5.89 (1.27) 5.80 (1.27) 5.76 (1.35) 5.83 (1.30) F(2.9, 651.0)=0.60, p=.613 








 F(3,639) = 6.83, p<.001 
Tamoxifen consequences  8.89 (3.62) 9.26 (3.51) 9.42 (3.89) 9.40 (3.80)  F(2.89,615.7)=2.32, p=.077 








  F(3,639)=2.99, p=.030 
Cure  15.37 (3.25) 15.13 (3.27) 15.37 (3.22) 15.65 (3.10)  F(2.93,625.6)=2.23, p=.085 
Coherence  15.61 (2.77) 15.68 (2.94) 15.56 (3.23) 15.89 (2.94) F(4.63,609.6)=1.68, p=.174 
Emotional representations 12.91 (4.31) 13.00 (4.18) 12.98 (4.18) 12.66 (4.27)  F(3,639)=1.08, p=.355 
Personal control  13.97 (3.11) 13.90 (2.89) 14.00 (2.98) 14.16 (2.99) F(3,639)=0.83, p=.479 
Treatment control  15.68 (2.45) 15.46 (2.52) 15.62 (2.32) 15.44 (2.52) F(2.93,623.6)=1.26, p=.288 








 F(2.8, 622.1)=61.96, p<.001 








  F(1.4,309.6)=12.37, p=.005 


























 F(2,9,650.7)=4.01, p=.008 








 F(2.9, 638.0)= 8.49,p=<.001 








 F(2.3,505.4)=3.34, p=.030 
Subjective norm  6.00 (1.11) 5.84 (1.01) 5.84 (1.07) 5.84 (0.99)  F(2.7,609.5)=2.45, p=0.68 
Perceived Behavioural Control  6.26 (1.11) 6.31 (0.83) 6.24 (0.97) 6.28 (0.85)  F(2.5, 558.7)=0.37, p=.740 








 F(3,612)=3.24, p=.022 
Note. 
*
Indicates significant main effect of time at p<0.05, 
**
 indicates significant main effect of time at p<0.01, 
*** 






Figure 8.5 Changes in illness perceptions (risk of recurrence, breast cancer consequences, 








Figure 8.6 Changes in illness perceptions (coherence, identity, personal control, treatment 










Figure 8.7 Changes in necessity beliefs and concerns over time. 
 





8.3.6.1. Theory of Planned Behaviour  
The main effect of time for TPB intention to take tamoxifen was significant. Post-hoc tests 
indicated a significant decrease between 3 and 12 months (p=.008). Attitudes towards 
tamoxifen became less positive over time. Post-hoc tests indicated significant decreases 
between baseline and 12 months (p=.043). There was no significant effect of time for 
subjective norms or for PBC (Figure 8.8).  
8.3.7. Latent growth modelling (LGM) 
Scores on the MARS were positively skewed which violates the assumptions of the 
continuous linear LGM.  Therefore, instead of the continuous data, the dichotomous non-
adherence scores were used to model non-adherence. A univariate LGM was conducted on 
the non-adherence values to determine if there was any change in non-adherence over time 
and if this growth followed a linear pattern. This model is shown in Figure 8.9. This basic 
model was then repeated with the addition of a quadratic function to see if this better 
represented the change over time.  
The loglikelihood and BIC values for the linear and quadratic model are shown in Table 8.4. 
Results show that the original linear model had superior model fit. This is supported by 
Figure 8.10 which shows there is more discrepancy between the estimated and observed 
values in the quadratic model. Furthermore, the quadratic estimate was very small and non-
significant, whereas the original linear slope showed a significant effect. There was a 
significant positive correlation between the intercept and slope (r=0.63, p=.009). The 
proportion of women classed as non-adherence increased at each time point. There was 


































Figure 8.9 Latent growth model for non-adherence scores over time. 






Table 8.4 Model fit statistics for linear and quadratic models for overall non-adherence 
Model Loglikelihood BIC Slope factor  Quadratic factor  
Linear  -616.64 1262.49 0.12 (p<.001)  
Quadratic -614.56 1281.71  0.01 (p=.723) 
Note. Lower loglikelihood and BIC values indicate superior model fit.  
 
 
Figure 8.10 Expected and observed values for non-adherence, based on the linear (top 




Once the unconditional LGM was established, baseline covariates were added to the model 
to identify their effects on the intercept or slope. Potential clinical, demographic and 
behavioural covariates were chosen based on their correlations with non-adherence (See 
Appendix F). All CSM and TPB variables were tested in the LGMs. Variables with a 
significant effect on the intercept or slope at p≤.10 were entered into the final models.  
Women who were employed, who were younger and who had higher distress scores at 
baseline had increased odds of non-adherence at the intercept and increased odds of non-
adherence over time (Table 8.5).  Higher odds of non-adherence at the intercept were also 
associated with previously having chemotherapy, lower levels of social support and not 
being white. There was a significant effect of side effects and menopausal status on the 
slope, with women experiencing more side effects having higher odds of becoming non-
adherent over time and women who were post-menopausal at diagnosis having lower risks 
of becoming non-adherent over time.  
In terms of CSM variables, women who had more positive necessity/concerns differentials 
and who reported fewer tamoxifen consequences at baseline had lower odds of non-
adherence at the intercept and lower odds of non-adherence over time. Attributing more 
symptoms to tamoxifen and believing psychological stress was a cause of recurrence was 
associated with increased odds of non-adherence. Women who reported higher breast cancer 
consequences had increased odds of non-adherence over time. From the TPB, more positive 
attitudes towards tamoxifen, higher subjective norms and PBC were all associated with 
increased odds of non-adherence. Attitudes and PBC also showed a negative effect on the 
odds of becoming non-adherent over time.  
To test the CSM, variables which were significant predictors of either the intercept or the 
slope at p≤0.10 in the bivariate LGMs were entered into a multivariate LGM. Ethnicity was 
the only factor with a significant effect on the intercept, with women who were not white 
having nine times higher odds of non-adherence than women who were white (Table 8.6). 
All other variables showed no significant effects on the intercept. When controlling for other 
covariates, there were significant effects of the necessity/concern differential and identity on 
the slope of non-adherence over time. Women with more positive necessity/concern 
differentials had lower odds of non-adherence over time, as did women who attributed more 
symptoms to tamoxifen. The effects for job status and distress on the slope of non-adherence 















Ethnicity (black/minority ethnic groups) 9.67 (p=.017) 0.11 0.19 (p=.326)  
Job (employed)  2.33 (p=.081) -0.01 0.18 (p=.029)  
Menopausal status (post-menopausal) 0.54 (p=.187) 0.18 -0.12 (p=.095) 
Chemotherapy  2.53 (p=.030) 0.11 0.03 (p=.645)  
Age 0.96 (p=.077) 0.57  -0.01 (p=.035)  
Months since prescribed tamoxifen 1.05 (p=.388) 0.18 -0.01 (p=.289)  
Distress 1.05 (p=.048) -0.32  0.02 (p=.001)   
Social support 0.68 (p=.026) 0.37 -0.04 (p=.143)  
Side effect intensity 1.51 (p=.189) -0.04     0.01 (p=.006)  
Necessity/concerns differential 0.91 (p=.023) 0.18 -0.02 (p=.002)  
Risk of recurrence 1.01 (p=.875)   0.07 0.01 (p=.554)  
Breast cancer consequences 2.66 (p=.281) -0.16 0.02 (p=.023)  
Personal control 1.01 (p=.912)  0.17 -0.00 (p=.820)  
Treatment control 1.02 (p=.818)  0.52 -0.03 (p=.113)  
Coherence 0.89 (p=.132)  0.33 -0.01 (p=.336)  
Emotional representations 1.01 (p=.824) -0.04 0.01 (p=.123)  
Cure 0.95 (p=.490)   0.38 -0.02 (p=.153)  
Tamoxifen consequences 1.13 (p=.031)   -0.17 0.03 (p=.004)  
Cause: health behaviour 1.40 (p=.253) 0.23 -0.03 (p=.491)  
Cause: psychological attributions 1.48 (p=.092) 0.12 -0.00 (p=.985)  
Symptoms attributed to tamoxifen (identity) 1.08 (p=.101) 0.09 0.01 (p=.414) 
Attitude towards tamoxifen 0.93 (p=.018) 0.75 -0.02 (p=.011)  
Subjective Norm 0.72 (p=.085) 0.45 -0.06 (p=.157)  
Perceived Behavioural Control 0.46 (p<.001) 0.63 -0.08 (p=.072)  
Note. All covariates were measured at baseline.  
 







Model slope   -0.19  
Ethnicity (black/minority ethnic groups) 9.11 (p=.035)   -0.00 (p=.986) 
Job (employed) 2.86 (p=.083)  0.18 (p=.054) 
Menopausal status (post-menopausal) 1.64 (p=.416)  -0.11 (p=.189) 
Age  0.98 (p=.621)  0.00 (p=.791) 
Chemotherapy  2.66 (p=.088)  0.01 (p=.913) 
Distress 1.00 (p=.981)  0.01 (p=.059) 
Social support  0.83 (p=.334)  -0.01 (p=.803) 
Side effect intensity  0.97 (p=.398)  0.00 (p=.460) 
Necessity/concerns differential  0.94 (p=.220)  -0.02 (p=.006) 
Breast cancer consequences  0.92 (p=.321)  0.01 (p=.546) 
Tamoxifen consequences  1.11 (p=.210)  0.01 (p=.294) 
Symptoms attributed to tamoxifen (identity) 1.06 (p=.336)  -0.02 (p=.043)  
Cause: psychological attributions  1.26 (p=.384)  -0.06 (p=.097) 





The same analysis was run to test the TPB. All three TPB variables were significantly 
associated with non-adherence at p≤0.10 so were entered into the multivariate LGM. As 
with the CSM model, ethnicity was significantly related to the intercept, with women who 
were non-white having higher odds of non-adherence (Table 8.7). In addition to ethnicity, 
PBC also showed a significant effect on the intercept, with higher levels of PBC being 
associated with lower odds of non-adherence. There was a significant effect of distress on 
the slope. Women who were distressed had higher odds of non-adherence over time. 
 




Slope Effect on slope  
Model slope   0.59  
Ethnicity (black/minority ethnic groups) 23.1 (p=.010)  -0.09 (p=.594) 
Job (employed) 2.35 (p=.145)  0.11 (p=.176) 
Menopausal status (post-menopausal)  1.57 (p=.425)  -0.11 (p=.225) 
Chemotherapy  1.85 (p=.242)  0.02 (p=.824) 
Age  0.99 (p=.691)   -0.00 (p=.802) 
Distress 0.97 (p=.553)  0.01 (p=.048) 
Social support  0.70 (p=.069)  -0.02 (p=.521) 
Side effect intensity   0.98 (p=. 773)  0.00 (p=.993) 
Attitude towards tamoxifen 0.97 (p=.242)   -0.01 (p=.064) 
Subjective Norm 1.22 (p=.408)  0.01 (p=.819) 
Perceived Behavioural Control  0.38 (p<.001)  -0.05 (p=.293) 
Note. All covariates were measured at baseline.  
8.3.7.1. LGM for intentional non-adherence  
As with the cross-sectional study, separate analyses were carried out to identify if there were 
unique predictors of intentional and unintentional non-adherence. Very few women were 
categorised as intentionally non-adherent, although this did increase slightly over time (see 
Figure 8.4). Whilst neither the linear nor the quadratic model provided a good fit for the data 
(Figure 8.11), the linear model was slightly better (Table 8.8). Whilst the slope factor for this 
model was not significant, the size of the slope was equivalent to the slope for total non-
adherence, representing similar increases in the odds of becoming non-adherent each month. 
It is likely that the slope factor was non-significant because of the small proportion of 
women classed as intentionally non-adherent (7-10%). Due to this lack of power, it was 
unlikely that significant predictors of the slope would be identified.  
Table 8.8 Model fit statistics for linear and quadratic models for intentional non-adherence 
 Model Loglikelihood BIC  Slope factor  Quadratic factor  
Linear  -270.67 570.55 0.12 (p=.514)  
Quadratic  -275.70 604.00  -0.08 (p=.258) 























In bivariate analyses the following variables were associated with increased odds of non-
adherence at the intercept: distress, intensity of side effects, breast cancer consequences, 
tamoxifen consequences, beliefs in psychological stress as a cause of recurrence and 
attributing more symptoms to tamoxifen. Social support, higher necessity/concern 
differentials, higher treatment control beliefs, more positive attitudes towards tamoxifen and 
higher PBC were associated with decreased odds of non-adherence at the intercept. These 
variables were entered into multivariate LGMs to test the CSM and TPB. As expected, there 
were no significant effects on the slope at p<.05, but attributing health behaviours as a cause 
of recurrence showed an effect on the slope at p<.10 (Table 8.9).  
Figure 8.11 Expected and observed values for intentional non-adherence, based on the 




In the CSM model, the only effect which remained significant when controlling for other 
variables, was the effect of necessity/concern differential on the intercept, with a 1 point 
higher score on the differential being associated with 20% lower odds of intentional non-
adherence (Table 8.10). In the TPB model, the only effect which remained significant was 
the effect of PBC on the intercept, with higher PBC being associated with decreased odds of 
non-adherence (Table 8.11). There were no significant effects for covariates on the slope for 
intentional non-adherence. 
 
Table 8.9 Effects of covariates on the intercept and slope for intentional non-adherence 














Ethnicity (black/minority ethnic groups) 0.70 (p=.822) 0.11 0.26 (p=.159) 
Job (employed)  0.79 (p=.770) 0.16 -0.04 (p=.580) 
Menopausal status (post-menopausal) 2.02 (p=.345) 0.18 -0.05 (p=.417) 
Chemotherapy  1.71 (p=.444) 0.14 -0.04 (p=.603) 
Age 0.99 (p=.726) 0.24 -0.00 (p=.563) 
Months since prescribed tamoxifen 1.14 (p=.157) 0.14 -0.01 (p=.396) 
Distress 1.15 (p=.004) 0.07 0.00 (p=.832) 
Social support 0.63 (p=.087) 0.10 0.00 (p=.966)  
Side effect intensity 1.08 (p=.007) 0.14 -0.00 (p=.821) 
Necessity/concerns differential 0.76 (p=.003) 0.10 0.00 (p=.714) 
Risk of recurrence 0.97 (p=.820) 0.14 -0.00 (p=.862) 
Breast cancer consequences 1.23 (p=.080) 0.08 0.00 (p=.810) 
Personal control 0.97 (p=.857) 0.25 -0.01 (p=.455)  
Treatment control 0.76 (p=.097)  0.13 -0.00 (p=.953) 
Coherence 0.78 (p=.235) -0.14 0.02 (p=.235) 
Emotional representations 1.04 (p=.600) 0.09 0.00 (p=.827) 
Cure 1.04 (p=.752) 0.23 -0.01 (p=.527) 
Tamoxifen consequences 1.33 (p=.012) 0.08 0.00 (p=.740) 
Cause: health behaviour 0.99 (p=.995) 0.43 -0.09 (p=.074) 
Cause: psychological attributions 2.54 (p=.062) 0.30 -0.06 (p=.169) 
Symptoms attributed to tamoxifen (identity) 1.20 (p=.018) 0.14 -0.01 (p=.605) 
Attitude towards tamoxifen 0.87 (p=.006) -0.17 0.01 (p=.255)  
Subjective Norm 0.73 (p=.288) 0.22 -0.02 (p=.633) 












Model slope   0.28  
Distress 1.08 (p=.251)  0.00 (p=.866) 
Social support  1.00 (p=.993)  0.00 (p=.877) 
Side effect intensity 1.00 (p=.977)  -0.00 (p=.538) 
Necessity/concerns differential  0.81 (p=.020)  0.01 (p=.452) 
Tamoxifen consequences  1.06 (p=.662)  0.02 (p=.188) 
Breast cancer consequences  0.91 (p=.462)  0.01 (p=.474) 
Symptoms attributed to tamoxifen (identity) 1.08 (p=.389)  -0.01 (p=.363) 
Treatment control 1.03 (p=.859)  0.00 (p=.967) 
Cause: health behaviour 0.63 (p=.385)  -0.09 (p=.179) 
Cause: psychological attributions  1.81 (p=.228)  -0.05 (p=.337) 
    Note. All covariates were measured at baseline.  
 
 
Table 8.11 Results of the multivariate LGM testing variables from the TPB: Intentional non-
adherence 
Variable 
Effect on intercept 
(OR) 
Slope  Effect on slope  
Model slope   0.01  
Distress 1.08 (p=.197)  -0.00 (p=.942) 
Social support  0.99 (p=.429)  -0.01 (p=.726) 
Side effect intensity 1.01 (p=.788)  -0.00 (p=.839) 
Perceived Behavioural Control 0.36 (p=.002)  -0.01 (p=.883) 
Attitude towards tamoxifen 0.95 (p=.221)  0.01 (p=.358) 
Note. All covariates were measured at baseline.  
8.3.7.2. LGM for unintentional non-adherence  
The results of the univariate LGM for unintentional non-adherence are shown in Table 8.12. 
Results show that the linear model provided superior model fit, which is supported by the 
expected and observed values shown in Figure 8.12. The slope factor was significant and 
represents a significant increase in the odds of non-adherence per month.  
The following variables were associated with increased odds of non-adherence at the 
intercept: being non-white, being employed and having had chemotherapy. The following 
variables were associated with decreased odds of non-adherence at the intercept: being older, 
higher levels of social support, higher necessity/concerns differential, more positive attitudes 
towards tamoxifen, stronger subjective norms and higher PBC. 
Table 8.12 Model fit statistics for linear and quadratic models for unintentional non-
adherence 
Model Loglikelihood BIC  Slope factor  Quadratic factor  
Linear  -592.11 1213.44 0.11, p<.001  
Quadratic  -590.90 1234.39  0.00, p=.916 




Higher scores on the distress scale were associated with increased odds of becoming non-
adherent over time, as were experiencing more side effects and higher breast cancer and 
tamoxifen consequences. Having a positive necessity/concerns differential and more positive 
attitudes towards tamoxifen were associated with lower odds of becoming non-adherent over 
time (Table 8.13).  
These variables were then entered into models to test the CSM and TPB models.  In the 
CSM model, ethnicity and job status were significantly related to the intercept, with women 
from minority ethnic groups and women who were employed having higher odds of non-
adherence (Table 8.14). Necessity/concerns differential was associated with the slope of 
non-adherence, with less positive differentials being associated with increased odds of non-
adherence over time. In the TPB model, there was a significant effect of ethnicity on the 
intercept, with women from minority ethnic groups having increased odds of non-adherence. 
Figure 8.12 Expected and observed values for unintentional non-adherence, based 




Higher levels of PBC were associated with increased odds of non-adherence at the intercept 
but not over time.  
 




Slope  Effect on slope  
Ethnicity (black/minority ethnic groups) 11.65 (p=.015) 0.11 0.02 (p=.874) 
Job (employed) 3.79 (p=.019) 0.04 0.09 (p=.257) 
Menopausal status (post-menopausal) 0.47 (p=.156) 0.16 -0.10 (p=.144) 
Age  0.46 (p=.027) 0.37 -0.01 (p=.205) 
Chemotherapy  2.65 (p=.040) 0.10 0.02 (p=.751) 
Distress 1.04 (p=.220) -0.18 0.01 (p=.013) 
Social support  0.66 (p=.025) 0.24 -0.02 (p=.357) 
Side effect intensity 1.02 (p=.412) -0.01 0.01 (p=.011) 
Necessity/concerns differential  0.92 (p=.076) 0.15 -0.02 (p=.014) 
Recurrence  1.03 (p=.690) 0.07 0.01 (p=.571) 
Breast cancer consequences  1.10 (p=.182) -0.07 0.02 (p=.087) 
Personal control  1.00 (p=.964) 0.08 0.00 (p=.734) 
Treatment control  1.01 (p=.940) 0.36 -0.02 (p=.276) 
Coherence 0.88 (p=.141) 0.17 -0.00 (p=.821) 
Emotional representations  1.05 (p=.443) 0.00  0.01 (p=.227) 
Tamoxifen consequences  1.09 (p=.166) -0.07 0.02 (p=.017) 
Cause: psychological attributions 1.37 (p=.224) 0.14 -0.01 (p=.728) 
Cause: health behaviours  1.50 (p=.227) 0.16 -0.02 (p=.679) 
Symptoms attributed to tamoxifen (identity) 1.05 (p=.287) 0.09 0.01 (p=.381) 
Attitude towards tamoxifen 0.94 (p=.061) 0.53 -0.01 (p=.041) 
Subjective norms 0.67 (p=.092) 0.34 -0.04 (p=.342) 
Perceived Behavioural Control 0.52 (p=.005) 0.43 -0.05 (p=.212) 
Note. All covariates were measured at baseline.  
 








Model slope   -0.08  
Ethnicity (black/minority ethnic group) 11.76 (p=.017)  -0.11 (p=.375) 
Job status (employed) 4.06 (p=.037)  0.08 (p=.373) 
Age  0.99 (p=.818)  -0.00 (p=.614) 
Chemotherapy  2.07 (p=.206)  -0.01(p=.864) 
Distress 1.02 (p=.682)  0.01 (p=.178) 
Social support  0.75 (p=.155)  0.01 (p=.794) 
Side effect intensity 0.98 (p=.549)  0.00 (p=.666)  
Necessity/concerns differential  0.94 (p=.207)  -0.01 (p=.045) 
Tamoxifen consequences  1.03 (p=.737)  0.00 (p=.721) 
Breast cancer consequences  1.00 (p=.982)  0.00 (p=.979) 













Slope  Effect on slope  
Model slope   0.50  
Ethnicity (black/minority ethnic group) 27.38 (p=.004)  -0.15 (p=.248) 
Job (employed) 3.01 (p=.084)  0.06 (p=.451) 
Age  1.00 (p=.841)  -0.01 (p=.244) 
Chemotherapy  0.99 (p=.419)  -0.01 (p=.864) 
Distress 1.01 (p=.811)  0.01 (p=.127) 
Social support  0.71 (p=.074)  -0.00 (p=.976) 
Side effect intensity 0.97 (p=.302)  0.00 (p=.877) 
Attitude towards tamoxifen 0.97 (p=.391)  -0.01 (p=.074) 
Subjective norms 1.07 (p=.798)  0.00 (p=.998) 
Perceived Behavioural Control 0.51 (p=.011)  -0.03 (p=.074) 
  Note. All covariates were measured at baseline.  
8.3.8. Model fit  
The predictive probabilities from the CSM and TPB models for total non-adherence (Table 
8.6/8.7) were exported into Stata in order to conduct ROC analyses. The analysis tested the 
ability of both models to discriminate between adherent and non-adherent participants. The 
ROC area indicates the predictive ability of each model. Table 8.16 shows the results for 
each time point and for the overall assessment. Both models provided excellent ability to 
discriminate between adherent and non-adherent participants, with very high values for the 
ROC area (0.96-0.99). The accuracies of the CSM and the TPB were very similar, 
suggesting both models were able to discriminate well between adherent and non-adherent 
participants. A separate analysis was conducted which ignored the time trend, to see how 
important the time trend was to predictive accuracy. Results showed this reduced the 
predictive accuracies of the models, suggesting that the time trend is important to the 
predictive accuracies shown below.  
Table 8.16 ROC analyses to compare predictive ability of CSM and TPB 
 CSM ROC area 
(95% CI) 
TPB ROC area 
(95% CI) 
Baseline 0.96 (0.95-0.98) 0.96 (0.94-0.98) 
3 months 0.97 (0.95-0.99) 0.97 (0.96-0.99) 
6 months 0.98 (0.97-0.99) 0.99 (0.97-1.00) 
12 months 0.98 (0.97-0.99) 0.98 (0.97-1.00) 
Overall 0.98 (0.96-0.98) 0.97 (0.97-0.98) 







8.3.9. Sensitivity analysis for cut-offs on the MARS  
There are no set guidelines as to the cut-offs for categorising women as non-adherent on the 
MARS. Previous studies have used a range of different cut-offs, with the majority using the 
<25 used in the present study (Huther et al., 2013; Timmers et al., 2014; Timmers et al., 
2016; van der Laan et al., 2017). This high cut-off is recommended as it helps to overcome 
social desirability bias by including all reports of non-adherence (Huther et al., 2013). 
However, other studies have used more stringent cut off points of <23 (van den Bemt et al., 
2009; Zwikker, van Dulmen, den Broeder, van den Bemt & van den Ende, 2014c) or <20 
(Ediger et al., 2007). In order to examine whether results would differ if a more stringent cut 
off was used, a sensitivity analysis was run using a cut off on the MARS of <24. Using these 
new cut offs, non-adherence rates increased from 14% at baseline to 23% at 12 months, 
replicating the pattern of increases shown in the main analysis (See Appendix G). LGMs to 
test individual predictors, as well as the CSM and TPB were also run, showing a similar 
pattern of results to the main analyses (see Appendix G). However, whilst ethnicity and job 
status were significant predictors of non-adherence in the main analysis, this was not 
replicated in the sensitivity analysis. In addition, menopausal status was a significant 
predictor of non-adherence in the sensitivity analysis (effect on slope: -0.212, p=.023), but 
this was not shown in the main analysis. Similar results were found for the effects of 
distress, social support and side effects on non-adherence. In terms of the model variables, 
attitudes, PBC, necessity/concerns differential, identity, breast cancer consequences and 
tamoxifen consequences were significant bivariate predictors in both sets of analyses.  
Coherence beliefs had a significant effect on the intercept of non-adherence in the sensitivity 
analysis (OR=0.78, p=.006), an effect which was not found in the main analyses. The 
multivariate analyses testing the CSM and TPB showed very similar results to the main 
analysis. The necessity/concerns differential and identity remained significant predictors of 
non-adherence when controlling for other variables, as found in the main analyses. However, 
in the sensitivity analyses, tamoxifen consequences also remained a significant predictor of 
increased non-adherence (0.05, p=.018). The sensitivity analyses also replicated the effects 
shown in the main analyses for TPB variables.  
8.4.  Discussion  
This was one of the first studies to use a longitudinal design to identify psychosocial 
predictors of tamoxifen non-adherence. Results showed that 37% of women in their first 
year of treatment reported being non-adherent, and that these reports increased significantly 
over the one year follow up period. Several predictors of non-adherence were identified, the 




differentials, and lower PBC. These results provide important information to help support 
women taking tamoxifen.  
As hypothesised, results showed that reported non-adherence rates increased significantly 
over time, even across this relatively short follow up period. This is in line with previous 
studies showing increases in tamoxifen non-adherence rates over time (Partridge et al., 2003; 
Seneviratne et al., 2015; Wu et al., 2012). The proportion of non-adherent women was high, 
reinforcing the need to intervene to support these women. Furthermore, the true incidence of 
non-adherence is likely higher than the rates reported here, as non-adherent women were less 
likely to return their follow up questionnaires at each time point. It is also likely that non-
adherent women would be less likely to consent to take part in the study. There may also be 
issues with the MARS failing to correctly identify non-adherent participants. Self-report 
measures of adherence often have weak sensitivity for identifying non-adherence (Lam & 
Fresco, 2015; Stirratt et al., 2015).  
Only 41 participants (12%) discontinued tamoxifen during the study period. This is much 
lower than previous estimates of 40-50% (Hadji et al., 2013b; Makubate et al., 2013; 
McCowan et al., 2008; Owusu et al., 2008). Furthermore, whilst 12% discontinued over the 
study period, only seven of these reported making their own choice to discontinue treatment 
and eight reported making a joint decision with their doctor. The remaining participants 
were either discontinued by their doctor or switched to another medication. This represents a 
very low proportion of patients who have reported making a deliberate and volitional 
decision to discontinue treatment. There are three potential reasons these discontinuation 
rates may be lower than those seen in previous studies. Firstly, these rates are only across a 
twelve month period and only show women in their first 2 years of treatment. Higher 
discontinuation rates may be seen if patients were followed up for a longer period. However, 
comparable studies have shown that 22-39% of women discontinued within the first 2 years 
(Brito et al., 2014b; Huiart et al., 2012; Kostev et al., 2013; Nekhylvdov et al., 2011; van 
Herk-Sukel et al., 2010), which is still considerably higher than the current rates. However, 
as discussed in Chapter 2, the majority of previous studies fail to differentiate why someone 
may become non-persistent. Therefore, another reason the previous studies report higher 
discontinuation rates is that they likely include women who have been discontinued by their 
doctor or who have been switched to another medication, and they may not represent 
accurate rates of women who have decided to discontinue treatment. Finally, this study used 
self-report measures and women may not feel comfortable admitting that they have 
completely stopped their medication. Objective measures such as prescription refill rates 
may have provided higher rates of non-persistence. Due to the low rates of non-persistence 




specifically. Instead, women who made a deliberate decision to discontinue were categorised 
as non-adherent for the purpose of analysis. Future research should investigate if there are 
distinct determinants of non-adherence or non-persistence.   
Contrary to what is often suggested clinically to patients, side effects did not abate over 
time. Instead, reported intensity of side effects increased significantly over the 12 month 
period. This supports the analysis shown in Chapter 7 and suggests that side effects do not 
actually diminish over time or that women do not appear to be getting better at managing 
their symptoms over time. There is therefore a need to support women with their side 
effects, both at the beginning of treatment and across the treatment trajectory, in order to 
improve quality of life in these patients. This has implications for the intervention 
development, and suggests that side effect management should be something offered to all 
women, not just women in the beginning of treatment. It may also be important to give 
women more accurate expectations of how long the side effects may last.  
There were some changes over time to illness and medication beliefs. Risk of recurrence 
beliefs increased significantly, but these changes were small. Identity, beliefs in 
psychological stress as a cause of recurrence and beliefs in health behaviours as a cause of 
recurrence also increased over time. This supports previous research showing changes in 
illness perceptions over time (Bijsterbosch et al., 2009; Dempster et al., 2011) and provides 
some support for the proposed self-regulatory nature of the CSM. The fact that risk of 
recurrence beliefs changed over time is contrary to what would be expected, but these 
changes are small and could be an artefact of repeated measurement. Women attributed more 
symptoms to tamoxifen over time, which may be of interest clinically, as it may cause 
women to feel more negatively about the drug. However, negative perceptions or attitudes 
towards tamoxifen did not increase in this study. As hypothesised, tamoxifen consequences 
remained stable. The set of changes shown in this study does not reflect changes to 
perceptions seen in other conditions. However, this lack of consistency makes theoretical 
sense, as every condition has a distinct illness trajectory (Bonsaksen, Lerdal & Fagermoen, 
2015). The CSM assumes that illness representations will be shaped by the appraisal of 
coping strategies, such as adherence (Leventhal et al., 1992). However, unless BCS 
experience a recurrence, there is no physiological feedback from tamoxifen adherence or 
non-adherence. Therefore, the success or failure of this coping strategy will not necessarily 
influence their illness perceptions. This may account for the stable nature of the majority of 
illness perceptions in this study.   
Necessity beliefs increased over time, which contrasts with a previous study showing that 




patients (Massey et al., 2015). Concerns also decreased over time, and the 
necessity/concerns differential became more positive, suggesting that women begin to weigh 
their beliefs up more positively over time. However, the changes in necessity and concern 
beliefs were relatively small and may not represent clinically relevant changes. Very little 
research has investigated the dynamic nature of the TPB, and the model lacks the self-
regulatory component of the CSM. However, the results of this study show that there are 
some changes to TPB constructs. Attitudes towards tamoxifen became less positive over 
time and there were very small decreases in intention to take tamoxifen over time.  
Increased non-adherence was seen in women from minority ethnic groups, with up to 27 
times increased odds of non-adherence when controlling for other covariates. This is an 
important finding as studies have shown that women from minority ethnic groups tend to 
show poorer clinical outcomes in breast cancer than white women (Chlebowski et al., 2005; 
Clegg et al., 2002; Eley et al., 1994). Potential explanations for this include socioeconomic 
status, lack of engagement in screening and treatment or biological differences (Carey et al., 
2006). These results suggest that higher rates of non-adherence may contribute to the poorer 
clinical outcomes seen in women from minority ethnic groups. The systematic review in 
Chapter 3 showed an inconsistent relationship between race and non-adherence, but there 
was some evidence to suggest that black women were more likely to be non-adherent than 
white women. Furthermore, a recent review has supported the relationship between HT non-
adherence and race (Roberts, Wheeler & Reeder-Hayes, 2015). Therefore, there is a need to 
investigate this relationship further and to identify ways to support women from minority 
ethnic groups with their treatment. The fact that ethnicity was related specifically to 
unintentional but not intentional non-adherence provides potential avenues for intervention. 
There may be a need to support these women with remembering to take their medication 
every day and developing a structured medication taking routine. However, the proportion of 
women from minority ethnic groups was very small and the results should be interpreted 
with caution.  
Women who were employed had up to four times higher odds of unintentional non-
adherence. Whilst the systematic review in Chapter 3 showed no consistent effects for 
employment status on adherence, several recent studies have supported the current findings, 
showing an association between being employed and higher HT non-adherence (Brett et al., 
2016; Quinn et al., 2016). This might be related to the fact that women who are employed 
are more likely to be younger, but effects remained significant when controlling for age. 
However, women in the qualitative study in Chapter 4 discussed difficulties with working 
when experiencing side effects such as hot flushes or fatigue. Therefore, this increase in 




effects in the workplace. Job status was related to non-adherence in the analysis for total 
non-adherence and for unintentional non-adherence, which may suggest that working 
women are more likely to forget their medication. Activities around goal and routine setting 
may help these women to remember to take tamoxifen whilst at work and at home. Other 
predictors of non-adherence include distress, with higher distress scores at baseline being 
associated with increased odds of non-adherence over time. This supports the studies in the 
systematic review showing a positive relationship between depression and HT non-
adherence. Results suggest that intervening to improve distress in this population may help 
to improve adherence rates. Social support was also identified as a potential target for 
intervention, as low social support was associated with increased odds of non-adherence.  
More intense side effects at baseline were associated with increased odds of non-adherence 
over time, consistent with several studies showing that side effects are a key reason women 
discontinue treatment (Grunfeld et al., 2005; Moon et al., 2017b; Wells et al., 2016). This is 
also in line with the qualitative findings that experience of side effects contributes to women 
becoming non-adherent or non-persistent (Chapter 4). These results suggest that intervening 
to improve management of side effects may help to improve adherence rates. This is 
particularly important as several studies have shown that tamoxifen side effects may be an 
indication of treatment success (Cuzick et al., 2008; Fontein et al., 2013; Mortimer et al., 
2008). Interestingly, side effects were associated with increased odds of non-adherence over 
time, but not at the intercept, suggesting that side effects may have more of a delayed impact 
on non-adherence. Again, this is in keeping with the qualitative analyses which showed that 
women weigh up their side effects against their beliefs. It may be that this weighing up 
process causes a knock on effect on later non-adherence, rather than immediately causing 
women not to adhere. However, as with the cross-sectional analyses, the effect of side 
effects on adherence did not remain significant when controlling for the CSM or TPB 
variables. This suggests that these psychological variables might contribute to the 
relationship between side effects and non-adherence. Many researchers and clinicians 
assume that side effects are the main driver of non-adherence, but this research suggests that 
it may be more important to consider these psychological variables alongside side effects.  
Both the CSM and the TPB provided useful explanation of non-adherence, supporting the 
results found in the cross-sectional analyses. The ROC analyses showed that both models 
provided excellent discrimination of adherent and non-adherent women. This supports the 
utility of these models and further highlights their use in their intervention development. 
However, whilst the discriminative abilities of both models were very high (0.96-0.99), this 
reduced to 0.74-0.76 when the time trend was removed. This suggests that the inclusion of 




ROC analysis. Nonetheless, results show good predictive ability even when the time trend 
was removed, and the results were comparable across the TPB and the CSM. These results 
also have theoretical implications, by suggesting that whilst these are distinct theories, both 
are equally as effective at predicting non-adherence. Chapter 6 suggested that the models 
were complemented well by each other, a finding which is supported here, as constructs 
from both models appear to be important in understanding non-adherence. Combining the 
key constructs from both models to create a more parsimonious model may provide superior 
prediction of medication adherence in future studies. Future research should investigate if 
this is also the case in the prediction of other health behaviours. Any interventions to 
improve adherence may also benefit from combining elements from both theories, rather 
than focussing solely on one model.  
As hypothesised, the necessity/concerns differential at baseline was associated with 
increased odds of initial non-adherence and increased odds of non-adherence over time. The 
differential remained significant in all analyses when controlling for other covariates. This 
highlights the importance of medication beliefs in understanding tamoxifen adherence and 
intervening to improve adherence. The importance of this variable has also been shown in 
the analysis presented in Chapter 3, Chapter 4 and Chapter 6, as well as in other research in 
HT non-adherence (Brett et al., 2016; Fink et al., 2004). Other illness perceptions were also 
related to non-adherence, such as tamoxifen consequences and beliefs that psychological 
stress caused a recurrence, but these did not remain significant in the multivariate analyses. 
However, these results suggest that establishing more accurate perceptions around risk of 
recurrence and reducing the impact of side effects may improve adherence. Attributing more 
symptoms to tamoxifen (higher tamoxifen identity) was associated with lower odds of non-
adherence over time for the total adherence analysis, and increased odds of non-adherence in 
the analysis for intentional non-adherence. This discrepancy is likely due to the fact that the 
analysis for total non-adherence is made up mainly of unintentionally non-adherent women, 
for whom tamoxifen identity is not a significant predictor. This therefore likely reduces the 
effects of tamoxifen identity in the combined total adherence model.   
Variables from the TPB also helped explain non-adherence. More positive attitudes to 
tamoxifen were associated with increased odds of intentional non-adherence and increased 
odds of unintentional non-adherence over time, but these did not remain significant in the 
multivariate analysis. PBC was associated with increased odds of both intentional and 
unintentional non-adherence but had no significant effects on overall non-adherence over 
time. This is supported by previous research into medication adherence showing the 
importance of attitudes and PBC (Kagee & van der Merwe, 2006; Lin et al., 2016). 




norms were not a strong predictor of non-adherence. Results indicate the usefulness of these 
variables at understanding tamoxifen adherence and highlight modifiable targets for 
intervention. The TPB has come under significant criticism in recent years (Sniehotta et al., 
2014), with several of the criticisms focussing on the inability of the TPB to predict 
behaviour in longitudinal analysis. The results from this study provide support for the TPB 
in understanding non-adherence, but support the criticism that TPB constructs are unable to 
predict later non-adherence. This makes some theoretical sense, as variables such as PBC are 
likely to vary over time and are likely to only be relevant to current medication taking 
behaviour. 
As in the cross-sectional study in Chapter 6, differences were seen for the prediction of 
intentional and unintentional non-adherence. This further supports the conclusions made in 
Chapter 6 that these behaviours should be targeted separately in interventions. Prediction of 
total non-adherence provided a similar pattern to unintentional non-adherence, as it was 
comprised mainly of unintentional non-adherers. Similar to the cross-sectional analysis, 
demographic and clinical variables, such as ethnicity, job status, chemotherapy and age, 
were associated with unintentional non-adherence but not intentional non-adherence. More 
research is needed to identify how to support these women with remembering to take their 
medication. However, whilst the cross-sectional analyses showed no association between 
psychosocial variables and unintentional non-adherence, the longitudinal analyses did find 
some relationships. A higher necessity/concerns differential was associated with a flatter 
slope for the odds of unintentional non-adherence over time, but this was a relatively small 
effect compared to the effect on intentional non-adherence. Similarly, more positive attitudes 
towards tamoxifen and higher PBC were associated with decreased odds of unintentional 
non-adherence, but the effects on intentional non-adherence were larger. Tamoxifen 
consequences, distress, side effects and identity showed relationships with intentional but 
not unintentional non-adherence. Therefore, future research and interventions should make 
distinctions between intentional and unintentional non-adherence. Similar to the cross-
sectional analysis, unintentional non-adherence was reported much more frequently than 
intentional non-adherence. Therefore, helping women to remember their medication should 
be a strong focus of any intervention.  
Strengths of this study include the large sample size, the longitudinal design, the use of 
validated models and questionnaires and the robust statistical analysis. However, there were 
several limitations with the study that should be addressed. First, whilst retention rates were 
relatively high, significant differences were seen between responders and non-responders. 
Women who did not respond were more likely to be younger and non-white which suggests 




also more likely to be non-adherent at baseline, which creates a bias in the results. There 
were very few non-white women in the study and yet these women appeared to be more 
non-adherent. There is a need to conduct future research with a more representative sample 
in order to explore this relationship further.  
To conclude, results show that non-adherence rates rise significantly over a one year follow 
up period. Unintentional non-adherence was reported more frequently than intentional non-
adherence and was associated with a unique set of predictors. Key predictors of non-
adherence were ethnicity, medication beliefs, and PBC. The research has identified several 
potentially modifiable targets which can form the basis of interventions to improve non-
adherence in this population. Drawing on the results from Chapters 2-8, the development of 
a psychoeducational self-management intervention to support BCS taking tamoxifen is 























9. Development of a psychoeducational intervention to support women taking 
tamoxifen 
9.1. Chapter overview  
The current chapter describes the development of a psychoeducational self-management 
intervention to support breast cancer survivors (BCS) with their tamoxifen treatment. As 
there is strong evidence to suggest that rates of non-adherence to tamoxifen are high and that 
non-adherence to tamoxifen is associated with poor clinical outcomes (Hershman et al., 
2011), there is a real clinical need to intervene to improve adherence rates. However, to date 
there have been no published interventions that have attempted to improve adherence to 
tamoxifen. This chapter first presents an introduction to interventions for improving 
adherence, before outlining the framework used to develop the current intervention. This 
framework is then described in detail with an overview of the intervention materials.  
9.2. Introduction  
Several reviews have concluded that current methods to improve adherence in chronic 
conditions are complex and not very effective (Haynes, Ackloo, Sahota & McDonald, 2008; 
McDonald, Garg &Haynes, 2002). These reviews covered a diverse range of interventions, 
including education, counselling, reminders, family interventions, simplified dosing and 
Cognitive Behavioural Therapy (CBT). A Cochrane review in 2008 found that while 36 of 
83 studies reported improved adherence, only 25 led to improvements in treatment outcome 
(Haynes et al., 2008). An update of this review reported a lack of convincing evidence 
among studies with the lowest risk of bias, with only 5 of 17 new studies reporting 
improvements in adherence and clinical outcomes (Nieuwlaat et al., 2014). Conn and Rupar 
(2017) conducted a comprehensive review of studies published up to 2015, with 771 papers 
included. The standardised mean difference effect size between the intervention and control 
groups was 0.29. The only intervention components associated with better adherence 
outcomes were habit analysis and pairing adherence to existing habits. The authors 
concluded that there is much room for improvement in interventions to improve medication 
adherence rates.  
There are several criticisms of the literature on adherence which may explain the lack of 
effective interventions. Firstly, the majority of previous research has failed to consider both 
intentional and unintentional non-adherence (Horne et al., 2005). The quantitative analysis 
in Chapter 6 showed unique correlates for each type of non-adherence, supporting the need 




criticised for not including a theoretical framework or evidence-based theories (Holmes et 
al., 2014; Horne et al., 2005). Theory based interventions provide a better understanding of 
what to target in an intervention by specifying a set of potential mechanisms of change. 
These mechanisms help to evaluate which elements work well within the intervention. They 
also aid with replicating the intervention results and reproducing the interventions across 
different contexts or behaviours (Michie, Johnston, Francis, Hardeman & Eccles, 2008). 
Finally, many previous adherence studies have included any participants regardless of their 
adherence levels (Nieuwlaat et al., 2014). This creates a ceiling effect which means it is hard 
to show any effects of the intervention. A review of interventions to improve adherence to 
anti-cancer drugs found that studies with high rates of baseline adherence did not find 
differences between intervention and control groups (Mathes, Antoine, Pieper & Eikermann, 
2014). Another review found that only 3 of 50 studies screened for non-adherence, making it 
hard to determine the effectiveness of the interventions in the remaining studies (Jeffery et 
al., 2014). Moreover, it is not cost-effective to provide interventions to participants who are 
not in need of assistance with adherence (Hugtenburg, Timmers, Elders, Vervloet, & van 
Dijk, 2013).  
Few interventions have been developed specifically to target Hormone Therapy (HT) non-
adherence. Heisig et al. (2015) compared routine clinical information to enhanced 
information in 137 BCS taking HT in Germany. The enhanced information improved 
satisfaction with information and knowledge. Higher satisfaction, learning and 
comprehension directly after the intervention ended were correlated with higher adherence at 
3 months follow-up. However, the authors did not report changes over time for adherence 
and they did not correct for multiple testing. Therefore, it is not possible to know if there 
were any changes to adherence as a result of the intervention. A similar study was carried 
out in France to improve adherence to adjuvant HT through a therapeutic educational 
approach. A three-session educational program was developed based on a series of patient 
interviews. Medication adherence was not measured, but significant improvements were 
found in knowledge, and a trend was found for improvements in trust in treatment 
(Bourmaud et al., 2016).  
Several studies have used educational materials (EM) to improve adherence to Aromatase 
Inhibitors (AIs) specifically. However, none of these studies have shown significant 
differences in adherence rates between the intervention and control groups (Hadji et al., 
2013a; Neven et al., 2014; Yu et al., 2012; Ziller et al., 2013). For example, the PACT study 
randomised 4844 BCS to EM or standard care (Hadji et al., 2013a). Intervention participants 
received nine letters and brochures by post as well as monthly medication reminders and low 




study recruited 2700 women across the world and randomised them to EM or standard care. 
Intervention participants were sent EM eight times a year, but again, no significant 
differences were found in adherence across the groups (Neven et al., 2014). Ziller et al. 
(2013) also compared EM to standard care to improve adherence to AIs in Germany. They 
randomised participants to one of three conditions; letter group, telephone group or control 
group. The letter group received information leaflets and reminder letters throughout their 
treatment. The telephone group received nurse phone calls covering individualised 
information, feedback to questions and strategies for remembering their medication. Whilst 
the original analysis across groups showed no significant differences, post-hoc pooled 
analysis showed that the two intervention groups had significantly higher adherence rates 
(63% for telephone, 65% for letter) than the control group (48%, p=.039).  
There were several limitations with these studies which might contribute to the lack of 
significant effects. Firstly, the authors provided little information on how they developed the 
interventions or what the materials were based on. Secondly, validated measures of 
adherence were not used. Finally, ceiling effects were likely as adherence rates in most of 
these studies were already very high (up to 95%). In order to elicit a significant change in 
measured adherence, interventions may need to focus on women who are struggling with 
adherence, rather than being offered to all women. The lack of a significant effect may also 
signify the lack of efficacy of EM alone, indicating that they should be combined with other 
intervention strategies. As yet, no interventions have been carried out to target tamoxifen 
adherence, and no HT adherence interventions have attempted to move beyond simply 
providing EM. Therefore, there was a need to develop a more complex intervention which 
was theoretically based, to try and improve adherence rates in this population.  
The current study has overcome the limitations associated with previous studies by using the 
Common Sense Model of Illness Representations (CSM) and the Theory of Planned 
Behaviour (TPB) as a framework for intervention development and by basing intervention 
development on a series of empirical studies. Furthermore, only women who show signs of 
non-adherence were invited to participate in the study.  
9.3. Framework for intervention development  
The Medical Research Council (MRC) has provided guidance for the development of 
complex interventions (Craig et al., 2008). These guidelines recommend that preliminary 
development work is carried out prior to commencement of a large RCT. This allows 
researchers to evaluate the feasibility and acceptability of the intervention as well as 




should be developed systematically based on theory and empirical evidence and should be 
tested with a series of pilot studies and a definitive evaluation. The current intervention was 
developed in accordance with the MRC guidance.  
As well as following the MRC guidance, the intervention was also developed in line with the 
Intervention Mapping (IM) framework (Bartholomew et al., 2011; Kok et al., 2016). This 
framework was developed for health promotion interventions and describes the process for 
planning and developing interventions in line with theoretical constructs and empirical 
evidence. A five-stage process based on IM is shown in Figure 9.1. Each stage of IM is 
informed by the previous stage, but planning is also an iterative process whereby researchers 
can move fluidly between different stages and revisit earlier stages.  Firstly, a needs 
assessment is carried out. This establishes the extent of the problem and identifies 
determinants associated with the problem behaviour. The next stage is to identify 
intervention objectives based on this needs assessment, and to establish which behavioural 
determinants should be targeted in the intervention. The third stage is to select theory based 
behaviour change methods and techniques which match the pre-identified determinants, and 
to translate these into practical applications. The fourth stage of the framework is to integrate 
these practical applications into an organised programme and to establish the format of the 
intervention. The final stages relate to the implementation and evaluation of the intervention 
and are discussed in the following chapter. As mentioned, both the MRC and IM processes 
are iterative and cyclical and encourage researchers to move between development and 
evaluation.  
Other methods and strategies have also been proposed for intervention development. The IM 
framework was chosen as it provides a clear overview of how the intervention was 
developed and why certain strategies were used. Even when studies report basing 
interventions on theory, very few provide any description on how theory was used to inform 
the intervention (Michie & Prestwich, 2010). IM was chosen as it overcomes this by clearly 
specifying the steps involved in intervention development. Furthermore, IM is a flexible 
process which is not restrained to one single theory, but allows the best theory or evidence 











Stage One Needs Assessment  Establish the extent of the problem 
Identify behavioural and environmental 
determinants associated with the problem 
behaviour 
 Stage Two Identity Intervention 
Objectives  
Identify expected outcomes and 
performance objectives for intervention 
Establish which behavioural determinants 
should be targeted  
 
Stage Three Theory based 
methods and 
practical strategies   
Select or design practical applications to 
deliver change methods  
Select theory and evidence based 
intervention methods based on pre-
identified determinants  
 Stage Four  Develop intervention  Integrate these practical applications into 
an organised programme  
Establish the format of the intervention 
Draft and refine materials (consult with 
intended users)  
 Stage Five  Implementation and 
evaluation plan   
Identify intended users  
Develop indicators and measures for 
assessment  






Figure 9.1 Intervention Mapping framework. Adapted from Bartholomew et al. (1998) 
 
9.3.1. Stage one: Needs Assessment  
The aim of the needs assessment was to establish the extent of non-adherence in this 
population and to identify behavioural and environmental determinants associated with non-
adherence. The needs assessment was informed by the previous body of research discussed 
in Chapters 2 to 7. This included a systematic review, qualitative study, cross-sectional study 
and a longitudinal study. In addition to this, a broader literature review was also carried out. 












9.3.2. Stage two: Identify Intervention Objectives  
The needs assessment highlighted that non-adherence was a problem in this population, and 
that unintentional non-adherence was reported much more frequently than intentional non-
adherence. Furthermore, Chapter 6 showed that there were unique determinants for both 
intentional and unintentional non-adherence. Therefore, these two behaviours will be 
targeted separately in the intervention, with a strong focus on helping people to remember to 
take their medication. Key barriers and facilitators of tamoxifen non-adherence identified by 
the needs assessment are shown in Table 9.1. Modifying these barriers and facilitators 
formed the objectives of the intervention. Medication beliefs were a consistent predictor 
throughout all studies. Chapter 8 showed that the necessity/concerns differential was a 
significant predictor of later non-adherence after controlling for other covariates. Specific 
concerns about tamoxifen, such as the risk of endometrial cancer, were identified in the 
qualitative study (Chapter 4). The cross-sectional and longitudinal studies also identified 
several illness perceptions which were related to adherence, including lower tamoxifen 
consequences, higher beliefs around a risk of recurrence, attributing symptoms to tamoxifen 
and believing that health behaviours can cause a recurrence. Believing that psychological 
stress caused a recurrence was associated with decreased odds of adherence. However, these 
illness perceptions were not as strong predictors of non-adherence as the necessity/concerns 
differential. Chapters 3, 6, and 8 all highlighted that TPB variables were related to 
adherence. Intentions to take tamoxifen, positive attitudes towards tamoxifen and Perceived 
Behavioural Control (PBC) were all identified as facilitators of tamoxifen adherence.  
Side effects were shown to be a key barrier to adherence across all studies, although results 
suggest that the impact of side effects on adherence may depend on the patient’s illness or 
treatment beliefs. Chapters 4 and 8 highlighted specific side effects which were bothersome 
for patients. Chapters 3, 4, 6 and 8 all highlighted social support as a potential facilitator of 
adherence. Chapter 8 showed that distress may be associated with non-adherence. 
Knowledge about tamoxifen was also identified as a facilitator of adherence.  
Some of these factors overlap or map onto each other and can therefore be targeted together. 
For example, increasing knowledge should help to increase necessity beliefs and create more 
positive attitudes towards tamoxifen, which should also increase intentions to take tamoxifen 
(Bender et al., 2010; Jones, Ellis, Nash, Stanfield, & Broadbent, 2016; O’Carroll et al., 
2014). Encouraging more accurate risk of recurrence perceptions may also increase necessity 
beliefs. Furthermore, women’s concerns focused on side effects, and therefore increasing 




a more favourable cost-benefit analysis. The key aims of the intervention are shown in 
Figure 9.2.  
Table 9.1Key determinants of non-adherence (and non-persistence) identified by the needs 
assessment 
 Barrier to tamoxifen adherence  




Concerns about medication 
4
 







Positive differential between 







Causal beliefs (psychological 
attributions)
 6  

















Self-efficacy for taking 
medication 
3 
Perceived behavioural control 
6,8 
 
Side effects Number/intensity of side effect 
experience 
3,4,6,7,8 







Perceived social support 
3,6,8 
Importance of support from 




Knowledge Lack of information 
3,6 
 














Information obtained from Chapter 3, 
4
Information obtained from Chapter 4, 
6
Information obtained 
from Chapter 6, 
7
Information obtained from Chapter 7, 
8
 Information obtained from Chapter 8, 
*Information obtained from additional literature review 
 
9.3.3. Stage three: Theory based methods and practical strategies   
The third stage of the IM process was to identify health behaviour change methods and 
techniques which match the determinants identified in the previous sections. A brief review 
of potential methods and strategies is presented below. These are then mapped onto the 




















Reduce concerns  
Address and overcome common 
concerns 
Reduce impact of side effects 




beliefs (& knowledge) 
Modify unhelpful illness or 
treatment beliefs 
Provide easy to understand 




Provide information for a 
more accurate perception 
of breast cancer, risk of 
recurrence and causes of 
recurrence 
 
Reduce forgetting  
Provide tips and strategies to 
improve PBC  
Implementation intentions (goal 
setting) to bridge gap between 
intention & behaviour  
Information on health 
consequences of forgetting  
 
Increase social support 
Encourage people to seek 
support from friends and 
family  










9.3.3.1. Modifying illness and treatment beliefs  
The CSM posits a self-regulatory process whereby the selection of a coping behaviour, such 
as adherence, is driven by the patient’s illness perceptions. These illness perceptions 
determine the action plans or coping behaviours used to manage the illness threat. Therefore, 
there is reason to believe that modifying illness perceptions, to provide a more accurate 
illness model, may help improve medication adherence by encouraging the use of more 
appropriate coping strategies. As tamoxifen prevents future recurrence rather than treating 
current symptoms, patients have no active reinforcement to continue taking their medication. 
Providing more accurate perceptions of recurrence and illness timeline may help patients to 
recognise that they need treatment, even when asymptomatic (McAndrew et al., 2008). 
Modifying additional illness perceptions, such as identity, causal beliefs or consequences 
may also be beneficial. Several studies have shown that it is possible to modify illness 
perceptions through intervention (Broadbent, Ellis, Thomas, Gamble & Petrie, 2009; 
Glattacker, Heyduck & Meffert, 2012; Petrie, Cameron, Ellis, Buick & Weinman, 2002). 
These interventions focused on providing information to debunk myths, discussing 
behaviour change methods, symptoms and concerns.  
However, few interventions have used these techniques to improve adherence. The few 
studies conducted in this area have shown some success at improving adherence rates 
(Elliott, Barber, Clifford, Horne & Hartley, 2008; Seyyesdrasooli, Parvan, Rahmani & 
Rahimi, 2013).  For example, Petrie et al. (2012) used tailored text messages to modify 
asthma patients’ illness and treatment beliefs. Example text messages included ‘Your 
preventer works best if taken every day’ and ‘Asthma doesn’t take a holiday. Even if you 
don’t have symptoms, your asthma is still there.’ After 18 weeks of receiving tailored text 
messages, the intervention group had increased necessity and timeline beliefs. Furthermore, 
the intervention group showed improved adherence over the follow-up period. A similar 
study was conducted by O'Carroll et al. (2013) with 62 stroke survivors. Participants were 
given a simple, brief intervention to modify any unhelpful illness or treatment beliefs and to 
establish a better medication taking routine. The necessity/concerns differential improved 
over time, as did adherence, over and above any effect of increased patient contact or mere 
measurement. Treatment effects were mediated by reductions in forgetting and concerns 
about medication (O'Carroll, Chambers, Dennis, Sudlow, & Johnston, 2014).    
Zwikker et al. (2014b) conducted a group based motivational interviewing intervention in 
patients with Rheumatoid Arthritis. However, this intervention showed no improvements in 
adherence, which may be due to ceiling effects, as beliefs and adherence had changed 




et al. (2010) used an interactive voice response intervention based on educational messages 
and encouraging patients to communicate with Healthcare Professionals (HCPs). The 
intervention resulted in favourable shifts in necessity/concerns differential, which were 
correlated with changes in adherence. Karamanido, Weinman and Horne (2008) conducted a 
psychoeducation intervention aiming to improve understanding of the need for phosphate 
control in End Stage Renal Disease patients undergoing haemodialysis. This involved 
patients being given a leaflet and a demonstration of the mode of action. The intervention 
resulted in positive changes in knowledge, treatment coherence and medication outcome 
efficacy beliefs in the intervention group in comparison to the control group. However, these 
improvements were not associated with improvements in perceived need for treatment or for 
adherence. Similarly, Jones et al. (2016) used a brief animated intervention to improve 
adherence in acute coronary syndrome. Post intervention, the intervention group had 
increased treatment control beliefs and decreased medication concerns. At the seven week 
follow-up, improvements were also seen in timeline beliefs and number of symptoms. These 
diagrams work by changing intangible information into more concrete recommendations 
(Jones & Petrie, 2017). However, as with the previous study, these improvements in illness 
and treatment beliefs were not accompanied by improvements in medication adherence. The 
authors suggest that improvements may be seen over a longer term follow-up period.  
Only a small number of studies have been able to translate changes in illness perceptions to 
changes in behaviour (Petrie et al., 2012; O’Carroll et al., 2013). There may be 
methodological issues preventing the remaining studies from seeing improvements in 
adherence, such as ceiling effects or improper measurement of adherence. Alternatively, the 
self-regulatory framework may not be operating in the assumed way, meaning that changes 
to illness perceptions do not result in adjustments to coping behaviours such as adherence. 
More research with longer term follow-up is needed to determine whether these changes to 
illness and treatment beliefs will result in changes to adherence behaviour.  
9.3.3.2. Changing TPB variables and overcoming forgetting  
As with the CSM, previous interventions have also been developed based on the TPB. These 
interventions target the key TPB constructs; intentions, attitudes, subjective norms and PBC. 
It is assumed that improving attitudes and PBC will increase intentions to take medication, 
which should lead to increases in actual medication taking (Ajzen, 1998). For example, a 
psychoeducational intervention based on the TPB improved adherence and clinical 
symptoms in children with Attention Deficit Hyperactivity Disorder (Bai, Wang, Yang & 
Niu, 2015). One of the most popular techniques based on the TPB is implementation 




2008).  Implementation intentions involve pairing a critical cue (i.e. morning coffee) with 
the goal directed response (i.e. taking medication). They work by establishing a strong habit 
and removing the cognitive burden for patients to remember their medication. Studies using 
implementation intentions have been effective at improving adherence rates (Brown et al., 
2009; Webb & Sheeran, 2006). In the intervention mentioned previously by O’Carroll et al. 
(2013), participants were asked to repeat their plan until they could memorise it without 
looking at it. This increases the automaticity of the response. They found significant 
improvements in adherence, which were mediated by reductions in forgetting. A 
psychoeducational program based on the TPB has also improved attitudes and foot care 
adherence in patients with type II diabetes (Beiranvand, Asadizaker, Fayazi, Yaralizadeh, 
2016).  
9.3.3.3.  Managing side effects 
Cancer side-effect management and quality of life (QOL) can be improved with the use of 
psycho-educational interventions (Badger, Braden & Mishel, 2001; Gaston-Johansson et al, 
2013; Golant, Altman & Martin, 2003). These interventions include strategies such as 
providing clinical information about side effects, sharing experiences to empower patients, 
cognitive reframing, enhancing problem solving and coping skills, and relaxation. CBT 
techniques can also help with successful symptom management. CBT models have been 
developed to help people understand how their symptoms might be affected by their 
thoughts, feelings and behaviours, and to identify precipitating and perpetuating factors 
associated with the symptom. Guided and self-management CBT interventions have been 
shown to reduce fatigue in illnesses such as breast cancer and Multiple Sclerosis (Gielissen, 
Verhagen & Bliejenberg, 2007; van Kessel et al., 2008; Moss-Morris et al., 2012). These 
treatments involve targeting cognitive and behavioural variables which are associated with 
fatigue, such as all-or-nothing responses or negative beliefs about fatigue (Skerret & Moss-
Morris, 2006). CBT interventions have also been successful in reducing the impact of hot 
flushes and night sweats (HFNS) in BCS (Mann et al., 2012). This is based on a cognitive 
model of HFNS which explains how the perception, attribution and appraisal of menopausal 
symptoms are influenced by cognitive factors, beliefs and mood (Hunter & Mann, 2010). 
For example, negative thoughts such as embarrassment, disgust and worry are linked to 
more problematic hot flushes (Rendall, Simonds & Hunter, 2008). Group CBT sessions 
significantly reduced HFNS problem rating at 9 and 26 weeks (Mann et al, 2012). Women in 




9.3.3.4. Improving knowledge  
Previous educational interventions have been shown to improve medication adherence in a 
range of conditions (Clerisme-Beaty et al. 2011; Munoz, Dorado, Guerrero & Martinez,  
2014; Newman-Casey et al., 2013; Yu, Chair, Chan & Choi, 2015; Zullig, McCant, Melnyk 
& Danus, 2014). Studies have also shown that educational interventions can result in clinical 
improvements (Kuntz et al., 2014). However, other studies have found that educational 
materials are not effective at improving medication adherence (Alvaro et al., 2015; Sabate, 
2003). Costa et al. (2015) concluded that whilst educational interventions can improve 
knowledge, they often do not influence adherence levels, suggesting that it may be more 
effective to combine patient education with behavioural interventions. This is supported by 
the studies described previously showing a lack of an effect of educational materials on AI 
adherence (Hadji et al., 2013a; Yu et al., 2012; Ziller et al., 2013). This suggests that 
education or knowledge may be beneficial for improving adherence but they are not 
sufficient alone.  
9.3.3.5. Overview of methods and strategies    
The key determinants of tamoxifen non-adherence are shown in Table 9.1. Based on the 
techniques described above, Table 9.2 maps specific methods and techniques on to these key 
determinants. Several of these strategies overlap, such as providing information on how 
tamoxifen works, which should increase knowledge as well as necessity beliefs and 
potentially increasing intentions to take tamoxifen and attitudes towards tamoxifen. As 
shown in Table 9.2., these methods and strategies are targeted in different sections across the 
intervention. They will be discussed in turn in the relevant sections below.  
9.3.4. Stage four: Develop intervention   
9.3.4.1.  Format of intervention  
A key step in this stage of intervention development was to establish the format of the 
intervention. In this case, a self-management intervention was chosen as it was felt this 
would have the widest reach. Many tips for improving non-adherence to tamoxifen focus on 
the patient/provider relationship and the healthcare setting (McCue, Lorh & Pick, 2014; 
Partridge et al., 2007), but this is less relevant in the UK where patients are receiving less 
contact with their physician. The NHS is currently implementing Open Access Follow Up, 
which means that regular follow-up clinics will be replaced with annual mammograms and 
appointments with Clinical Nurse Specialists (CNS) where needed. BCS are being 




appropriate choice within this context. As the intervention requires very little input from 
researchers or clinicians, it also has the potential to be widely rolled out at a very low cost, 
which improves clinical utility (Jones et al., 2016). The MRC guidance recommends that 
researchers think about implementation at early stages of intervention development, which is 
in line with Normalisation Process Theory (NPT; Murray et al., 2010), which suggests that 
failing to consider implementation at the early stages may result in an intervention which is 
effective but not able to be implemented. NPT outlines a process for creating an intervention 
which can become embedded into normal practice, such as involving stakeholders at early 
stages of the research, thinking about who will deliver the intervention, what the costs will 
be and what the context or setting for the intervention will be. A full application of NPT was 
not feasible during the development of this intervention but it was felt that a self-
management intervention, if successful, had more potential to be implemented as it does not 
require many resources.  
Similar self-management interventions have been well received by patients and have 
improved a range of clinical and psychosocial outcomes (Coffey et al., 2016; Goldberg, 
Hinchley, Feder & Schulman-Green, 2016; Lee et al., 2014). For example, Taking 
CHARGE is a self-management program for BCS which provides women with the skills to 
self-manage concerns and provides information on survivorship topics. The program was 
well received with women reporting that it was timely, relevant and had high utility. As well 
as improving QOL, self-management interventions have shown promise in improving 
adherence rates. Anglada-Martinez et al. (2016) found that while a medication self-
management app did not approve adherence rates as measured by prescription refill rates, 
there were improvements in self-reported adherence rates. This intervention included good 
adherers at baseline which may explain the lack of an effect on objective measures of 
adherence. The World Health Organisation (WHO) report on medication adherence 
suggested that interventions aiming to enhance self-management or self-regulation 










Table 9.2 Key behaviour change strategies used in intervention 
Key 
determinants 
General method for 
addressing 
determinant 








Provide evidence and 
information on why tamoxifen is 
necessary, how it works and what 
happens if doses are missed, 
visual information (diagrams) to 
demonstrate the mode of action, 
quotes/ videos for social 
comparison. 
1,2 
Address concerns  
 
Provide information to address 
common concerns (e.g. risk of 
endometrial cancer), activity to 
list concerns and come up with 
response for concerns, challenge 






beliefs about illness 
Provide information to modify 
inaccurate perceptions (e.g. 
causal beliefs, risk of recurrence, 






Provide tips to increase self-
efficacy for symptom 
management, goal setting 
exercise, videos and quotes for 







develop more positive 
attitudes  
Address concerns associated with 
tamoxifen, provide information 
and evidence on tamoxifen to 
encourage more positive 
attitudes, activity to address 
concerns, information on 
consequences of 
forgetting/missed doses.  
1,2,3 
Bridge gap between 
intentions and 
behaviour  
Implementation intentions, goal 
setting/action planning, 
evaluation of goal setting.  
2 
Improve perceived 
behavioural control   
Provide tips for taking tamoxifen, 
social comparison, goal 
setting/action planning.  
2 
Side effects 
Develop coping skills 
and enhance self-
efficacy 
Symptom monitoring, provision 
of practical tips and coping 
strategies for common side 
effects, quotes and videos for 
social comparison, enhance 
confidence for dealing with 
symptoms, psychoeducation on 








General method for 
addressing 
determinant 
Specific strategies/techniques  
Intervention 
Section 
Side effects  
Develop coping skills 
and enhance self-
efficacy 
Symptom monitoring, provision of 
practical tips and coping 
strategies for common side 
effects, quotes and videos for 
social comparison, enhance 
confidence for dealing with 
symptoms, psychoeducation on 
why common side effects occur. 
3 
Set goals for managing 
symptoms 
Formulate SMART goals, 
implement goals, evaluate goal 
setting. 
3 
Use CBT strategies to 
help reduce impact of 
HFNS  
Psychoeducation on the 
physiology of HFNS, identify 
potential triggers, challenge 
negative thoughts about HFNS, 
develop more helpful responses, 






encourage women to 
seek support  
Provide information on the 
importance of asking for help, 
quotes and videos for social 
comparison. Provide resources 
for seeking social support 
elsewhere and for seeking 
professional help.  
4 
Knowledge Information provision 
Psychoeducation, visual 
information, signposting to 




Strategies to help 




Social comparison, practical tips, 
implementation intentions, 




9.4. Developing and piloting the intervention content   
Before the intervention was written, interviews were carried out with three patient 
representatives. In these interviews, women discussed ideas for the overall content of the 
intervention and the format of the materials. The intervention was developed in an iterative 
process following the key determinants and strategies identified in stages two and three of 
the IM framework. These strategies were grouped into sections which were reviewed by the 
research team. The material was then written up, with input from the research team.  The 
MRC guidance recommends that patients or ‘users’ are involved in all stages of the 
development, process and analysis of a complex intervention. Once finalised within the 




each section and sent feedback by email or telephone. The first chapter was also reviewed by 
two clinical nurse specialists. The overall feedback was very positive (Table 9.3), but some 
small changes were made based on patient feedback. Constructive suggestions included 
reducing some repetitive information, adding additional infographics and providing 
additional clinical information. Negative feedback tended to be focussed more around 
pragmatic issues, such as the use of the colour pink or the ordering of some information. 
One woman was not happy with the quotes presented from other BCS, but the general 
feedback for these was positive. The intervention booklet is included in Appendix I, along 
with the accompanying Activity Booklet.  
The intervention booklet includes quotes from other BCS taken from the qualitative study 
presented in Chapter 4. As well as these quotes, several videos were made where BCS 
discussed their experiences and provided tips on how to manage tamoxifen. These types of 
videos have been found to be one of the most powerful tools in self-management 
interventions (Clarkesmith, Pattison, Borg & Lane, 2016). The aim was to normalise the 
experiences that women are going through and to let them know that they are not alone. 
Coffey et al. (2016) found that hearing other people’s experiences helps patients to validate 
their own experiences.  Furthermore, it was hoped that these videos would help to legitimise 
the project and show it has been developed with help from other BCS. Initial patient 
feedback suggested that women may be sceptical of any support materials which had been 
created by people who had not gone through cancer or tamoxifen treatment. 
 
Table 9.3 Feedback on the intervention materials from patient representatives 
Quotes from PPI representatives on the intervention materials  
“Very excited about this booklet as it is desperately needed”  
“I think it’s great!! It’s easy to read, very informative, more so than when I was 
originally diagnosed. The exercises are a great idea”  
“This all looks great to me, really informative and I can't think of anything that you 
haven't covered. I wish I had something like this to read when I started Tamoxifen!”   
“The diagrams are brilliant as they really help explain everything”  
“The information given is very detailed and useful. I especially like (and can identify 
with) the comments given by ladies taking Tamoxifen.” 
“Wish I’d had this booklet from the beginning!”  
“All I can say is wow. I have read through all of it and have made mental notes to 
myself on how I will cope for the next 5 years. I can’t see anything negative to report 
back on” 




The booklet is separated into four sections (Table 9.4). All women complete section one. At 
the end of section one, women perform a needs assessment where they identify which 
sections will be most beneficial for them. This involves women answering a series of 
questions to determine which issues they are struggling with. They then complete one or all 
of the following sections. The sections were developed following the determinants and 
strategies identified in Table 9.1 and 9.2.  
Table 9.4 Intervention sections 
Intervention sections  
Section one What is tamoxifen  
Section two  How to take tamoxifen  
Section three  Managing common side effects  
Section four Finding and utilising support  
 
9.5. Intervention content  
9.5.1. Section 1: What is tamoxifen?  
The first section of the booklet provides information on what tamoxifen is and how it works. 
This was included at the start of the intervention as it was felt that it would be relevant for all 
participants, and it was an easy section to ease them into the booklet. Information is 
provided under a series of subheadings, covering breast cancer, risk of recurrence, the role of 
oestrogen, how tamoxifen works, how effective it is and why it is important to take it every 
day. Each of these subsections includes easy to understand information, tested using the 
Flesch Kincaid reading comprehension score set to age 12. Each page includes a glossary of 
key terms to support participants’ understanding of key concepts. In addition to this, 
diagrams are used to supplement the written material. For example, one diagram shows how 
oestrogen receptors work and illustrates the mechanism of action for tamoxifen (Figure 9.3). 
An additional diagram also demonstrates what would happen if doses of tamoxifen were 
missed. A figure was created to illustrate the risk of recurrence per 100 women with and 
without tamoxifen. At the end of the section, women are signposted to resources for further 




The rationale for this section was based on previous literature showing that many women 
reported a need for more information about HT. For example, focus groups have shown that 
BCS wished they had access to a knowledge source showing how their medication works 
and why they have been prescribed it (Van Londen et al., 2014b). These wishes were echoed 
by participants in the qualitative study presented in Chapter 4.  Studies across Europe show 













receiving information about side effects, 26% reported receiving information about risk of 
recurrence and only 13% felt their questions were answered (Quinn et al., 2016; Wengstrom, 
Aapro, Leto di Priolo, Cannon & Georgiou, 2007; Wuensch et al., 2015). 
There is a need to overcome this knowledge deficit in order to support BCS with making an 
informed choice about treatment. Furthermore, this information deficit has been linked to 
adherence rates. Many researchers and clinicians have proposed that providing clear 
information on how tamoxifen works should improve adherence rates by increasing positive 
beliefs about tamoxifen (Arriola et al., 2014; Burstein et al., 2014; Fink et al., 2004; 
Wengstrom, 2008). This has been supported by a range of other studies. Longitudinal and 
cross-sectional studies have shown that women who have their questions answered and who 
feel more informed about their HT have better adherence and persistence (Cluze et al., 2012; 
Sheppard et al., 2014; Wouters et al., 2014; Wuensch et al., 2015). Grunfeld et al. (2005) 
found that 50% of non-adherers reported that no benefit could be gained from taking 
tamoxifen, compared to just 16% of adherers. Providing information on the clinical benefits 





of tamoxifen is particularly important in a medication like tamoxifen where the benefits are 
hidden, and where no reduction in symptoms can be attributed to medication taking (Meyer 
et al., 1985). This means there is no overt positive reinforcement for the patient to continue 
taking the medication. As discussed earlier in the chapter, previous educational interventions 
have been effective at improving adherence rates (Clerisme-Beaty et al., 2011; Newman-
Casey et al., 2013).  
Some of the information presented in Section 1 focuses on what would happen if doses were 
missed. This was included because the qualitative study in Chapter 4 showed that women 
talked about skipping or halving doses or taking long treatment breaks but still wanting to 
appreciate the full clinical benefits of treatment. This was also found in Harrow et al.’s 
(2014) qualitative study, in which women often missed tablets without realising the full 
potential consequences of this action.  In an online survey, 89% of BCS reported that 
knowing adherence would improve clinical outcomes was an important factor for improving 
adherence levels (Kirk & Hudis, 2008). The rationale for including diagrams in this section 
was to cater for women who preferred a more visual style of learning. Previous health 
interventions have been shown to be more effective when they contain visual elements as 
well as written information (Joplin, van der Zwan, Joshua & Wong, 2015). Furthermore, 
providing visual imagery around medication taking has been shown to improve adherence in 
several studies (El Miedany, Gaafary & Palner, 2012; Perera, Thomas, Moore, Faasse & 
Petrie, 2014).  
Fear of recurrence or perceptions of the risk of recurrence have been associated with 
adherence (Table 9.1). Section one covers information on risk of recurrence, aiming not to 
increase people’s fear and to scare them into taking tamoxifen, but to provide clear 
information on what the risk means and what the overall risks are, to ensure patients are 
fully informed. Participants are asked to assess their confidence in their knowledge about 
different aspects of tamoxifen pre- and post- reading Section one. After finishing Section 
one, women review which sections of the booklet they feel will be most helpful and to move 
on to the corresponding section.  
9.5.2.  Section 2: How to take tamoxifen  
Section two focuses on how to take tamoxifen and addresses both forgetting to take 
tamoxifen and deliberately skipping doses. The aim throughout this chapter is to educate 
patients on the importance of taking tamoxifen as prescribed, whilst normalising forgetting 
and understanding that for some women, non-adherence or non-persistence may be the best 
solution based on their risk level and their QOL. The aim was to reassure women and 




of discussing any changes to their medication with their Breast Team. Participants complete 
a short activity to decide which non-adherent behaviours are relevant for them, before 
reading the corresponding sections.  
As forgetting was reported much more frequently than deliberately skipping doses in the 
quantitative analysis, this behaviour is addressed first and is allocated more time. As 
discussed above, efforts were made to ensure that the language remained non-judgemental. 
The information and diagrams in section one relating to what happens when doses are 
missed is reiterated here, as understanding what would happen when doses are missed 
appears to be an important part of improving adherence (Chapter 4; Cheung, Lai, Ruan, 
Chang & Setoguchi, 2015; Harrow et al., 2014; Kirk & Hudis, 2008; Wells et al., 2016). 
Participants are given tips from other women on how to remember to take tamoxifen, what 
to do when going on holiday and how to improve planning. These tips were largely taken 
from the qualitative study presented in Chapter 4. After reading these tips and learning about 
the importance of taking tamoxifen as prescribed, participants are referred to an 
implementation intentions activity. In this activity, women pair the behaviour of taking 
tamoxifen to a key activity in their day, such as a morning cup of coffee. This increases the 
automaticity in which the behaviour is performed and removes the burden of having to 
remember. Participants write their plan down in the template provided, visualise it and 
repeat it until they know it from memory. Example plans are provided to help give 
participants inspiration. Several similar interventions have shown success of these activities 
at reducing rates of forgetting (Brown et al., 2009; O’Carroll et al., 2013; Webb & Sheeran, 
2006). 
The rationale for this activity was based on the evidence from the needs assessment that self-
efficacy for medication taking, PBC and intentions were predictors of adherence, and 
evidence from the qualitative study showing that many adherent women had good routines 
in place (Table 9.1). Furthermore, in a large review of interventions to improve adherence, 
significantly larger effect sizes were found for interventions which linked medication taking 
with existing habits or which incorporated prompts (Conn, Ruppar, Enriquez & Cooper, 
2016).  
A subsection in this section is dedicated to deliberately skipping doses. Again, efforts were 
made to ensure that language was non-judgemental. However, in order to ensure that women 
were making fully informed decisions about these behaviours, information was provided on 
the clinical implications of missing doses. Women are also encouraged to discuss their 
concerns with their HCPs in order to find the best solution for them. Five key concerns are 




get another type of cancer; tamoxifen is a reminder that I am unwell; and I prefer to use 
natural products and medicines. These concerns were drawn from previous literature and the 
qualitative study conducted in Chapter 4. After reading responses to these concerns, women 
are asked to complete an activity where they can list their own concerns and create a 
response to overcome the concerns. Examples are provided to help women understand this 
activity. For example, a concern around getting another type of cancer is overcome by 
stating that the chance of getting endometrial cancer is tiny, and whilst tamoxifen does 
increase this, it is still only a tiny risk compared to the benefits of taking tamoxifen.  
9.5.3. Section 3: Side effects of tamoxifen   
The third section is on how to manage common side effects. Women are given information 
on what side effects may be associated with tamoxifen and general tips for symptom 
management. They are introduced to the link between thoughts, feelings and behaviours. 
Participants complete a symptom monitoring diary before reading the sections for the side 
effects which are troubling them. After reading the corresponding tips, participants are 
referred to information on tips for SMART goal setting, along with example goals for each 
side effect. Women create their own goals for symptom management and spend two weeks 
trying to implement this goal, before reviewing its effectiveness. The side effects were 
chosen based on the information in Chapter 4 and Chapter 6 and included (1) HFNS, (2) 
vaginal dryness/itchiness/discharge, (3) tiredness/fatigue, (4) changes in mood, (5) weight 
loss, (6) leg cramps/joint pain.  Each of these subsections included a description of the 
symptom, an explanation of why people might experience the symptom and tips for 
managing the symptom.    
The section on HFNS was informed by the successful CBT treatment for HFNS (Mann et 
al., 2012). Participants were also provided with a video of Professor Myra Hunter describing 
the treatment. A paced breathing exercise is provided to help women remain calm through 
the hot flush. Other tips are also provided on how to keep cool and how to avoid HFNS 
triggers. The sections on tiredness, fatigue and insomnia also utilise CBT techniques by 
reiterating the link between thoughts, feeling and behaviours and providing fatigue 
management techniques such as balancing rest and activity, keeping a fatigue diary and 
practising good sleep hygiene. The remaining sections provide a range of different tips for 
managing the symptoms, as well as quotes from BCS and resources for more information or 
support.  
This section was included because side effects are consistently identified as a barrier to 
adherence in qualitative and quantitative studies (Grunfeld et al., 2005; Moon et al., 2017b; 




improve adherence rates (Chirgwin et al., 2016; Doggrell, 2011; Kirk & Hudis, 2008). 
Evidence suggests that patients weigh their side effects up against their necessity beliefs 
when making decisions about taking tamoxifen. Reducing the impact of side effects may 
cause the cost-benefit analysis to become more favourable. Studies suggest that women 
often feel unprepared for the side effects and that they are given little support in dealing with 
them (Moon et al., 2017b; van Londen et al., 2014b; Wuensch et al., 2015). Researchers 
have suggested that knowing what side effects to expect may help patients to deal with them, 
potentially improving adherence (Fallowfield, 2008; Partridge et al., 2007; Wood, 2012). 
Qualitative studies have shown that women often do not feel recognised and validated by 
their HCPs, which makes the burden of HT heavier (Moon et al., 2017b; Verbrugghe et al., 
2015). One aim of this section was to help patients to feel recognised and validated in their 
experiences. This was also achieved by the inclusion of quotes and videos of other BCS.  
The aim of the section was not to remove the side effects, but to improve women’s 
confidence in dealing with them and to reduce their impact on QOL. In patients with 
haematological disease, non-adherence was found to be associated with the difficulty of 
handling side effects, rather than the presence or frequency of side effects (Richardson, 
Marks & Levine, 1988). Furthermore, in BCS, greater self-efficacy for coping with 
symptoms was associated with greater functional, emotional and social wellbeing after 
controlling for physical symptoms (Shelby et al., 2014). Self-efficacy also mediated the 
relationship between wellbeing and physical symptoms. If a woman had high self-efficacy 
for coping with symptoms, then physical symptoms had no impact on wellbeing. In addition 
to this, the quantitative analysis in Chapter 6 showed that tamoxifen consequences was 
related to non-adherence. Therefore, this section aims to help women feel more confident in 
coping with these symptoms, and reduce the consequences of taking tamoxifen on people’s 
daily lives.  
9.5.4. Section 4: Support  
The final section focuses on social support. This is the shortest section and was included as 
evidence from the needs assessment suggested that increased social support may be 
associated with higher rates of adherence and persistence (Table 9.1). This section discusses 
why women may still need support at this stage in their treatment, and why it is important to 
ask for help. This was included as women in the qualitative study complained that their 
friends and family underestimated the impact of tamoxifen and expected them to be ‘back to 
normal’. Women are given information on the importance of telling their friends and family 
if they are struggling with tamoxifen and are encouraged not to worry about feeling a 




of social support are also discussed. A list of potential online groups is provided, along with 
quotes from other women showing how helpful they found these groups. The benefits of 
face-to-face groups are then discussed and women are referred to websites to find local 
groups. Finally, a list of helplines and support centres is presented. The final section 
encourages women to discuss their concerns with their HCPs, especially with regards to 
discontinuing tamoxifen treatment. Tips for communicating with HCPs are provided, both 
for overall discussions and for more sensitive topics.  
9.6. Summary  
This chapter described the development of a psychoeducational self-management 
intervention to support BCS taking tamoxifen. The intervention was developed following the 
IM framework and was informed by empirical research and theories of health behaviour. 





















10. Feasibility and acceptability of a psychoeducational intervention for breast 
cancer survivors prescribed tamoxifen  
10.1. Chapter overview  
This chapter describes the initial feasibility and acceptability testing of a self-management 
psycho-educational intervention to support Breast Cancer Survivors (BCS) taking 
tamoxifen. The intervention provides information and activities with the aim of increasing 
necessity beliefs and knowledge, decreasing concerns about tamoxifen, helping women to 
manage their symptoms, modifying unhelpful illness perceptions, and increasing perceived 
behavioural control (PBC). The intervention was informed by the research described 
Chapters 3, 4, 6, 7 and 8. The development of the intervention is described in Chapter 9.  
The Medical Research Council guidance on developing complex interventions recommends 
that feasibility testing is carried out prior to a large randomised controlled trial (RCT) (Craig 
et al., 2008). These feasibility studies are useful as they can determine whether an 
intervention is appropriate for further testing, they can identify any methodological 
challenges, and they are helpful for planning and justifying later RCTs (Anderson & 
Prentice, 1999; Bowen et al., 2009; Feeley et al., 2009). These studies can also assess the 
acceptability of the intervention. Whilst feasibility assesses the ability to provide the 
intervention and conduct the study, acceptability measures the suitability or favourability of 
the intervention from the service user’s perspective (Feeley et al., 2009). Questions to be 
assessed in feasibility studies include whether the recruitment strategy is feasible, if there is 
any interest in the study, if the target population is large enough, if the study procedures are 
feasible, if the timeframe is sufficient and whether any additional resources are needed. 
Establishing these issues in pilot or feasibility studies reduces the likelihood of any problems 
at the RCT stage (Fain, 2010). Feasibility studies may include randomisation even if they are 
not powered to detect differences between groups. This helps to test the feasibility and 
acceptability of the randomisation procedures. However, due to time constraints, it was not 
possible to randomise participants in this study. Non-randomised feasibility studies, 
however, still enable the intervention and other study processes to be evaluated prior to a 
future larger trial and they therefore still add value. A recent review found that around a 
third of pilot or feasibility studies were non-randomised (Eldridge et al., 2016).  
10.1.1. Study aims  
The primary outcomes are of the study are:  




a) The percentage of eligible women within the recruitment centres 
b) The percentage of eligible women agreeing to participate (the uptake rate)  
c) The percentage of women completing the intervention (the retention rate)  
d) The percentage of women who switch medications during the intervention 
period.  
The secondary outcomes are to:  
1. Calculate effect size of any changes in adherence rates  
2. Calculate effect size of any changes in illness and/or treatment perceptions 
which are related to adherence  
3. Calculate effect size of any changes in quality of life (QOL), distress, 
confidence in dealing with symptoms, and satisfaction with information about 
medicines.  
10.2. Methods  
10.2.1. Ethical approval   
Full NHS REC and HRA approval was granted by London South East Research Ethics 
Committee (REC Ref: 16/LO/1205). 
10.2.2. Design 
An exploratory pre-post design was used with all participants being allocated to the 
intervention condition. The intervention duration was around four to six weeks.  
10.2.3. Participants  
10.2.3.1. Inclusion and exclusion criteria  
The inclusion criteria for the study were:  
(i) Diagnosis of primary breast cancer  
(ii) Prescribed adjuvant tamoxifen  
(iii) Over the age of 18  
(iv) Able to consent for themselves  
(v) Ability to read and understand English  
(vi) Suboptimal levels of adherence, as evidenced by scoring < 25 on the 
Medication Adherence Rating Scale (MARS).  
The exclusion criteria for the study were:  




(ii) Prescribed course of tamoxifen has ended, or is due to end during the study 
period  
(iii) Received a diagnosis of depression in the past year  
10.2.3.2. Recruitment    
Recruitment took place over 6 months (November 2016-April 2017). Participants were 
recruited through breast clinics, online advertisements and through a previous database of 
participants.  
Recruitment through breast clinics 
Patients were recruited through breast clinics at four NHS trusts. Clinic staff identified 
potential participants. If patients were interested in the research they were given an 
information sheet and had the opportunity to ask any questions about the research. They then 
completed a Screening Questionnaire to assess their eligibility, including the MARS. 
Informed consent was taken from eligible patients who were interested in taking part. 
Recruitment at three London NHS trusts was carried out by local clinic staff, and 
recruitment at the final trust was carried out by the research team.  
Online recruitment 
Advertisements were placed on Facebook support groups, with permission by group admins. 
The advertisements provided some brief information about the study and asked interested 
patients to contact the researcher for more information. Patients were then sent the 
Information Sheet, Consent Form and Screening Questionnaire and were asked to return 
these to the researcher by email or post.  
Recruitment through previous database  
As part of the previous cross-sectional study (Chapter 6), participants were asked if they 
consented to being contacted about a future intervention study. Participants who consented 
to this were screened based on the information they provided as part of the previous study. 
Participants who were potentially eligible were sent an invitation letter or email, along with 
the Information Sheet, Consent Form and Screening Questionnaire. Patients were asked to 
complete the forms and return them to the researcher if they were interested in taking part. 
They had the opportunity to ask questions before providing consent. The forms could be 




10.2.4. Procedure  
Once informed consent had been taken, participants were given the baseline questionnaire to 
complete. They could do this on paper and return it to the researcher using a stamped 
addressed envelope, or complete the questionnaire online. The online questionnaire was 
hosted on Bristol Online Survey and took around 15 minutes to complete. If the baseline 
questionnaire was not completed within a week, a reminder email or letter was sent. After 
completing the baseline questionnaire, women were sent the intervention booklets 
(Appendix I). Once the intervention materials were complete, participants were asked to 
answer the follow up questionnaire, which they could either do online or as a paper copy. 
Participants were then invited to take part in an interview to discuss their experiences of the 
intervention. These interviews took place over the phone and lasted around 20 minutes. They 
were based on a semi-structured interview schedule. Participants were encouraged to guide 
the interview and to bring up topics which they felt were relevant. They were asked how 
they found the intervention, what was particularly helpful and what could be improved.  
10.2.5. Outcome measurements  
Primary outcomes  
The primary outcome was to assess the feasibility and acceptability of the intervention. The 
feasibility was assessed by measuring:  
a. The percentage of eligible women within the recruitment centres. 
b. The percentage of eligible women agreeing to participate (i.e. the uptake rate). 
c. The percentage of women remaining until the close of the study (retention rate). 
d. The percentage of women who switch medications during the intervention period.  
The acceptability was measured using semi-structured interviews with women who took part 
in the intervention, and by the percentage of women who completed the intervention. 
Unfortunately, it was not possible to analyse the interviews within the time frame of the PhD 
and they will therefore be presented at a later date.  
Secondary outcomes 
Medication Adherence Report Scale (MARS)  
The MARS (Horne et al., 2001) includes five statements about taking medication, which are 
each scored on a five-point scale from never to always. The scale attempts to avoid any 
issues regarding social desirability by asking questions in a non-threatening and non-
judgemental way. It includes four questions on intentional non-adherence and one on 




retest reliability (reliability coefficient: 0.83; Horne et al., 2001). It has been used multiple 
times in breast cancer patients (Boonstra et al., 2013; Kim et al., 2014). As well as 
completing the MARS, patients were asked a single question to determine if they had 
discontinued tamoxifen treatment, and if so, why.  
Beliefs about Medicines Questionnaire (BMQ)  
The BMQ-Specific measures beliefs surrounding the necessity of taking medications and 
concerns about adverse effects (Horne et al., 1999). Each item is rated on a 5 point Likert 
type scale. A higher score on each subscale indicates stronger necessity or concern beliefs. 
The scale has been used many times in breast cancer patients with Cronbach’s alpha values 
of 0.79–0.86 and 0.72–0.84 for the necessity and concerns scales, respectively (Bender et al., 
2014; Corter, Findlay, Broom, Porter, & Petrie, 2013; Jacob Arriola et al., 2014). The word 
‘medication’ was replaced with ‘tamoxifen’ on all items.  
Revised Illness Perceptions Questionnaire for Breast Cancer Survivors (IPQ-BCS) 
The IPQ-BCS was used to measure illness perceptions (Moon et al., 2017c). This is a 
modified version of the Revised Illness Perceptions Questionnaire (IPQ-R). The 
development and validation of this scale is described in Chapter 5. The IPQ-BCS shows 
good psychometric properties. It contains ten subscales; identity, tamoxifen consequences, 
breast cancer consequences, cure, risk of recurrence, treatment control, personal control, 
coherence, emotional representations and causal beliefs. The identity scale includes a list of 
symptoms where participants are asked to indicate if they have experienced a symptom and 
if they attribute it to their breast cancer or tamoxifen treatment. The causal beliefs scale 
includes two subscales, psychological stress and health behaviours. Participants tick on a 
five-point scale to indicate the extent to which they agree or disagree that each factor causes 
a recurrence. The remaining scales each include four items scored on a 5-point Likert-type 
scale, with participants indicating the extent to which they agree or disagree with each item.   
Hospital Anxiety and Depression Scale (HADS)  
The HADS is a 14-item measure with depression and anxiety subscales (Zigmond & Snaith, 
1983). The overall Global Distress scale was used in this study, as a recent study has 
suggested the scale does not differentiate well between anxiety and depression (Norton et al., 
2013).  Each item is scored on a scale of 0 – 3, with higher scores reflecting higher levels of 
depression and anxiety. Internal consistency values in patients with breast cancer were 
α=0.81 – 0.86 for depression and α=0.83 – 0.85 for anxiety (Matthews et al., 2014; Stanton 





Quality of life  
The FACT-ES is a QOL scale for patients with breast cancer who are on endocrine therapy. 
The FACT-ES has demonstrated good test-retest reliability (Fallowfield et al., 1999). 
Patients provide an answer on a five-point scale from ‘not at all’ to ‘very much’ to indicate 
how much they have experienced each concern. It contains subscales on physical wellbeing, 
functional wellbeing, social/family wellbeing and emotional wellbeing. An additional 
concerns subscale lists potential side effects of endocrine treatment that women may have 
experienced.  
Confidence in dealing with symptoms  
To identify whether women feel confident in their ability to manage their symptoms, a 
modified version of a standard self-efficacy scale was used. The scale asks women to rate 
their confidence in their ability to cope with a series of symptoms on a 10-point scale 
ranging from 10 (not confident) to 100 (very confident). This modified self-efficacy scale 
has been used previously in this population and has shown good reliability (Shelby et al., 
2014).  
Satisfaction with Information about Medicines Scale  
The Satisfaction with Information about Medicines Scale (SIMS) was used to determine 
how informed people feel about 17 different aspects of their treatment. Answers range from 
“Too much” to “Too little”, with additional options for “None needed” and “None received”. 
The SIMS shows satisfactory internal consistency and test-retest reliability (Horne et al., 
2001). It has been used previously in a sample of women with breast cancer and has shown 
good reliability (0.90; Heisig et al., 2015).  
10.2.6. Intervention  
The intervention involved participants completing the materials described in Chapter 9 
(Appendix I). Participants were sent the Intervention booklet and the accompanying Activity 
booklet. An initial phone call was then carried out with participants, where they were given 
an overview of the materials by the researcher, and asked to identify which areas may be 
particularly beneficial for them. This phone call lasted around ten minutes. Participants then 
worked through the four sections of the booklet and the associated activities for four to six 
weeks. The researcher telephoned participants two to three weeks into the intervention to 
give additional support with the activities and to discuss goal-setting. This also served as a 
reminder for participants to engage with the materials. Participants were then left to 
complete the rest of the materials, with the option of contacting the researcher to discuss any 




10.2.7. Statistical analysis  
Sample size calculation  
Little guidance is provided on the required sample size for feasibility studies. The National 
Institute for Health Research (NIHR) recommends that the sample size needs to be large 
enough to estimate the proportion of eligible people who are willing to participate, of 
participants who drop out of the trial or of participants who comply with their intervention 
(NIHR, 2015). A review of previous feasibility studies found that the average study had 36 
participants per arm (Arain, Campbell, Cooper, & Lancaster, 2010). This is consistent with 
recommendations given by Lancaster, Dodd, and Williamson (2004) who suggest an overall 
sample size of 30. Other recommendations range from 24 (Julious, 2005) to at least 50 (Sim 
& Lewis, 2012). Based on these recommendations, the recruitment aim for this study was 40 
participants to account for an expected attrition rate of 20%. 
Statistical analysis  
Statistical analysis was carried out using SPSS v21. Summaries of continuous variables were 
reported as means and standard deviations. Summaries of categorical variables were reported 
as percentages. Independent samples t-tests or chi-squared tests were used to compare 
women who completed the study procedures with women who withdrew or were lost to 
follow up. Paired samples t-tests were used to examine changes over time to study variables. 
Wilcoxin Signed Rank Test was used to examine changes over time in data which was not 
normally distributed.  As this was a feasibility study not powered to detect significant 
changes, Cohen’s d was calculated to assess the effect sizes based on the mean differences 
between pre- and post-intervention.  
10.3. Results  
10.3.1. Missing data 
Baseline questionnaires were completed by 33 participants. Follow up questionnaires were 
completed by 27 participants. Of the six women not completing follow up questionnaires, 
only one woman actually took part in the intervention. The remaining five women were lost 
to follow up and did not engage with the intervention. The baseline data was carried forward 
for the participants who did not complete the follow up questionnaires (n=6). Individual item 
missing data was very low (<5%) and was therefore replaced using mean substitution.  
10.3.2. Recruitment and uptake  
Figure 10.1 and Figure 10.2 show the recruitment and uptake rates from the previous study 




study described in Chapter 6. Of these, 53 responded, giving a 54% response rate. Of those 
that responded, only 36% were eligible (n=19). Reasons for ineligibility are shown in Figure 
10.2. All 19 eligible participants consented into the study, giving a 100% uptake rate. Across 
five NHS sites, 158 patients were approached. Of these, only 26 were eligible (14%). The 
most common reason for ineligibility was being adherent (n=86). In addition to this, a 
further 150 women who were not prescribed tamoxifen were approached at the Guy’s clinic. 
This was avoided at the remaining clinics, as it was possible to screen records and only 
approach women who were prescribed tamoxifen. Of the 26 eligible women recruited from 
NHS clinics, 76% (n=20) agreed to take part in the study. In addition to this, adverts were 
places on two Facebook groups and seven women responded to the study adverts. Of these, 
three women returned their screening questionnaires. All three women were eligible and 



















 Not eligible (n=132) 
 DCIS/metastatic (n=5) 
 Adherent (n=86) 
 Learning difficulties, language 
barrier, dementia (n=17) 
 Stopping tamoxifen soon (n=13) 
 Unknown (n=2) 
 Depression (n=5) 




Not consented (n=6) 
   Patient not interested (n=1) 
   Patient too busy (n=2) 











 sites   
Figure 10.1 Flowchart showing recruitment from NHS sites.  
























































Invites sent to participants (n=99) 
Not eligible (n=35) 
  Not on tamoxifen (n=5) 
 DCIS (n=4) 
 Adherent (n=12) 
 Depression (n=5) 
 Learning difficulties, 
language barrier, dementia 
(n=1) 
 Stopping tamoxifen soon 
(n=5) 
 Not interested in research 
(n=2) 





No response to letter (n=46) 
 
Figure 10.2 Flowchart showing recruitment from previous study. 




























10.3.3. Study retention and participation  
Forty one women consented into the study. Retention through the study is shown in Figure 
10.3. Eight women did not complete their baseline questionnaires and did not continue with 
the study. Of the 33 women who did complete the baseline questionnaire (80%), 28 
completed the intervention materials (68% of recruited sample, 85% of those beginning 
study procedures). Five women did not complete the intervention materials, four of whom 
were lost to follow up after completing the initial phone call and one who was too busy to 
Completed follow up questionnaire 
(n=27) 
Recruited from previous study (n=18) 
Recruited from clinics (n=20) 
Recruited from Facebook (n=3) 
Gave informed consent (n=41) 
Completed baseline questionnaires 
(n=33) 
Completed initial phone call (n=32) 
Did not complete baseline questionnaires 
(n=8) 
 No longer wants to participate (n=1) 
 Stressful life events (n=1) 
 No response (n=6) 
 
Did not complete initial phone call (n=1) 




Completed intervention materials 
(n=28) 
Did not complete intervention materials 
(n=4) 
 Too busy (n=1) 
 Other stressful life events (n=1) 
 No response (n=2) 
 
 
Did not compete follow up questionnaire 
(n=1) 
 




take part in the study. Reasons for attrition are shown in Figure 10.2. Follow up 
questionnaires were completed by 27 women (66% of total recruited sample, 82% of those 
beginning study procedures).  Participants took on average seven weeks (SD=2.6) to 
complete the intervention procedures, but this ranged from two to 12 weeks. The qualitative 
interviews will provide insight into how many sections were completed by each woman. 
However, the telephone sessions conducted by the researcher showed that the women who 
took part in the intervention (n=28) were engaged and were happy to work their through the 
activities in the booklet. Women did not report any issues with completing the materials and 
only needed very low levels of support. The remaining five women were lost to follow up 
and it is not possible to tell whether they engaged with or adhered to the intervention.  
Independent sample t-tests and chi-squared
 
tests were run to identify any differences 
between women completing the full study and women who were not retained (Appendix J). 
Results showed that women who did not complete the study had lower MARS unintentional 
adherence scores at baseline (M=3.00, SD=0.00) than women who did complete the study 
(M=3.67, SD=0.6, t[26]=5.59, p<.001), indicating more unintentional non-adherence. No 
other differences were seen across groups.  
10.3.4. Participant demographics  
Participant demographics are shown in Table 10.1. Participant age ranged from 41 to 67, 
with a mean age of 51 (SD=6.1). The majority of women were White British (79%), were 
married or in a Civil Partnership (52%) and were employed (89%). Participants were mostly 
pre or peri-menopausal at diagnosis (76%) and had stage I (39%) or stage II (43%) breast 
cancer.  
10.3.5. Baseline adherence rates  
Higher scores on the MARS indicate higher adherence rates. Participants had to score below 
25 in order to be eligible for the study. At baseline, mean MARS scores were 22.8 (SD=1.6). 
The MARS can also be separated into intentional and unintentional non-adherence. 
Intentional adherence is measured using four items, with a total score of 20 indicating full 
adherence. Mean scores were 19.3 (SD=1.4). Unintentional adherence is measured using one 
item, with a total score of 5 indicating full adherence. Mean baseline unintentional non-
adherence scores were 3.5 (SD=0.6). At baseline, 30% of participants were intentionally 
non-adherent and 97% were unintentionally non-adherent. 21% of participants reported both 






10.3.6. Side effects 
Table 10.2 shows the side effects reported by participants at baseline.  Hot flushes were 
reported by 91% of participants, with 52% reporting moderate or severe symptoms. High 
levels of night sweats (79%), changes in mood (79%) and joint pain (85%) were also 
reported. Around half of participants reported problems with vaginal health, fatigue or sleep 
difficulties.  
10.3.7. Relationship between adherence and covariates at baseline  
Pearson’s correlations were run to identify if any covariates were associated with adherence 
scores at baseline. Higher MARS scores were associated with higher QOL (r=.42, p=.016), 
less intense side effects (r=-40, p=-.022), more positive necessity/concerns differentials 
(r=.51, p=.002), participants feeling more informed about treatment (r=.45, p=.008), having 
fewer tamoxifen consequences (r=-.45, p=.009) and attributing fewer symptoms to 
tamoxifen (r=-.51, p=.003).  Higher baseline MARS scores were also associated with higher 
self-efficacy for managing insomnia (r=.51, p=.002) and changes in mood (r=.38, p=.030).  
 




Completed follow up 
questionnaires (n=27)  
Age  41-68  
M=51, SD= 6.1 
42 – 67 
M=52, SD=6.3 
Ethnicity  
   White British  
   Other  









Relationship status  
   Single 
   Married/Civil Partnership  
   Separated/Divorced 











Job status  
   Employed  
   Unemployed  
   Retired  











Age left full time education  
   16 or under 







Menopausal status at diagnosis  
   Pre/peri-menopausal  
   Post-menopausal  









Breast cancer stage  
   Stage I 
   Stage II 












Previous treatment  
   Lumpectomy  
   Single Mastectomy  
   Double Mastectomy  
   Chemotherapy  













Hormone receptor status  
   Positive  
   Negative  









Years since prescribed 
tamoxifen  
   <1 year 
   1-2 years 
   2-3 years 
   3-4 years 
   4-5 years 
















   0  
   1 


















Hot flushes 91% 52% 
Night sweats 79% 49% 
Vaginal dryness, discharge or 
irritation 
59% 28% 
Fatigue 55% - 
Sleep difficulties 52% - 
Changes in mood  79% 36% 
Joint pain 85% 48% 
 
10.3.8. Changes to adherence  
Table 10.3 shows the mean scores on the MARS pre and post intervention. There were no 
significant differences across time in the total MARS scale or the intentional scale. There 
was a small improvement in unintentional MARS scores but this did not reach significance 
(p=.058). The proportion of women classed as non-adherent fell from 100 to 91%. The 
proportion of women classed as intentionally non-adherent remained stable at 30%, but the 
percentage of unintentional non-adherence fell from 97 to 88%. Analysis was also conducted 
to assess the percentage of women who showed improvements on the MARS. Sixteen 
women (59%) showed no change in total MARS scores. Improvements in MARS scores 




(15%). One of these women discontinued tamoxifen during the study period at the 
suggestion of her Clinical Nurse Specialist, who recommended she took a break to assess 
whether her symptoms were caused by tamoxifen.  
 






Cohen’s d  
Comparison of 
pre-and post-
scores   
MARS total 22.8 (1.6) 23.1 (1.3) 0.15 p=.391
†
 
MARS intentional 19.3 (1.4) 19.4 (1.1) 0.06 p=.786 
MARS unintentional 3.5 (0.6) 3.7 (0.7) 0.31 p=.058 
†
 
% Non-adherent 100% 91% - - 
% Intentionally non-adherent 30% 30% - - 
% Unintentionally non-
adherent  
97% 88% - - 
Note. † Indicates that Wilcoxin Signed Ranks Test was used to compare means. Scores of 25 indicate 
total adherence. Scores of 20 indicate full intentional adherence. Scores of 5 indicate full 
unintentional adherence.  
10.3.9. Changes to illness and treatment beliefs  
BMQ necessity and concern scores increased and decreased respectively between baseline 
and follow up, but these were small effects and were not statistically significant (Table 
10.4). There was, however, a significant increase in the BMQ differential score from 
baseline to follow up, with a small to medium effect size (t[32]=2.3, p=.031). There were 
very small non-significant changes to cure beliefs, risk of recurrence, tamoxifen 
consequences, breast cancer consequences, treatment control, emotional representations, 
causal beliefs or identity. Medium to large effect sizes were seen for improvements in 
personal control (t[32]=3.32, p=.002) and coherence beliefs (t[32]=4.36, p<.001).  
10.3.10. Changes to side effects, quality of life and distress 
Changes to side effects, QOL, distress and knowledge are shown in Table 10.4. HADS 
distress scores decreased significantly from pre to post intervention (t[32]=-3.03, p=.005), 
but the effect size was small. FACT-ES scores increased over time but the effect was very 
small and the differences were not statistically significant. The additional symptoms 
subscale of the FACT-ES was analysed independently to assess the extent to which the 
intervention improved symptom experience. Results showed that the symptom experience 

















post- scores   
Necessity  15.88 (3.1) 16.61 (3.2) 0.16 p=.199 
Concerns 13.36 (4.5) 12.39 (3.8)  -0.23 p=.065 




  0.36 p=.031 
Cure  14.61 (2.2) 14.91 (2.6) 0.13 p=.339 
Risk of recurrence  11.79 (3.6) 10.93 (3.4) -0.17 p=.082 
Tamoxifen consequences 11.97 (4.4) 11.42 (4.0) -0.13 p=.198 
Breast cancer consequences 13.61 (3.2) 13.21 (3.1) -0.13 p=.196 




  0.46 p=.002 
Treatment control 15.24 (2.2) 15.42 (2.0) 0.06 p=.634 
Coherence 13.88 (3.7)
 *** 16.51 (2.7)
 ***
 0.58 p<.001 
Emotional representations 14.36 (4.0) 14.33 (4.3) -0.01 p=.953 
Cause: psychological 
attributions 
3.24 (0.9) 3.23 (1.0) 0.02 p=.935 
Cause: health behaviours  3.51 (0.5) 3.58 (0.5) 0.15 p=.362 
Cause: hormonal influence 4.31 (0.7) 4.34 (0.7)  0.05 p=.712 
Symptoms attributed to 
tamoxifen (identity) 
7.03 (5.3) 7.36 (5.1) 0.06 p=.589 




 -0.23 p=.005 
Quality of life total 132.55 (28.5) 135.03 (25.8) 0.09 p=.188 




 0.15 p=.044 
Self-efficacy for managing HF  68.48 (24.8) 71.21 (23.0) 0.08 p=.519 
Self-efficacy for managing NS 69.09 (26.7) 71.81 (19.9) 0.12 p=.472 
Self-efficacy for managing leg 





  0.31 p=.020  






 0.51 p=.001 






 0.41 p=.001 






 0.40 p=.007 
Self-efficacy for managing 
changes in mood  
50.64 (29.1) 58.79 (25.5) 0.30 p=.073 






 0.46 p=.004 




 0.35 p=.007 
Note. SIMS. Satisfaction with Information about Medicines Scale. Higher symptom scores indicate 
reduced impact of side effects. 
* 
Indicates a significant difference at p<0.05, 
**
 indicates a significant 
difference at p<0.01, 
***
indicates a significant difference at p<0.001  
Significant improvements were seen in women’s self-efficacy to manage leg cramps/joint 
pain (p=.020), vaginal health (p=.001), fatigue (p=.001) and insomnia (p=.007), with a large 
effect size for improving vaginal health. A small improvement was seen for self-efficacy for 
managing changes in mood. However, only very small non-significant changes were seen to 
self-efficacy to manage hot flushes, night sweats and changes in mood. The extent to which 
participants felt informed about treatment (t[32]=3.14, p=.004) and their satisfaction with 
information about medications also increased significantly from baseline to follow up 




10.4. Discussion  
This chapter described the initial acceptability and feasibility testing of a psychoeducational 
self-management intervention for women prescribed tamoxifen. This was the first 
intervention designed to improve adherence in BCS taking tamoxifen. The aims of the 
intervention were to improve adherence through a series of key mechanisms; improving 
knowledge, addressing the necessity/concerns differential, reducing the impact of side 
effects, providing a routine for medication taking and modifying any unhelpful illness 
beliefs. The aim of the pilot study was to assess the acceptability and feasibility of the 
intervention prior to a larger scale RCT being carried out.  
This pilot data suggests that a larger scale RCT would be feasible in this population. 
Reasonable response rates were seen from study advertisements and uptake from eligible 
women was high, especially compared with similar self-management interventions 
(Bourmaud et al., 2015; Foster et al., 2016; Lee et al., 2014). However, a large proportion of 
women did not meet the inclusion criteria for the study, with the main reason for ineligibility 
being high levels of adherence. This low rate of eligibility may present a barrier for 
recruitment in future studies. Non-adherent women may be less likely to attend follow up 
clinics, which may account for the low number of non-adherent women identified. 
Therefore, future trials may benefit from advertising across a range of sources including 
support centres and online support groups. In addition to this, many women were not eligible 
due to the fact that they were taking an Aromatase Inhibitor (AI) instead of tamoxifen. 
Whilst there are some differences between tamoxifen and AIs, there are many similar issues 
associated with both drugs, as described in Chapter 1. Therefore, future research could 
benefit from extending the intervention to be suitable for women on both tamoxifen and AIs.  
Furthermore, although many women in clinic were not eligible due to high rates of 
adherence, they expressed a strong desire to participate in the intervention due to wanting to 
improve their side effects. Therefore, the intervention could also be applied to improving 
QOL and side effects in adherent women with the aim of preventing the non-adherence and 
non-persistence that occurs over time, as shown in Chapter 3 and Chapter 8. 
The feasibility data also showed that only two thirds of the women recruited were retained to 
the end of the study. However, of the thirteen women who were lost to follow up, only five 
women completed the baseline questionnaires and were sent the intervention materials. The 
retention rate based on the proportion of women who received intervention materials was 
higher (81%). This suggests that once women engage with the intervention they are 
motivated to complete the materials, indicating good acceptability. However, it should be 




study. This suggests that the self-management nature of the intervention may not suit 
everyone, and that some participants may need additional support. Unfortunately, it was not 
possible to interview these women to ascertain why they did not complete the study, as the 
researcher could not reach them. Women who did not take part in the full intervention had 
significantly lower baseline unintentional adherence scores than women who completed the 
study, suggesting they were more non-adherent and therefore could have benefited more 
from the intervention. 
Nonetheless, the intervention appears to be acceptable and feasible in around two thirds of 
women entering the study, and around 85% of women who received the intervention 
materials. Qualitative interviews are being carried out with women after the intervention 
which will provide further details on acceptability of the intervention, but it was not possible 
to analyse these within the time frame of the PhD. However, the quantitative data shows 
promise for future research. Women did not report issues with any part of the study or 
intervention procedures. 
The main aim of the study was to assess acceptability and feasibility of the intervention, and 
the study was not powered to detect differences in other outcomes. Despite this, some 
significant changes were seen during the intervention period. The necessity/concerns 
differential became significantly more positive from pre- to post-intervention. This suggests 
that women have begun to weigh up tamoxifen more favourably, which was a key aim of the 
intervention materials. Whilst the effect size was small, this improvement has important 
implications, as more positive necessity/concerns differentials were associated with 
decreased odds of non-adherence over the longitudinal study, and were also correlated with 
baseline adherence in the current study. This suggests that improving the necessity/concerns 
differential may cause women to become more adherent over time.  
Whilst the necessity/concerns differential improved significantly, no differences over time 
were seen to treatment control. Interestingly, however, personal control did increase 
significantly from pre- to post-intervention, with a medium effect size. The intervention 
provided information and diagrams aimed at improving beliefs around the extent to which 
tamoxifen could control the risk of recurrence, so it is surprising that treatment control did 
not increase. However, scores on treatment control were higher at baseline than scores on 
personal control which might explain the lack of improvement in this variable. Participants 
may also perceive that taking tamoxifen is something they can do personally to control their 
risk, which would explain why perceptions of personal control increased significantly. 
Studies have shown some overlap and cross-loading between the constructs of personal and 




factor analysis in Chapter 5 (Moss-Morris et al., 2002).  However, the intervention materials 
also provided information around the effects that exercise can have on risk of recurrence, 
which may be responsible for the improvements in personal control.  
Coherence beliefs increased significantly after the intervention, as did the extent to which 
participants felt informed and their satisfaction with information about medication. These 
were all medium to large effects. These improvements are in line with the aims of the 
intervention. The extent to which participants felt informed about treatment also correlated 
with adherence at baseline, suggesting that improvements in this variable could be 
associated with improvements in adherence. No improvements were seen to tamoxifen 
consequences over time, despite the intervention aiming to reduce the impact of side effects.  
The intervention also aimed to improve participants’ ability to manage their side effects, 
with the potential for reducing the intensity of side effects. Results showed that side effect 
intensity improved, as did self-efficacy for managing several symptoms, including fatigue, 
insomnia and vaginal health. Whilst there were medium sized effects for improvements in 
self-efficacy, the improvement in side effects was small. Results suggest that the Cognitive 
Behavioural Therapy (CBT) strategies for managing fatigue may have been beneficial in this 
population, supporting previous RCTs (Gielissen et al., 2007; Moss-Morris et al., 2012; van 
Kessel et al., 2008).  However, self-efficacy for managing Hot flushes or Night sweats 
(HFNS) did not improve significantly in the study, despite the inclusion of CBT strategies 
which have shown to be effective in BCS (Mann et al., 2012). This is particularly troubling 
as results showed that a large proportion of participants experienced HFNS, and that around 
half of participants reported moderate to severe symptoms.  Participants may need more help 
to engage with the CBT strategies for HFNS. The qualitative interviews will provide useful 
information as to whether women read and engaged with these sections.  
These improvements to symptom management are important as they likely improve patient’s 
day to day lives, as well as having the potential to improve adherence. Side effects have 
been shown in the previous chapters to be a driver for non-adherence, and therefore 
improving side effect experience could lead to later improvements in adherence. The 
longitudinal analysis showed that side effects may have more of a knock-on effect on 
adherence, which was supported by research by Corter (2013). Therefore, there may be a 
delay before improvements in side effects result in improvements in adherence. The 
improvements in self-efficacy for managing symptoms are also particularly important, as 
this variable was correlated with adherence in the baseline analysis. Furthermore, studies 
have shown that non-adherence may be related more to the difficulty of handling side 




women with breast cancer, greater self-efficacy for coping with symptoms mediated the 
relationship between physical symptoms and impact on wellbeing (Liang et al., 2016; 
Shelby et al., 2014). However, improvements in QOL were not seen in this study. In 
addition to improving symptom management, the intervention also improved ratings of 
distress, which was associated with non-adherence in the longitudinal analysis, but this was 
a small improvement.  
Whilst improvements were seen in study variables which are related to adherence, no 
significant improvements in overall adherence were found, and four women became more 
non-adherent over time (15%). However, 26% of women showed improvements in their 
total MARS scores (n=7), which shows some positive impact of the materials. Furthermore, 
there was a small improvement in unintentional non-adherence scores. The lack of an 
improvement in intentional non-adherence may be due to several factors. Firstly, the sample 
recruited may have been too adherent at baseline to detect any improvement. Mean 
intentional non-adherence scores were 19.2, which is close to the maximum score of 20. 
Efforts were made to only recruit women who were non-adherent, but this did not specify 
intentional or unintentional non-adherence. Furthermore, the cut off for non-adherence was 
high, and women only had to select that they “seldom” forget their medication in order to be 
eligible. Therefore, there may not be much room for improvement in these women. Mathes 
et al. (2014) reviewed interventions to improve adherence and found that studies with high 
rates of baseline adherence were less likely to find improvements in adherence. Secondly, 
the MARS may not be sensitive to changes in adherence, especially across this relatively 
short follow up period. The wording on the questionnaire does not refer to a specific 
timeframe, and therefore, in the follow up questionnaire, participants may be answering 
based on the medication taking behaviour both pre-and post the intervention. Questionnaires 
with a specific time-period may be more suitable at demonstrating change over time 
(Garfield, Clifford, Eliasson, Barber & Willson, 2011). Future trials could benefit from using 
a different measure of medication adherence. 
An alternative explanation is that the intervention did not result in changes in intentional 
non-adherence. It may be that the changes in key mechanisms of adherence, such as 
necessity/concerns differential, will lead to later improvements in adherence rates. 
Furthermore, the longitudinal analysis in Chapter 8 showed that adherence rates decreased 
significantly between baseline and three months. Therefore, the fact that adherence did not 
decrease across the intervention is a positive finding. There was a small improvement in 
unintentional non-adherence, which may improve over as time as women continue to 
implement the strategies they learnt during the intervention. The qualitative interviews may 




Previous interventions for Hormone Therapy (HT) adherence have shown that educational 
materials can improve knowledge and satisfaction about information, but these studies did 
not investigate changes in adherence (Bourmaud et al., 2016; Heisig et al., 2015). As 
discussed in Chapter 9, educational materials alone are not sufficient to improve adherence 
rates (Costa et al., 2015; Sabate, 2003) and several studies have shown that educational 
materials do not improve adherence to AIs (Hadji et al., 2013b; Neven et al., 2014; Ziller et 
al., 2013). However, these studies simply aimed to provide information and they did not 
specify how they developed the intervention. The current intervention improves on these 
previous studies. Results show that by following a rigorous, theory based procedure for 
developing interventions, it is possible to elicit changes in key factors that have previously 
been shown to relate to non-adherence, and to show small improvements in non-adherence 
rates.  
The improvements in treatment beliefs and knowledge may be partly due to the inclusion of 
diagrams, as previous studies have shown that visual representations and demonstrations of 
action can improve knowledge and medication beliefs (Jones et al., 2016; Karamanidou et 
al., 2008). The results also support two previous studies showing that providing information 
can result in changes to illness and treatment beliefs (O’Carroll et al., 2013; Petrie et al., 
2012). Both of these studies also found improvements in adherence, which were not seen in 
the current study. However, these studies included a longer follow up period which may 
have allowed for more change in adherence.  
The intervention appears to be acceptable and feasible and has success in modifying several 
key variables. Low uptake and high attrition is a problem associated with self-management 
interventions, and yet uptake and retention were relatively high in this study compared with 
previous studies (Coffey et al., 2016). Future research should develop this intervention 
further, before testing it in a larger RCT. The current study did not compare the intervention 
to a control group which is a limitation of the study, as improvements cannot be 
conclusively attributed to the intervention.  
Future developments to the intervention will be informed largely by the qualitative 
interviews. For example, the interviews will provide information on whether women 
engaged with the CBT for HFNS section, as improvements in management of these 
symptoms were not seen. There may be a need to increase support around this section. In 
addition to these modifications, the materials could be transferred to an online platform. 
Similar web-based self-management interventions have been well received by BCS (Foster 
et al., 2016; Kanera et al., 2016; van den Berg, 2015). These online interventions have 




they can be rolled out and implemented to larger numbers of women. Furthermore, they may 
be more convenient for participants, as the materials and activities are easy to access. The 
qualitative interviews will assess whether participants in this study would be receptive to 
receiving an online intervention. Moving the materials online would also allow the content 
to be tailored to the individual, where an initial assessment may determine which sections 
the participant completes. Materials could also be tailored to both tamoxifen and AIs, with 
participants only being shown information which is relevant to them. Tailoring intervention 
materials has been suggested as a potential for improving the efficacy of adherence 
interventions (Horne et al., 2005; Hugtenburg et al., 2013). As high baseline levels of 
adherence have been shown to affect efficacy of interventions, future studies may benefit 
from recruiting women with lower rates of adherence.  
Whilst developing the intervention further, efforts need to be taken to engage women who 
have been shown to be at high risk of non-adherence in the previous studies, such as women 
who are younger, who are working and who are from minority ethnic groups. There is a 
need to tailor intervention content to ensure that these women are supported and that the 
intervention is relevant to women at the highest risk of non-adherence.  
To conclude, this study has shown that a self-management psycho-educational intervention 
booklet appears to be acceptable and feasible in this population and has shown success in 
improving medication beliefs, side effect management, distress, personal control and 
knowledge. This shows the importance of using a rigorous, theory-based process to develop 
interventions. Whilst no significant improvements were seen to adherence over the study 
period, there was a small improvement to unintentional non-adherence, and larger 
improvements were seen in variables which have been shown to predict adherence. 
Therefore, there is potential that adherence rates will improve. Future research should 
develop this intervention further before trialling it in a larger powered RCT. The 









11. Overall discussion  
11.1. Chapter overview  
The aim of this chapter is to provide a summary of the results described in Chapters 3 – 10. 
After summarising the results, novel contributions to the literature and theoretical and 
clinical implications will be discussed. Strengths and limitations of the research will then be 
reviewed, followed by suggestions for future research and overall conclusions.  
11.2. Summary of aims and main findings   
The aims of this PhD were to identify barriers associated with tamoxifen adherence in Breast 
Cancer Survivors (BCS), using validated models of health behaviour, and to develop an 
intervention to support BCS taking tamoxifen. These aims were achieved through a series of 
empirical studies described in Chapters 3-10. The main findings across the studies are 
summarised below.  
High rates of non-adherence were identified, with more women reporting unintentional than 
intentional non-adherence. The longitudinal analysis showed that rates of both intentional 
and unintentional non-adherence increased significantly over time. Results suggest that these 
are somewhat distinct behaviours, with intentional non-adherence being predicted mainly by 
psychological factors and unintentional being predicted mainly by a small number of 
demographic factors. A key finding from the systematic review was that clinical and 
demographic factors were not consistent predictors of Hormone Therapy (HT) adherence or 
persistence. The quantitative analysis largely supported this, showing that the majority of 
demographic and clinical variables showed no relationship to adherence. However, women 
from minority ethnic groups and women who were younger and who were employed were 
more likely to be non-adherent in both the cross-sectional and longitudinal analyses. Longer 
time since initiation of tamoxifen was also associated with increased odds of non-adherence.   
Both the qualitative (Chapter 4) and quantitative analysis (Chapter 7) showed that BCS 
taking tamoxifen experience a significant side effect burden which can have a major impact 
on quality of life (QOL). The systematic review showed an inconsistent relationship between 
side effects and adherence. This was supported somewhat by the qualitative study which 
showed that the impact of side effects on adherence was dependent on the patient’s illness 
and treatment beliefs. If a woman felt that there was a strong benefit of taking tamoxifen and 
she was motivated to avoid a recurrence, she may continue taking tamoxifen despite her side 
effects. However, if she was less certain tamoxifen was necessary for her, then she may be 




spoke about being conflicted between the importance of taking tamoxifen and the impact of 
the side effects. This relationship was supported by the quantitative analysis which showed 
that whilst side effects were associated with increased odds of non-adherence, this effect was 
no longer significant once the psychological variables were added to the models.  
The Common Sense Model (CSM) and the Theory of Planned Behaviour (TPB) provided 
good explanation of non-adherence in the cross-sectional and longitudinal analyses. The 
ROC analysis in Chapter 8 showed that both models showed good ability at discriminating 
between adherent and non-adherent women, and neither model showed superior 
discrimination ability. In the cross-sectional analysis, a combination of both models 
explained more variance in overall non-adherence than either model alone. Key CSM 
variables associated with non-adherence across the studies included weaker beliefs in risk of 
recurrence, lower beliefs that health behaviours cause a recurrence, higher beliefs that stress 
causes a recurrence, less positive necessity/concerns differentials and higher tamoxifen 
consequences. From the TPB, predictors of non-adherence included lower Perceived 
Behavioural Control (PBC) and less positive attitudes towards tamoxifen.  
In addition to the CSM/TPB variables, several other modifiable variables were associated 
with non-adherence, including lower social support, which was associated with baseline 
non-adherence, and higher levels of distress, which were associated with increased odds of 
non-adherence over time. The systematic review showed that women who were treated by a 
specialist had higher odds of persistence than women who were treated in general care. This 
was supported by studies in the review showing that a more positive patient/physician 
relationship was associated with better odds of adherence. 
As well as changes to adherence rates over time, results also showed changes to several 
illness and treatment beliefs, supporting the self-regulatory component of the CSM. Levels 
of side effects increased significantly across the twelve month follow up period, as did 
beliefs around risk of recurrence, causal beliefs, symptoms attributed to tamoxifen and 
necessity beliefs. Significant decreases over time were seen in breast cancer consequences, 
concerns, intentions, and attitudes.  
Based on the results of the previous studies, a self-management intervention was developed 
to support patients with their tamoxifen treatment. The initial pilot results suggest that this 
intervention is acceptable and feasible. Improvements were seen in unintentional non-
adherence, treatment beliefs, personal control, distress, side effect intensity, ability to 





11.3. Contributions to the literature  
The research described above makes several novel contributions to the literature, as well as 
supporting previous research and theory. The key novel contributions are listed below: 
 Unintentional non-adherence was reported much more frequently than intentional 
non-adherence, and was associated with unique determinants. Previous research in 
HT adherence has largely failed to differentiate between intentional and 
unintentional non-adherence, but these studies highlight the importance of 
understanding both types of non-adherence. Unintentional non-adherence tended to 
be associated with demographic factors, whilst intentional non-adherence was 
associated more with psychological factors. This was a novel finding which adds to 
the understanding of intentional and unintentional non-adherence, and provides 
insight into how to modify these behaviours.  
 Previous research has shown high rates of HT non-persistence, but these studies did 
not remove women who may have been discontinued by their doctors. This current 
study provides important clinical information by showing that rates of non-
persistence where intervention may be possible, are lower than previously thought.  
 Chapter 7 highlights the significant side effect burden associated with tamoxifen. 
Little previous research has investigated the prevalence and severity of these 
symptoms. Over 80% of participants reported hot flushes or night sweats in the past 
week, and 60% of these reported moderate to severe symptoms. Intensity of side 
effects was maintained over time, which contradicts advice often given clinically 
that side effects will diminish over time.  
 These studies contribute important information on the relationship between side 
effects and tamoxifen adherence. Previous research has been inconclusive as to 
whether side effects are related to non-adherence. These studies suggest that the 
extent to which side effects are related to non-adherence is dependent on the beliefs 
women hold about tamoxifen and their risk of recurrence. Some women are happy to 
tolerate side effects because they believe strongly in the necessity of taking 
tamoxifen. The same level of side effects may cause another woman to become non-
adherent, if her necessity beliefs are weaker. This provides important information 
for designing future research in this area and for developing ways to improve 
adherence.  
 The IPQ-BCS is an adapted and validated version of the Revised Illness Perceptions 
Questionnaire for use in BCS. This will be of use to researchers investigating illness 




 This was the first study to apply the CSM and TPB to medication adherence in BCS. 
Both models provided good explanation and prediction of non-adherence to 
tamoxifen over 12 months. 
 The CSM nor the TPB provided similar prediction of overall non-adherence, and the 
combination of models provided better explanation of non-adherence than either 
model alone. This suggests that the models complement each other and that neither 
model is sufficient alone for understanding non-adherence, which provides 
important information for future research and for intervention design.  
 The research highlighted several new modifiable variables which were associated 
with increased odds of non-adherence. This provides important information for 
designing interventions to improve adherence rates.  
 No previous research has examined changes to illness perceptions in BCS taking 
tamoxifen. The results of these studies show that these illness perceptions are 
dynamic and they show significant changes across a 12 month period.  
 The intervention described in Chapter 10 was the first study to develop and pilot a 
self-management intervention to improve adherence to tamoxifen. Whilst no 
significant differences were seen in adherence, improvements were seen in key 
variables relating to adherence, such as the necessity/concerns differential, side 
effects and the extent to which patients feel informed about treatment, and there was 
a small improvement in unintentional non-adherence.  
11.4. Theoretical implications  
As discussed in Chapter 2, the CSM and the TPB have received large amounts of research 
interest and have shown success at predicting non-adherence in a range of conditions. 
However, no research has applied these models to medication adherence in breast cancer. 
The results from these studies have important theoretical implications for the TPB and the 
CSM. Results suggest that both models provide good explanation of non-adherence and are 
able to discriminate well between adherent and non-adherent women.  
11.4.1. The Common Sense Model of Illness Representations  
The CSM assumes that individuals will attempt to solve or control any health threat or 
illness they are faced with, and that the coping strategy used will depend on the way the 
individual perceives the illness or health threat. Within this framework, tamoxifen adherence 
can be conceptualised as a coping behaviour which is carried out to control the threat of a 
breast cancer recurrence. Following from this, the CSM would assume that whether 




beliefs. This was supported by the current results, as baseline illness and treatment 
perceptions could predict non-adherence over a 12-month period. In addition, cross-sectional 
analyses showed that CSM variables could explain up to 26% of the variance in non-
adherence.  
Women who had higher tamoxifen consequences had increased odds of non-adherence at 
baseline and over the 12 month follow up period. The tamoxifen consequences variable was 
created during the modification of the IPQ-BCS and it represents a different construct to the 
original illness consequences variable, as it measures consequences associated with the 
medication rather than the illness. The CSM assumes that an individual with high illness 
consequences will be motivated to adhere to their medication to reduce these consequences. 
However, higher tamoxifen consequences were associated with lower odds of adherence in 
this study. This is likely because if the medication has large consequences on a patient’s life, 
they may be less motivated to take it. This was also supported in the qualitative study, with 
women discussing the impact of the side effects on their QOL as a motivator for non-
adherence or non-persistence. Some women described side effects which prevented them 
from working or which impacted on their relationships with friends or family. Higher breast 
cancer consequences at baseline were also associated with increased odds of becoming non-
adherent over time. This shows that the perceptions women hold about their previous breast 
cancer can still affect their health behaviour up to one year later. However, the relationship 
between breast cancer consequences and adherence was not significant in the multivariate 
analysis.  
 Higher perceptions around risk of recurrence were associated with increased odds of non-
adherence in the cross-sectional analysis, but not in the longitudinal analysis. This was a 
new variable added to the IPQ-BCS, and the current results support its predictive utility. It 
makes theoretical sense that women who believe more strongly that they will have a 
recurrence will be more likely to be adherent, in an attempt to control this risk. This was also 
supported in the qualitative study, with avoiding a cancer recurrence being a key motivator 
for taking tamoxifen. Interestingly, causal beliefs were also related to non-adherence. In the 
cross-sectional analysis, beliefs that psychological stress causes a recurrence were associated 
with increased odds of intentional non-adherence, and believing that health behaviours cause 
a recurrence was associated with decreased odds of intentional non-adherence. This suggests 
that if women perceive that a recurrence is caused by factors outside of their control, such as 
stress, they are less likely to engage in behaviours to control the risk of recurrence, such as 
taking tamoxifen. These results support the findings of Jessop & Rutter (2003) who found 




Similar relationships were seen between causal beliefs and adherence in the longitudinal 
analysis, but these did not reach statistical significance.  
Attributing more symptoms to tamoxifen was associated with decreased odds of non-
adherence over the 12 month follow up period. However, in the separate analysis for 
intentional non-adherence, attributing more symptoms to tamoxifen was associated with 
increased odds of non-adherence. Previous studies have found no relationship between 
symptom attribution and HT adherence (Corter, 2013; Walker et al., 2016). Therefore, more 
research may be needed in order to understand the relationship between attributing 
symptoms to tamoxifen and adherence.  
In both the cross-sectional and longitudinal analyses, illness perceptions were better able to 
explain intentional than unintentional non-adherence. Intentional non-adherence was 
predicted by higher tamoxifen consequences, more symptoms attributed to tamoxifen and 
less positive necessity/concerns differentials. In addition to this, treatment control, breast 
cancer consequences and beliefs that psychological stress caused a recurrence were all 
associated with intentional non-adherence at p<0.10. The proportion of women categorised 
as intentionally non-adherent was quite small, and these effects may have become significant 
given a larger sample size. That these variables were associated with intentional non-
adherence more than unintentional is in line with theoretical assumptions of the CSM. The 
model describes individuals carrying out deliberate and intentional actions in order to 
control a health threat and should therefore be better able to predict someone deliberately 
skipping doses than someone simply forgetting. However, there were some associations 
between unintentional non-adherence and illness/treatment beliefs in the longitudinal 
analysis, which supports previous research showing some overlap between intentional and 
unintentional non-adherence (Molloy et al., 2014).  
No significant relationships were seen between emotional representations and adherence, in 
contrast to previous studies showing a relationship for these variables (Ross et al., 2004; Van 
der Have, 2016; Zugelj et al., 2010). These results suggest that the cognitive processing 
system may be more relevant to tamoxifen adherence than the emotional processing system. 
Whilst emotional representations around risk of recurrence were not associated with 
adherence, the perceived risk of recurrence was, suggesting that the cognitive perception of 
the risk is more important than patient’s emotional responses to this risk. However, this 
could be due to measurement issues of the emotional representations construct, which was 
adapted in the IPQ-BCS.    
This was the first study to apply the CSM to medication adherence in BCS. Overall, the 




useful framework for understanding and predicting medication adherence. This suggests that 
interventions based on CSM constructs may be effective at improving medication adherence 
in this population. These results are contradictory to the conclusions of two recent meta-
analyses, which found weak relationships between illness perceptions and adherence to self-
management behaviours, concluding that the CSM was not a good framework for adherence 
(Aujla et al., 2016; Brandes & Mullan, 2014). The poor results in the meta-analyses may be 
due to the authors combining results across conditions and health behaviours, and failing to 
include medication beliefs. Some illness perceptions in this study showed no relationship 
with adherence. However, the CSM does not assume that all illness perceptions will be 
relevant in every condition or health behaviour, and this is not therefore a criticism of the 
theory. As well as supporting the predictive ability of illness perceptions, the results from 
these studies also support the self-regulatory nature of the model, as several illness 
perceptions were shown to change over time. For example, causal beliefs increased over 
time, which may be the result of new information from the media or significant others. 
Breast cancer consequences decreased over time, which suggests that as women move 
further away from their breast cancer treatment they perceive it to have less of an impact on 
their lives. Furthermore, the intervention described in chapters 9 and 10 was able to modify 
several of these illness and treatment beliefs through enhanced education. 
The current results also provide support for the necessity/concerns framework, by showing 
that medication beliefs at baseline predicted later non-adherence. Previous research in HT 
adherence has shown mixed results, with some studies showing that medication beliefs were 
associated with adherence or persistence (Brett et al., 2016; Bright et al., 2016; Grunfeld et 
al., 2005; Arriola et al., 2014; Stanton et al., 2014) and others showing no significant effects 
(Bender et al., 2014; Friese et al.. 2013; Walker et al., 2016). The lack of effects in previous 
studies may be due to methodological weaknesses, such as using non-validated 
questionnaires or having very high rates of adherence. Most of the studies in the systematic 
review measuring beliefs were of low to moderate quality. Furthermore, the current study 
used the differential between necessity and concerns, whereas the previous studies have all 
utilised the individual scales. As the qualitative study in Chapter 4 clearly described a 
process of weighing these beliefs up against each other, it was felt that the differential would 
be a stronger predictor than either necessity or concerns alone. A woman may have very 
strong concerns about taking tamoxifen, but as long as her necessity beliefs are also high, 
she may remain adherent. The necessity/concerns differential attempts to capture both these 
elements, which explains why it may perform better than the individual components alone.  
Previous research has been inconclusive as to the extent to which medication beliefs predict 




medication beliefs were only predictive of intentional non-adherence (Clifford et al., 2008; 
Wroe & Thomas, 2003; Wroe, 2002). However, others have shown that these beliefs also 
predict unintentional non-adherence (Gadkari & McHorney, 2012; Unni & Farris, 2011; 
Wray et al., 2006). In the cross-sectional analyses, medication beliefs were only associated 
with intentional non-adherence. In the longitudinal analysis, the necessity/concerns 
differential predicted both intentional and unintentional non-adherence, but the effect on 
intentional non-adherence was larger. These results suggest that medication beliefs have a 
stronger effect on intentional non-adherence, but that they may also act on unintentional 
non-adherence, perhaps by reducing a patient’s motivation to remember the medication.  
11.4.2. The Theory of Planned Behaviour  
The TPB has come under significant criticism in recent years, with critics accusing it of not 
accounting for much variance in health behaviour, of being a static model, for its focus on 
rational processes and for being less effective when used outside university students (Conner 
& Sparks, 2005; Sheeran, Gollwitzer & Bargh, 2013; Sneihotta et al., 2014). The results 
from these studies suggest that at least some of these criticisms may be unfounded. In a 
clinical population of BCS, the TPB showed good explanation of non-adherence and was 
able to differentiate between adherers and non-adherers.  
Higher intentions to take tamoxifen were associated with decreased odds of non-adherence 
in the cross-sectional analysis, which supports the central tenant of the TPB. However, this 
variable was removed from the longitudinal analysis due to it being highly positively 
skewed. Subjective norms were not associated with adherence in either the cross-sectional or 
longitudinal analyses. This may be a measurement issue as the scale showed poor reliability 
in this sample. However, other studies have also found subjective norms to be a poor 
predictor of non-adherence, suggesting there may be an issue with the construct itself 
(Armitage & Conner, 2001; Chisholm et al., 2007; Kagee & van der Merwe, 2006; Lin et al., 
2016).  Ajzen & Fishbein (2004), however, stated that not all TPB factors would be 
significant in predicting all behaviours, so this should not necessarily be seen as a criticism 
of the model. Furthermore, the TPB assumes that subjective norms would act indirectly on 
behaviour through intentions, which was not tested in the current study.  
Attitudes towards tamoxifen were not associated with non-adherence in the cross-sectional 
analysis. In the longitudinal study, however, more positive attitudes towards tamoxifen were 
associated with decreased odds of non-adherence at the intercept and reduced risk of 
becoming non-adherent over time, although these effects did not remain significant in the 
multivariate analysis. The only TPB variable significant in the multivariate LGM was PBC, 




p<.001). Similar results were seen for the prediction of both intentional and unintentional 
non-adherence. This is supported by previous studies showing that self-efficacy for 
medication taking, a similar variable to PBC, was associated with unintentional non-
adherence in patients prescribed HT (Kimmick et al., 2015; Wouters et al., 2014).   
Several researchers have criticised the TPB for its lack of predictive power (McEachan et al., 
2011; Sneihotta et al, 2014). The results from this study provide some support for this 
criticism, as PBC was predictive of baseline non-adherence but was not predictive of non-
adherence over the 12 month follow up period. This may be because changes to personal 
circumstances during the follow up period may have reduced the accuracy of baseline PBC. 
PBC refers to a patient’s perception of their ability to perform a given behaviour, and it 
might not necessarily represent an accurate perception of this ability, especially regarding 
the ability to perform the behaviour one year later where unforeseen external factors may 
inhibit someone’s ability to perform the behaviour. As greater accuracy of PBC is shown to 
be associated with improved predictive power (Sheeran, Trafimow & Armitage, 2003), this 
may explain why baseline PBC is unable to account for future adherence rates. Nonetheless, 
results suggest that PBC is an important factor in understanding tamoxifen adherence and 
intervening to improve adherence. As this factor is not covered within the CSM, this 
highlights the importance of considering multiple models of health behaviour.  
Overall, the results highlight the utility of the TPB in understanding medication adherence; 
supporting previous studies showing similar results (Bane et al., 2006; Chisholm et al., 2007; 
Kagee & van der Merwe, 2006), and suggesting that some of the criticisms towards the TPB 
may be unfounded. However, the results show that there are issues with several of the 
constructs within the TPB, suggesting that the theory may benefit from improvements in 
measurement. The variable intentions to take tamoxifen was removed from analysis in the 
longitudinal study, meaning a large part of the TPB was not able to be tested. Furthermore, 
the strongest correlate of non-adherence, PBC, was not predictive of later non-adherence, 
which provides support for the criticism that the theory does not have predictive utility. 
Finally, TPB constructs were complemented by CSM variables, suggesting that the TPB 
alone does not provide a complete explanation of tamoxifen non-adherence.  
11.4.3. Comparison of the CSM and the TPB  
As discussed in Chapter 2, it was felt that focussing solely on TPB or CSM variables may 
provide insufficient explanation of adherence behaviour, and that combining elements from 
both models may present greater understanding of non-adherence. There are shortcomings 




alternative model. For example, the CSM overlooks the ease or difficulty of actually 
performing a behaviour such as medication adherence. The TPB covers this but fails to 
consider the patient’s cognitive or emotional representations of their illness. Results from 
these studies support these hypotheses, showing that the models complement each other and 
that neither model provided superior prediction of non-adherence. When deciding whether to 
adhere to tamoxifen, women appear to undergo a dual processing system, where they 
appraise both the medication taking behaviour itself (TPB), and how this fits with their 
perception of the medication and the associated illness (CSM). This supports previous 
research suggesting that the explanation of behaviour could be enhanced by use of both the 
CSM and the TPB (Hunter et al. 2003; Orbell et al, 2006; Sivell et al., 2011).  
This suggests that future studies should consider using multiple models of health behaviour 
when predicting behaviours such as adherence. Only using one model as a framework may 
mean that important constructs are missed, resulting in poorer prediction of health 
behaviour. Researchers have suggested that integrating multiple models into a single 
framework may provide a more complete theory of behaviour change, resulting in more 
effective behaviour change interventions (Corda et al., 2010; Michie et al., 2008; Nigg & 
Jordan, 2005; Reid & Aiken, 2011). Whilst little research has compared models of health 
behaviour in this manner, it provides important information for intervening to improve 
adherence rates. The intervention described in Chapters 9 and 10 was developed by 
incorporating elements from both the CSM and the TPB. For example, activities were 
designed to improve participant’s PBC as well as to address medication concerns and 
unhelpful illness perceptions. Whilst the intervention did not have a significant effect on 
adherence, there was a small improvement in unintentional non-adherence which may be 
significant in a larger trial over a longer time period. Furthermore, the intervention prevented 
women from becoming more non-adherent over time, which was seen over three months in 
the longitudinal study. Improvements were also seen to key variables associated with 
adherence, which suggests the intervention may have a later knock on effect on adherence. 
Therefore, future interventions to improve medication adherence or other health behaviours 
may benefit from incorporating elements from both theories.  
Two previous studies have compared the CSM and the TPB in the prediction of health 
behaviour (Hunter et al., 2003; Orbell et al., 2006). Hunter et al. (2003) found that a 
combination of constructs from the CSM and TPB explained the most variance in the 
context of help-seeking for breast symptoms, providing support for the results shown here. 
Orbell et al. (2006) compared the models in women receiving abnormal cervical smear 
results. Results showed that TPB variables explained 42% of the variance in intentions to 




variance. Further, CSM variables did not significantly improve the model fit for predicting 
clinic attendance. However, both models were important in distinguishing between those 
who attended all their appointments as scheduled after being prompted, or ceased attending. 
This contrasts with the results from the current study which suggests that both models were 
useful in predicting medication non-adherence. The reason for this inconsistency may be 
because in the colposcopy study, women did not yet have an illness and they may therefore 
not have formed strong perceptions around this illness. In this context, beliefs around 
actually carrying out the health behaviour, which are more salient in the TPB, are likely to 
be more relevant. Combining this with the results from the current studies suggest that CSM 
and TPB may complement each other within individuals who have already been diagnosed 
with an illness, but that the TPB may be more useful in healthy populations.  
However, whilst these psychological models explained significant amounts of variance in 
non-adherence, there was still a large proportion of variance unexplained. This suggests 
there may be other key predictors which are not being captured by these models. 
Frameworks such as the COM-B and the Theoretical Domains Framework (Jackson, 
Eliasson, Barber & Weinman, 2014; Michie et al., 2008) have collated variables across 
different social cognition models. For example, the COM-B covers factors relating to 
capability (comprehension of disease, cognitive functioning, dexterity), opportunity (costs, 
social support, stigma) and motivation (mood, self-efficacy, illness/treatment beliefs). These 
frameworks were designed to facilitate the development of behaviour change interventions. 
Future research applying more constructs from these frameworks may enhance the 
explanation of tamoxifen non-adherence and may help identify future targets for 
intervention. However, these frameworks cover large numbers of constructs and guidance is 
not currently provided on how to operationalise some of the constructs.  
The CSM and TPB were better at predicting and explaining intentional than unintentional 
non-adherence. As intentional non-adherence was reported much less frequently than 
unintentional non-adherence, this may reduce the clinical utility of the models. However, 
whilst less frequently reported, intentional non-adherence may be harder to intervene upon, 
and therefore understanding this behaviour could have great benefit in improving adherence 
rates. Furthermore, intentional non-adherence is more likely to lead to non-persistence, as 
non-persistence reflects an intentional decision. Therefore, reducing rates of intentional non-
adherence may have more of an impact on persistence rates than reducing rates of 




11.5. Clinical implications  
Around three quarters of all BCS are prescribed HT to reduce the risk of their cancer 
returning. Yet studies show that up to 50% of women do not take their HT as prescribed for 
the full duration, which is associated with increased risk of recurrence and mortality. There 
are over 150 women diagnosed with breast cancer every day in the UK, and incidence rates 
are projected to rise over the next twenty years (Cancer Research UK, 2016). Therefore, 
understanding this behaviour and developing ways to support women could have real 
clinical implications for the large numbers of women prescribed tamoxifen. The research 
identifies two main ways in which adherence rates in this population may be improved: by 
identifying women who may be at risk of non-adherence, and by developing ways to support 
these women and improve adherence rates.  
Firstly, the research highlights several demographic variables which may be used to identify 
women who are at greater risk of non-adherence. These demographic variables often had a 
stronger effect on non-adherence than the psychological variables. For example, results 
suggest that women who are younger, who are not white and who are working are more 
likely to be non-adherent. Clinicians should identify these women early on in treatment and 
assess if they will need extra support in adhering to their medication. Whilst not tested 
statistically, it is possible that the reason both younger and employed women were more 
non-adherent is because they are more likely to struggle with side effects of tamoxifen. It 
may be hard for younger women to adjust to the symptoms of an early menopause, and for 
women in the workplace to manage their workload around fatigue or hot flushes. Therefore, 
providing extra support in managing side effects may be beneficial for these women. 
However, results show that these demographic variables are associated with unintentional 
rather than intentional non-adherence. This suggests that these women could benefit from 
support with managing their medication taking routine and remembering to take tamoxifen.  
The psychological variables identified as predictors of non-adherence, such as the 
necessity/concerns differential, tamoxifen consequences and PBC, may also be useful to 
identify women at risk of non-adherence, by use of a screening questionnaire administered 
clinically. A short screening tool, administered near the beginning of treatment may be able 
to identify women who are at later risk of non-adherence, thus allowing clinicians to offer 
greater support to these women. The longitudinal results also showed that higher levels of 
distress were associated with increased odds of non-adherence across the follow up period. 
This has been seen in patients with breast cancer and across other long term conditions 
(DiMatteo et al., 2000; Grenard et al., 2011; Mausbach, Schwab & Irwin, 2015). Therefore, 




Secondly, the results provide insight into how to intervene to improve adherence in this 
population. Based on the body of research described in Chapters 2-8, a self-management 
intervention was developed to support women taking tamoxifen. This intervention was 
trialled in a small pilot study which showed promising results. Uptake and retention were 
good which suggests the intervention may be acceptable and feasible for these women. In 
addition to this, improvements were seen in several key variables. There was a small 
improvement in unintentional non-adherence. The necessity/concerns differential improved, 
which is shown to be associated with lower risk of non-adherence. Coherence, satisfaction 
with information and the extent to which patients feel informed about treatment also 
increased. There were improvements in side effect intensity and ability to manage side 
effects, which are important clinically. It is not possible to eliminate side effects entirely, but 
empowering women to manage their side effects more effectively should reduce their impact 
on daily life, which may prevent women from discontinuing treatment. Future research 
needs to test the intervention in a larger powered RCT, but these pilot results are promising. 
The intervention is a self-management booklet and needs little input from researchers or 
clinicians. Therefore, it is low cost and has the potential to be scaled out and delivered 
widely.  Future research should ensure that the intervention materials are tailored to women 
who are at higher risk of non-adherence, such as women who are younger or who are 
working.  
These results suggest that intentional and unintentional non-adherence are relatively distinct 
behaviours, with unique correlates. Unintentional non-adherence was reported much more 
frequently and does not appear to be explained well by psychological variables. Therefore, 
as well as the more complex self-management intervention, simple interventions to help 
patients to remember to take tamoxifen may be effective in this population. These 
interventions would not address any psychological components but would act simply as a 
reminder for participants. For example, text message reminders have shown some efficacy in 
increasing adherence rates (Thakkar et al., 2016; Vervloet et al., 2012). In addition, a large 
study across Walmart pharmacies in the US found that the use of calenderised blister 
packaging for medications, where days are printed onto the pill packaging, was associated 
with increased medication adherence (Zedler, Joyce, Murrelle, Kakad & Harpe, 2011). 
Tamoxifen is not currently packaged with calendarized blister packaging, and this presents a 
scalable intervention with the potential to help hundreds of thousands of women.  
Additional clinical implications include the importance of helping patients to manage their 
side effects. Chapter 4 and chapter 7 showed that women experience a significant side effect 
burden, and yet many women described a lack of support with side effects. Participants in 




needed. In some cases, women felt that they were dismissed by their healthcare team, which 
left them feeling unvalidated. Similar results were also found in a qualitative study of 
women prescribed HT (Verbrugghe et al., 2015). Interestingly, many women are told that 
their side effects will likely improve over time, and yet the analysis in Chapter 7 showed that 
symptom burden remains high across all five years of treatment. Furthermore, the perceived 
intensity of side effects also increased significantly over the twelve month longitudinal 
study. As side effects have been shown to increase risk of non-adherence, this highlights the 
need to ensure that women are supported throughout treatment with their side effects. 
Helping women to manage their side effects should have dual benefits of improving both 
QOL and tamoxifen adherence.  
Side effects appear to have more of a knock-on effect, affecting later non-adherence rather 
than immediate non-adherence. This is supported by a similar study where HT symptoms 
assessed at baseline were a predictor of non-adherence at follow up, but symptoms assessed 
at follow up were not (Corter, 2013). This suggests that women may be attempting to 
manage and cope with their side effects for some time before they consider non-adherence. 
This was supported by the quotes from women in the qualitative study who were weighing 
up the costs and benefits of treatment and trying to make a decision as to whether to 
continue treatment. Clinically, this suggests that there is potential to intervene once women 
experience symptoms, and to prevent these symptoms from leading to later non-adherence. 
Intervening early is particularly important, as both side effect intensity and rates of non-
adherence increase significantly over time.  
11.6. Strengths and limitations  
Limitations relating to specific studies are discussed in the relevant chapters. Limitations 
relating more broadly to the body of work are discussed below.  
One main limitation with the research is the assessment of medication adherence, which was 
carried out using the Medication Adherence Rating Scale (MARS). Self-report measures are 
known to over-estimate adherence rates and may not always provide good concordance with 
objective measures (Berg & Arnsten, 2006; Bruxvoort et al., 2015; Ziller et al., 2009). 
However, the MARS overcomes some of the limitations associated with self-report 
measures by utilising a validated scale, using optimised question response formats and by 
utilising non-judgemental statements to normalise non-adherence (Horne et al., 2001; Stirratt 
et al., 2015). Furthermore, O’Carroll et al. (2013) found high correlations between MARS 
adherence and adherence measured using Medication Event Monitoring System (MEMS) in 




the quantitative analysis. This was chosen on the basis of previous studies and on 
recommendations that high cut offs help to balance out the over-estimation of adherence 
rates (Huther et al., 2013; Stirratt et al., 2015; Timmers et al., 2016; van der Laan et al., 
2017). However, this high cut off may have led to inflated levels of non-adherence. 
Nonetheless, rates were comparable with other studies using pharmacy refill rates to assess 
HT adherence (Cheung et al., 2015; Hershman et al., 2010; Partridge et al., 2003). 
Furthermore, sensitivity analysis using a lower cut off on the MARS showed a similar 
pattern of predictors as in the main longitudinal analysis.  
This same high cut-off was also used to screen women for eligibility to the intervention 
study. Despite improvements to study variables associated with non-adherence, no 
significant improvements in adherence were seen. This may be associated with an inability 
of the MARS to detect changes over time (Garfield et al., 2011). Future work on the 
intervention should consider using an alternative measure of adherence; should triangulate 
from multiple sources; or should consider a lower cut-off to allow for more room for 
improvement in adherence. However, there was a small improvement in unintentional non-
adherence, which suggests some ability of the MARS to detect change over time.  
Due to the limitations associated with different measurements of adherence, it has been 
recommended that the best approach is to triangulate from multiple sources (Lam & Freso, 
2015; Lehmann et al., 2014; Sabate, 2003). However due to time and financial constraints 
during the PhD, it was not possible to take multiple measures of adherence. Taking less than 
80% of the prescribed medication, as assessed with pharmacy refill rates, is associated with 
reduced survival in BCS taking tamoxifen. Unfortunately, it is not possible to determine if 
the levels of non-adherence reported here would be associated with poor clinical outcomes. 
Women who had higher rates of non-adherence at baseline were less likely to return their 
follow up questionnaires at 3, 6 and 12 months. This means the true rates of non-adherence 
are likely to be higher than the levels reported here. As non-adherent women were less likely 
to complete the follow up questionnaires, it is also likely that they would also be less likely 
to be recruited into the study. Therefore, there is a need to identify ways to engage and retain 
non-adherent participants, in order to better understand non-adherence. A further limitation 
is that it was only possible to predict adherence rates. Future research should extend these 
results to investigate predictors of tamoxifen non-initiation or non-persistence. Recruiting 
women at the point of being offered tamoxifen would allow for identification of predictors 
of non-initiation. Due to the low rates of non-persistence identified in this study, it was not 
possible to identify predictors of non-persistence.  Extending the follow up for a longer 




Whilst retention rates in the longitudinal study were quite high, there was some attrition over 
time, and this was found to be related to ethnicity, adherence rates, side effects, distress and 
age. This creates some risk of bias in the results, as the data is not missing at random.  
However, the fact that non-adherent women were less likely to return their questionnaires 
suggests that the non-adherence rates may actually be higher than what is reported here. 
Retaining these non-adherent women may have strengthened the relationships seen here 
between predictor variables and non-adherence.  
A further limitation with the study is the lack of generalisability with regards to the ethnicity 
of the women in the quantitative analysis. Whilst this is somewhat typical of the population, 
as white women have significantly higher age standardised breast cancer incidence rates 
compared to other ethnicities (Jack, Davies, & Moller, 2009), the rates of other ethnicities in 
this study were very low. Furthermore, women who were not white were less likely to return 
their follow up questionnaires, which further reduces the generalisability of the results. 
Future research needs to look at ways to ensure that women from a range of different 
ethnicities and cultural backgrounds are properly represented. Results showed that women 
who were not white were less adherent to tamoxifen. This is consistent with studies showing 
worse clinical outcomes in women with breast cancer from minority ethnic groups 
(Chlebowski et al., 2005; Clegg et al., 2002; Eley et al., 1994). These poor clinical outcomes 
may be driven by health behaviours like non-adherence, by biological differences or by 
differences in socioeconomic status (Carey et al., 2006). Large, generalizable studies are 
needed to fully understand the effect of ethnicity on adherence. However, whilst there were 
issues with the ethnic diversity in the quantitative analysis, both the qualitative and the 
intervention studies provided more generalizable samples.  
Whilst the cross-sectional analysis in Chapter 6 showed that the CSM and TPB were able to 
explain up to 46% of the variance in non-adherence, there were still large amounts of 
variance unexplained, especially with regards to unintentional non-adherence. Therefore it is 
likely that there are several important variables which were not assessed in the current study. 
One such variable might be the perceived quality of the patient/provider relationship, which 
showed some association with tamoxifen adherence in the systematic review. This 
relationship is also supported across studies in a range of long term conditions (Beach, 
Keruly, & Moore, 2006; Jackson et al., 2010; Haskard Zolnierek & DiMatteo, 2009). 
However, BCS in the UK are being moved to Open Access Follow Up, which replaces 
traditional regular follow up specialist clinics. Therefore, the patient/provider relationship 
may not be as relevant as in other conditions where patients receive regular follow up from a 
specialist. Another variable which might help to explain unintentional non-adherence is 




functioning may find it harder to remember to take their medication daily. Several studies 
have supported this, showing increased non-adherence in patients with deficits in attention, 
mental flexibility or working memory (Hinkin et al., 2002; Stilley, Bender, Dunbar-Jacob, 
Sereika, & Ryan, 2010). This may be particularly relevant in BCS, as many women report 
poor cognitive functioning after chemotherapy or whilst taking tamoxifen (Castellon et al., 
2004; Jim et al., 2012; Schilder et al., 2010). In an RCT of tamoxifen for prevention of 
primary breast cancer, odds of non-adherence were lower for women who showed better 
scores on measures of verbal memory (Klepin et al., 2014).  
Another explanation for the unexplained variance is that the studies failed to assess the 
complete CSM or TPB. Static measures such as the Illness Perception Questionnaires have 
been criticised by developers of the CSM for failing to consider additional factors such as 
intra-individual variation and change, or unique illness contexts (Leventhal et al., 2016; 
Phillips et al., 2017). In addition to this, updates to the CSM have also stressed the 
importance of understanding planning processes and habit formation (Leventhal et al., 
2016). Incorporating these variables may have enhanced the predictive ability of the model. 
Furthermore, it was not possible to fully test the appraisal and feedback loops inherent to the 
CSM. Likewise, issues with measurement of the TPB may have prevented the model from 
reaching its potential predictive power.  
There were also limitations with the intervention, mainly relating to the lack of a control 
group. Randomised controlled trials are the gold standard for assessing the effectiveness of 
interventions, as they allow for identification of cause and effect between treatment and 
outcome. As the pilot study did not compare the intervention to an alternative treatment or 
wait list control, it is not possible to determine if changes are due to the treatment or to other 
factors. Future research should extend the pilot results and test the intervention in a larger 
RCT. A further limitation with the intervention is that the same researcher was involved in 
delivering the intervention and collecting follow up data. However, as the follow up data 
was collected by self-report questionnaires which were mainly carried out online, this is 
unlikely to have affected the results. To counter the potential influence of familiarity with 
the researcher, a second independent researcher carried out interviews with participants after 
completing the intervention to elicit their feedback. 
There were also several strengths associated with the body of research. It was the first study 
to apply these psychological models to tamoxifen non-adherence, and to identify modifiable 
predictors in both a large cross-sectional study and a 12 month longitudinal study. The long 
follow up period allows for testing of causal relationships, which was largely lacking in 




and this has been linked to the lack of a theoretical framework and the failure to consider 
both intentional and unintentional non-adherence (Holmes et al., 2014; Horne et al., 2005). 
Therefore, the use of the CSM/TPB is a strength of the current body of research, as is the 
consideration of both intentional and unintentional non-adherence. 
 
A further strength with the research is the robust statistical analysis. LGM is a valuable 
methodology which moves beyond traditional longitudinal analysis by modelling both fixed 
and random effects (Duncan, Duncan & Strycker, 2013; Hertzog, von Oertzen, Ghisletta & 
Lindenberger, 2008). The use of LGM allows for investigation of inter-individual 
differences in change over time and for identification of antecedents of change (Preacher , 
2010). Another strength of the research is the mixed methodology; bringing together a range 
of different methodologies allows for clearer interpretation of results and for consistent 
patterns to be identified. Results seen in the cross-sectional analysis were strengthened by 
the results from the longitudinal analysis. Furthermore, the qualitative research in Chapter 4 
helps with interpretation of the quantitative results and provides context for the body of 
research.  
11.7. Future work  
Several potential directions for future directions have been discussed in the sections above 
and in the relevant chapters. One of the most important avenues for future research would be 
to further develop and test the intervention, as described in Chapter 10. The pilot data shows 
promising results, but the study was limited by the lack of a control group. Future research 
should trial the intervention in an RCT. The materials may also benefit from being moved to 
an online platform, where they could be tailored to each participant. Furthermore, future 
research could consider trialling a modified version of the intervention to support adherent 
women who are struggling with side effects to prevent later discontinuation.  
Future research should also consider variables which are missing from the current analysis, 
such as patient/provider relationship, habit strength or cognitive functioning. These variables 
may increase explanation of non-adherence and therefore suggest future avenues for 
intervention. Further research should also be undertaken to examine some of the 
relationships seen in this study. For example, women from minority ethnic groups and 
women who were employed had higher odds of non-adherence. In order to identify the best 
ways to support these women, more research needs to be conducted to understand the 
driving force of non-adherence in these populations. Qualitative research might provide 




Unintentional non-adherence was reported more frequently than intentional non-adherence 
but was not explained well by psychological variables. This suggests that more simple 
interventions based purely on reminders, and not on modifying beliefs, may be effective at 
improving adherence in this population. Whilst these kinds of intervention are likely only 
effective in women who are motivated to take their medication, they do show some promise 
and are relatively easy to design and implement. Future research should examine if these 
reminder interventions would have any efficacy in this population. In addition to this, future 
research could examine if there is any clinical utility to using psychosocial variables 
identified in this study as a screening tool to identify women at risk of non-adherence.  
Finally, there is scope for future research around the models of health behaviour used in this 
study. Results suggest that the CSM and TPB complement each other well when explaining 
and predicting non-adherence to tamoxifen Therefore, future research could apply this 
combined CSM/TPB to medication adherence in other conditions. This may improve on 
other research using one of these models in isolation, and may provide important insights 
into intervention design. In addition to this, both models could also be explored in more 
detail. For example, within the CSM, there is scope to test feedback loops and causal 
pathways between illness perceptions, medication beliefs and health behaviour. Several 
studies have shown that illness perceptions may act indirectly through medication beliefs 
(Horne & Weinman, 2002; Ross et al., 2004), but this was not tested in the current study. 
Furthermore, cluster analysis has shown interesting results in identifying distinct clusters of 
illness perceptions (Harrison et al., 2014; McCorry et al., 2013a; Unni & Shiyanbla, 2016). 
Within the TPB, future research could test the hypothesised causal pathways between 
constructs, such as the prediction of intentions by attitudes, PBC and subjective norms.  
11.8. Overall conclusions  
The current body of research highlights the importance of understanding tamoxifen non-
adherence and of intervening to improve adherence. The studies described show that non-
adherence is reported frequently by patients and that reported rates of non-adherence 
increase over time. This was the first study to apply the CSM and TPB to non-adherence in 
BCS and it makes several novel contributions to the literature. Results show that non-
adherence is a complex behaviour which is best understood by a combination of 
demographic factors and variables from the CSM and TPB. The models complemented each 
other well, which has theoretical implications which could be applied to medication 
adherence in other conditions. Key variables associated with non-adherence across studies 
include ethnicity, working status, medication beliefs, perceived risk of recurrence and PBC. 




treatment beliefs. An important finding was that intentional and unintentional non-adherence 
appear to be relatively distinct behaviours with unique correlates.  
The results from these studies have important implications for identifying those at risk of 
non-adherence and for intervening to improve adherence in this population. This was the 
first study to develop and pilot an intervention to improve adherence to tamoxifen. Initial 
pilot results are promising, suggesting the intervention is acceptable and feasible, and that it 
is associated with improvements in key mechanisms of non-adherence. Future research 
should develop the intervention further, perhaps on an online platform, and should test the 
intervention in a large RCT with the aim of improving quality of life and prognosis of breast 
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Appendix A  
Supplementary material for systematic review (Chapter 3) 
Database 
 
Dates Search terms  
Medline 1946 –18th 
April 2016 
1. Medication Adherence/  
2. Patient Compliance/ 
3. (adher* or complian*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
4. (persist* or discont*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
5. 1 or 2 or 3 or 4 
6. Tamoxifen/ 
7. tamoxifen.mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
8. aromatase inhibitors/ 
9. aromatase inhibitor*.mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier] 
10. Endocrine therapy.mp 
11. Hormon* therapy.mp 
12. 6 or 7 or 8 or 9 or 10 or 11  
13. Breast Neoplasms/ 
14. Breast cancer*.mp 
15. breast neoplasm*.mp 
16. 13 or 14 or 15 
17. 5 and 12 and 16 
18. Limit 17 to female  
 
Psychinfo 1806 –18th 
April 2016 
 
1. Exp Treatment compliance/ 
2. (adher* or complian*).mp. [mp=title, abstract, heading word, 
table of contents, key concepts, original title, tests & 
measures] 
3. Exp Treatment Termination/ 
4. (persist* or discont*).mp. [mp=title, abstract, heading word, 
table of contents, key concepts, original title, tests & 
measures] 
5. 1 or 2 or 3 or 4  
6. Exp Hormone therapy/ 
7. tamoxifen.mp. [mp=title, abstract, heading word, table of 
contents, key concepts, original title, tests & measures] 
8. endocrine therapy.mp. [mp=title, abstract, heading word, 
table of contents, key concepts, original title, tests & 
measures] 
9. aromatase inhibitor*.mp. [mp=title, abstract, heading word, 
table of contents, key concepts, original title, tests & 
measures] 
10. hormon* therapy.mp. [mp=title, abstract, heading word, table 
of contents, key concepts, original title, tests & measures] 
11. 6 or 7 or 8 or 9 or 10  
12. Exp breast neoplasm/ 
13. (breast cancer* or breast neoplasm*).mp. [mp=title, abstract, 
heading word, table of contents, key concepts, original title, 
tests & measures] 




15. 5 and 11 and 14 
16. Limit 15 to female  
Embase 1974 - 18th 
April 2016 
1. Patient compliance/ 
2. (persist* or discont*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword] 
3. (adher* or complian*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword] 
4. 1 or 2 or 3 
5. Tamoxifen/ or tamoxifen.mp. 
6. Aromatase inhibitor/ 
7. Hormonal therapy/ 
8. aromatase inhibitor*.mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, 
device manufacturer, drug manufacturer, device trade name, 
keyword] 
9. hormon* therapy.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, 
keyword] 
10. endocrine therapy.mp. [mp=title, abstract, subject headings, 
heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, 
keyword] 
11. 5 or 6 or 7 or 8 or 9 or 10  
12. Breast cancer/ 
13. (breast neoplasm* or breast cancer*).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
14. 12 or 13  
15. 4 and 11 and 14  
16. Limit 16 to female  
Web of Science  
 
Up to 18th 
April 2016 
1. Adher* or complian* 
2. Persist* or discontin* 
3. 1 or 2  
4. Tamoxifen 
5. Aromatase inhibitor* 
6. Hormon* therapy 
7. Endocrine therapy  
8. 4 or 5 or 6 or 7  
9. breast cancer* or breast neoplasm* 
10. 3 and 8 and 9  
CINAHL  
 
Up to 18th 
April 2016 
1. (MH "Medication Compliance") OR (MH "Patient 
Compliance")  
2. adher* or complian* or persist* or discontin*  
3. 1 or 2  
4. (MH "Tamoxifen") OR (MH "Aromatase Inhibitors") OR 
(MH "Hormone Therapy") 
5. Tamoxifen OR Aromatase inhibitor* OR Hormon* therapy 
OR Endocrine therapy 
6. 4 or 5 
7. (MH "Breast Neoplasms")  
8. Breast cancer* or breast neoplasm* 
9.  7 or 8  













































Patient Information Sheet Phase 1 
REC reference number: 14/EM/1207 









What is the purpose of the Study? 
 
This study aims to understand what it is like to take Tamoxifen. We would like to find out 
about your experiences and perceptions of Tamoxifen. This is part of a larger study to 
identify factors associated with how women with breast cancer use Tamoxifen. The results 
from these studies will be used to design ways to support women on Tamoxifen. The 
research is being carried out as part of a PhD at King’s College London.  
 
Why have I been asked to take part?  
 
We have asked you to take part in the study because we are interested in hearing from 
women who have been prescribed Tamoxifen. We are especially interested in speaking to 
people who are in their first few weeks or months of treatment. There will be around 20 – 
30 women taking part in the study. 
 
Do I have to take part?  
 
It is up to you if you would like to join the study – you do not have to if you do not want to. 
If you are interested in taking part, we will call you in two days to arrange an interview. At 
the interview we will ask you to sign a consent form. You are free to change your mind and 
to withdraw at any time. This will not affect your standard of care. 
 
We would like to invite you to take part in a research study conducted by King’s College 
London and Guy’s and St Thomas’ Foundation NHS Trust.  
The study will investigate women’s experiences of Tamoxifen in breast cancer. Before you 
decide if you would like to participate, we will tell you why the research is being done and 
what it will involve for you. 
One of our team will go over this information sheet with you and give you the opportunity to 
ask any questions. You will then be able to decide if you are interested in taking part in the 
study. If you would like more time to think about it, you can contact the researcher at a later 





What will the study involve?  
 
The study will involve you taking part in an interview about your experience of taking 
Tamoxifen. The interview will be informal and will be one on one and face to face. You may  
also be interviewed over the telephone. It will last between 40 minutes and an hour. The 
researcher will have a list of topics that she would like to discuss but we are interested in 
your experience and so you are free to focus the discussion on what you think is important. 
The topics will include your experiences and perceptions of Tamoxifen. The researcher will 
also ask some general information about you and may collect clinical information about 
your breast cancer treatment. The interview will take place at a time and place to suit you 
and you will only be asked to meet once. We would like to record the interview using an 
audio recorder so that the researcher can fully concentrate on what you are saying. The 
recordings will be deleted once they have been typed up. 
We will also ask you if you are happy to be contacted again in the future to review some 
questionnaires for us. This is completely voluntary. It would involve you reading over the 
questionnaire on the telephone with the researcher and sharing your thoughts.  
Will I be reimbursed for my time?  
 
We can reimburse you up to £10 for your travel costs.  
 
Will my information be kept confidential?  
 
Your personal information will be kept confidential. The interview will be recorded using an 
audio recorder, and the interview will be typed up. The recording will be deleted and the 
typed up interview will be made anonymous. Any personal details or identifiable 
information will be removed. Contact details will be stored separately in a locked filling 
cabinet. Only the researchers will have access to the data. The information will be kept 
securely at King’s College London. The information will be destroyed five years after the 
research has finished. If you withdraw during the study your data will be destroyed. Data 
cannot be withdrawn once the results have been analysed and written up (June 2015). In 
the unlikely event of any risk such as self-harm or suicide risk, confidentiality will need to 
be broken. Your safety is very important. Both you and your clinical team will be made 
aware of the breach of confidentiality. 
 
What are the possible disadvantages / benefits of taking part?  
 
The risk of taking part is very minimal. You will only need to meet with the researcher once. 
This will be done at a time and place convenient to you. The interview will be conducted in 
a private place. The nature of the interview is unlikely to be sensitive. You are free to not 
answer certain questions if you find them distressing. There will be no direct benefits to 
you for taking part in this study. However, the results will provide more information about 
women’s experiences with Tamoxifen. This will help improve the treatment of women with 







What if there is a problem? 
 
If at any time during the interview you would like to stop then please inform the researcher 
and they will stop the interview immediately. If the interview raises any issues that you 
would like to discuss further, the researcher will be able to put you in contact with the 
relevant person. If you have a concern about any aspect of this study, you can speak to the 
Principal Investigator or any other researchers involved in the study. The contact details are 
at the bottom of this sheet. 
 
What will happen to the results of the research study?  
 
The results of this study may be published in scientific journals. You will not be identified in 
any report. Where quotes may be used, they will be completely anonymous. A report will 
be made available through Breast Cancer Campaign and a lay summary will be sent to 
participants.  
 
Who has reviewed the study?  
 
This study has been checked by Northampton Research Ethics Committee, an independent 
group of people, to protect your safety, rights, wellbeing and dignity. 
 
How has the study been funded? 
 
The study has been funded by Breast Cancer Campaign. It is part of a three year funded 
project to understand more about how women take Tamoxifen and how to improve 
Tamoxifen use.  
  
Any further queries?  
 
If you have any questions or concerns about the study, you may contact the 
following organisations  
 
For independent advice on participating in NHS research:  
Patient Advice and Liaison Service (PALS) - 0207 188 8803  
For independent advice about making a complaint:  
South London Independent Complaints Advisory Service (ICAS) – 0300 456 2370  
For information from the researchers:  
Miss Zoë Moon: zoe.moon@kcl.ac.uk 0207 188 9324 (Principal 
Investigator)  










CONSENT FORM Phase 1  
Title of Project: Investigating how women with breast cancer view 
Tamoxifen  
Name of researcher: Zoë Moon  
 
Please initial each box 
1. I confirm that I have read and understood the information sheet dated 20/10/2014 (v2) 
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.  I 
understand that data cannot be withdrawn once the results have been analysed and 
written up (June 2015).  
 
 
3. I understand that relevant sections of my medical notes may be looked at by the 
research team and that research data collected during the study may be looked at by 
individuals from King’s College London, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 
4. I agree that the interview may be audio recorded.  
 
 
5. I agree to be contacted in the future about follow up studies to this project. 
 
 
6. I agree to be contacted in future to discuss the development of a questionnaire.  
 




Patient’s name  
………………………………………………………… 
Patient’s signature 
Date: …………………………………………  
 
…………………………………………………………. 
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Patient Information Sheet Phase 2  
REC reference number: 14/EM/1297 









What is the purpose of the Study? 
 
The purpose of the study is to understand what it is like to take Tamoxifen. We would like 
to find out how you feel about Tamoxifen and breast cancer. This is part of a larger study to 
identify factors associated with how women with breast cancer use Tamoxifen. The results 
from these studies will be used to design ways to support women on Tamoxifen. The 
research is being conducted as part of a PhD at King’s College London.  
 
Why have I been asked to take part?  
 
We have asked you to take part in the study because we are interested in hearing from 
women who have been prescribed Tamoxifen. We are especially interested in speaking to 
people who are in their first few weeks or months of treatment. There will be around 520 
women taking part in the study. We are interested in your thoughts and opinions, even if 
you have stopped taking Tamoxifen. 
  
Do I have to take part?  
 
It is up to you if you would like to join the study. If you are interested in taking part, we will 
ask you to sign a consent form. You are free to change your mind and to withdraw at any 
time. This will not affect your standard of care.  
 
We would like to invite you to take part in a research study conducted by King’s College 
London and Guy’s and St Thomas’ Foundation NHS Trust. 
The study will investigate women’s experiences of Tamoxifen in breast cancer. Before you 
decide if you would like to take part, we will tell you why the research is being done and 
what it will involve for you.  
One of our team will go over this information sheet with you and give you the opportunity 
to ask any questions. You will then be able to decide if you are interested in taking part in 
the study. If you would like more time to think about it, you can contact the researcher at 





What will the study involve?  
 
The study will involve you completing a series of questionnaires. The questionnaires have 
all been approved by the NHS research ethics committee. You will be asked about your 
experiences, thoughts and beliefs. The questionnaires should take around twenty minutes 
to complete. After completing the questionnaire you can either return it to the researcher 
or use the stamped addressed envelope provided to post it to the researcher free of 
charge. You can also complete the questionnaire online by accessing this link:  
 
https://kings.onlinesurveys.ac.uk/tamoxifen 
If you are within your first year of treatment, we will ask you to complete the 
questionnaires again in three, six and twelve months’ time. This will allow us to see how 
your thoughts and experiences change over time. We will ask for your postal or email 
address so we can send you the follow up questionnaires. You can choose to receive an 
online questionnaire or a paper questionnaire with a stamped addressed envelope.  
A group of patients will be asked to complete a subset of the questionnaire at two different 
time points. They will be asked to complete the questionnaire once when they consent to 
the study and once again two weeks later. This questionnaire should take five to ten 
minutes to complete.  
Will my information be kept confidential?  
 
Your personal information will be kept confidential. The questionnaires will be inputted 
into a computer. Only the researchers will have access to the computer which will have a 
password to protect all confidential files. Any personal details or identifiable information 
will be removed and contact details will be stored separately in a locked filling cabinet. The 
data will be kept securely at King’s College London. It will be destroyed five years after the 
research has finished. Your contact details will be destroyed as soon as the study has 
finished. Data cannot be withdrawn once the results have been analysed and written up 
(December 2016). In the unlikely event of any risk such as self-harm or suicide risk, 
confidentiality will need to be broken. Your safety is very important. Both you and your 
clinical team will be made aware of the breach of confidentiality. 
 
What are the possible disadvantages / benefits of taking part?  
 
The risk of taking part is extremely minimal. You will only need to complete a questionnaire 
which can be done at home or in the clinic. The questionnaire has been used previously and 
should not cause any distress. There will be no direct benefits to you for taking part in this 
study. However, the answers that you give will provide the researchers with more 
information about Tamoxifen. This information will help improve the treatment of women 
with breast cancer in the future.  
 
What if there is a problem? 
 
If the questionnaire raises any issues that you would like to discuss further with a health 
professional, the researcher will be able to put you in contact with the relevant person. You 




aspect of this study, you can speak to the Principal Investigator, or any other researchers 
involved in the study. The contact details are at the bottom of this sheet.  
 
What will happen to the results of the research study?  
 
The results of this study may be published in scientific journals and at medical and 
psychological academic conferences. You will not be identified in any report or publication.  
A report will be made available through Breast Cancer Campaign and a lay summary will be 
sent to participants.  
 
Who has reviewed the study?  
 
This study has been checked by Northampton Research Ethics Committee, an independent 
group of people, to protect your safety, rights, wellbeing and dignity.  
 
Any further queries?  
 
If you have any questions or concerns about the study, you may contact the following 
organisations  
 
For independent advice on participating in NHS research:  
Patient Advice and Liaison Service (PALS) - 0207 188 8803  
 
For independent advice about making a complaint:  
South London Independent Complaints Advisory Service (ICAS) – 0300 456 2370  
 
For information from the researchers:  
 
Miss Zoë Moon: zoe.moon@kcl.ac.uk 0207 188 9324 (Principal 
Investigator)  
















CONSENT FORM Phase 2  
Title of Project: Investigating how women with breast cancer 
view Tamoxifen  
Name of researcher: Zoë Moon  





1. I confirm that I have read and understood the information sheet dated 20/10/2014 (v2) 
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected. I 
understand that data cannot be withdrawn once the results have been analysed and 
written up (December 2016). 
 
 
3. I understand that relevant sections of my medical notes may be looked at by the 
research team and that research data collected during the study may be looked at by 
individuals from King’s College London, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 
4. I agree to take part in the above study. 
 
5. I agree to be contacted in the future to complete follow up questionnaires.   
 
6. I agree to be contacted in the future about a follow up intervention study.  
 
…………………………………………………………. 
Patient’s name  
………………………………………………………… 
Patient’s signature 
Date: …………………………………………  
 
…………………………………………………………. 









Please provide your contact details below.  
 
Name:  ………………………………………………………… 






Email address:  ............................................... 
 
If you are in your first year of treatment, we would like to send you follow up 
questionnaires at 3, 6 and 12 months’ time. Please specify how you would like to receive 
the questionnaire: 
 
I would prefer to receive the questionnaire   in the post  
 
                                                                                       electronically (e-mail)  
           
          
Your contact details will be kept separately from your data and will be destroyed once 
the research is over.  
 
Please keep my contact details on file to send me a summary of the results:             Yes  
            
                  No  
 




QUESTIONNAIRE PACK  
Screening questions 
The following questions will determine if you are eligible to take part in 
the study. Please complete these before moving to the next set of 
questions. Circle the correct answer.  
1. Are you female? 
YES NO 
2. Are you aged 18 or over? 
YES NO 
3. Have you been diagnosed with primary breast cancer? 
YES NO 
4. Have you been prescribed Tamoxifen?  
YES NO 
 
If you have answered yes to all the above questions then you are eligible 
to complete the rest of the questionnaire. When you are ready to 
complete the questionnaire, please continue and answer the remaining 
questions.  
We are interested to find out your experiences since being prescribed 
Tamoxifen, even if you have stopped taking it.  











Please complete the following questions by ticking the box for the most 
appropriate answer.  
1. What is your date of birth (DD/MM/YY)?  ……………………………. 
 
2. What is your ethnic group? Choose one option that best describes your ethnic 
group or background. 
White - English / Welsh / Scottish / 
Northern Irish / British  
 
White – Irish 
 
White - Gypsy or Irish Traveller  Any other White background  
White and Black Caribbean  White and Black African  
White and Asian 
 Any other Mixed / Multiple ethnic 
background 
 
Indian  Pakistani  
Bangladeshi  Chinese  
Any other Asian background  African  
Caribbean 
 Any other Black / African / Caribbean 
background 
 
Arab  Any other ethnic group  
 
3. What is your relationship status?  
4. Which of the following best describes your current job status? 
Employed full time  Employed part time   
Homemaker   Unemployed (unrelated to breast cancer)  
Unemployed/Retired (as a result of 




Other     
 





Single  Married  
Widowed  Co-habiting   




6. How often have you visited your GP for any reason in the last four weeks?  
 
 
7. When were you diagnosed with breast cancer (MM/YY)? ………………………….. 
 
8. What stage was your breast cancer at diagnosis? (please tick the most 
appropriate answer) 
 
9. What was the size of your breast cancer tumour?  
Under 2cm   Larger than 5cm   
Between 2cm – 5cm   Unsure   
 
10. What treatment for breast cancer have you received?  
Lumpectomy (surgery to remove the cancerous lump)  
Single Mastectomy (surgery to remove the whole breast)  
 
Double Mastectomy (surgery to remove both breasts)   
Chemotherapy (the use of anti-cancer drugs to kill the cancer cells)   
Radiotherapy  (the use of controlled radiation to kill cancer cells)   
 
11. When did you complete surgery / radiotherapy / chemotherapy (MM/YY)?  
………………………………………………… 
12. Was your breast cancer Oestrogen positive (ER+)? This means the breast cancer 
cells have oestrogen receptors.  
Yes   No  
Unsure    
 
 
Stage 1 (tumour was 2cm or smaller and had not spread to lymph nodes)  
Stage 2 (tumour was between 2 – 5cm and / or the lymph nodes in the armpit were 
affected) 
 
Stage 3 (tumour was between 2 – 5cm and may be attached to structures in the breast. The 
lymph nodes in the armpit were affected) 
 








13. What was your menopausal status when diagnosed with breast cancer?  
Pre-menopausal (no change in your patterns of periods)  
Menopausal (irregular periods)  
Post-menopausal (no period for 12 months)  
Unsure  
 
14. When were you first prescribed Tamoxifen (MM/YY)? If you cannot remember 
exactly, please write a rough estimate.  
............................................... 
15. What kind of healthcare professional prescribed you Tamoxifen?  
 
 
16. Were you prescribed Tamoxifen for five or ten years? 
 
 
17. Have you had any follow up appointments since being prescribed Tamoxifen?  
Yes – GP   Yes – Consultant   
Yes – Nurse   No  
 
18. What is your current Tamoxifen dosage? 
10mg  20mg  
40mg  Unsure   
 
19. Have you been switched from Tamoxifen to a different hormone therapy to 
prevent the risk of recurrence? 
No  Yes – Anastrozole (Arimidex)  
Yes – Letrozole (Femara)   Yes – Exemestane (Aromasin)  







20. Do you have any other medical conditions (e.g. asthma)? 





Please read the following statements and tick the box to demonstrate the extent 
to which you agree or disagree with each statement. We are interested in your 












Tamoxifen disrupts my life      
Having to take Tamoxifen worries me      
I sometimes worry about becoming too 
dependent on Tamoxifen  
     
Tamoxifen is a mystery to me       
I sometimes worry about the long term effects 
of Tamoxifen  
     
My life would be impossible without Tamoxifen      
My health in the future will depend on 
Tamoxifen  
     
Without Tamoxifen I would be very ill      
Tamoxifen prevents me from becoming worse      












Emotions play an important part in most illnesses.  This questionnaire is designed 
to help us know how you feel.  Read each item and circle one of the replies below 
each item which comes closest to how you have been feeling during the past 
week.  Don't take too long over your replies; your immediate reaction to each 
item will probably be more accurate than a long thought out response. 
 
1. I feel tense or ‘wound up’: 
 
0 Most of the time  
1 A lot of the time  
2 From time to time, occasionally  
3 Not at all   
 
6. I feel cheerful:  
 
0 Not at all  
1 Not often  
2 Sometimes  
3 Most of the time  
  
2. I still enjoy the things I used to enjoy:  
 
0 Definitely as much  
1 Not quite as much  
2 Only a little 
3 Hardly at all  
 
7.  I can sit at ease and feel relaxed: 
 
0 Definitely  
1 Usually  
2 Not often 
3 Not at all  
 
3. I get a sort of frightened feeling as if something 
awful is about to happen: 
 
0 Very definitely and quite badly  
1 Yes, but not too badly  
2 A little, but it doesn’t worry me  
3 Not at all  
 
8. I feel as if I am slowed down: 
 
0 Nearly all the time  
1 Very often  
2 Sometimes  
3 Not at all  
 
4. I can laugh and see the funny side of things:  
 
0 As much as I always could  
1 Not quite as much as now  
2 Definitely not so much now 
3 Not at all  
 
9. I get a sort of frightened feeling like  
‘butterflies’ in the stomach:  
 
0 Not at all  
1 Occasionally   
2 Quite often  
3 Very often  
 
5. Worrying thoughts go through my mind:  
 
0 A great deal of the time  
1 A lot of the time  
2 From time to time but not too often  
3 Only occasionally  
10. I have lost interest in my 
 appearance:  
 
0 Definitely  
1 I don’t take as much care as I should   
2 I may not take quite as much care as ever  





11. I feel restless as if I have to be on the move:  
 
0 Very much indeed  
1 Quite a lot  
2 Not very much   
3 Not at all  
 
13. I get sudden feelings of panic:  
 
0 Very often indeed 
1 Quite often  
2 Not very often  
3 Not at all 
 
12. I look forward with enjoyment to things:  
 
0 As much as I ever did  
1 Rather less than I used to  
2 Definitely less than I used to  
3 Hardly at all  
 




1 Sometimes   
2 Not often  
3 Very seldom  
 
Many people find a way of using their medicines which suits them. This may differ 
from the instructions on the label or from what their doctor had said. Here are 
some ways in which people have said they use their medicines. For each 
statement, please tick the box which best applies to you.  
 Never Seldom 
Some-
times 
Often  Always  
I forget to use Tamoxifen       
I adjust the dosage of my Tamoxifen       
I stop using Tamoxifen for a while       
I decide to skip Tamoxifen doses      
I take fewer Tamoxifen tablets than prescribed 
to me  
     
 
 Yes No 




If you have stopped taking Tamoxifen completely, please explain why:  









Please read the statements and circle a number on the scale between 1 and 7. For 
example, circling 1 in the first statement indicates that you strongly agree.  
People who are important to me 
think I should take Tamoxifen daily 
Strongly agree 1    2    3    4    5    6    7 
Strongly 
disagree 
It is expected of me to take 
Tamoxifen every day  
Strongly agree 1    2    3    4    5    6    7 
Strongly 
disagree 
I feel in control of whether I take 
Tamoxifen each day  
Strongly agree 1    2    3    4    5    6    7 
Strongly 
disagree 
I am confident that I can take 
Tamoxifen daily 




My healthcare professionals think I 
should take Tamoxifen   
Strongly agree  1    2    3    4    5    6    7 
Strongly 
disagree 
My family think I should take 
Tamoxifen  
Strongly agree  1    2    3    4    5    6    7 
Strongly 
disagree 
I will try to take Tamoxifen daily 
over the next year 
Definitely will 1    2    3    4    5    6    7 
Definitely will 
not 
How confident are you that you can 
overcome obstacles that stop you 
from taking Tamoxifen?  
Very confident  1    2    3    4    5    6    7 
Not at all 
confident 
For me to take Tamoxifen daily will 
be… 
Very easy  1    2    3    4    5    6    7 Very difficult 
I intend to take Tamoxifen daily over 
the next year 
Definitely do 1    2    3    4    5    6    7 
Definitely do 
not 
I feel under social pressure to take 
Tamoxifen 




Most people who have breast 
cancer take Tamoxifen every day 
Strongly agree 1    2    3    4    5    6    7 
Strongly 
disagree 
Whether I take Tamoxifen or not is 
entirely up to me 
Strongly agree 1    2    3    4    5    6    7 
Strongly 
disagree 
My friends think I should take 
Tamoxifen    
Strongly agree  1    2    3    4    5    6    7 
Strongly 
disagree 
Having free time makes it easier to 
take Tamoxifen   
Strongly agree  1    2    3    4    5    6    7 
Strongly 
disagree 
I want to take Tamoxifen daily over 
the next year   







How important is it for you to do 
what your friends think you should 
do?    
Extremely 
important 




How important is it for you to do 
what your family think you should 




1    2    3    4    5    6    7 
Extremely 
unimportant 
How important is it for you to do 
what your healthcare professional 
thinks you should do?    
Extremely 
important 
1    2    3    4    5    6    7 
Extremely 
unimportant 
I have free time  Never 1    2    3    4    5    6    7 Frequently  
 
Taking Tamoxifen daily is…. Good     1    2    3    4    5    6    7    Bad 
 Harmful     1    2    3    4    5    6    7    Beneficial  
 Unpleasant     1    2    3    4    5    6    7    Pleasant 
 Foolish     1    2    3    4    5    6    7    Wise 
 Necessary     1    2    3    4    5    6    7    Unnecessary 
 
 
Below is a list of statements that other people with your illness have said are 
important.  
Please tick one box per line to indicate your response as it applies to the past 7 
days. 
 










I have hot flashes       
I have cold sweats       
I have night sweats       
I have vaginal discharge       












a bit  
Very 
much  
I have vaginal dryness      
I have pain or discomfort with intercourse      
I have lost interest in sex      
I have gained weight       
I feel lightheaded (dizzy)      
I have been vomiting       
I have diarrhoea      
I get headaches       
I feel bloated       
I have breast sensitivity / tenderness      
I have mood swings       
I am irritable       
I have pain in my joints       
 
We would like to find out how informed you feel about your treatment. Please 













I feel that I have received adequate information 
about Tamoxifen from my healthcare team. 
     
I fully understand why I have been prescribed 
Tamoxifen.  
     
I feel confident in my understanding of how 
Tamoxifen helps me.  
     
Whether or not I take Tamoxifen correctly each 
day will affect how it works.  







Listed below are a number of symptoms that you may or may not have 
experienced. Please indicate by ticking the box in the first column if you have 
experienced any of these symptoms since your breast cancer. If you have 
experienced a symptom, please tick in any of the next three columns to indicate 
that you think the symptom is related to your breast cancer, tamoxifen treatment 
or previous treatment.  
 
  If you have experienced a symptom, please tick below to 
indicate if you think the symptom was related to your breast 
cancer, tamoxifen treatment or previous / other treatment. 
You may tick more than one box or leave the boxes clear.  
 I have experienced 
this 
symptom since my 
breast cancer 
This symptom is 
related to 
my breast cancer 




This symptom is 
related to my 
previous / other 
treatment 
Pain     
Upset stomach     
Change in sex drive      
Nausea     
Breathlessness     
Hot flushes     
Leg cramps     
Sore throat     
Weight loss / gain      
Loss of 
concentration 
    
Night sweats     
Fatigue     




    
Headaches     
Sleep difficulties     
Dizziness     
Loss of strength     
Feeling down      
Sore / itchy eyes     
Changes to periods     
Feeling 
lightheaded 







We are interested in views you hold currently about your breast cancer. Please 
indicate how much you agree or disagree with the following statements about 













IP1 My treatment has been effective in curing 
my breast cancer  
     
IP2 
I no longer have breast cancer       
IP3 
My breast cancer is cured       
IP4 
I still see myself as having cancer       
IP5 I expect to have breast cancer for the rest of 
my life 
     
IP6 Tamoxifen has major consequences on my 
life  
     
IP7 I can’t function normally whilst taking 
tamoxifen  
     
IP8 Taking tamoxifen has had an impact on 
those around me 
     
IP9 My work / social life has been affected by 
taking tamoxifen 
     
IP10 I struggle to cope with the side effects of 
tamoxifen  
     
IP11 There’s a good chance my cancer will come 
back  
     
IP12 I expect to have a recurrence of cancer in 
the future   
     
IP13 
I am extremely likely to have a recurrence      
IP14 
The chance of my cancer coming back is low       
IP15 My breast cancer still has major 
consequences on my life 
     
IP16 My breast cancer currently does not have 
much effect on my life  
     
IP17 I still experience long lasting effects from my 
original treatment for breast cancer   
     
IP18 My breast cancer currently causes 
difficulties for those who are close to me 
(e.g. emotional difficulties)  
     
IP19 
There are things I can do to stop the cancer 
coming back 























What I do has an influence on whether my 
cancer comes back  
     
IP21 
There is nothing I can do to help my risk of 
recurrence 
     
IP22 
My actions will have no effect on the risk of 
cancer coming back  
     
IP23 
Tamoxifen treatment can reduce my risk of 
recurrence 
     
IP24 
There is very little that can be done to  stop 
the cancer coming back 
     
IP25 
 Taking tamoxifen will help stop the cancer 
coming back 
     
IP26 
There is nothing that can help my risk of 
recurrence  
     
IP27 Tamoxifen  is a mystery to me      
IP28 
I understand how tamoxifen helps prevent 
cancer recurrence  
     
IP29 
I don’t understand how much tamoxifen can 
help me 
     
IP30 
I have a good understanding of why I am 
taking tamoxifen 
     
IP31 
I get depressed when I think about my risk of 
recurrence 
     
IP32 I worry about my risk of recurrence      
IP33 My risk of recurrence makes me feel angry       
IP34 
When I think about the cancer coming back I 
get upset 
     




We are interested in what you think about possible causes or risk factors of 
recurrence. We are interested in your views and there are no correct answers. The 
factors below may or may not be related to cancer risk. Please indicate by ticking 
the appropriate box to show the extent you agree or disagree that any of the 









C1 Stress or worry      
C2 Runs in the family       
C3 A Germ or virus      
C4 Diet or eating habits      
C5 Chance or bad luck      
C6 Carcinogens in products (e.g. 
deodorant)  
     
C7 Pollution in the environment      
C8 My own behaviour      
C9 Exercise       
C10 Family problems or worries       
C11 My emotional state e.g. feeling 
down, lonely, anxious, empty 
     
C12 Ageing      
C13 Smoking (leave blank if not 
applicable) 
     















We are interested in how you feel about the following statements. Read each 




Thank you for completing the questionnaire. Please return 
this to the researcher or post it using the stamped 























There is a special person around when I 
am in need 
 
  
    
There is a special person with whom I 
can share my joys and sorrows 
 
  
    
My family really tries to help me         
I get the emotional help and support I 
need from my family  
 
  
    
I have a special person who is a real 
source of comfort to me  
 
  
    
My friends really try to help me        
I can count on my friends when things 
go wrong  
 
  
    




    
I have friends with whom I can share 
my joys and sorrows  
 
  
    
There is a special person in my life who 
cares about my feelings 
 
  
    




    










Supplementary material for IPQ-R modification study (chapter 5) 
 












My breast cancer will last a short time 
My treatment has been effective in curing my breast 
cancer  
My breast cancer is likely to be permanent 
rather than temporary 
My breast cancer is cured  
My breast cancer will last for a long time I no longer have breast cancer  
Breast cancer will pass quickly I still see myself as having breast cancer  
I expect to have breast cancer for the rest of 
my life 























 Tamoxifen has major consequences on my life  
 I can’t function normally whilst taking tamoxifen  
 Taking tamoxifen has had an impact on those around me 
 
My work / social life has been affected by taking 
tamoxifen 


















 There’s a good chance my cancer will come back  
 I expect to have a recurrence of cancer in the future   
 I am extremely likely to have a recurrence 



























My breast cancer is a serious condition 
I still experience long lasting effects from my original 
treatment for breast cancer  
My breast cancer has major consequences on 
my life 
My breast cancer still has major consequences on my 
life  
My breast cancer does not have much effect 
on my life 
My breast cancer currently does not have much effect on 
my life  
My breast cancer strongly affects the way 
others see me Item removed 
My breast cancer has serious financial 
consequences Item removed  
My breast cancer causes difficulties for 
those who are close to me 
My breast cancer currently causes difficulties for those 

















There is a lot which I can do to control my 
symptoms 
There are things I can do to stop the cancer coming back  
What I do can determine whether my breast 
cancer gets better or worse 
What I do has an influence on whether my cancer comes 
back  
The course of my breast cancer depends on 
me 
Item removed  
Nothing I do will affect my breast cancer There is nothing I can do to help my risk of recurrence  
I have the power to influence my breast 
cancer 




My actions will have no effect on the 
outcome of my breast cancer 
My actions will have no effect on the risk of cancer 


















There is very little that can be done to 
improve my breast cancer 
There is very little that can be done to stop the cancer 
coming back  
My treatment will be effective in curing my 
breast cancer 
Taking tamoxifen will help stop the cancer coming back  
The negative effects of my breast cancer can 
be prevented (avoided) by Tamoxifen 
treatment 
Item removed  
Tamoxifen treatment can control my breast 
cancer Tamoxifen treatment can reduce my risk of recurrence  
There is nothing which can help my breast 











The symptoms of breast cancer are puzzling 
to me 
I understand how tamoxifen helps prevent cancer 
recurrence  
My breast cancer is a mystery to me Tamoxifen is a mystery to me  
I don’t understand my breast cancer I don’t understand how much tamoxifen can help me  
My breast cancer doesn’t make any sense to 
me 
Item removed  
I have a clear picture or understanding of my 
breast cancer 

















The symptoms of my breast cancer change a 
great deal from day to day 
Item removed 
My symptoms come and go in cycles Item removed 
My breast cancer is very unpredictable Item removed 
I go through cycles in which my breast 
cancer gets better and worse 
Item removed 
 























 I get depressed when I think about my breast 
cancer I get depressed when I think about my risk of recurrence  
When I think about my breast cancer I get 
upset When I think about the cancer coming back I get upset  
My breast cancer makes me feel angry My risk of recurrence makes me feel angry** 
My breast cancer does not worry me Item removed 
Having breast cancer makes me feel anxious Item removed 
My breast cancer makes me feel afraid My risk of recurrence makes me feel afraid  
Note. Items in italics are new and not on the original IPQ-R. ** indicates that the item was removed 













Appendix E  
Supplementary material for published paper in Chapter 6 
 
Supplementary table showing associations between individual variables and intentional 





Side effects total (rb) 0.44** 0.14** 
HADS distress (rb) 0.37** 0.08 
Informed (rb) -0.13* -0.03 
Social support (rb) -0.19** -0.14** 
Age (rb) 0.01 -0.22** 
Age left full time education (rb) 0.01 .12** 
Ethnicity: White vs. Other (Cramer’s V)  0.02 0.09**  
Relationship status: Single vs. with partner (Cramer’s V) 0.01 0.13** 
Job status: Employed vs. not employed (Cramer’s V) 0.01 0.22*** 
Type of physician prescribed tamoxifen (Cramer’s V) 0.11 0.12 
Previous treatment: chemotherapy (Cramer’s V) 0.02 0.08* 
Previous treatment: radiotherapy (Cramer’s V) 0.07 0.00 
Previous treatment: single mastectomy (Cramer’s V) 0.05 0.06 
Previous treatment: double mastectomy (Cramer’s V) 0.10** 0.00 
Previous treatment: lumpectomy (Cramer’s V) 0.04 0.01 
Cancer stage (Cramer’s V) 0.01 0.03 
Menopausal status at diagnosis (Cramer’s V) 0.04 0.11**  
Comorbidities (rb) 0.04 -0.08 
Months since prescribed tamoxifen  (rb) 0.17** 0.21** 
Duration of tamoxifen treatment (5 or 10 years) 
(Cramer’s V) 
0.07 0.11 
*correlation is significant at the 0.05 level, ** correlation is significant at the 0.01 level, *** 






Appendix F  
Baseline correlations between adherence and potential covariates (Chapter 8) 








Ethnicity (White vs. 
Black/Minority 
Ethnic)†  
0.13 (p=.014)  0.11 (p=.050)  0.14 (p=.018)  0.03 (p=.670)  
Age (rb)  -0.11 (p=.099)  -0.23 (p=.002)  -0.14 (p=.061)  -0.20 (p=.010)  
Relationship status 
(Single vs. with 
partner) †  
0.06 (p=.279)  0.06 (p=.278)  0.05 (p=.438)  0.05 (p=.397)  
Job status (Employed 
vs. not employed) †  
0.11 (p=.053)  0.12 (p=0.37)  0.18 (p=.004)  0.19 (p=.003)  
Age left full time 
education (rb)  
0.10 (p=.155)  0.17 (p=.018)  0.04 (p=.605)  0.02 (p=.778)  
Cancer stage †  0.07 (p=.599)  0.16 (p=0.40)  0.11 (p=.333)  0.06 (p=.842)  
Tumour size †  0.04 (p=.917)  0.11 (p=.309)  0.08 (p=.593)  0.06 (p=.844)  
Type of physician 
prescribed tamoxifen 
†  
0.08 (p=.927)  0.12 (p=.644)  0.15 (p=.358)  0.16 (p=.365)  
Previous treatment: 
chemotherapy †  
0.10 (p=0.58)  0.14 (p=.013)  0.09 (p=.150)  0.08 (p=.215)  
Previous treatment: 
radiotherapy †  
0.05 (p=.370)  0.05 (p=.338)  0.07 (p=.224)  0.08 (p=.232)  
Previous treatment: 
single mastectomy †  
0.01 (p=.813)  0.01 (p=.914)  0.02 (p=.682)  0.04 (p=.569)  
Previous treatment: 
double mastectomy †  
0.03 (p=.539)  0.10 (p=0.09)  0.01 (p=.828)  0.04 (p=.531)  
Previous treatment: 
lumpectomy †  
0.00 (p=.997)  0.01 (p=.891)  0.06 (p=.327)  0.07 (p=.282)  
HR status †  0.05 (p=.700)  0.12 (p=0.94)  0.14 (p=.058)  0.05 (p=.696)  
Menopausal status at 
diagnosis †  




0.07 (p=.297)  -0.00 (p=.960)  -0.03(p=.664)  -0.01 (p=.920)  
Duration of 
tamoxifen treatment 
(5 or 10 years) †  
0.08 (p=.844)  0.15 (p=.213)  0.14 (p=.376)  0.20 (p=.076)  
Number of follow up 
appointments †  
0.17 (p=.041)  0.07 (p=.822)  0.08 (p=.802)  0.16 (p=.194)  
Brand of tamoxifen †  0.12 (p=.223)  0.09 (p=.517)  0.12 (p=.287)  0.13 (p=.267)  
Comorbidities (rb)  -0.08 (p=.273)  -0.06 (p=.459)  0.01 (p=.891)  -0.03 (p=.766)  
Social support (rb)  -0.18 (p=.011)  -0.14 (p=0.47)  -0.19 (p=.013)  -0.20 (p=.012)  
Side effects total (rb)  0.01 (p=.153)  0.05 (p=.458)  0.20 (p=.009)  -0.20 (p=.012)  
Distress (rb)  0.12 (p=0.83)  0.12 (p=.103)  0.31 (p<.001)  0.26 (p=.001)  
Informed (rb)  -0.07 (p=.282)  -0.10 (p=.179)  -0.15 (p=.048)  -0.00 (p=.318)  









Appendix G  
Sensitivity analysis using lower MARS cut off (Chapter 8)  
 
Table 1. Univariate LGM results for linear and quadratic functions  
 
Model Loglikelihood  BIC Slope factor Quadratic factor 
Linear  -447.87  924.96  -0.08 (p=.426)   
Quadratic  --442.00  936.59   0.10 (p=.143) 
 
Table 2. Non-adherence rates at each time point 
Time-point  % non-adherent  
T1  14%  
T2  17%  
T3  17%  
T4  23%  
 
Table 3. Bivariate associations between covariates and intercept / slope 
Variable 
Effect on intercept 
(OR) 
Slope Effect on slope 
Ethnicity (black/minority ethnic)  3.34 (p=.157) -0.09 0.11 (p=.617) 
Job (employed)  1.93 (p=.262) -0.20 0.15 (p=.221) 
Menopausal status (post-
menopausal)  
1.46 (p=.479) 0.02 -0.19 (p=.089) 
Chemotherapy  2.40 (p=.094) -0.07 -0.05 (p=.659) 
Age  0.98 (p=.391) 0.38 -0.01 (p=.137) 
Months since prescribed tamoxifen  1.07 (p=.318) -0.02 -0.01 (p=.460) 
Distress  1.11 (p=.002) -0.37 0.01 (p=.134) 
Social support  0.72 (p=.097) 0.24 -0.05 (p=.143) 
Side effect intensity  1.06 (p=.005) -0.17 0.01 (p=.215) 
Necessity/concerns differential  0.79 (p=.001) -0.04 -0.02 (p=.134) 
Risk of recurrence  1.03 (p=.693) -0.01 0.00 (p=.813) 
Breast cancer consequences  1.15 (p=.057) -0.16 0.01 (p=.512) 
Personal control  0.96 (p=.706) 0.22 -0.02 (p=.207) 
Treatment control  0.85 (p=.160) 0.30 -0.02 (p=.235) 
Coherence  0.78 (p=.006) -0.01 -0.00 (p=.834) 
Emotional representations  1.08 (p=.172) 0.03 -0.01 (p=.535) 
Cure  0.97 (p=.680) 0.13 -0.01 (p=.395) 
Tamoxifen consequences  1.22 (p=.006) -0.33 0.03 (p=.036) 
Cause: health behaviour  1.18 (p=.612) -0.05 -0.01 (p=.892) 
Cause: psychological attributions  1.72 (p=.073) -0.27 0.06 (p=.382) 
Symptoms attributed to tamoxifen 
(identity)  
1.15 (p=.014) -0.07 -0.00 (p=.720) 
Attitude towards tamoxifen  0.88 (p=.001) 0.26 -0.01 (p=.352) 
Subjective Norm  0.66 (p=.086) 0.18 -0.04 (p=.326) 









Table 4. CSM variables as predictors of non-adherence 
Variable Slope  Effect on intercept (OR) Effect on slope 




1.79 (p=.299)  -0.16 (p=.096)  
Chemotherapy   3.12 (p=.055)  -0.07 (p=.504)  
Distress   1.06 (p=.212)  0.01 (p=.603)  
Social support   1.03 (p=.886)  -0.04 (p=.349)  




0.84 (p=.013)  -0.02 (p=.195)  
Breast cancer consequences   0.94 (p=.435)  -0.01 (p=.431)  
Coherence   0.94 (p=.496)  0.03 (p=.128)  
Tamoxifen consequences   1.02 (p=.812)  0.05 (p=.018)  
Cause: psychological stress   1.13 (p=.675)  0.01 (p=.931)  
Symptoms attributed to 
tamoxifen  
 
1.09 (p=.238)  -0.04 (p=.034)  
 
Table 5. TPB variables as predictors of non-adherence 
Variable Slope  Effect on intercept (OR) Effect on slope 
 0.44   
Menopausal status (post-
menopausal)  
 2.62 (p=.109)  -0.21 (p=.023)  
Chemotherapy   2.98 (p=.073)  -0.12 (p=.167)  
Distress   1.06 (p=.243)  0.01 (p=.559)  
Social support   0.83 (p=.395)  -0.02 (p=.468)  
Side effect intensity   0.98 (p=.566)  0.00 (p=.957)  
Attitude towards tamoxifen   0.93 (p=.034)  -0.01 (p=.573)  
Subjective Norm   1.19 (p=.510)  0.00 (p=.958)  
Perceived Behavioural 
Control  























































Patient Information Sheet  
REC reference number: 193598 
Feasibility and Acceptability of a Psychoeducational Booklet to 









What is the purpose of the Study? 
 
The purpose of the study is to test whether a psychoeducational booklet is acceptable and 
helpful for women who have been prescribed tamoxifen. The booklet will provide you with 
some information on what tamoxifen is and how it works, what side effects you may be 
experiencing, strategies for managing these side effects and tips for remembering to take 
tamoxifen. We would like to find out how the booklet made you feel, whether it was 
helpful and how it could be improved. The results from this study will help to develop the 
intervention further, allowing it to be rolled out to more women.  The research is being 
conducted as part of a PhD at King’s College London.  
 
Why have I been asked to take part?  
 
We have asked you to take part in the study because we are would like to test the 
intervention in a small group of women who have been prescribed tamoxifen but are 
finding it difficult to manage. There will be around forty women taking part in the study.  
 
Do I have to take part?  
 
It is up to you if you would like to join the study. If you are interested in taking part, we will  
ask you to sign a consent form. You are free to change your mind and to withdraw at any 
time. This will not affect your standard of care.  
 
 
We would like to invite you to take part in a research study conducted by King’s 
College London and Guy’s and St Thomas’ Foundation NHS Trust. 
The study will develop and trial a psychoeducational booklet aimed to support women 
who have been prescribed tamoxifen. Before you decide if you would like to take part, 
we will tell you why the research is being done and what it will involve for you.  
One of our team will go over this information sheet with you and give you the 
opportunity to ask any questions. You will then be able to decide if you are interested 
in taking part in the study. If you would like more time to think about it, you can 






What will the study involve?  
 
The study will involve you receiving the psychoeducational booklet for around 4 – 6 weeks. 
You will work your way through the booklet, completing one chapter per week. This will 
involve reading the information and completing exercises which will take about one hour 
for each chapter. You do not have to complete the whole chapter in one go, although we 
would like you to complete each chapter in the assigned week. One of the researchers will 
call you half way through the study to see how you are getting on. You will be asked to 
complete a series of questionnaires before starting the study and after you have completed 
the intervention. We will also contact you three months later to ask you to complete these 
questionnaires again.  
You will also be asked to take part in an interview after the intervention to discuss your 
experiences and what you found helpful. This is to help us make any changes necessary to 
improve the booklet. The interview will be informal and can either take place face to face 
or over the telephone. We would like to record the interviews using an audio recorder so 
that the researcher can fully concentrate on what you are saying. The recordings will be 
deleted once they have been typed up.  
 
Will I be reimbursed for my time?  
We will reimburse you £20 for taking part in the intervention study. We will also reimburse 
you for any travel costs for attending an interview.   
 
Will my information be kept confidential?  
 
Your personal information will be kept confidential. The questionnaires will be inputted 
into a computer. Only the researchers will have access to the computer which will have a 
password to protect all confidential files. The interview will be recorded using an audio 
recorder, and the interview will be typed up. The recording will be typed up by an external 
company who have experience dealing with confidential data. The recording will be deleted 
and the typed up interview will be made anonymous. Any personal details or identifiable 
information will be removed and contact details will be stored separately in a locked filling 
cabinet. The data will be kept securely at King’s College London. It will be destroyed five 
years after the research has finished. Your contact details will be destroyed as soon as the 
study has finished. Data cannot be withdrawn once the results have been analysed and 
written up (June 2017).   
In the unlikely event of any risk such as self-harm or suicide risk, confidentiality will need to 
be broken. Your safety is very important. Both you and your clinical team will be made 
aware of the breach of confidentiality. 
What are the possible disadvantages / benefits of taking part?  
The risk of taking part is extremely minimal. You will need to read the booklet and 
complete a series of questionnaires. These questionnaires have been used previously and 
should not cause any distress. The booklet has been developed alongside feedback from 




you through your treatment and therefore you should benefit from taking part in the study. 
The information you provide us about the intervention will help us to develop the booklet 
further, which will help to support more women in the future.  
What if there is a problem? 
If the booklet raises any issues that you would like to discuss further with a health 
professional, the researcher will be able to put you in contact with the relevant person. You 
are free to withdraw from the study at any point. If you have a concern about any aspect of 
this study, you can speak to the Principal Investigator, or any other researchers involved in 
the study. The contact details are at the bottom of this sheet.  
 
What will happen to the results of the research study?  
The results of this study may be published in scientific journals and at medical and 
psychological academic conferences. You will not be identified in any report or publication. 
A report will be made available through Breast Cancer Now and a lay summary will be sent 
to participants.  
Who has reviewed the study?  
 
This study has been checked by London South East Research Ethics Committee, an 
independent group of people, to protect your safety, rights, wellbeing and dignity.  
 
Any further queries?  
 
If you have any questions or concerns about the study, you may contact the following 
organisations  
 
For independent advice on participating in NHS research:  
Patient Advice and Liaison Service (PALS) - 0207 188 8803  
 
For independent advice about making a complaint:  
South London Independent Complaints Advisory Service (ICAS) – 0300 456 2370  
 
 
For information from the researchers:  
 
Miss Zoë Moon: zoe.moon@kcl.ac.uk 0207 188 9324 (Principal 
Investigator)  











CONSENT FORM  
Title of Project: Feasibility and Acceptability of a 
Psychoeducational Booklet to Support Women who have 
been Prescribed Tamoxifen 
IRAS number: 193598 
Name of researcher: Zoë Moon  
Please initial each box  
 
………………………………………………………….                               ………………………………………………………… 
Researcher’s name                                                                 Researcher’s signature  
Date: …………………………………………… 
1. I confirm that I have read and understood the information sheet dated 07/11/2016 (v3) 
for the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. I 
understand that data cannot be withdrawn once the results have been analysed and 
written up (June 2017). 
 
 
3. I understand that relevant sections of my medical notes may be looked at by the research 
team and that research data collected during the study may be looked at by individuals 
from King’s College London, from regulatory authorities or from the NHS Trust, where 
it is relevant to my taking part in this research. I give permission for these individuals to 
have access to my records.  
 













Please provide your contact details below.  
 
Name:  ………………………………………………………… 






Email address:  ............................................... 
 
            
Your contact details will be kept separately from your data and will be destroyed once 
the research is over.  
 
Please keep my contact details on file to send me a summary of the results:  Yes  
                     No 
             
 










SCREENING QUESTIONS  
Please tick the answer which most applies to you.   
1. Are you currently being prescribed tamoxifen for a diagnosis of primary breast cancer? 
 
 
2. Are you currently undergoing chemotherapy or radiotherapy? 
 
 









5. Has your healthcare professional discussed switching you to another drug within the 
next four weeks? 
 
 
6. Have you been diagnosed with Ductal Carcinoma In Situ (DCIS)? 
 
 
7. Have you been diagnosed with secondary or metastatic breast cancer? 
 
 










Many people find a way of using their medicines which suits them. This may differ 
from the instructions on the label or from what their doctor had said. Here are 
some ways in which people have said they use their medicines. For each statement, 
please tick the box which best applies to you.  
 Never Seldom Some-
times 
Often  Always  
I forget to use Tamoxifen       
I adjust the dosage of my Tamoxifen       
I stop using Tamoxifen for a while       
I decide to skip Tamoxifen doses      


























Appendix I  










































Appendix J  
T-tests and Chi-squared tests to compare participants who were lost to follow up to those 





Did not complete 





Age 53 (6.3) 48 (SD=2.5) t(31)=1.69, p=.100 
Months since 
prescribed 
34 (16.9) 43 (SD=52.8) 
t(5.2)=-0.41, 
p=.696 
Ethnicity (% white) 81% 83% Χ2=0.02 (p=.885) 
Relationship status 
(% with partner) 
59% 50% Χ2=0.17 (p=.678) 
Job status (% 
employed) 
89% 83% Χ2=0.14 (p=.706) 
Age left full time 
education (% <16) 
30% 17% Χ2=0.42 (p=.519) 
Menopausal status at 
diagnosis (% pre-
menopausal) 
72% 83% Χ2=0.33 (p=.569) 
MARS total 23.0 (1.6) 22.2 (1.0) t(31)=1.19, p=.244 
MARS intentional 19.3 (1.5) 19.2 (1.0) t(31)=0.26, p=.794 
MARS unintentional 3.7 (0.6) 3.0 (0.0) t(26)=5.59, p<.001 
 
